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Abstract
Which method is best for the induction of labour?
A systematic review, network meta-analysis and
cost-effectiveness analysis
Zarko Alfirevic,1* Edna Keeney,2 Therese Dowswell,1 Nicky J Welton,2
Nancy Medley,1 Sofia Dias,2 Leanne V Jones,1 Gillian Gyte1
and Deborah M Caldwell2
1Centre for Women’s Health Research, University of Liverpool and Liverpool Women’s Hospital,
Liverpool, UK
2School of Social and Community Medicine, University of Bristol, Bristol, UK
*Corresponding author Zarko@liverpool.ac.uk
Background: More than 150,000 pregnant women in England and Wales have their labour induced each
year. Multiple pharmacological, mechanical and complementary methods are available to induce labour.
Objective: To assess the relative effectiveness, safety and cost-effectiveness of labour induction methods
and, data permitting, effects in different clinical subgroups.
Methods: We carried out a systematic review using Cochrane methods. The Cochrane Pregnancy and
Childbirth Group’s Trials Register was searched (March 2014). This contains over 22,000 reports of
controlled trials (published from 1923 onwards) retrieved from weekly searches of OVID MEDLINE (1966 to
current); Cochrane Central Register of Controlled Trials (The Cochrane Library); EMBASE (1982 to current);
Cumulative Index to Nursing and Allied Health Literature (1984 to current); ClinicalTrials.gov; the World
Health Organization International Clinical Trials Registry Portal; and hand-searching of relevant conference
proceedings and journals. We included randomised controlled trials examining interventions to induce
labour compared with placebo, no treatment or other interventions in women eligible for third-trimester
induction. We included outcomes relating to efficacy, safety and acceptability to women. In addition,
for the economic analysis we searched the Database of Abstracts of Reviews of Effects, and Economic
Evaluations Databases, NHS Economic Evaluation Database and the Health Technology Assessment
database. We carried out a network meta-analysis (NMA) using all of the available evidence, both direct
and indirect, to produce estimates of the relative effects of each treatment compared with others in a
network. We developed a de novo decision tree model to estimate the cost-effectiveness of various
methods. The costs included were the intervention and other hospital costs incurred (price year 2012–13).
We reviewed the literature to identify preference-based utilities for the health-related outcomes in the
model. We calculated incremental cost-effectiveness ratios, expected costs, utilities and net benefit.
We represent uncertainty in the optimal intervention using cost-effectiveness acceptability curves.
Results: We identified 1190 studies; 611 were eligible for inclusion. The interventions most likely to
achieve vaginal delivery (VD) within 24 hours were intravenous oxytocin with amniotomy [posterior rank 2;
95% credible intervals (CrIs) 1 to 9] and higher-dose (≥ 50 µg) vaginal misoprostol (rank 3; 95% CrI 1 to 6).
Compared with placebo, several treatments reduced the odds of caesarean section, but we observed
considerable uncertainty in treatment rankings. For uterine hyperstimulation, double-balloon catheter had
the highest probability of being among the best three treatments, whereas vaginal misoprostol (≥ 50 µg)
was most likely to increase the odds of excessive uterine activity. For other safety outcomes there were
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insufficient data or there was too much uncertainty to identify which treatments performed ‘best’.
Few studies collected information on women’s views. Owing to incomplete reporting of the VD within
24 hours outcome, the cost-effectiveness analysis could compare only 20 interventions. The analysis
suggested that most interventions have similar utility and differ mainly in cost. With a caveat of considerable
uncertainty, titrated (low-dose) misoprostol solution and buccal/sublingual misoprostol had the highest
likelihood of being cost-effective.
Limitations: There was considerable uncertainty in findings and there were insufficient data for some
planned subgroup analyses.
Conclusions: Overall, misoprostol and oxytocin with amniotomy (for women with favourable cervix) is
more successful than other agents in achieving VD within 24 hours. The ranking according to safety of
different methods was less clear. The cost-effectiveness analysis suggested that titrated (low-dose) oral
misoprostol solution resulted in the highest utility, whereas buccal/sublingual misoprostol had the lowest
cost. There was a high degree of uncertainty as to the most cost-effective intervention.
Future work: Future trials should be powered to detect a method that is more cost-effective than
misoprostol solution and report outcomes included in this NMA.
Study registration: This study is registered as PROSPERO CRD42013005116.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Amniotomy Surgical rupture of the amniotic membranes.
Apgar score A scoring system (0–10) to describe the condition of the newborn. A score > 7 at
5 minutes after the birth suggests that the infant is in a good condition.
Bishop score A scoring system to measure changes in the cervix (cervical length and dilatation); a Bishop
score < 6 is often referred to as an unripe cervix (unfavourable), whereas ≥ 6 is referred to as a ripe
cervix (favourable).
Catheter A length of rubberised tubing with an inflatable balloon to anchor the tubing in place.
Urinary catheters are used to drain urine from the bladder (a Foley catheter is a type of urinary catheter).
A catheter can be passed through the cervical canal and small balloon(s) is (are) inflated with sterile
solution to hold the catheter in place. Catheters used for the induction of labour may have a single balloon
(e.g. Foley catheter) or specially designed catheters with two balloons can be used.
Cluster randomised trial A type of randomised trial in which groups rather than individual participants
are randomised to intervention or control.
Cochrane Collaboration International not-for-profit organisation preparing, maintaining and promoting
the accessibility of systematic reviews of the effects of health-care interventions.
Consistency The fundamental assumption underpinning a network meta-analysis. The assumption is also
known as transitivity and states that (the benefit of A over B) is equal to (the benefit of A over C) minus
(the benefit of B over C). Consistency suggests that the sets of studies used to obtain the indirect
comparison are sufficiently similar in characteristics that potentially moderate the intervention effect.
Direct comparison A comparison of two or more interventions made within a study.
Direct evidence Evidence on the relative effects of interventions derived entirely from direct comparisons.
Expectant management Care that involves a period of observation rather than immediate intervention.
In the context of planned induction of labour, this would give time to allow for the spontaneous onset
of labour.
Gestational age The length of the pregnancy from the date of the last menstrual period; gestational age
is usually recorded in weeks plus days.
Indirect comparison A comparison of two interventions via one or more common comparator. For
example, the combination of intervention effects from AB and intervention effects from BC studies may
(in some situations) be used to learn about the intervention effect AC.
Indirect evidence Evidence on the relative effectiveness of two interventions derived entirely from indirect
comparisons. Indirect evidence may be available via more than one intermediate comparator.
Induction of labour Interventions (pharmacological, mechanical, complementary or alternative) to
artificially stimulate the start of labour.
Intra Into (e.g. intravaginal, intracervical; when drugs are introduced into the vagina or cervical canal).
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Laminaria Devices that can be introduced into the cervical canal, which expand to stimulate
cervical dilatation.
Membrane sweep Membrane sweeping or stripping involves the midwife or doctor detaching the
amniotic membranes from the lower section of the uterus by a circular movement of an examining finger;
this has been used to stimulate labour.
Meta-analysis Synthesis (pooling) of data from more than one study to estimate an overall result.
Network diagram A graphical depiction of how each intervention is connected to the others through
direct comparisons. Each line, or edge, depicts a direct comparison between two intervention nodes.
Network meta-analysis The simultaneous comparison of multiple competing treatments in a single
statistical analysis (also known as a mixed-treatment comparison). The method uses both direct and
indirect evidence to estimate the relative effects of each treatment compared with all others in the
network, even though some treatments may not have been directly compared with each other in trials.
Nitric oxide donors Chemicals produced by the body that have a role in many functions. Commercially
produced nitric oxide donors are used to stimulate changes in the cervix as part of induction of labour.
Types of nitric oxide donors include isosorbide mononitrate, isosorbide dinitrate, nitroglycerin and
sodium nitroprusside.
Oxytocin A hormone produced by the body that has an important role in childbirth. Commercially
manufactured oxytocin is used in the induction of labour to stimulate cervical dilatation and
uterine contractions.
Parity Relates to the number of times a woman has given birth. A nulliparous woman has not given birth
before; a multiparous woman has given birth at least once before.
Post term A pregnancy continuing beyond 41+0 weeks (also known as post dates).
Preterm birth Birth before 37+0 weeks of pregnancy.
Prostaglandin E1 A type of Q4 prostaglandin (misoprostol is a synthetic analogue of PGE1 used in the
induction of labour).
Prostaglandin E2 A type of prostaglandin used in the induction of labour (dinoprostone).
Prostaglandin F2 A type of prostaglandin used in the induction of labour.
Prostaglandin F2 alpha A naturally occurring prostaglandin, pharmaceutically termed dinoprost,
used in medicine to induce labour and as an abortifacient.
Prostaglandins Hormones produced by the body, which are important in the onset of labour;
synthetically manufactured prostaglandins can be used to start labour.
Rankogram A two-dimensional treatment-specific plot, presenting on the horizontal axis the possible
ranks of the treatment and on the vertical axis the probability for the treatment to assume each of the
possible ranks according to a specific outcome.
Systematic review A review of literature focused on a research question that uses prespecified methods
to identify, evaluate, select and synthesise research evidence. A systematic review may include
meta-analysis.
GLOSSARY
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Transitivity See Consistency.
Uterine hyperstimulation Contractions of the uterus that are too strong, too long or too frequent.
Uterine hyperstimulation can result in changes in the fetal heart rate (uterine hyperstimulation syndrome).
Uterine hypersystole Uterine contractions that are too strong.
Uterine tachysystole Uterine contractions that are too frequent.
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List of abbreviations
CCT clinical controlled trial
CEAC cost-effectiveness acceptability
curve
CENTRAL Cochrane Central Register of
Controlled Trials
CPCG Cochrane Pregnancy and
Childbirth Group
CrI credible interval
CS caesarean section
DIC deviance information criterion
EQ-5D™ European Quality of Life-5
Dimensions
EVPI expected value of perfect
information
EVPPI expected value of partial
perfect information
FHR fetal heart rate
HIV human immunodeficiency virus
HTA Health Technology Assessment
ICER incremental cost-effectiveness ratio
ICU intensive care unit
ISMN isosorbide mononitrate
i.v. intravenous
MCMC Markov chain Monte Carlo
NHS EED NHS Economic Evaluation Database
NICE National Institute for Health and
Care Excellence
NICU neonatal intensive care unit
NMA network meta-analysis
NO nitric oxide
OR odds ratio
PGE1 prostaglandin E1
PGE2 prostaglandin E2
PGF2 prostaglandin F2
PGF2α prostaglandin F2 alpha
PICO population, intervention and
relevant comparators, outcomes
PRISMA Preferred Reporting Items for
Systematic Reviews and
Meta-Analyses
PROM prelabour rupture of the
amniotic membranes
QALY quality-adjusted life-year
RCT randomised controlled trial
RE random effect
SD standard deviation
VAS visual analogue scale
VD vaginal delivery
VD24 vaginal delivery within 24 hours
VD > 24 vaginal delivery after 24 hours
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Plain English summary
More than 150,000 pregnant women in England and Wales have their labours induced each year.Multiple pharmacological, non-pharmacological, mechanical and complementary methods are
available to induce labour. As the number of women facing induction increases, and as new evidence from
trials emerges, it has become urgent to address questions about which methods of inducing labour are
most effective, cost-effective, safe and acceptable to women.
We carried out a systematic review, network meta-analysis (NMA) and cost-effectiveness analysis to look at
all the evidence on different methods for inducing labour. NMA produces estimates for each treatment
compared with every other in a network, even though some pairs may not have been directly compared.
We included 611 trials in the review. Results suggest that oxytocin with amniotomy and misoprostol are
more successful than other methods in achieving vaginal delivery within 24 hours. The safety profile
of different methods in terms of risk of caesarean section, instrumental delivery, too-strong uterine
contractions, admission to neonatal care unit and Apgar score < 7 at 5 minutes was less clear.
In the cost-effectiveness analysis, titrated (low-dose) oral misoprostol solution had the best outcomes
for mothers and babies, whereas buccal/sublingual misoprostol had the lowest cost to the UK NHS.
Uncertainty in our findings suggests further research is warranted to find better, safer and cheaper
methods. We urge researchers to explore women’s views of the process as part of any future trial, report
outcomes completely, and measure the impact from the perspective of the mother and baby.
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Scientific summary
Background
More than 150,000 pregnant women in England and Wales will have their labours induced each year.
There are multiple pharmacological, non-pharmacological, mechanical and complementary methods
available to induce labour. Different induction methods have advantages and disadvantages; they vary in
effectiveness, safety and cost. We carried out a systematic review, network meta-analysis (NMA) and
cost-effectiveness analysis to identify the best method for induction of labour. Findings have implications
for women, clinicians and the UK NHS.
Objectives
To assess the effectiveness and safety of a range of induction methods to determine which method
(or methods) achieves the best outcomes by providing a quantitative summary of the evidence on the
relative effects of different methods; to develop a decision model to evaluate the cost-effectiveness of the
different methods for induction; and if evidence is available, to explore effectiveness and cost-effectiveness
in different clinical subgroups [with intact or ruptured membranes, at different gestational ages, in women
following a previous caesarean section (CS) and with low (< 6) or higher Bishop scores].
Methods
We carried out a systematic review using Cochrane methods. The search was carried out by an information
specialist using a predefined strategy. The final search date was March 2014. Two reviewers independently
assessed all reports identified by the search for eligibility for inclusion. Studies were included if they were
randomised controlled trials (RCTs) examining interventions to induce labour compared with placebo, no
treatment or other interventions. Participants were women who were eligible for third-trimester induction
of labour. We focused on key outcomes relating to efficacy, safety and acceptability of the method to
women: vaginal delivery (VD) not achieved within 24 hours; uterine hyperstimulation with fetal heart rate
(FHR) changes; CS; serious neonatal morbidity or death; serious maternal morbidity or death; instrumental
delivery; maternal satisfaction with the method used; neonatal intensive care unit admission; Apgar score
< 7 at 5 minutes.
We extracted data on the type of intervention and, when appropriate, dose and route of administration.
We assessed risk of bias as high, low or unclear, based on the method used to conceal allocation. We
noted whether or not the method was used in hospital (inpatient) or outpatient settings. We recorded
information on characteristics of participants, including gestational age, parity, previous CS, state of
amniotic membranes and Bishop score.
For key outcomes we carried out a NMA. The method uses all of the available evidence, both direct and
indirect, to produce estimates of the relative effects of each treatment compared with every other in a
network, even though some pairs may not have been directly compared. This method allows the relative
effects of a range of treatments to be compared for the outcome of interest.
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We developed a de novo decision tree model to estimate the cost-effectiveness of various methods for the
induction of labour using the data obtained from the systematic review and NMA. We adapted the NMA
to account for multiple outcomes to inform probabilities for all of the outcomes and interventions in the
model. This was done using Bayesian Markov chain Monte Carlo simulation, so that all correlations and
uncertainties were fully reflected in the estimates. The costs included in the economic analysis were the
intervention costs, costs of method of delivery, and length of neonatal stay in level I, II or III units.
The price year was 2012–13. We attributed a utility score to each of the outcomes in our model, which
represents the strength of preferences for a set of health-related outcomes, where utility scores take
values of between 0 and 1, with ‘1’ representing perfect health. We reviewed the literature to identify
preference-based utilities for the health-related outcomes in the model. We performed a probabilistic
cost-effectiveness analysis, conceptualised as a hypothetical cohort of patients who vary in their
probabilities, utilities and costs, and who experience the consequences of each induction strategy.
Total utilities and costs are then averaged over this cohort to obtain the expected total utility and expected
total cost for each induction strategy. We conducted a fully incremental analysis, reporting incremental
cost-effectiveness ratios, interpreted as the additional expected cost per additional unit gain in utility for an
intervention compared with the previous non-dominated intervention, and cost-efficiency frontiers, which
plot expected cost against expected utility for each intervention. We report expected costs, expected
utilities and expected net benefit (the difference between expected utilities and costs, for which utilities are
monetaried by multiplying by the willingness-to-pay per unit increase in utility). We prefer the intervention
that maximises expected net benefit. We represent uncertainty in the optimal intervention using
cost-effectiveness acceptability curves and the cost-effectiveness plane.
Results
A total of 1508 reports corresponding to 1190 separate studies were identified.
Thirty-four active treatment types/regimens were included in our review, including different dose regimes
and routes of administration. Overall, the search identified > 1000 studies and, after eligibility assessment
using our PICO criteria (population, intervention and relevant comparators, outcomes), 579 studies were
excluded and 611 trials were included in the review. Together, the included trials reported findings for
> 100,000 women who were randomised to different methods for third-trimester induction of labour.
The active interventions most likely to achieve VD within 24 hours were intravenous (i.v.) oxytocin with
amniotomy (mainly tested in trials recruiting women with favourable cervix), higher-dose ≥ 50 µg of vaginal
misoprostol and vaginal prostaglandin E2 (PGE2; a type of prostaglandin used in the induction of labour)
pessary (normal release). Titrated (low-dose) oral misoprostol solution and sustained-release misoprostol
vaginal pessary also performed well; however, there was greater uncertainty around the effect of these
interventions for this outcome.
Compared with placebo, several treatments showed statistically significant reduction in the odds of CS:
titrated low-dose misoprostol, vaginal misoprostol at both ≥ 50 µg and < 50 µg, vaginal PGE2 gel,
intracervical PGE2, oral misoprostol tablet (≥ 50 µg), Foley catheter, membrane sweeping and buccal/
sublingual misoprostol. In this group, titrated oral misoprostol achieved the lowest odds of an eventual CS
but there was still considerable uncertainty in this finding, as observed by the posterior mean rank order of
sixth (out of 33) and 95% credible interval from second to thirteenth (out of 33). There was little to
distinguish between the other interventions and, again, we observed considerable uncertainty in
treatment rankings.
Uterine hyperstimulation with FHR changes was one of the key safety outcomes. Here, double-balloon
catheter had the highest probability of being among the best three treatments, whereas vaginal
misoprostol (≥ 50 µg), which was among the best treatments for efficacy, was most likely to increase the
odds of excessive uterine activity.
SCIENTIFIC SUMMARY
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For other safety outcomes there were insufficient data or there was too much uncertainty around
estimates to identify which treatments performed ‘best’.
Very few studies collected information on women’s views. On the whole, women tended to have positive
views, or at least accepted the induction process, but there was insufficient information to determine
whether or not some methods were preferred over others.
There was considerable uncertainty of our cost-effectiveness estimates, with the majority of the
interventions having very similar utility values, and mainly differing in total costs. The cost-effectiveness
analysis suggested that all of the methods of induction were cost-saving compared with no treatment, and
titrated (low-dose) misoprostol solution and buccal/sublingual misoprostol had the highest probability of
being cost-effective, although this was very uncertain.
Only two subgroup analyses were possible with the data available, and these were based on a small
number of studies and so should be interpreted as hypothesis generating. In the subgroup of women with
intact membranes, and limiting to interventions feasible on the NHS, i.v. oxytocin with amniotomy was
identified as the intervention most likely to be most cost-effective. In the subgroup of women with an
unfavourable cervix, titrated low-dose oral misoprostol solution and buccal/sublingual misoprostol were
found to be the interventions that were most likely to be most cost-effective.
Conclusions
Our NMA suggested that oxytocin with amniotomy and higher-dose (≥ 50 µg) vaginal misoprostol were
more successful than other agents in achieving VD within 24 hours, although the former was tested in
trials predominantly recruiting women with favourable cervix. The safety profile of different methods was
less clear. The cost-effectiveness analysis suggested that titrated (low-dose) oral misoprostol solution is the
intervention with the highest utility for mothers and babies, whereas buccal/sublingual misoprostol has the
lowest cost to the NHS. Both of these interventions had the highest chance of being most cost-effective.
However, the considerable uncertainty in our findings points the way for further research. When induction
of labour is clinically indicated, placebo or no-intervention arms may not be feasible or even ethical.
Therefore, rather than restrict RCTs to low-risk women, we suggest that titrated oral misoprostol solution
should be used as a comparator, particularly in the NHS setting. Future RCTs should be powered to detect
a method that is more cost-effective that misoprostol solution. We urge all triallists to report 11 outcomes
included in this NMA in all future RCTs. There is also an urgent need to explore women’s views of the
process as part of any future trial, and measure utilities from the perspective of the mother and baby,
preferably using the European Quality of Life-5 Dimensions instrument.
Study registration
This study is registered as PROSPERO CRD42013005116.
Funding
Funding for this study was provided by the Health Technology Assessment Research programme of the
National Institute for Health Research.
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Chapter 1 Introduction
Description of the health problem
There were 698,512 live births in England and Wales in 2013.1 More than one in five births followed
labour induction; this represents > 150,000 pregnant women in England2 and Wales3 per year. There is
evidence that the number of labour inductions has been steadily increasing over the past two decades.
NHS England maternity statistics for 2010 noted that 21.3% of births followed induction of labour, and by
2012–13 this figure had increased to 23.3%.4
Induction of labour is carried out for a number of clinical indications.5,6 The most common reasons include
post-term pregnancy (defined as 41+0 weeks’ gestation), prelabour rupture of the amniotic membranes
(PROM) or when the well-being of the woman or baby may be compromised by prolonging the pregnancy
(e.g. in cases of fetal growth restriction or pre-eclampsia).
There is a broad range of methods available for induction of labour. The choice of method may depend
on national guidelines and local protocol, as well as individual clinical factors. The advantages and
disadvantages of different methods vary, and the choice of method has implications for women and the
UK NHS.
From a clinical perspective, the decision about which method to use for induction of labour can be
influenced by the woman’s readiness for labour, for example whether or not membranes have ruptured
spontaneously or whether or not the cervix remains undilated at the start of the induction process.
Different methods used for inducing labour have different mechanisms of action, and vary in terms of
how quickly birth is achieved and the likelihood of causing complications in women with different clinical
characteristics. Thus, the choice of method will take into account the reason for induction and its
urgency. The woman’s obstetric and medical history is also considered. For example, there is evidence
that women may be more sensitive to drugs that stimulate the uterus if they have had a previous birth,
and women who have a scar from a previous caesarean birth are at increased risk of uterine rupture,
which can result in hysterectomy and fetal death.7
Different methods also have different direct costs, and some methods require continuous monitoring of
the woman throughout labour. Consequently, the choice of induction method may have significant
implications for NHS resources, especially if the method is known to increase the risk of complications
requiring a caesarean section (CS).
Women may wish to experience a natural onset of labour, and there is evidence that an induced labour can
have a negative impact on their overall experience of childbirth.8 Some methods of induction are painful or
unpleasant, and some are associated with distressing side effects, such as headache or nausea. Women
may also have preferences about which method is used and may prefer non-pharmacological approaches.
On the other hand, women will want their baby to be born safely, and timely induction may improve
outcomes for women and babies.5 Women facing decisions about induction of labour require up-to-date
information about the range of options available, including alternative and complementary methods.
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Description of available interventions and current service
provision/policy
In the NHS context, choice of induction method is typically between prostaglandins and oxytocin combined
with artificial rupture of membranes. UK clinical guidelines published in 20089 identified vaginal
prostaglandin E2 (PGE2) as ‘the preferred method of induction’. We note that this recommendation was
not based on a quantitative overview of the evidence of the effects and safety of all available methods,
or from the synthesis and analysis of data from a range of comparisons. Furthermore, this guideline9 did
not recommend any particular type (gel, tablet or pessary) or dose of PGE2 because trial evidence has rarely
compared different PGE2 preparations. Potential updating of the current guidance is awaiting the
publication of this report.10
Despite its importance, the question of resource use for the NHS has been relatively under-studied, and
uncertainty remains about the costs that are associated with induction of labour. There is evidence that
inducing labour in women with complications is associated with lower health-service costs than costs
associated with expectant management.11–13 However, there is little evidence on the costs associated with
specific methods of induction compared with others. Randomised trials in which one method of induction
has been compared with another have only rarely included economic analyses.14
A broad range of pharmacological, mechanical, complementary and alternative methods have been used
to induce labour. In the remaining sections of this chapter, we describe all of the pharmacological and
mechanical methods for third-trimester induction of labour or cervical ripening which have been used in
clinical practice and that have been examined in randomised trials. Complementary or alternative methods
have been less commonly used in NHS settings but have been used in comparable settings in other
countries. Complementary and alternative methods are included here, as information on the effects and
safety of such methods may be important for women who prefer a less medicalised birth.
Pharmacological methods for the induction of labour
Prostaglandins: prostaglandin E2 and prostaglandin F2 alpha
Prostaglandins are hormones produced naturally by the body that are important in the onset of labour.
Synthetically manufactured prostaglandins have been used in clinical practice since the 1960s to ripen the
cervix and induce uterine contractions. They are more frequently used in women when the cervix is unripe
(i.e. with a Bishop score < 6). Prostaglandins promote cervical ripening and encourage the onset of labour
by acting on cervical collagen so as to encourage the cervix to soften and stretch in preparation for
childbirth. Prostaglandins may also stimulate uterine contractions.
Despite the widespread use of prostaglandins as part of labour induction, they can cause a number of side
effects, including nausea, vomiting, diarrhoea and fever. In addition, because of their effect on the uterus,
prostaglandins can cause contractions that last too long, or are too frequent or are too strong. Excessive
uterine activity, or hyperstimulation, may be associated with fetal distress, and in a small number of cases
can lead to uterine rupture, especially in those women who have uterine scarring from surgery or a
previous caesarean birth.
A large number of prostaglandin preparations have been available for labour induction, including
prostaglandin F2 alpha (PGF2α, dinoprost), prostaglandin E2 (PGE2), prostaglandin E (PGE1) and misoprostol
(a synthetic analogue of PGE1, which is described separately: see Misoprostol). In the past, PGF2α was
frequently used in clinical practice but, more recently, PGE2 (dinoprostone) has become the most
commonly used formulation. Commercially produced PGE2 analogues are expensive and require
refrigeration. These factors have limited use in low-resource settings.
Prostaglandins are available in a variety of formulations and doses, and may be given via various routes of
administration, including vaginally, intracervically, orally and, less frequently, intravenously.
INTRODUCTION
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Vaginal and intracervical administration
Prostaglandin preparations for vaginal and intracervical administration include gels, lactose-based vaginal
tablets, suppositories, pessaries or inserts.15,16 Dosages of prostaglandins (mainly PGE2) vary, depending on
route and local protocol (frequently 0.5mg for intracervical use, 2–3mg for intravaginal use and 10mg for
sustained-release pessaries). There is also variation in terms of the number of applications and time
intervals between repeated doses. Sustained-release vaginal pessaries have been developed to reduce the
number of applications and vaginal examinations that are needed during induction of labour. Vaginal and
intracervical administration are the most common forms of administration in current practice.
In the meta-analysis we have treated different types of vaginal and intracervical PGE2 as different
interventions as different preparations may vary in terms of rate of absorption, safety and cost. We have
therefore included as separate interventions:
l PGE2 vaginal tablets (lactose based).
l PGE2 vaginal pessaries normal release (also sometimes referred to as suppositories), manufactured
using various base materials, including wax and glycerine. [Note that this intervention includes a
heterogeneous group of vaginal PGE2 preparations of varying composition. The base material used was
not always clear, and pessaries were frequently produced in local pharmacies (i.e. not commercially
available). We included this group of interventions in the network meta-analysis (NMA) and the cost
analysis for completeness, even though they are not generally reproducible or available in the UK NHS.]
l PGE2 vaginal pessaries sustained release (10- to 12-mg pessaries, single application).
l PGE2 gel introduced via vaginal applicator.
l PGE2 for intracervical administration.
Extra-amniotic administration
The administration of extra-amniotic prostaglandin gel was first carried out in the early 1970s. The gel is
administered via a Foley catheter inserted through the cervix into the extra-amniotic space. The catheter is
frequently left in place with the balloon inflated, and light traction may also be applied by taping the
catheter to the woman’s leg. Extra-amniotic administration is no longer common in current practice.17
Intravenous administration
Intravenous (i.v.) prostaglandins are associated with increased rates of maternal vomiting and diarrhoea
and are rarely used in current practice.18
Oral administration
Oral PGE2 and PGF2α have been available since the early 1970s. Oral administration is associated with
gastrointestinal side effects and is seldom used nowadays.19
Misoprostol
Misoprostol is a PGE1 analogue that is known to be effective in stimulating uterine contractions.
Misoprostol is inexpensive and requires no special storage facilities. Several routes of administration and
regimens of misoprostol have been studied, including oral (swallowed as a tablet or dissolved in a titrated
solution), vaginal (inserted into the vagina as a tablet or gel), rectal (inserted into the rectum as a tablet)
and buccal or sublingual (the tablet is dissolved in the cheek or under the tongue, respectively).20–22
Different routes of administration have advantages and disadvantages. Oral misoprostol achieves rapid
onset of action, whereas vaginal administration is associated with slower absorption but more prolonged
action. Over the past decade, slow-release misoprostol vaginal pessaries have also been tested in trials.
Although misoprostol is widely used in obstetric practice for other indications (e.g. abortion), there have
been concerns about its use due to the increased risk of serious adverse effects, such as uterine rupture.
Several small studies have reported excessive uterine activity that is associated with the use of misoprostol,
such as uterine tachysystole (more than five contractions per 10 minutes for at least 20 minutes), uterine
DOI: 10.3310/hta20650 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 65
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Alfirevic et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
3
hypersystole/hypertonus (a contraction lasting ≥ 2 minutes) and/or uterine hyperstimulation syndrome
[uterine tachysystole or hypersystole with fetal heart rate (FHR) changes such as persistent decelerations].
A meta-analysis examining the use of vaginal misoprostol suggested that despite excess uterine activity,
misoprostol was not associated with adverse fetal outcomes especially at a lower dose (< 25 µg).23
Oxytocin
Oxytocin is a hormone that is produced naturally by the body, and which has a range of functions,
including the stimulation of uterine contractions in the second and third stages of labour. Oxytocin
analogues, administered intravenously, are the commonest induction agents used worldwide. Oxytocin is
frequently administered when the cervix is dilated (or favourable) and may be combined with artificial
rupture of the amniotic membranes (amniotomy). Oxytocin may cause excess uterine activity, especially in
settings where equipment is not available to titrate doses accurately and monitor contractions.
Current i.v. oxytocin regimens usually involve incremental increases in dosage. Lower-dose regimens
typically involve 0.5–2.0milliunits (mU)/minute starting doses, with incremental increases of 1.0–2.0mU/
minute every 15–60 minutes. Higher-dose regimens have starting doses up to 6.0mU/minute, with
incremental increases of 2.0–6.0 mU/minute every 15–40 minutes. There are advantages and
disadvantages of high- or low-dose regimens; higher doses may lead to a shorter period to delivery, but
may increase the risk of hyperstimulation, whereas lower doses may increase risk of infection if labour
is prolonged.24–27
Nitric oxide donors
Nitric oxide (NO) is thought to be involved in cervical ripening, and in recent years NO donors [isosorbide
mononitrate (ISMN), isosorbide dinitrate, nitroglycerin and sodium nitroprusside] have been used to
promote cervical ripening. NO is administered as a vaginal tablet.28
Mifepristone
Mifepristone is a progesterone antagonist that has been used in the past in combination with
prostaglandins in first trimester and early second trimester pregnancy terminations. Mifepristone has been
proposed as a method to induce labour because it acts to increase uterine contractions. Mifepristone is
administered as an oral tablet.29
Oestrogens, corticosteroids, relaxin and hyaluronidase
Oestrogens have a role in promoting cervical ripening and, historically, have been administered intravenously
or into the extra-amniotic space. There are no commercially available preparations for use in cervical ripening
or induction of labour, and the two included trials of this agent date back to 196730 and 1981.31
The role of corticosteroids in the process of labour is not well understood, and they are currently not used
in clinical practice for the induction of labour.32
Relaxin is a hormone that is thought to encourage cervical ripening, which has been tested in a very small
number of trials.33 Similarly, hyaluronidase is also thought to be implicated in cervical ripening.34 Both
agents have been administered in vaginal or intracervical gel, but neither is common in current practice.
Mechanical and physical methods for induction of labour
Mechanical methods to induce labour have been available for many years. Mechanical devices include
various types of catheters and laminaria tents, introduced into or through the cervix and into the extra-
amniotic space. The introduction of devices into the cervix may cause the cervix to dilate. Their presence
may also increase prostaglandin or oxytocin secretion, which, in turn, may increase cervical dilatation and
stimulate uterine contractions.35 Here we also include descriptions of membrane sweep and amniotomy
since they may be considered a physical method of inducing labour.
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Catheters
Foley urinary catheters have been used for the induction of labour, as have double-balloon and other
catheters that are specifically designed for use in induction of labour (e.g. Cook catheter). The catheter is
introduced into the extra-amniotic space, and then the balloon(s) is (are) inflated to keep the catheter in
place. Traction may be applied by taping the catheter to the woman’s leg. Catheters are usually left in situ
until they are expelled. In some cases a saline infusion is introduced into the extra-amniotic space via
the catheter.
Laminaria tents
Laminaria tents are made from sterile seaweed or synthetic materials. These devices are introduced into the
cervical canal and expand to gradually stretch the cervix.
Membrane sweep
Stripping or sweeping of the membranes has been used for many years to induce labour, and continues
to be carried out in many clinical settings. Membrane sweeping involves the clinician detaching the
membranes from the lower uterine segment by a circular movement of the examining finger. Membrane
sweeping is thought to lead to an increased production of prostaglandins. When the cervix is closed,
a cervical massage may be carried out instead of a membrane sweep to stimulate the production
of prostaglandins.36
Amniotomy
During labour the amniotic membranes usually rupture spontaneously as the cervix dilates and stretches in
preparation for the descent of the fetus. Amniotomy refers to rupture of the membranes using a plastic
hooked instrument or, occasionally, surgical forceps.
Amniotomy may be carried out alone or in combination with oxytocin or prostaglandins to induce labour.
It can be carried out only if the amniotic membranes are accessible to the midwife or doctor, and this may
not happen until the cervix has started to dilate.
Amniotomy may cause some potentially serious adverse effects, including cord prolapse. The procedure
may introduce infection. For women known to be human immunodeficiency virus (HIV) positive the
procedure is avoided because it may increase the risk of mother-to-child transmission of HIV.25
Breast stimulation
Manual breast stimulation has been used in the past to stimulate uterine contractions.37 It is thought that it
may trigger the release of oxytocin.
Sexual intercourse
Sexual intercourse at term has been thought to lead to the onset of labour.38 The hypothesised mechanism
of action here is the prostaglandin contained within semen.
Complementary and alternative methods for induction of labour
Castor oil
Castor oil is derived from the bean of the castor plant, and has been used in oral form as a method of
stimulating labour.39 Castor oil has laxative properties, stimulating the intestines and bowel. It is this
stimulation that is hypothesised to initiate uterine contractions and labour as a secondary effect.
Acupuncture
Acupuncture involves the insertion of fine needles by trained staff into the skin at specified points on the
body. Stimulation of particular acupuncture points is intended to initiate uterine contractions and labour.40
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Homeopathy
Homoeopathy involves the use of highly diluted solutions that contain tiny amounts of the original substance.
Homeopathic preparations are popular and are available over the counter in pharmacies and health food
shops. Some homeopathic preparations have been recommended to promote the onset of labour.41
Overall aims and objectives of assessment
Given the broad range of methods used to induce labour, the main research question addressed by this
review is ‘what is the best method for induction of labour?‘. The specific objectives were to:
1. assess the effectiveness and safety of a range of induction methods to determine which method or
methods achieves the best outcomes
2. provide a quantitative summary of the evidence on the relative effects of a broad range of induction
methods to identify which method works best
3. develop a decision model to evaluate the cost-effectiveness of the different methods for induction
4. explore, if sufficient evidence is available, the effect of different clinical subgroups [with intact or
ruptured membranes, at different gestational ages, in women following a previous CS and with low
(< 6) or higher Bishop scores] on effectiveness and cost-effectiveness.
Specification of the PICO research question
Population Pregnant women carrying a viable fetus and who are eligible for any method of third-trimester
cervical ripening or labour induction.
Intervention and relevant comparators No treatment, placebo, all pharmacological (all routes and doses),
mechanical and complementary methods used for the induction of labour.
Outcomes Our primary effectiveness outcome was (1) vaginal delivery (VD) not achieved within 24 hours,
and our primary measures of safety were (2) uterine hyperstimulation with FHR changes and (3) CS. Our
secondary outcomes for serious adverse events were (4) serious neonatal morbidity or perinatal death and
(5) serious maternal morbidity or death. Other outcomes included were (6) maternal satisfaction with the
induction method used, and, for use in the economic model, (7) cost, resource use and utilities.
Definition of the decision problem for the economic evaluation
Our aim was to answer the following question: what is the most cost-effective method (from the
interventions described above), for third-trimester cervical ripening or labour induction? Outputs from the
economic evaluation include expected costs, expected benefits, incremental cost-effectiveness ratios
(ICERs), expected net benefit and cost-effectiveness acceptability curves (CEACs).
Stakeholder involvement in project
The steering group (listed in Appendix 1) and project team included a consumer representative, a health
economist, a midwife and an obstetrician engaged in clinical practice.
A consumer representative was included as a collaborator on the project, and she contributed to the early
discussions on this project and drafting the application. Induction of labour is known to be of great
interest to pregnant women. In particular, women are interested in self-administered ways of initiating
labour and for this reason these methods were examined in the proposed work. The consumer
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representative co-ordinated the involvement of members of the CPCG (Cochrane Pregnancy and Childbirth
Group) consumer panel, National Childbirth Trust and the Association for Improvements in Maternity
Services (AIMS) who expressed an interest in participating. Members of these groups were asked for
comments to inform steering group meetings, to determine the final outcomes, to aid in the interpretation
of the findings and to shape the papers to be published. The authors of this report include a consumer
representative (GG).
The steering group commented on the study design, selection of outcomes, methods for the
cost-effectiveness analysis and dissemination strategies.
Overview of report
In Chapter 2 we describe the methods used for the assessment of clinical effectiveness, including the
methods for the systematic review to identify relevant evidence on clinical effectiveness, and the methods
for the NMA. In Chapter 3 we present the results from the systematic review and NMA, including the
relative effectiveness of interventions that have been used to induce labour in women at or near term.
In Chapter 4 we describe methods and present results of the cost-effectiveness analysis, taking a UK NHS
perspective. In Chapter 5 we summarise findings, set out the strengths and limitations of our approach,
consider the implications of our results on recommended practice, and indicate areas for which future
research would be beneficial.
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Chapter 2 Methods for assessment of
clinical effectiveness
Methods for reviewing clinical effectiveness
Identification of studies
We worked with an Information Specialist to identify trials for inclusion in the NMA. We searched the
CPCG’s Specialist Register [which incorporates pregnancy and postpartum searches of the Cochrane
Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the NHS Economic Evaluation
Database (NHS EED), relevant journals and conference proceedings]. The search strategy was finalised as
part of the early consultative stages of the project, and the final search on which this report is based was
carried out at the end of March 2014. The search strategy is set out in Appendix 2. A full-text copy of
every relevant trial report was obtained and assigned to a topic, depending on the intervention before
adding to the database. We then screened all reports that were assigned to the induction of labour topic.
Many of the trials identified by the search have already been included in published Cochrane reviews, but
further searches identified more recent trials which, when eligible, have been included in the analysis.
Inclusion and exclusion criteria
Interventions
All randomised controlled trials (RCTs) of induction interventions as identified in Chapter 1 of this report
were evaluated. Eligible trials compared any method of third-trimester cervical ripening or labour induction
with an alternative intervention, placebo or no treatment. For prespecified treatments we also included
trials that compared different means of administration (e.g. vaginal misoprostol vs. oral misoprostol) or
different doses [e.g. low-dose misoprostol (< 50 µg) vs. high-dose (≥ 50 µg) misoprostol]. We included
studies recruiting women with a viable fetus, but had no other restrictions relating to the indication for
labour induction, language or date of publication.
Trials in which women were randomised to receive a combination of interventions were not eligible,
except for a small number of prespecified combinations in common use (e.g. amniotomy with oxytocin).
We made the decision to exclude lesser-used combinations as the network was already large, and such
combinations are rarely used clinically and mainly reported in single trials.
We included all interventions for the induction of labour examined in trials even if such treatments are not
used in the NHS. Treatments no longer used may not have been abandoned for evidence-based reasons,
and their inclusion adds statistical power to the entire network.
We planned to include multiarm trials and cluster randomised trials with any necessary adjustments to
account for cluster design effect (if triallists had not already carried out appropriate adjustment).
Participants
We included trials that recruited pregnant women for third-trimester induction of labour, carrying a viable
fetus, with a range of obstetric characteristics, undergoing labour induction for varied reasons.
Outcomes
In consultation with the patient representative from the CPCG we defined seven key outcomes for the
clinical evaluation of induction interventions. The first five outcomes are common to all CPCG reviews on
induction of labour and have been set out in a generic protocol.42 Outcomes 6 and 7 were proposed by
the consumer representative as of importance to women. Outcomes 8 and 9 were not prespecified;
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however, in consultation with the steering group we extracted data on neonatal intensive care unit (NICU)
admission and Apgar score, as proxies for serious neonatal morbidity (as serious neonatal morbidity was
poorly reported and inconsistently defined in trials) (Box 1).
Exclusions
We excluded trials that did not report any of our key outcomes or evaluated combined interventions. The
full list of references for excluded studies and the reasons for exclusion are documented in Appendices 3
and 4, Table 37.
Data extraction and risk-of-bias assessment
We obtained full-text copies of all reports identified by the search. A minimum of two investigators
independently assessed all reports to determine whether or not trials used random allocation to groups,
included one or more of the selected interventions and comparisons, recruited women undergoing
third-trimester induction of labour, and included data on at least one of our primary outcomes. Trials
meeting all of the eligibility criteria were included in the systematic review.
Data extraction was carried out by one investigator and checked by a second. Preliminary statistical
analyses also highlighted some discrepancies in the extracted data, which were then doubled checked by
the reviewers, and corrected if appropriate. For all included trials, we extracted data on trial and patient
characteristics, and this is summarised in tables of included studies (see Appendix 5, Reference list for
included studies, and Appendix 6, Table of included studies characteristics, Table 38).11,14,30,31,43–936
Study quality was assessed using the methods described in the Cochrane Handbook.937 For use in a
prespecified sensitivity analysis, we assigned a judgement relating to risk of bias (low, high, unclear), based
on the allocation concealment domain. We based this decision on meta-epidemiological evidence
indicating the importance of this domain as a source of bias938 and on the design of obstetric trials, which
often precludes blinding of participants and personnel (although not, of course, of outcome assessors).
Information on study setting (country and whether or not the study was carried out in an inpatient or
outpatient setting), method and the type of intervention(s) (dose, mode of administration, type of
preparation, e.g. slow-release pessary vs. gel, regimen and any cointerventions) was extracted. We
extracted details on comparison arms (e.g. another active treatment, placebo or ‘usual care/no treatment’).
Treatment arms were categorised according to the initial randomised allocation, although subsequent
BOX 1 List of outcomes
Prespecified outcomes
1. VD not achieved within 24 hours (or period specified by trial authors).
2. Uterine hyperstimulation with FHR changes.
3. CS.
4. Serious neonatal morbidity or death.
5. Serious maternal morbidity or death.
6. Instrumental delivery.
7. Maternal satisfaction with the method used.
Post hoc defined outcomes
8. NICU admission (proxy outcome for serious neonatal morbidity).
9. Apgar score < 7 at 5 minutes (proxy outcome for serious neonatal morbidity).
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clinical management may have included further doses or an alternative treatment. For participants, we
recorded important obstetric characteristics, including parity, previous CS, state of cervix and whether or
not amniotic membranes were intact. These factors were a priori expected to be possible intervention
effect modifiers. There was an additional concern that patient characteristics may be linked to the
interventions that have been included in the studies. For example, if it were the case that all of the studies
comparing NO with placebo predominantly included women with a previous CS, whereas the studies
comparing misoprostol with placebo predominantly excluded women with a previous CS, then the indirect
comparison of NO with misoprostol may not be a fair reflection of the true underlying effect in either
subgroup of women. For NMA to be valid the different study populations are required to be ‘similar’ in
any effect modifying covariate (see Network meta-analysis for a description of the key assumption of
transitivity/consistency in NMA). It is therefore important to inspect tables of patient characteristics
according to intervention comparison to assess whether or not there is an a priori reason to suspect that
the transitivity/consistency assumption may not hold.
In summary, for each trial, information was extracted on:
l The interventions compared in trials (with details of dosage and regimen for pharmacological
interventions).
l Number of participants in trials.
l Parity of women recruited to trials (all nulliparous, all multiparous or mixed parity).
l Whether women had ruptured or intact membranes at recruitment (all ruptured, all intact or the
sample included women with both intact or ruptured membranes).
l Whether or not women had favourable or unfavourable cervical scores at recruitment (Bishop score all
< 6, ≥ 6 or included women with either favourable or unfavourable scores).
l Whether or not trials included women with multiple pregnancies.
l Gestational age at recruitment (all post dates, all > 37 weeks, or the sample included women at
< 37 weeks’ gestation).
l Treatment setting (women treated as inpatients or outpatients).
l Risk of bias (high, low or unclear risk of bias, based on allocation concealment).
l We also recorded whether or not the study had been funded or partly funded by pharmaceutical
sponsors.
We compared the distribution of these characteristics in tabular form before we conducted the NMA
(see Appendix 7, Table 39). Sensitivity analyses were planned to exclude studies that were assessed as
being of unclear or high risk of bias.
Methods of evidence synthesis
Network meta-analysis
A NMA was conducted to simultaneously compare the induction interventions, placebo or no treatment
for each outcome. In its simplest form, a NMA is the combination of direct and indirect estimates of
relative intervention effect in a single analysis. An indirect estimate of the relative intervention effect B
compared with C (dIBC ) can be formed by comparing direct trials of A compared with C with trials of A
compared with B, such that dIBC = d
D
AC − d
D
AB. A simple approach to combining the indirect and direct
estimates of B compared with C would be to take a weighted average, for example using an inverse
variance weighting.939 NMA extends the idea of an indirect comparison to simultaneously combine all
evidence in a connected network of intervention comparisons.940 For random-effects (REs) models, we
assume that the between studies variance is the same across all of the pairs of intervention comparisons
(known as the homogeneous variance assumption). In a NMA we assume that intervention A is similar
(in dose, administration, etc.) when it appears in the A versus B and A versus C studies, and also that every
patient included in the network has an equal probability of being assigned to any of the interventions:940
a concept called ‘joint randomisability’.941 A first step to assess this assumption is by comparing the
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distribution of potential effect modifiers across the different942 comparisons,942,943 as if there is an
imbalance in the presence of effect modifiers across the A versus B and A versus C comparisons, the
conclusions about B compared with C may be in doubt. A second step is to use statistical measures of
model fit to see if the direct estimate for a particular intervention comparison is discrepant with the NMA
estimate944 (see below). When direct data were available, pairwise meta-analyses were also performed for
all comparisons, and compared with the NMA treatment effect estimates to informally assess agreement.
All of the analyses were conducted within a Bayesian framework utilising OpenBUGS version 3.2.3
(www.openbugs.net; Medical Research Council Biostatistics Unit, Cambridge), using the NMA code given
by Dias et al.945–948 for binomial data. We provide example code in Appendix 8. A key feature of a Bayesian
analysis is that a joint distribution (called the ‘posterior’ distribution) of all model parameters (intervention
effect estimates and heterogeneity) is estimated, and results are reported as summaries from this posterior
distribution. For example, it is common to report the posterior median and 95% credible intervals
(CrIs, which are interpreted upon there being a 95% probability that the parameter lies within this range
of values, where 95% of the marginal distribution lies).
Studies with 0% or 100% events in all arms were excluded from the analysis because these studies
provide no evidence on relative effects.946 For studies with 0% or 100% events in one arm only, we
planned to analyse the data without continuity corrections when computationally possible. Where this
was not possible, we used a continuity correction where we added 0.5 to both the number of events
and the number of non-events, which has shown to perform well when there is an approximate 1 : 1
randomisation ratio across intervention arms.949 In Chapter 3, we report any adjustments made.
Both fixed-effects and REs (when sufficient data were available) models were considered on the basis of
model fit. Goodness of fit was measured using the posterior mean of the residual deviance, which is a
measure of the magnitude of the difference between the observed data and the model predictions for
those data.950 Smaller values are preferred, and in a well-fitting model the posterior mean residual deviance
should be close to the number of data points.950 Of course, improvements in model fit can always be
achieved by making the model more and more complex, but at the risk of losing generalisability and
interpretability. To account for this we report the deviance information criterion (DIC), which penalises
model fit with model complexity.950 Finally, we report the between-studies standard deviation (SD)
(heterogeneity parameter) to assess the degree of statistical heterogeneity. Model selection was based on
all of these statistics: posterior mean residual deviance, posterior median between-study heterogeneity,
and DIC. In comparing models, differences of ≥ 5 points for posterior mean residual deviance and DIC
were considered meaningful,950 with lower values being favoured. Heterogeneity was reported as the
posterior median between trial SD (τ) with its 95% CrI.
We planned to conduct sensitivity analyses excluding studies at high risk of bias for allocation
concealment, for all analyses. Consistency between the different sources of indirect and direct evidence
was explored statistically by comparing the fit of a model assuming consistency with a model that allowed
for inconsistency (also known as an unrelated treatment-effect model). If the inconsistency model had
the smallest posterior mean residual deviance, heterogeneity, or DIC value then this indicates potential
inconsistency in the data. When model fit was suggestive of inconsistency our first step was to restrict trials
to those at low risk of bias. If model fit was not improved, we planned further subgroup analyses using the
potential treatment effect modifiers identified above (see Data extraction and risk-of-bias assessment).
A Bayesian analysis requires prior distributions to be specified on all model parameters that are being
estimated. A prior distribution reflects our belief about the values that a parameter can take in advance of
observing the data. Vague (flat) prior distributions were specified for treatment effect and heterogeneity
parameters, so that our results are driven by the observed data (see Appendix 9 for full details of the prior
distributions assumed). Convergence was assessed using the Brooks–Gelman–Rubin diagnostic951 and was
satisfactory by 68,000 simulations for all outcomes.952 A further simulation sample of at least 58,000
iterations post convergence was obtained, on which all reported results were based.
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Relative intervention effects are reported as posterior median odds ratios (ORs) and 95% CrI. All reported
outcomes are negative events and so an OR < 1 is interpreted as the active intervention reducing the odds
of the event. We calculated the probability of each treatment being first, second, third, etc. most effective
for each outcome and report the results using ‘rankograms’. Peaks in the rankogram graph indicate the
most likely rank for each intervention type. Flat lines indicate a high degree of uncertainty for the ranking
of that intervention type. As this metric can be unstable and difficult to interpret (e.g. when there is a high
probability of being both ‘best’ and ‘worst’ on an outcome), we also report posterior mean rank of each
treatment (and 95% CrI), with the convention that the lower the rank the better the treatment. We also
report the absolute probability of an event for each intervention. To estimate the absolute probability, we
selected vaginal PGE2 (tablet) as the baseline intervention and conducted a fixed-effects meta-analysis on
vaginal PGE2 arms to produce only an ‘average’ intervention effect to which the relative treatment effects
(as estimated from the NMA) were added. Note that this is modelled externally to the NMA. We note that
this may not generalise to any one setting, as it is based on all of the trials in the NMA, and refer the
reader to Chapter 4, Assessment of cost-effectiveness for UK-specific absolute estimates.
Pairwise meta-analyses
For completeness, and to informally assess the consistency assumption of NMA, we conducted pairwise
meta-analyses for all intervention comparisons for which direct head-to-head evidence was available.
The method of estimation was identical to that described above for the NMA, except that we did not
apply the consistency assumption, so that we obtained separate intervention effect estimates for each
pairwise comparison. For the REs models, we assumed that the heterogeneity parameter was common
across intervention comparisons, to reflect the assumption made in the NMA and allow a fair comparison
of the intervention effect estimates.
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Chapter 3 Results for assessment of
clinical effectiveness
Results of the systematic review
The results of the search and the eligibility assessment are summarised in the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) flow diagram, which indicates the number of included
and excluded trials (Figure 1). We identified 1508 reports corresponding to 1190 separate studies. A total
of 611 trials that fulfilled our prespecified inclusion criteria were included in the review. Details of the 579
excluded studies (references and reasons for exclusion) are set out in Appendices 3 and 4, Table 37.
There were a total of 103,041 women studied in the 611 trials included in this review. Several multiarm
trials were identified: one five-arm trial, four four-arm trials and 42 three-arm trials (see Appendix 6,
Table 38). The total number of arms in trials relating to different interventions for the induction of labour
is set out in Appendix 10.
It is important to bear in mind that trials may not have reported findings for all of the seven prespecified
outcomes. We have indicated, in Table 1, the number of studies reporting each of our prespecified outcomes.
Trials that did not report any prespecified outcomes were not included in the review, as they did not
contribute data to the pairwise analysis or the NMA (see Appendix 4, Table 37, for reasons for exclusion from
the review).
More than 95% of trials reported CS, and data were available for almost 100,000 women for this outcome.
However, the proportions of trials reporting our other key outcomes were considerably lower: instrumental
delivery was reported in approximately half of trials (49%) and infant Apgar score < 7 at 5 minutes was
reported in a similar number of studies (47%). Mean Apgar score at 5 minutes was occasionally reported,
but there were insufficient studies reporting this outcome for us to be able to use these data.
Uterine hyperstimulation with FHR changes was reported in 41% of trials. A larger number of trials
reported outcomes relating to abnormal uterine activity (tachysystole or hypertonus), but we have included
data only for those that were clearly associated with changes in FHR and, therefore, matched our outcome
definition for inclusion.
Studies identified through searching
the CPCG database
(n = 1190)
(1508 reports)
Studies included in the
systematic review
(n = 611)
(900 reports)
Studies excluded from the systematic review
(n = 579)
(608 reports)
Reasons for exclusion from
systematic review
•  Not a RCT, n = 48
•  No relevant outcome data, n = 213
•  Not a relevant comparison, n = 239
•  Not a relevant participant group, n = 22
•  Methodological issues, n = 26
FIGURE 1 A PRISMA study flow diagram for the systematic review.
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Less than one-quarter of trials reported the number of women achieving VD within 24 hours.
Neonatal death was reported in 21% of trials (with data for 32,248 babies) and a composite outcome of
maternal death or serious morbidity in 12.6%. As expected, event rates were very low for both of these
outcomes and most trials reported no events for either outcome.
Infant admission to NICU was reported for trials that, together, included > 50,000 babies, but findings
related to this outcome need to be interpreted with some caution. Results demonstrate that there was
considerable variation between trials in terms of rates of admission, and it is possible that this variation
may relate to definitions of neonatal intensive care and other types of special care units, rather than being
a true reflection of variation in serious infant morbidity in different trial settings. There was very rarely clear
information on the level of care provided in facilities described as NICU or special care baby unit or on
criteria for admission.
Only 29 trials reported any outcomes relating to satisfaction, and the way satisfaction outcomes were
defined and operationalised in questionnaires meant that we were unable to carry out any quantitative
analysis. We have, therefore, set out findings in tabular and narrative form.
Although Box 2 sets out the number of trials reporting specific outcomes, we were not able to use all of
the reported outcome data in the NMA. Studies that reported no events in either arm were excluded from
the NMA. In a small number of cases outcome data were excluded from the analysis for other reasons
(see Box 2).
TABLE 1 Outcome data reported
Outcome
Number of
trials reporting
this outcome
% included
trials (613)a
Number of
women/infants Number of events
Events
as %
Serious maternal
morbidity or deathb
77 12 19,112 5 deaths
14 uterine rupture
1 ICU admission
0.1
Neonatal death 131 21 32,248 94 0.3
VD not achieved within
24 hours
142 23 28,845 11,885 41.2
Uterine hyperstimulation
with (FHR) changes
251 41 43,612 1594 3.6
CS 587 96 99,821 19,297 19.3
Instrumental delivery 302 49 54,511 8020 14.7
NICU admission 226 37 52,931 4224 8.0
Apgar score < 7 at
5 minutes
289 47 58,367 1244 2.1
Maternal satisfactionc 29 5 11,901 NA NA
ICU, intensive care unit; NA, not applicable.
a Of our trials, 2 out of 611 were split and data were entered separately for all outcomes because they reported data
separately for two different clinical subgroups. This is why we have 613 as the total number of trials here.
b Serious maternal morbidity has been defined as uterine rupture or infection requiring ICU admission.
c Maternal satisfaction was measured in such a number of different ways that meaningful analysis was not possible.
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BOX 2 Studies included and excluded from the NMA analysis for each outcome
No vaginal delivery within 24 hours (141 studies included)
Removed because no data reported (471).
Removed because of 100% cells in both arms (1).
Hyperstimulation (180 studies included)
Removed because no data were reported (362).
Removed because of zeros in both arms (71).
Caesarean section (307 studies included)
Removed because no data were reported (26).
Removed because of zero cells in both arms (2).
Removed because of high risk of bias (276).
Removed because of automatic CS after 24 hours (2).
Neonatal death (42 studies included)
Removed because no data were reported (482).
Removed because of zero events in both arms (89).
Maternal serious morbidity or death (16 studies included)
Removed because no data were reported (536).
Removed because of zero cells in both arms (61).
Instrumental delivery (299 studies included)
Removed because no data were reported (311).
Removed because of zero cells in both arms (2).
Removed because of serious protocol deviation (1).
Apgar score < 7 at 5 minutes (200 studies included)
Removed because no data were reported (324).
Removed because of zero cells in both arms (81).
Removed because of inconsistency in reporting (8).
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Characteristics of women participating in included trials
Summary characteristics of participants and intervention setting across the 611 included studies are
reported in Table 2.
Trials varied considerably in terms of inclusion/exclusion criteria. For those trials that reported parity as an
inclusion criterion, most (83%) recruited both women expecting their first baby and those who had given
birth before. More than two-thirds of trials explicitly excluded women who had experienced a previous CS
(64.6%). However, 175 trials did not specifically mention excluding these women but may have reported
excluding women at ‘high risk’, which may have included women with complications during a previous
birth. Women with multiple pregnancies were generally excluded. The majority of trials (73%) that
specified inclusion criteria relating to gestational age specifically excluded women at < 37 completed
weeks’ gestation. Of these 405 trials, 72 recruited women with post-term pregnancies only, usually
defined as gestational age of > 41 weeks. Other trials included a small number of women with preterm
pregnancies, although we specifically excluded trials including women with extremely preterm pregnancies
as our focus was on third-trimester induction of labour.
Neonatal intensive care unit admission (204 studies included)
Removed because no data were reported (387).
Removed because of zero cells in both arms (21).
TABLE 2 Number of included clinical trials reporting participant characteristics
Effect modifier Number of trials
Parity Mixed Multiparous only Nulliparous only NR
456 15 79 63
Previous CS None with CS All with CS Some with CS NR
396 5 37 175
Cervix Unfavourable Favourable Mixed NR
399 28 111 75
Membranes All intact All ruptured Mixed NR
296 98 68 151
Gestational age All post term All > 37 weeks Mixed (some pre term) NR
72 333 149 59
Multiple pregnancy All singleton All multiple Mixed NR
453 1 13 146
Setting Inpatient Some/all arms outpatient NR
524 79 10
Pharmaceutical company funding No funding Some funding NR
109 55 449
NR, not reported.
BOX 2 Studies included and excluded from the NMA analysis for each outcome (continued)
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Most studies recruited women with intact membranes (64% of those trials specifying inclusion criteria
relating to membrane status), although some trials specifically focused on induction of labour for women
with premature rupture of the amniotic membranes (21% of trials specifying membrane status).
Finally, the induction process was mainly commenced in those women with a Bishop score < 6 (unfavourable
cervix); 28 trials (4.6%) recruited only women with a favourable cervix, although approximately 20% of trials
that described membrane status at recruitment included women with a range of Bishop scores.
Other trial characteristics
The vast majority of trials were carried out in hospital settings and women remained inpatients throughout
the induction process. For many pharmacological agents constant maternal and fetal monitoring was
considered mandatory, and facilities for CS and newborn specialist care were close by in case of
complications. Trials looking at non-pharmacological methods of inducing labour (e.g. membrane
sweeping) were more likely to take place in outpatient settings.
Trials were assessed for risk of bias relating to the method used to conceal allocation. There was a fairly
even balance between those trials assessed as being at low risk of bias and those assessed as being at high
or unclear risk of bias (both of these categories were treated as high risk of bias in the sensitivity analysis).
There were 300 trials that were judged to be at high risk of bias for allocation concealment compared with
313 trials that were judged to be at low risk of bias.
Finally, we also extracted information from trial reports regarding whether or not the trial was funded by a
pharmaceutical company. Unfortunately, the source of funding for most trials was not reported. Of the
164 trials that did report source of funding, one-third were funded by a drug company, although this
funding may have been partial (provision of study medication and placebo preparations only).
Results: network and pairwise meta-analysis
The outcome-specific network diagrams are presented in Figure 2 for failure to achieve VD in 24 hours,
Figure 3 for CS, Figure 4 for instrumental delivery, Figure 5 for uterine hyperstimulation, Figure 6 for NICU
admission and Figure 7 for Apgar score < 7 at 5 minutes. Studies were excluded when there were 0% or
100% events in every arm, for that outcome only. Network diagrams are presented within each relevant
section and by outcome. The edges (lines) connecting each pair of interventions represent a direct
comparison and are drawn proportional to the number of trials making each direct comparison.953 However,
this weighting is relative within each graph, and edge thickness should not be compared across graphs. For
information on the number of trials in each analysis please see Appendix 14. As noted above (see Results of
the systematic review), there were insufficient data on serious maternal morbidity or death (20 events) to be
used in a NMA. Therefore, these data are summarised narratively below (see Neonatal and maternal
mortality and severe morbidity). In addition, only a small proportion of trials reported outcomes relating to
women’s perceptions of their care during childbirth and their satisfaction with the induction of labour
process. Furthermore, when these outcomes were reported they were defined and measured in different
ways across trials. For these reasons we were not able to analyse maternal satisfaction outcomes in a NMA,
but we have included a narrative description in the text (see Maternal satisfaction with care and induction of
labour method).
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FIGURE 2 Failure to achieve VD in 24 hours. Network diagram of all of the studies included in analysis. The width of
the lines is proportional to the number of trials comparing directly each pair of interventions. The size of each node
is proportional to the number of randomised participants (sample size). Interventions are numbered as follows:
1, no intervention; 2, placebo; 3, vaginal PGE2 (tablet); 4, vaginal PGE2 (gel); 5, vaginal PGE2 pessary (slow release);
6, intracervical PGE2; 7, vaginal PGE2 pessary (normal release); 8, vaginal misoprostol (dose < 50µg); 9, vaginal
misoprostol (dose ≥50µg); 10, oral misoprostol tablet (dose < 50µg); 11, oral misoprostol tablet (dose ≥50µg);
12, titrated (low-dose) oral misoprostol solution; 13, sustained-release misoprostol insert; 14, i.v. oxytocin;
15, i.v. oxytocin with amniotomy; 16, NO; 17, mifepristone; 18, mechanical methods – Foley catheter; 19, mechanical
methods – double-balloon or Cook’s catheter; 20, extra-amniotic PGE2; 21, buccal/sublingual misoprostol.
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FIGURE 3 Caesarean section. Network diagram of all of the studies included in analysis. The width of the lines
is proportional to the number of trials directly comparing each pair of interventions. The size of each node is
proportional to the number of randomised participants (sample size). Interventions are numbered as follows:
1, no intervention; 2, placebo; 3, vaginal PGE2 (tablet); 4, vaginal PGE2 (gel); 5, vaginal PGE2 pessary (slow release);
6, PGF2 gel; 7, intracervical PGE2; 8, vaginal PGE2 pessary (normal release); 9, vaginal misoprostol (< 50 µg);
10, vaginal misoprostol (≥ 50µg); 11, oral misoprostol tablet (< 50 µg); 12, oral misoprostol tablet (≥ 50 µg);
13, titrated (low-dose) oral misoprostol solution; 14, sustained-release misoprostol insert, 15, i.v. oxytocin,
16, amniotomy; 17, i.v. oxytocin with amniotomy; 18, NO; 19, mifepristone; 20, oestrogens; 21, corticosteroids;
22, relaxin; 23, hyaluronidase; 24, Foley catheter; 25, laminaria; 26, double-balloon or Cook’s catheter;
27, membrane sweeping; 28, extra-amniotic PGE2; 29, i.v. prostaglandin; 30, sexual intercourse; 31, acupuncture;
32, oral prostaglandins; 33, buccal/sublingual misoprostol.
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FIGURE 4 Instrumental delivery. Network diagram of all of the studies included in analysis. The width of the lines
is proportional to the number of trials directly comparing each pair of interventions. The size of each node is
proportional to the number of randomised participants (sample size). Interventions are numbered as follows:
1, no intervention; 2, placebo; 3, vaginal PGE2 (tablet); 4, vaginal PGE2 (gel); 5, vaginal PGE2 pessary (slow release);
6, PGF2 gel; 7, intracervical PGE2; 8, vaginal PGE2 pessary (normal release); 9, vaginal misoprostol (< 50 µg);
10, vaginal misoprostol (≥ 50µg); 11, oral misoprostol tablet (< 50 µg); 12, oral misoprostol tablet (≥ 50 µg);
13, titrated (low-dose) oral misoprostol solution; 14, sustained-release misoprostol insert; 15, i.v. oxytocin;
16, amniotomy; 17, i.v. oxytocin with amniotomy; 18, NO; 19, mifepristone; 20, oestrogens; 21, relaxin; 22, Foley
catheter; 23, laminaria; 24, double-balloon or Cook’s catheter; 25, membrane sweeping; 26, extra-amniotic PGE2;
27, i.v. prostaglandin; 28, sexual intercourse; 29, acupuncture; 30, homeopathy; 31, oral prostaglandins; 32, buccal/
sublingual misoprostol.
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FIGURE 5 Hyperstimulation with FHR changes. Network diagram of all of the studies included in analysis. The width
of the lines is proportional to the number of trials directly comparing each pair of interventions. The size of each
node is proportional to the number of randomised participants (sample size). 1, no intervention; 2, placebo; 3, vaginal
PGE2 (tablet); 4, vaginal PGE2 (gel); 5, vaginal PGE2 pessary (slow release); 6, intracervical PGE2; 7, vaginal PGE2 pessary
(normal release); 8, vaginal misoprostol (< 50µg); 9, vaginal misoprostol (≥ 50µg); 10, oral misoprostol tablet
(<50µg); 11, oral misoprostol tablet (≥50µg); 12, titrated (low-dose) oral misoprostol solution; 13, sustained-release
misoprostol insert; 14, i.v. oxytocin; 15, i.v. oxytocin with amniotomy; 16, NO; 17, mifepristone; 18, Foley catheter;
19, laminaria; 20, double-balloon or Cook’s catheter; 21, buccal/sublingual misoprostol.
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FIGURE 6 Neonatal intensive care unit admission. Network diagram of all of the studies included in analysis.
The width of the lines is proportional to the number of trials directly comparing each pair of interventions.
The size of each node is proportional to the number of randomised participants (sample size). 1, no intervention;
2, placebo; 3, vaginal PGE2 (tablet); 4, vaginal PGE2 (gel); 5, vaginal PGE2 pessary (slow release); 6, PGF2 gel;
7, intracervical PGE2; 8, vaginal PGE2 pessary (normal release); 9, vaginal misoprostol (dose < 50 µg); 10, vaginal
misoprostol (dose ≥ 50 µg); 11, oral misoprostol tablet (dose < 50 µg); 12, oral misoprostol tablet (dose ≥ 50µg);
13, titrated (low-dose) oral misoprostol solution; 14, sustained-release misoprostol insert; 15, i.v. oxytocin;
16, amniotomy; 17, i.v. oxytocin with amniotomy; 18, NO; 19, mifepristone; 20, oestrogens; 21, Foley catheter;
22, laminaria; 23, double-balloon or Cook’s catheter; 24, membrane sweeping; 25, extra-amniotic PGE2;
26, sexual intercourse; 27, acupuncture; 28, oral prostaglandins; 29, buccal/sublingual misoprostol.
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FIGURE 7 Apgar score < 7 at 5 minutes. Network diagram of all of the studies included in analysis. The width of the
lines is proportional to the number of trials directly comparing each pair of interventions. The size of each node is
proportional to the number of randomised participants (sample size). 1, no treatment; 2, placebo; 3, vaginal PGE2
(tablet); 4, vaginal PGE2 (gel); 5, vaginal PGE2 pessary (slow release); 6, intracervical PGE2; 7, vaginal PGE2 pessary
(normal release); 8, vaginal misoprostol (dose < 50µg); 9, vaginal misoprostol (dose ≥ 50µg); 10, oral misoprostol
tablet (dose < 50µg); 11, oral misoprostol tablet (dose ≥ 50µg); 12, titrated (low-dose) oral misoprostol solution;
13, sustained-release misoprostol insert; 14, i.v. oxytocin; 15, amniotomy; 16, i.v. oxytocin with amniotomy; 17, NO;
18, mifepristone; 19, Foley catheter; 20, laminaria; 21, double-balloon or Cook’s catheter; 22, membrane sweeping;
23, extra-amniotic PGE2; 24, i.v. prostaglandin; 25, sexual intercourse; 26, acupuncture; 27, oral prostaglandins;
28, buccal/sublingual misoprostol.
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Vaginal delivery not achieved within 24 hours
After excluding trials with zero events in all arms, 141 trials of 19 active interventions were included for
the outcome VD not achieved within 24 hours. Placebo and no intervention comparisons were also
included. No trials comparing PGF2, amniotomy, oestrogens, corticosteroids, relaxin, hyaluronidase,
laminaria, membrane sweeping, i.v. prostaglandin, sexual intercourse, acupuncture, breast stimulation,
homeopathy, castor oil or oral prostaglandins reported this outcome. No meaningful differences were
observed in posterior mean residual deviance or DIC values, suggesting that there was no evidence of
inconsistency (see Appendix 11, Table 44). Reported results are therefore based on the REs NMA model
assuming consistency (Table 3 and Figure 8).
TABLE 3 Odds ratios and 95% CrI for failure to achieve VD within 24 hours for every intervention compared
with placebo
Active intervention vs. placebo
NMA Pairwise meta-analysis
Direct trialsOR 95% CrI OR 95% CrI
i.v. oxytocin with amniotomy 0.05 0.07 to 0.32 – – 0
Vaginal misoprostol ≥ 50 µg 0.09 0.06 to 0.24 – – 0
Titrated (low-dose) oral misoprostol solution 0.10 0.07 to 0.29 – – 0
Vaginal misoprostol < 50 µg 0.11 0.09 to 0.32 – – 0
Sustained-release misoprostol vaginal pessary 0.11 0.05 to 0.22 – – 0
Buccal/sublingual misoprostol 0.11 0.05 to 0.19 – – 0
Vaginal PGE2 pessary (normal release) 0.11 0.04 to 0.16 0.67 0.06 to 2.76 1
Vaginal PGE2 (gel) 0.13 0.08 to 0.50 – – 0
Vaginal PGE2 pessary (slow release) 0.15 0.08 to 0.29 – – 0
Oral misoprostol tablet ≥ 50 µg 0.16 0.05 to 0.20 0.12 0.03 to 0.31 2
Vaginal PGE2 (tablet) 0.16 0.03 to 0.26 – – 0
Intracervical PGE2 0.18 0.09 to 0.38 0.09 0.03 to 0.19 5
Double-balloon or Cook’s catheter 0.18 0.01 to 0.16 – – 0
Foley catheter 0.19 0.09 to 0.46 – – 0
i.v. oxytocin 0.20 0.21 to 1.97 – – 0
NO 0.22 0.08 to 0.36 1.07 0.30 to 2.78 1
Oral misoprostol tablet < 50 µg 0.22 0.07 to 0.39 – – 0
Extra-amniotic PGE2 0.41 0.07 to 1.33 – – 0
Mifepristone 0.76 0.05 to 0.20 0.81 0.16 to 2.52 1
Results from NMA and pairwise meta-analysis (when possible). An OR of > 1 favours placebo (i.e. fewer events occur on a
placebo than active intervention). An OR of < 1 favours the active intervention, i.e. fewer undesirable events occurred on
the active intervention. Empty cells indicate that direct evidence was not available for that comparison. The column
‘Direct trials’ reports the number of trials available for the direct comparisons vs. placebo only.
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FIGURE 8 Rankograms for each of the 20 induction interventions for hyperstimulation and VD not achieved within
24 hours. Ranking indicates the probability of being the best intervention, the second best, the third best, etc. The x-axis
shows the relative ranking and the y-axis the probability of each ranking. (a) No treatment; (b) placebo; (c) vaginal PGE2
(tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) intracervical PGE2; (g) vaginal PGE2 pessary
(normal release); (h) vaginal misoprostol (dose <50 µg); (i) vaginal misoprostol (dose ≥50 µg); (j) oral misoprostol tablet
(dose <50 µg); (k) oral misoprostol tablet (dose ≥50 µg); (l) titrated (low-dose) misoprostol; (m) sustained-release
misoprostol insert; (n) i.v. oxytocin; (o) NO; (p) i.v. oxytocin with amniotomy; (q) mifepristone; (r) Foley catheter;
(s) laminaria including dilapan; (t) double balloon or Cook’s catheter; and (u) extra-amniotic PGE2. (continued )
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FIGURE 8 Rankograms for each of the 20 induction interventions for hyperstimulation and VD not achieved within
24 hours. Ranking indicates the probability of being the best intervention, the second best, the third best, etc. The x-axis
shows the relative ranking and the y-axis the probability of each ranking. (a) No treatment; (b) placebo; (c) vaginal PGE2
(tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) intracervical PGE2; (g) vaginal PGE2 pessary
(normal release); (h) vaginal misoprostol (dose <50 µg); (i) vaginal misoprostol (dose ≥50 µg); (j) oral misoprostol tablet
(dose <50 µg); (k) oral misoprostol tablet (dose ≥50 µg); (l) titrated (low-dose) misoprostol; (m) sustained-release
misoprostol insert; (n) i.v. oxytocin; (o) NO; (p) i.v. oxytocin with amniotomy; (q) mifepristone; (r) Foley catheter;
(s) laminaria including dilapan; (t) double balloon or Cook’s catheter; and (u) extra-amniotic PGE2. (continued )
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FIGURE 8 Rankograms for each of the 20 induction interventions for hyperstimulation and VD not achieved within
24 hours. Ranking indicates the probability of being the best intervention, the second best, the third best, etc. The x-axis
shows the relative ranking and the y-axis the probability of each ranking. (a) No treatment; (b) placebo; (c) vaginal PGE2
(tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) intracervical PGE2; (g) vaginal PGE2 pessary
(normal release); (h) vaginal misoprostol (dose <50 µg); (i) vaginal misoprostol (dose ≥50 µg); (j) oral misoprostol tablet
(dose <50 µg); (k) oral misoprostol tablet (dose ≥50 µg); (l) titrated (low-dose) misoprostol; (m) sustained-release
misoprostol insert; (n) i.v. oxytocin; (o) NO; (p) i.v. oxytocin with amniotomy; (q) mifepristone; (r) Foley catheter;
(s) laminaria including dilapan; (t) double balloon or Cook’s catheter; and (u) extra-amniotic PGE2. (continued )
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FIGURE 8 Rankograms for each of the 20 induction interventions for hyperstimulation and VD not achieved within
24 hours. Ranking indicates the probability of being the best intervention, the second best, the third best, etc. The x-axis
shows the relative ranking and the y-axis the probability of each ranking. (a) No treatment; (b) placebo; (c) vaginal PGE2
(tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) intracervical PGE2; (g) vaginal PGE2 pessary
(normal release); (h) vaginal misoprostol (dose <50 µg); (i) vaginal misoprostol (dose ≥50 µg); (j) oral misoprostol tablet
(dose <50 µg); (k) oral misoprostol tablet (dose ≥50 µg); (l) titrated (low-dose) misoprostol; (m) sustained-release
misoprostol insert; (n) i.v. oxytocin; (o) NO; (p) i.v. oxytocin with amniotomy; (q) mifepristone; (r) Foley catheter;
(s) laminaria including dilapan; (t) double balloon or Cook’s catheter; and (u) extra-amniotic PGE2. (continued )
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Despite the observation of high between-trials heterogeneity, relative to the size of the intervention effect
estimates, [τ= 0.54 (95% CrI 0.44 to 0.65)] there was strong evidence that all interventions, except for
mifepristone and extra-amniotic PGE2, increased the probability of vaginal birth within 24 hours (see
Table 3). We note that there was some indication that the direct and NMA results were inconsistent for
NO, as the point estimate from the NMA (OR 0.21) lies outside the CrI from the direct evidence (95% CrI
0.30 to 2.78). However, the CrIs for both the NMA and direct evidence were overlapping. The full results
of each intervention compared with every other have been reported in Appendix 12 (see Table 50) and
compared with the direct evidence when it is available.
Figure 8 shows the distribution of the ranks for each of the 20 interventions. The x-axis reports each of the
possible ranks, for which position 1 means that the intervention is ranked the highest and position 21 the
lowest. Note the number of interventions varies across outcomes because of trial design and reporting.
The y-axis shows the probability with which each intervention has been ranked at each of the 21 possible
positions and therefore fully encapsulates the uncertainty in the intervention rankings. The peaks in the
rankogram plots show the most likely rank for a given intervention. Flat lines indicate a high degree of
uncertainty for the ranking of that intervention type.
The highest ranked intervention was i.v. oxytocin with amniotomy, with a probability of being best of
75%, a posterior mean rank of ‘2’ (95% CrI 1 to 10) and an OR of 0.05 (95% CrI 0.01 to 0.14).
Intravenous oxytocin with amniotomy had the lowest absolute probability of not achieving VD within
24 hours at 17% (95% CrI 3% to 44%) (Table 4). The probability of being ranked in the top three
interventions was 88% for i.v. oxytocin with amniotomy, 51% for vaginal misoprostol (≥ 50 µg) (posterior
mean rank 4 (95% CrI 2 to 7), and 50% for vaginal PGE2 pessary (normal release) (posterior mean rank 4
(95% CrI 1 to 11). The probability of being ranked in the bottom three interventions (i.e. poorest in terms
of achieving a vaginal birth within 24 hours) was 80% for mifepristone with a posterior mean rank of 19
(95% CrI 17 to 21). We note from Table 3 that for mifepristone the OR is 0.72 and the 95% CrIs are
consistent with both harm and benefit (0.20 to 1.85).
Results were largely robust to a preplanned sensitivity analysis excluding studies at high risk of bias for
allocation concealment. The posterior mean ranks were altered for two interventions. A posterior mean
rank for vaginal PGE2 pessary (normal release) changed from 4 to 10, although the 95% CrIs were still
overlapping. Sustained-release misoprostol insert changed from 5 to 10. Again 95% CrIs were consistent
between the two analyses. Results for the sensitivity analysis are reported in Appendix 13 (see Table 56).
0.0
0.2
0.4
0.6
0.8
1.0
1 3 5 7 9 11 13
(u)
15 17 19 21
Pr
o
b
ab
ili
ty
Ranking
Extra-amniotic PGE2
VD not achieved
within 24 hours
FIGURE 8 Rankograms for each of the 20 induction interventions for hyperstimulation and VD not achieved within
24 hours. Ranking indicates the probability of being the best intervention, the second best, the third best, etc. The x-axis
shows the relative ranking and the y-axis the probability of each ranking. (a) No treatment; (b) placebo; (c) vaginal PGE2
(tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) intracervical PGE2; (g) vaginal PGE2 pessary
(normal release); (h) vaginal misoprostol (dose <50 µg); (i) vaginal misoprostol (dose ≥50 µg); (j) oral misoprostol tablet
(dose <50 µg); (k) oral misoprostol tablet (dose ≥50 µg); (l) titrated (low-dose) misoprostol; (m) sustained-release
misoprostol insert; (n) i.v. oxytocin; (o) NO; (p) i.v. oxytocin with amniotomy; (q) mifepristone; (r) Foley catheter;
(s) laminaria including dilapan; (t) double balloon or Cook’s catheter; and (u) extra-amniotic PGE2.
RESULTS FOR ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
28
Caesarean section
After the exclusion of trials with 0% or 100% events in all arms, 586 trials with 96,771 women were
eligible for inclusion in the NMA. This included 33 active interventions in addition to placebo and
no intervention.
Important differences were observed in posterior mean residual deviance and DIC values suggesting that,
for the full network, there was evidence of inconsistency (see Appendix 11, Table 45). The addition of
a continuity correction of 0.5 for studies with zero events (on either arm) did not improve model fit.
We conducted a prespecified sensitivity analysis examining the effect of removing trials at high risk of bias.
The REs model, continuity corrected and excluding trials at high risk of bias, provided an adequate fit to
the data (see Appendix 11, Table 45). Therefore, reported results are based on this model, with 307 trials
and 57,370 women (see Tables 5 and 6, and Figure 3). Thirty-one interventions, in addition to placebo and
no intervention are included in the analysis. No trials comparing breast stimulation, homeopathy or castor
oil were included in this analysis because of a high risk of bias.
Table 5 reports the posterior median ORs (95% CrI) for each intervention relative to placebo (the full
results for all comparisons are reported in Appendix 12, Table 51). As an informal check of consistency,
we note that for all interventions, the direct and NMA results are similar. Moderate to low between-trial
heterogeneity was observed for this outcome [τ= 0.16 (95% CrI 0.03 to 0.25)]. Using placebo as the
TABLE 4 Absolute probability of VD not occurring within 24 hours of induction for all 19 interventions and
placebo/no intervention included in the NMA. Posterior mean rank and 95% CrIs
Intervention
Absolute probability of VD not in 24 hours
Posterior
mean rank 95% CrIPosterior mean 95% CrI
i.v. oxytocin with amniotomy 0.33 0.11 to 0.61 2 1 to 9
Vaginal misoprostol ≥ 50 µg 0.48 0.34 to 0.61 3 1 to 6
Sustained-release misoprostol vaginal pessary 0.50 0.27 to 0.73 5 1 to 16
Titrated (low) oral misoprostol solution 0.50 0.34 to 0.67 5 1 to 10
Vaginal misoprostol < 50 µg 0.51 0.37 to 0.65 5 2 to 8
Buccal/sublingual misoprostol 0.51 0.35 to 0.67 5 2 to 11
Vaginal PGE2 pessary (normal release) 0.52 0.34 to 0.70 6 1 to 13
Vaginal PGE2 (gel) 0.57 0.42 to 0.70 8 5 to 12
Vaginal PGE2 pessary (slow release) 0.60 0.45 to 0.74 11 6 to 16
Vaginal PGE2 (tablet) 0.62 0.53 to 0.70 11 5 to 17
Oral misoprostol tablet ≥ 50 µg 0.62 0.48 to 0.75 12 7 to 16
Double-balloon or Cook’s catheter 0.63 0.44 to 0.80 12 4 to 18
Foley catheter 0.65 0.48 to 0.79 13 7 to 18
Intracervical PGE2 0.65 0.51 to 0.77 14 10 to 17
i.v. oxytocin 0.66 0.51 to 0.80 14 9 to 18
Oral misoprostol tablet < 50 µg 0.67 0.46 to 0.84 14 5 to 18
NO 0.68 0.46 to 0.84 14 5 to 18
Extra-amniotic PGE2 0.75 0.44 to 0.93 16 3 to 20
Mifepristone 0.86 0.66 to 0.96 19 16 to 21
No intervention 0.91 0.83 to 0.96 20 19 to 21
Placebo 0.94 0.86 to 0.98 21 19 to 21
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TABLE 5 Odds ratios and 95% CrI for CS for every intervention compared with placebo
Active intervention vs. placebo
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI Trials
Corticosteroids 0.53 0.20 to 1.12 0.72 0.25 to 1.65 1
Hyaluronidase 0.61 0.34 to 1.00 0.24 0.10 to 0.46 1
Titrated (low-dose) oral misoprostol solution 0.62 0.47 to 0.80 – – 0
Buccal/sublingual misoprostol 0.68 0.51 to 0.89 – – 0
PGF2 gel 0.70 0.40 to 1.16 0.65 0.27 to 1.30 3
Vaginal misoprostol < 50 µg 0.70 0.57 to 0.85 1.14 0.58 to 2.05 3
Mifepristone 0.71 0.45 to 1.08 0.63 0.39 to 0.95 5
Oral misoprostol tablet ≥ 50 µg 0.72 0.58 to 0.88 0.60 0.35 to 0.96 6
Oral prostaglandins 0.72 0.08 to 2.59 – – 0
Vaginal misoprostol ≥ 50 µg 0.73 0.59 to 0.88 1.32 0.17 to 4.64 2
Membrane sweeping 0.74 0.53 to 0.99 1.78 0.22 to 6.41 1
Foley catheter 0.76 0.61 to 0.95 – – 0
Vaginal PGE2 (gel) 0.79 0.65 to 0.94 0.95 0.63 to 1.37 10
Laminaria 0.80 0.43 to 1.38 – – 0
Acupuncture 0.81 0.52 to 1.20 0.76 0.46 to 1.16 4
NO 0.82 0.62 to 1.06 1.05 0.70 to 1.49 4
Vaginal PGE2 pessary (normal release) 0.82 0.62 to 1.09 0.76 0.41 to 1.29 3
Intracervical PGE2 0.83 0.69 to 0.98 0.85 0.66 to 1.09 17
Sexual intercourse 0.85 0.54 to 1.29 – – 0
Relaxin 0.88 0.33 to 1.98 0.90 0.32 to 2.03 3
i.v. oxytocin with amniotomy 0.89 0.57 to 1.34 – – 0
i.v. oxytocin 0.93 0.75 to 1.14 1.74 0.53 to 4.29 1
Vaginal PGE2 pessary (slow release) 0.89 0.69 to 1.12 0.62 0.26 to 1.21 2
Sustained-release misoprostol vaginal pessary 0.98 0.59 to 1.55 – – 0
Extra-amniotic PGE2 0.98 0.57 to 1.57 0.47 0.16 to 1.03 3
Vaginal PGE2 (tablet) 1.04 0.78 to 1.35 0.91 0.00 to 5.74 1
Amniotomy 1.06 0.51 to 2.02 – – 0
Double-balloon or Cook’s catheter 1.11 0.73 to 1.63 – – 0
Oral misoprostol tablet < 50 µg 1.11 0.64 to 1.81 – – 0
Oestrogens 1.27 0.62 to 2.32 1.97 0.66 to 4.49 1
i.v. prostaglandin 19.94 1.61 to 120.5 – – 0
Results from NMA and pairwise meta-analysis (when possible). An OR of > 1 favours placebo (i.e. fewer CSs occur on a
placebo than active intervention). An OR of < 1 favours the active intervention, i.e. fewer CSs occurred on the active
intervention. Empty cells indicate that direct evidence was not available for that comparison. The column ‘trials’ reports the
number of trials available for the direct comparisons vs. placebo only.
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TABLE 6 Absolute probability of CS all 31 interventions and placebo/no intervention included in the NMA
Intervention
Absolute probability of CS
Posterior mean
rank and 95% CrIPosterior mean 95% CrI
Corticosteroids 0.15 0.02 to 0.48 6 1 to 29
Titrated (low-dose) oral misoprostol solution 0.17 0.03 to 0.49 6 2 to 13
Hyaluronidase 0.17 0.02 to 0.50 7 1 to 26
Oral prostaglandins 0.17 0.01 to 0.61 10 1 to 32
Buccal/sublingual misoprostol 0.19 0.03 to 0.52 9 2 to 19
Vaginal misoprostol < 50 µg 0.19 0.03 to 0.52 9 4 to 16
Oral misoprostol tablet ≥ 50 µg 0.19 0.03 to 0.53 10 4 to 18
Mifepristone 0.19 0.03 to 0.54 11 2 to 28
Vaginal misoprostol ≥ 50 µg 0.19 0.03 to 0.53 11 5 to 18
PGF2 gel 0.19 0.03 to 0.54 11 1 to 29
Membrane sweeping 0.20 0.03 to 0.54 12 3 to 24
Foley catheter 0.20 0.03 to 0.55 14 6 to 22
Vaginal PGE2 (gel) 0.21 0.03 to 0.55 15 9 to 21
Laminaria 0.21 0.03 to 0.57 15 2 to 31
Acupuncture 0.21 0.03 to 0.57 16 2 to 30
NO 0.21 0.03 to 0.57 17 5 to 28
Sexual intercourse 0.21 0.03 to 0.58 17 3 to 31
Intracervical PGE2 0.21 0.04 to 0.57 18 11 to 24
Vaginal PGE2 pessary (normal release) 0.21 0.03 to 0.57 17 6 to 28
Relaxin 0.22 0.03 to 0.61 16 1 to 32
i.v. oxytocin with amniotomy 0.22 0.04 to 0.59 20 4 to 31
Vaginal PGE2 pessary (slow release) 0.22 0.04 to 0.58 21 12 to 28
No intervention 0.22 0.04 to 0.58 21 13 to 27
i.v. oxytocin 0.23 0.04 to 0.59 23 16 to 29
Placebo 0.24 0.04 to 0.61 26 19 to 31
Sustained-release misoprostol vaginal pessary 0.24 0.04 to 0.61 22 5 to 32
Extra-amniotic PGE2 0.24 0.04 to 0.62 22 4 to 32
Amniotomy 0.25 0.04 to 0.64 22 3 to 32
Vaginal PGE2 (tablet) 0.25 0.05 to 0.62 26 17 to 31
Oral misoprostol tablet < 50 µg 0.26 0.04 to 0.64 25 7 to 32
Double-balloon or Cook’s catheter 0.26 0.05 to 0.64 27 14 to 32
Oestrogens 0.28 0.05 to 0.68 27 5 to 32
i.v. prostaglandin 0.66 0.16 to 0.98 33 32 to 33
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reference, nine interventions resulted in significant reduction in CS, namely vaginal PGE2 (gel), intracervical
PGE2, vaginal misoprostol tablet < 50 µg, vaginal misoprostol tablet ≥ 50 µg, oral misoprostol tablet
≥ 50 µg, titrated (low-dose) oral misoprostol solution, Foley catheter, membrane sweeping and buccal/
sublingual misoprostol.
Corticosteroids, titrated (low-dose) oral misoprostol solution and hyaluronidase have the largest reduction
in odds of CS, but only misoprostol oral solution reached a conventional level of statistical significance.
Conversely, i.v. prostaglandin appears to increase odds of CS, although this does not reach
statistical significance.
Table 6 reports the posterior mean ranks and absolute probabilities for CS. The interventions with the
lowest posterior mean rank (6) were titrated (low-dose) oral misoprostol solution and corticosteroids, with
the lowest absolute probability of all interventions at 17% and 15%, respectively. However, the wide CrIs
around summary estimates suggest considerable uncertainty. The intervention with the worst posterior
mean rank is i.v. prostaglandin ranked 33 (95% CrI 32 to 33) and an absolute probability of CS of 66%,
albeit with wide CrIs (95% CrI 16% to 98%).
Figure 9 reports the rankograms for this outcome. We note that for all of the interventions the rankograms
are flat, with relatively low peaks – indicative of considerable uncertainty around the probability any
intervention is the ‘best’. We do not therefore include an assessment of which probability is best in our
summary for CS.
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FIGURE 9 Rankograms for each of the 33 induction interventions for CS and instrumental delivery. Ranking
indicates the probability of being the best intervention, the second best, the third best, etc. (a) No treatment;
(b) placebo; (c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel;
(g) intracervical PGE2; (h) vaginal PGE2 pessary (normal release); (i) vaginal misoprostol (dose < 50 µg); (j) vaginal
misoprostol (dose ≥ 50 µg); (k) oral misoprostol tablet (dose < 50 µg); (l) oral misoprostol tablet (dose ≥ 50 µg);
(m) titrated (low-dose) misoprostol; (n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v.
oxytocin with amniotomy; (r) NO; (s) mifepristone; (t) oestrogens; (u) corticosteroids; (v) relaxin; (w) hyaluronidase;
(x) Foley catheter; (y) laminaria including dilapan; (z) double balloon or Cook’s catheter; (aa) membrane sweeping;
(ab) extra-amniotic PGE2; (ac) i.v. prostaglandin; (ad) sexual intercourse; (ae) oral prostaglandins; (af) buccal/
sublingual misoprostol; and (ag) acupuncture. (continued )
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FIGURE 9 Rankograms for each of the 33 induction interventions for CS and instrumental delivery. Ranking
indicates the probability of being the best intervention, the second best, the third best, etc. (a) No treatment;
(b) placebo; (c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel;
(g) intracervical PGE2; (h) vaginal PGE2 pessary (normal release); (i) vaginal misoprostol (dose < 50 µg); (j) vaginal
misoprostol (dose ≥ 50 µg); (k) oral misoprostol tablet (dose < 50 µg); (l) oral misoprostol tablet (dose ≥ 50 µg);
(m) titrated (low-dose) misoprostol; (n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v.
oxytocin with amniotomy; (r) NO; (s) mifepristone; (t) oestrogens; (u) corticosteroids; (v) relaxin; (w) hyaluronidase;
(x) Foley catheter; (y) laminaria including dilapan; (z) double balloon or Cook’s catheter; (aa) membrane sweeping;
(ab) extra-amniotic PGE2; (ac) i.v. prostaglandin; (ad) sexual intercourse; (ae) oral prostaglandins; (af) buccal/
sublingual misoprostol; and (ag) acupuncture. (continued )
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FIGURE 9 Rankograms for each of the 33 induction interventions for CS and instrumental delivery. Ranking
indicates the probability of being the best intervention, the second best, the third best, etc. (a) No treatment;
(b) placebo; (c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel;
(g) intracervical PGE2; (h) vaginal PGE2 pessary (normal release); (i) vaginal misoprostol (dose < 50 µg); (j) vaginal
misoprostol (dose ≥ 50 µg); (k) oral misoprostol tablet (dose < 50 µg); (l) oral misoprostol tablet (dose ≥ 50 µg);
(m) titrated (low-dose) misoprostol; (n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v.
oxytocin with amniotomy; (r) NO; (s) mifepristone; (t) oestrogens; (u) corticosteroids; (v) relaxin; (w) hyaluronidase;
(x) Foley catheter; (y) laminaria including dilapan; (z) double balloon or Cook’s catheter; (aa) membrane sweeping;
(ab) extra-amniotic PGE2; (ac) i.v. prostaglandin; (ad) sexual intercourse; (ae) oral prostaglandins; (af) buccal/
sublingual misoprostol; and (ag) acupuncture. (continued )
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FIGURE 9 Rankograms for each of the 33 induction interventions for CS and instrumental delivery. Ranking
indicates the probability of being the best intervention, the second best, the third best, etc. (a) No treatment;
(b) placebo; (c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel;
(g) intracervical PGE2; (h) vaginal PGE2 pessary (normal release); (i) vaginal misoprostol (dose < 50 µg); (j) vaginal
misoprostol (dose ≥ 50 µg); (k) oral misoprostol tablet (dose < 50 µg); (l) oral misoprostol tablet (dose ≥ 50 µg);
(m) titrated (low-dose) misoprostol; (n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v.
oxytocin with amniotomy; (r) NO; (s) mifepristone; (t) oestrogens; (u) corticosteroids; (v) relaxin; (w) hyaluronidase;
(x) Foley catheter; (y) laminaria including dilapan; (z) double balloon or Cook’s catheter; (aa) membrane sweeping;
(ab) extra-amniotic PGE2; (ac) i.v. prostaglandin; (ad) sexual intercourse; (ae) oral prostaglandins; (af) buccal/
sublingual misoprostol; and (ag) acupuncture. (continued )
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FIGURE 9 Rankograms for each of the 33 induction interventions for CS and instrumental delivery. Ranking
indicates the probability of being the best intervention, the second best, the third best, etc. (a) No treatment;
(b) placebo; (c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel;
(g) intracervical PGE2; (h) vaginal PGE2 pessary (normal release); (i) vaginal misoprostol (dose < 50 µg); (j) vaginal
misoprostol (dose ≥ 50 µg); (k) oral misoprostol tablet (dose < 50 µg); (l) oral misoprostol tablet (dose ≥ 50 µg);
(m) titrated (low-dose) misoprostol; (n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v.
oxytocin with amniotomy; (r) NO; (s) mifepristone; (t) oestrogens; (u) corticosteroids; (v) relaxin; (w) hyaluronidase;
(x) Foley catheter; (y) laminaria including dilapan; (z) double balloon or Cook’s catheter; (aa) membrane sweeping;
(ab) extra-amniotic PGE2; (ac) i.v. prostaglandin; (ad) sexual intercourse; (ae) oral prostaglandins; (af) buccal/
sublingual misoprostol; and (ag) acupuncture. (continued )
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FIGURE 9 Rankograms for each of the 33 induction interventions for CS and instrumental delivery. Ranking
indicates the probability of being the best intervention, the second best, the third best, etc. (a) No treatment;
(b) placebo; (c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel;
(g) intracervical PGE2; (h) vaginal PGE2 pessary (normal release); (i) vaginal misoprostol (dose < 50 µg); (j) vaginal
misoprostol (dose ≥ 50 µg); (k) oral misoprostol tablet (dose < 50 µg); (l) oral misoprostol tablet (dose ≥ 50 µg);
(m) titrated (low-dose) misoprostol; (n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v.
oxytocin with amniotomy; (r) NO; (s) mifepristone; (t) oestrogens; (u) corticosteroids; (v) relaxin; (w) hyaluronidase;
(x) Foley catheter; (y) laminaria including dilapan; (z) double balloon or Cook’s catheter; (aa) membrane sweeping;
(ab) extra-amniotic PGE2; (ac) i.v. prostaglandin; (ad) sexual intercourse; (ae) oral prostaglandins; (af) buccal/
sublingual misoprostol; and (ag) acupuncture. (continued )
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FIGURE 9 Rankograms for each of the 33 induction interventions for CS and instrumental delivery. Ranking
indicates the probability of being the best intervention, the second best, the third best, etc. (a) No treatment;
(b) placebo; (c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel;
(g) intracervical PGE2; (h) vaginal PGE2 pessary (normal release); (i) vaginal misoprostol (dose < 50 µg); (j) vaginal
misoprostol (dose ≥ 50 µg); (k) oral misoprostol tablet (dose < 50 µg); (l) oral misoprostol tablet (dose ≥ 50 µg);
(m) titrated (low-dose) misoprostol; (n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v.
oxytocin with amniotomy; (r) NO; (s) mifepristone; (t) oestrogens; (u) corticosteroids; (v) relaxin; (w) hyaluronidase;
(x) Foley catheter; (y) laminaria including dilapan; (z) double balloon or Cook’s catheter; (aa) membrane sweeping;
(ab) extra-amniotic PGE2; (ac) i.v. prostaglandin; (ad) sexual intercourse; (ae) oral prostaglandins; (af) buccal/
sublingual misoprostol; and (ag) acupuncture. (continued )
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FIGURE 9 Rankograms for each of the 33 induction interventions for CS and instrumental delivery. Ranking
indicates the probability of being the best intervention, the second best, the third best, etc. (a) No treatment;
(b) placebo; (c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel;
(g) intracervical PGE2; (h) vaginal PGE2 pessary (normal release); (i) vaginal misoprostol (dose < 50 µg); (j) vaginal
misoprostol (dose ≥ 50 µg); (k) oral misoprostol tablet (dose < 50 µg); (l) oral misoprostol tablet (dose ≥ 50 µg);
(m) titrated (low-dose) misoprostol; (n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v.
oxytocin with amniotomy; (r) NO; (s) mifepristone; (t) oestrogens; (u) corticosteroids; (v) relaxin; (w) hyaluronidase;
(x) Foley catheter; (y) laminaria including dilapan; (z) double balloon or Cook’s catheter; (aa) membrane sweeping;
(ab) extra-amniotic PGE2; (ac) i.v. prostaglandin; (ad) sexual intercourse; (ae) oral prostaglandins; (af) buccal/
sublingual misoprostol; and (ag) acupuncture. (continued )
DOI: 10.3310/hta20650 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 65
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Alfirevic et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
39
0.0
0.2
0.4
0.6
0.8
1.0
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33
Pr
o
b
ab
ili
ty
Ranking
Oral prostaglandins
Instrumental delivery
CS 
(ae)
0.0
0.2
0.4
0.6
0.8
1.0
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33
Pr
o
b
ab
ili
ty
Ranking
Buccal/sublingual misoprostol
Instrumental delivery
CS 
(af)
0.0
0.2
0.4
0.6
0.8
1.0
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33
Pr
o
b
ab
ili
ty
Ranking
Acupuncture
Instrumental delivery
CS 
(ag)
FIGURE 9 Rankograms for each of the 33 induction interventions for CS and instrumental delivery. Ranking
indicates the probability of being the best intervention, the second best, the third best, etc. (a) No treatment;
(b) placebo; (c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel;
(g) intracervical PGE2; (h) vaginal PGE2 pessary (normal release); (i) vaginal misoprostol (dose < 50 µg); (j) vaginal
misoprostol (dose ≥ 50 µg); (k) oral misoprostol tablet (dose < 50 µg); (l) oral misoprostol tablet (dose ≥ 50 µg);
(m) titrated (low-dose) misoprostol; (n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v.
oxytocin with amniotomy; (r) NO; (s) mifepristone; (t) oestrogens; (u) corticosteroids; (v) relaxin; (w) hyaluronidase;
(x) Foley catheter; (y) laminaria including dilapan; (z) double balloon or Cook’s catheter; (aa) membrane sweeping;
(ab) extra-amniotic PGE2; (ac) i.v. prostaglandin; (ad) sexual intercourse; (ae) oral prostaglandins; (af) buccal/
sublingual misoprostol; and (ag) acupuncture.
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Instrumental delivery
After the exclusion of trials with 0% or 100% events in all arms, 299 trials were included in the NMA
for the instrumental delivery outcome (see Figure 4). There were no trials remaining that compared
corticosteroids, hyaluronidase, breast stimulation or castor oil. Model fit statistics for the model assuming
consistency were indicative of a lack of fit, but this was judged to be borderline. The residual deviance
indicated a slight improvement in fit for the model assuming inconsistency. This was accompanied by
an increase in heterogeneity and a higher DIC. On balance, therefore, a REs NMA model assuming
consistency was still preferred (see Appendix 11, Table 46). Reported results are based on this model, with
299 trials and 32 interventions (see Table 7 and Figure 4).
Table 7 reports the posterior median ORs (95% CrI) for each intervention relative to placebo (the full
results are reported in Appendix 12, Table 52). As a further check of consistency, we note that for all of
the interventions the direct and NMA results are similar. Using placebo as the reference intervention two
interventions resulted in significant reduction in instrumental delivery, namely vaginal PGE2 pessary (slow
release) and Foley catheter.
Table 8 reports the posterior mean ranks and absolute probabilities for instrumental delivery. The
intervention with the lowest mean rank (6) was Foley catheter, with a 95% CrI ranging from 2 to 12
(of 30 interventions). This intervention had lowest absolute probability of 13% (95% CrI 5% to 28%) jointly
with oestrogen (95% CrI 4% to 31%) and buccal/sublingual misoprostol (95% CrI 5% to 29%). However,
we note that although the posterior mean rank was ‘8’ for oestrogen and ‘7’ for buccal/sublingual
misoprostol, respective 95% CrI were wide (oestrogen: 1 to 28 and buccal misoprostol: 1 to 20). This
uncertainty is also reflected in the CrIs around the ORs for these interventions in Table 7. The intervention
with the highest absolute probability of instrumental delivery (i.e. worst) was i.v. prostaglandin at 30%
(95% CrI 10% to 58%).
Figure 9 reports the rankograms for instrumental delivery. We note that for all of the interventions the
rankograms are flat, with relatively low peaks – indicative of considerable uncertainty around the
probability any intervention is the ‘best’. We do not therefore include an assessment of which probability is
best in our summary for instrumental delivery.
See Appendix 13 (Table 59) for the results for the sensitivity analysis, excluding trials at high risk of bias.
Removing these trials also removed five interventions from the analysis. Consequently, posterior mean
ranks appear to have changed (although 95% CrI are overlapping between the two analyses).
Uterine hyperstimulation with fetal heart rate changes
After excluding trials with 0% or 100% events in all arms, 180 trials assessed the outcome of uterine
hyperstimulation. The analysis includes 19 interventions, in addition to placebo and no intervention.
There were no trials remaining that compared PGF2, amniotomy, oestrogens, corticosteroids, relaxin,
hyaluronidase, membrane sweeping, extra-amniotic PGE2, i.v. prostaglandin, sexual intercourse,
acupuncture, breast stimulation, homeopathy, castor oil or oral prostaglandins (see Figure 5). Model fit
statistics were suggestive of inconsistency for this network (see Appendix 11, Table 47). In the first
instance, a continuity correction of 0.5 was added to each cell for those studies with zero events in either
arm, allowing the log OR to be estimated. This improved the model fit, and the results presented below
are based on the continuity corrected REs NMA model assuming consistency.
Table 9 reports the posterior median ORs (95% CrI) for each intervention relative to placebo (the full
results for each intervention compared with every other are reported in Appendix 12, Table 53). We note
that for all of the interventions the direct and NMA results are similar. Relative to the size of the
intervention effect estimates, high to moderate between-trial heterogeneity was observed for this outcome
[τ= 0.54 (95% CrI 0.38 to 0.72)]. Figure 8 reports the rankograms for uterine hyperstimulation. The safest
intervention in terms of risk of uterine hyperstimulation was double-balloon or Cook’s catheter, with a
47% probability of being the best and a 91% probability of being in the top three interventions.
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TABLE 7 Odds ratios and 95% CrI for instrumental delivery for every intervention compared with placebo
Active intervention vs. placebo
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI Direct trials
Oestrogens 0.68 0.32 to 1.28 0.75 0.25 to 1.71 1
Mechanical methods – Foley catheter 0.68 0.50 to 0.91 – – 0
Buccal/sublingual misoprostol 0.69 0.44 to 1.03 – – 0
Vaginal PGE2 pessary (slow release) 0.72 0.50 to 0.99 1.05 0.40 to 2.26 2
Oral misoprostol tablet < 50 µg 0.74 0.34 to 1.38 – – 0
Oral prostaglandins 0.74 0.45 to 1.16 – – 0
Double-balloon or Cook’s catheter 0.75 0.47 to 1.14 – – 0
Vaginal misoprostol < 50 µg 0.80 0.59 to 1.05 0.64 0.09 to 2.23 1
Mechanical methods – laminaria 0.83 0.47 to 1.38 – – 0
Acupuncture 0.83 0.51 to 1.26 1.08 0.57 to 1.85 3
Oral misoprostol tablet ≥ 50 µg 0.84 0.63 to 1.09 0.54 0.25 to 1.00 5
PGF2 gel 0.86 0.58 to 1.25 0.74 0.43 to 1.20 3
Amniotomy 0.86 0.50 to 1.38 – – 0
Intracervical PGE2 0.89 0.68 to 1.14 1.09 0.61 to 1.79 6
Vaginal PGE2 (tablet) 0.91 0.67 to 1.22 – – 0
Extra-amniotic PGE2 0.91 0.49 to 1.52 0.88 0.32 to 1.91 3
Vaginal misoprostol ≥ 50 µg 0.92 0.70 to 1.18 1.21 0.35 to 3.12 2
NO 0.92 0.69 to 1.21 0.91 0.61 to 1.28 2
Vaginal PGE2 (gel) 0.93 0.72 to 1.18 1.18 0.38 to 2.85 3
Sustained-release misoprostol vaginal pessary 0.93 0.46 to 1.71 – – 0
i.v. oxytocin with amniotomy 0.93 0.64 to 1.31 – – 0
Titrated (low-dose) oral misoprostol solution 1.00 0.62 to 1.52 – – 0
Vaginal PGE2 pessary (normal release) 1.08 0.79 to 1.45 0.98 0.50 to 1.75 3
i.v. oxytocin 1.08 0.83 to 1.39 – – 0
Membrane sweeping 1.20 0.84 to 1.66 15.45 1.56 to 71.26 1
Sexual intercourse 1.29 0.68 to 2.24 – – 0
Relaxin 1.44 0.66 to 2.78 1.45 0.65 to 2.87 3
Mifepristone 1.68 1.05 to 2.59 1.84 1.08 to 2.98 5
i.v. prostaglandin 2.04 0.85 to 4.12 – – 0
Homeopathy 2.13 0.11 to 10.24 2.18 0.09 to 11.64 1
Results from NMA and pairwise meta-analysis (when possible). An OR of > 1 favours placebo (i.e. fewer events occur on a
placebo than active intervention). An OR of < 1 favours the active intervention, i.e. fewer events occurred on the active
intervention. Empty cells indicate that direct evidence was not available for that comparison. The column ‘Direct trials’
reports the number of trials available for the direct comparisons vs. placebo only.
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TABLE 8 Absolute probability of instrumental delivery across all 30 interventions and placebo/no intervention
included in the NMA. Posterior mean rank and 95% CrIs
Intervention
Absolute probability of instrumental delivery
Posterior mean
rank and 95% CrIPosterior mean 95% CrI
Oestrogens 0.13 0.04 to 0.31 8 1 to 28
Foley catheter 0.13 0.05 to 0.28 6 2 to 12
Buccal/sublingual misoprostol 0.13 0.05 to 0.29 7 1 to 20
Vaginal PGE2 pessary (slow release) 0.14 0.05 to 0.29 7 2 to 17
Oral misoprostol tablet < 50 µg 0.14 0.04 to 0.32 9 1 to 29
Oral prostaglandins 0.14 0.05 to 0.31 9 1 to 25
Vaginal misoprostol < 50 µg 0.15 0.06 to 0.31 11 4 to 20
Double-balloon or Cook’s catheter 0.15 0.05 to 0.31 9 1 to 24
PGF2 gel 0.16 0.06 to 0.34 14 2 to 28
Oral misoprostol tablet ≥ 50 µg 0.16 0.06 to 0.32 13 6 to 21
Amniotomy 0.16 0.06 to 0.34 13 2 to 29
Laminaria 0.16 0.05 to 0.34 12 1 to 29
Acupuncture 0.16 0.05 to 0.34 13 1 to 28
Vaginal PGE2 (tablet) 0.17 0.07 to 0.33 17 8 to 26
Vaginal PGE2 (gel) 0.17 0.07 to 0.35 18 11 to 24
Intracervical PGE2 0.17 0.06 to 0.34 15 8 to 23
Vaginal misoprostol ≥ 50 µg 0.17 0.07 to 0.34 17 10 to 24
Sustained-release misoprostol vaginal pessary 0.17 0.05 to 0.37 16 1 to 31
i.v. oxytocin with amniotomy 0.17 0.06 to 0.35 17 6 to 28
NO 0.17 0.06 to 0.36 17 5 to 28
Extra-amniotic PGE2 0.17 0.06 to 0.36 15 1 to 30
Titrated (low) oral misoprostol solution 0.18 0.07 to 0.37 19 5 to 30
No intervention 0.19 0.07 to 0.37 21 12 to 28
Vaginal PGE2 pessary (normal release) 0.19 0.07 to 0.38 23 13 to 30
Placebo 0.2 0.08 to 0.38 24 17 to 29
i.v. oxytocin 0.2 0.08 to 0.38 24 18 to 29
Membrane sweeping 0.21 0.08 to 0.41 26 16 to 31
Sexual intercourse 0.22 0.08 to 0.45 25 7 to 32
Relaxin 0.24 0.07 to 0.5 25 4 to 32
Homeopathy 0.24 0.01 to 0.77 18 1 to 32
Mifepristone 0.27 0.1 to 0.52 30 22 to 32
i.v. prostaglandin 0.3 0.1 to 0.58 30 15 to 32
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Table 10 reports the posterior mean ranks and absolute probabilities for this outcome. The mean rank for
double-balloon or Cook’s catheter was ‘2’, with a 95% CrI ranging from 1 to 7 (of 19 interventions).
Double-balloon or Cook’s catheter also had the lowest absolute probability of hyperstimulation at 1%
(95% CrI 0% to 3%). The probability of being ranked in the bottom three (i.e. intervention with highest
risk of uterine hyperstimulation) was 64% for sustained-release misoprostol insert and 59% for vaginal
misoprostol (≥ 50 µg). The intervention with the worst mean rank was vaginal misoprostol ≥ 50 µg: mean
rank 19 (95% CrI 17 to 21). The absolute probability of uterine hyperstimulation for vaginal misoprostol
≥ 50 µg was 9% (95% CrI 2% to 25%).
Results were largely robust to the pre-planned sensitivity analysis based on allocation concealment bias.
The posterior mean rank for sustained-release misoprostol insert changed from 18 (95% CrI 11 to 21) to
11 (95% CrI 3 to 19). Full sensitivity analysis results are reported in Appendix 13, Table 57.
TABLE 9 Odds ratios and 95% CrI for uterine hyperstimulation for every intervention compared with placebo
Active intervention
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI Direct trials
Double-balloon or Cook’s catheter 0.26 0.00 to 1.18 – – 0
NO 0.38 0.02 to 1.54 – – 0
Laminaria 0.52 0.01 to 2.62 – – 0
Foley catheter 0.92 0.37 to 1.93 – – 0
Oral misoprostol tablet < 50 µg 1.13 0.28 to 3.15 – – 0
Vaginal PGE2 pessary (normal release) 1.40 0.37 to 3.68 0.46 0.00 to 3.00 1
Intracervical PGE2 1.70 0.87 to 3.05 1.65 0.57 to 3.88 8
Titrated (low-dose) oral misoprostol solution 1.93 0.73 to 4.19 – – 0
Vaginal PGE2 (tablet) 1.99 0.78 to 4.25 0.78 0.00 to 5.12 1
i.v. oxytocin 2.12 0.97 to 4.10 0.34 0.00 to 2.19 1
Vaginal PGE2 (gel) 2.33 1.10 to 4.40 5.81 0.32 to 29.93 3
Vaginal misoprostol < 50 µg 2.75 1.36 to 5.04 2.46 0.25 to 10.23 2
Oral misoprostol tablet ≥ 50 µg 2.85 1.41 to 5.20 7.75 1.22 to 30.55 5
Vaginal PGE2 pessary (slow release) 2.97 1.36 to 5.73 27.00 2.01 to 131.2 3
Buccal/sublingual misoprostol 4.25 1.71 to 9.02 – – 0
Vaginal misoprostol tablet ≥ 50 µg 4.40 2.22 to 7.94 28.54 0.53 to 159.4 2
Sustained-release misoprostol vaginal pessary 5.58 1.58 to 14.57 – – 0
i.v. oxytocin with amniotomy 7.44 0.27 to 40.66 – – 0
Mifepristonea Not estimable Not estimable 1
a Results were from a single trial with zero events in one arm.
Results from NMA and pairwise meta-analysis (when possible). An OR of > 1 favours placebo (i.e. fewer events occur on a
placebo than active intervention). An OR of < 1 favours the active intervention (i.e. fewer undesirable events occurred on
the active intervention). Empty cells indicate that direct evidence was not available for that comparison. The column
‘Direct trials’ reports the number of trials available for the direct comparisons vs. placebo only.
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Neonatal and maternal mortality and severe morbidity
It was not possible to conduct a NMA for composite outcomes of neonatal mortality and serious morbidity
or maternal mortality and serious morbidity, as these were too rare or poorly reported to carry out
meaningful analysis. The full data sets for these outcomes are reported in Appendix 14 (Tables 64 and 65).
In addition, there is a lack of a universally accepted definition for serious infant or maternal morbidity.
Although we planned to include any such reported outcome by individual trials, the outcomes were still
rarely reported. Only 21.3% of included trials (131/611) reported perinatal deaths with an incidence of
0.3% (94/32,248). A total of 77 out of 611 trials (12.6%) reported a total of 20 maternal deaths or
serious morbidity [five deaths, 14 uterine ruptures and one intensive care unit (ICU) admission for
infection], that is, an incidence of 0.1%. For completeness, we included the network diagrams for both
outcomes (Figures 10 and 11). The network diagram includes those trials reporting at least one event
(42 of the included trials reported at least one perinatal death and 16 trials reported at least one case of
maternal death or severe morbidity).
TABLE 10 Absolute probability of uterine hyperstimulation across all 19 interventions and placebo/no intervention
included in the NMA. Posterior mean rank and 95% CrIs
Intervention
Absolute probability of hyperstimulation
Posterior mean
rank and 95% CrIPosterior mean 95% CrI
Double-balloon or Cook’s catheter 0.01 0.00 to 0.03 2 1 to 6
NO 0.01 0.00 to 0.04 3 1 to 8
Laminaria 0.01 0.00 to 0.06 3 1 to 13
Foley catheter 0.02 0.00 to 0.07 5 3 to 9
Placebo 0.02 0.00 to 0.08 6 3 to 10
Oral misoprostol tablet < 50 µg 0.03 0.00 to 0.09 6 2 to 15
Vaginal PGE2 pessary (normal release) 0.03 0.00 to 0.11 8 3 to 16
No treatment 0.03 0.00 to 0.12 8 3 to 17
Intracervical PGE2 0.04 0.01 to 0.12 10 6 to 13
Vaginal PGE2 (tablet) 0.04 0.01 to 0.11 11 6 to 17
Titrated (low-dose) oral misoprostol solution 0.04 0.01 to 0.14 11 5 to 17
i.v. oxytocin 0.05 0.01 to 0.14 12 7 to 17
Vaginal PGE2 (gel) 0.05 0.01 to 0.15 13 9 to 17
Vaginal misoprostol < 50 µg 0.06 0.01 to 0.18 15 11 to 18
Oral misoprostol tablet ≥ 50 µg 0.06 0.01 to 0.18 15 11 to 18
Vaginal PGE2 pessary (slow release) 0.06 0.01 to 0.19 15 10 to 19
Buccal/sublingual misoprostol 0.09 0.02 to 0.26 19 13 to 21
Vaginal misoprostol ≥ 50 µg 0.09 0.02 to 0.25 19 17 to 21
Sustained-release misoprostol vaginal pessary 0.11 0.02 to 0.34 18 10 to 21
i.v. oxytocin with amniotomy 0.11 0.00 to 0.52 14 3 to 21
Mifepristone 0.26 0.01 to 0.89 19 7 to 21
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FIGURE 10 Neonatal mortality. Network diagram of studies included in analysis. The width of the lines is proportional
to the number of trials directly comparing each pair of interventions. The size of each node is proportional to the
number of randomised participants (sample size). 1, no intervention; 2, placebo; 3, vaginal PGE2 (tablet); 4, vaginal
PGE2 (gel); 5, vaginal PGE2 pessary (slow release); 6, PGF2 gel; 7, intracervical PGE2; 8, vaginal PGE2 pessary (normal
release); 9, vaginal misoprostol (dose <50µg); 10, vaginal misoprostol (dose ≥50µg); 11, oral misoprostol tablet
(dose ≥50µg); 12, titrated (low-dose) oral misoprostol solution; 13, i.v. oxytocin; 14, i.v. oxytocin with amniotomy;
15, NO; 16, Foley catheter; 17, laminaria; 18, membrane sweeping; 19, extra-amniotic PGE2; 20, i.v. prostaglandin;
21, sexual intercourse; 22, breast stimulation; 23, oral prostaglandins; 24, buccal/sublingual misoprostol.
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FIGURE 11 Maternal mortality and serious morbidity. Network diagram of studies included in analysis. The width of
the lines is proportional to the number of trials directly comparing each pair of interventions. The size of each node
is proportional to the number of randomised participants (sample size). 1, no intervention; 2, placebo; 3, vaginal
PGE2 (tablet); 4, vaginal PGE2 (gel); 5, vaginal PGE2 pessary (slow release); 6, intracervical PGE2; 7, vaginal PGE2 pessary
(normal release); 8, vaginal misoprostol (dose < 50 µg); 9, vaginal misoprostol (dose ≥ 50 µg); 10, oral misoprostol
tablet (dose ≥ 50 µg); 11, i.v. oxytocin; 12, i.v. oxytocin with amniotomy; 13, mifepristone; 14, mechanical methods –
Foley catheter; 15, mechanical methods – laminaria; 16, buccal/sublingual misoprostol.
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Neonatal intensive care unit admission
After the exclusion of trials with 0% or 100% events in all arms, 205 trials assessed the outcome of
admission to the NICU and the network is shown in Figure 6. There were no trials remaining that
compared corticosteroids, relaxin, hyaluronidase, i.v. prostaglandin, breast stimulation, homeopathy or
castor oil. Model fit statistics indicated evidence of inconsistency for this network, with the inconsistency
model resulting in a considerable decrease in between-trial heterogeneity (see Appendix 11, Table 49).
Comparing the NMA estimates with those from the pairwise analysis identified 23 intervention
comparisons for which the NMA and direct evidence were in disagreement. A further investigation of this
apparent inconsistency was conducted using a ‘node-splitting’ approach.942 Node splitting separates
evidence on a particular comparison (node) into direct and indirect to identify how the indirect evidence
was combining with, or adding to, the direct evidence to form the NMA estimates. Using this approach,
3 out of 23 comparisons were highlighted as having significant differences in the contribution of the direct
and indirect evidence to the NMA estimate. The three comparisons were vaginal misoprostol (≥ 50 µg)
against NO, vaginal PGE2 pessary (slow release) against titrated (low-dose) oral misoprostol solution, and
no treatment against oral misoprostol tablet (≥ 50 µg). The first two of these were identified as being a
consequence of zero cells in the direct evidence estimating a very extreme treatment effect. However,
the remaining comparison between no treatment and oral misoprostol tablet (≥ 50 µg) had statistically
significant differences in the direct and indirect evidence (Bayesian p-value= 2.98401E-05), even when
trials with zero cells were removed.
Within the no treatment against oral misoprostol tablet (≥ 50 µg) comparison, one trial in particular, Rath
and Manus,701 was identified as deviant from the rest of the evidence and was therefore re-examined.
The criteria for admission to the NICU in this study were unclear, and the description of the facility was
given simply as ‘nursery’. A post hoc decision to remove this trial for this outcome was taken and a further
analysis was subsequently carried out. The REs model, excluding the Rath and Manus trial701 and assuming
consistency, was a good fit to the data, and the results presented here are therefore from this analysis.
Table 11 reports the posterior median ORs (95% CrI) for each intervention relative to placebo (full results
are reported in Appendix 12, Table 55). Relative to the size of the intervention effect estimates, moderate
between-trial heterogeneity was observed for this outcome [τ= 0.17 (95% CrI 0.04 to 0.30)]. Using
placebo as the reference only, extra-amniotic PGE2 resulted in significant reduction in NICU admission.
Table 12 reports the posterior mean ranks for NICU admission. Extra-amniotic PGE2 had the best mean
rank of all interventions (4), with a 95% CrI ranging from 1 to 15. This intervention also had the lowest
absolute probability of NICU admission at 4% (95% CrI 0.6% to 12%) and a 59% chance of being in the
top three interventions.
Figure 12 reports the rankograms for NICU admission. For all interventions the rankograms are flat and
indicative of considerable uncertainty around the probability any intervention is the ‘best’. We do not
therefore include an assessment of which probability is ‘best’ in our summary for this outcome as it would
be misleading.
All results were robust to the preplanned sensitivity analysis excluding studies at high risk of bias for
allocation concealment and are reported in Appendix 13, Table 58.
Apgar score < 7 at 5 minutes
After the exclusion of trials with 0% or 100% events in all arms, 200 trials of 28 interventions assessed the
outcome of Apgar score < 7 at 5 minutes (see Figure 7). There were no trials remaining that compared
PGF2 gel, oestrogens, corticosteroids, relaxin, hyaluronidase, breast stimulation, homeopathy or castor oil.
Residual deviance statistics, for the model assuming consistency, suggested a lack of fit, with the model
assuming inconsistency also having slightly lower heterogeneity. Further investigation indicated that this
was due to the number of zero events in trial arms rather than heterogeneity in study design. The REs
NMA model assuming consistency was therefore the preferred model and reported results are based
on this.
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TABLE 11 Odds ratios and 95% CrI for NICU admission for every intervention compared with placebo
Active intervention vs. placebo
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI Trials
Extra-amniotic PGE2 0.40 0.16 to 0.82 – – 0
Sexual intercourse 0.48 0.14 to 1.17 – – 0
PGF2 gel 0.56 0.18 to 1.36 – – 0
Sustained-release misoprostol vaginal pessary 0.59 0.31 to 1.03 – – 0
Double-balloon or Cook’s catheter 0.60 0.26 to 1.15 – – 0
Foley catheter 0.66 0.41 to 1.00 – – 0
Titrated (low-dose) oral misoprostol solution 0.67 0.39 to 1.07 – – 0
Oral prostaglandins 0.68 0.09 to 2.40 – – 0
Vaginal PGE2 pessary (slow release) 0.73 0.44 to 1.11 29.03 0.45 to 156.3 1
Buccal/sublingual misoprostol 0.73 0.42 to 1.19 – – 0
Vaginal misoprostol < 50 µg 0.74 0.49 to 1.06 0.95 0.38 to 1.94 2
Intracervical PGE2 0.76 0.48 to 1.12 1.06 0.08 to 4.41 2
i.v. oxytocin 0.76 0.50 to 1.12 0.78 0.06 to 3.02 1
Oral misoprostol tablet < 50 µg 0.79 0.31 to 1.63 – – 0
NO 0.82 0.54 to 1.20 0.92 0.56 to 1.43 5
Vaginal PGE2 (tablet) 0.83 0.42 to 1.44 – – 0
Oral misoprostol tablet ≥ 50 µg 0.83 0.55 to 1.20 0.75 0.28 to 1.61 3
Membrane sweeping 0.83 0.43 to 1.46 1.14 0.01 to 6.19 1
Amniotomy 0.84 0.22 to 2.26 – – 0
Vaginal misoprostol ≥ 50 µg 0.85 0.57 to 1.23 – – 0
Vaginal PGE2 (gel) 0.88 0.59 to 1.26 0.71 0.26 to 1.58 4
Vaginal PGE2 pessary (normal release) 0.88 0.51 to 1.40 0.86 0.30 to 1.94 3
Acupuncture 0.94 0.11 to 3.36 1.43 0.13 to 5.95 2
Oestrogens 1.43 0.01 to 7.80 2.29 0.02 to 12.21 1
Laminaria 1.54 0.40 to 4.31 – – 0
i.v. oxytocin with amniotomy 1.60 0.71 to 3.06 – – 0
Mifepristonea 1.71 0.73 to 3.55 1.15 0.38 to 2.75 1
a Data from a single trial with zero events in one arm.
Results from NMA and pairwise meta-analysis (when possible). An OR of > 1 favours placebo (i.e. fewer events occur on a
placebo than active intervention). An OR of < 1 favours the active intervention (i.e. fewer undesirable events occurred on
the active intervention). Empty cells indicate that direct evidence was not available for that comparison. The column ‘trials’
reports the number of trials available for the direct comparisons vs. placebo only.
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TABLE 12 Absolute probability of NICU admission across all 27 interventions and placebo/no intervention included
in the NMA
Intervention
Absolute probability of NICU admission
Posterior mean
rank and 95% CrIPosterior mean 95% CrI
Extra-amniotic PGE2 0.04 0.01 to 0.12 4 1 to 15
Sexual intercourse 0.04 0.01 to 0.14 6 1 to 25
PGF2 gel 0.05 0.01 to 0.16 8 1 to 26
Sustained-release misoprostol vaginal pessary 0.05 0.01 to 0.15 8 2 to 22
Double-balloon or Cook’s catheter 0.05 0.01 to 0.16 9 2 to 25
Vaginal PGE2 pessary (slow release) 0.06 0.01 to 0.18 13 6 to 23
Intracervical PGE2 0.06 0.01 to 0.18 14 7 to 23
Vaginal misoprostol < 50 µg 0.06 0.01 to 0.18 13 7 to 20
Titrated (low-dose) oral misoprostol solution 0.06 0.01 to 0.17 11 4 to 22
i.v. oxytocin 0.06 0.01 to 0.18 15 8 to 22
Foley catheter 0.06 0.01 to 0.16 10 5 to 19
Oral prostaglandins 0.06 0.00 to 0.23 10 1 to 29
Buccal/sublingual misoprostol 0.06 0.01 to 0.18 13 4 to 25
Vaginal PGE2 (tablet) 0.07 0.02 to 0.17 16 4 to 27
Vaginal PGE2 (gel) 0.07 0.02 to 0.20 20 13 to 25
Vaginal PGE2 pessary (normal release) 0.07 0.02 to 0.21 18 6 to 27
Vaginal misoprostol ≥ 50 µg 0.07 0.02 to 0.20 19 12 to 25
Oral misoprostol tablet < 50 µg 0.07 0.01 to 0.20 14 2 to 28
Oral misoprostol tablet ≥ 50 µg 0.07 0.02 to 0.19 18 10 to 24
Amniotomy 0.07 0.01 to 0.23 14 1 to 29
NO 0.07 0.01 to 0.20 17 5 to 26
Membrane sweeping 0.07 0.01 to 0.20 16 5 to 27
Placebo 0.08 0.02 to 0.23 23 16 to 27
No intervention 0.08 0.02 to 0.22 23 13 to 28
Acupuncture 0.08 0.00 to 0.32 14 1 to 29
Oestrogens 0.10 0.00 to 0.53 14 1 to 29
i.v. oxytocin with amniotomy 0.12 0.02 to 0.33 27 17 to 29
Laminaria 0.12 0.02 to 0.37 23 4 to 29
Mifepristone 0.13 0.02 to 0.37 26 13 to 29
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FIGURE 12 Rankograms for each of the 29 induction interventions for Apgar score < 7 at 5 minutes and NICU
admission. Ranking indicates the probability of being the best intervention, the second best, the third best, etc.
The x-axis shows the relative ranking and the y-axis the probability of each ranking. (a) No treatment; (b) placebo;
(c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel; (g) intracervical
PGE2; (h) vaginal pessary (normal release); (i) vaginal misoprostol (dose <50 µg); (j) vaginal misoprostol (dose ≥50 µg);
(k) oral misoprostol (dose <50 µg); (l) oral misoprostol (dose ≥50 µg); (m) titrated (low-dose) oral misoprostol solution;
(n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v. oxytocin plus amniotomy; (r) NO;
(s) mifepristone; (t) oestrogens; (u) Foley catheter; (v) laminaria including dilapan; (w) double balloon or
Cook’s catheter; (x) membrane sweeping; (y) extra-amniotic PGE2; (z) sexual intercourse; (aa) acupuncture;
(ab) oral prostaglandins; and (ac) buccal/sublingual misoprostol. (continued )
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FIGURE 12 Rankograms for each of the 29 induction interventions for Apgar score < 7 at 5 minutes and NICU
admission. Ranking indicates the probability of being the best intervention, the second best, the third best, etc.
The x-axis shows the relative ranking and the y-axis the probability of each ranking. (a) No treatment; (b) placebo;
(c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel; (g) intracervical
PGE2; (h) vaginal pessary (normal release); (i) vaginal misoprostol (dose <50 µg); (j) vaginal misoprostol (dose ≥50 µg);
(k) oral misoprostol (dose <50 µg); (l) oral misoprostol (dose ≥50 µg); (m) titrated (low-dose) oral misoprostol solution;
(n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v. oxytocin plus amniotomy; (r) NO;
(s) mifepristone; (t) oestrogens; (u) Foley catheter; (v) laminaria including dilapan; (w) double balloon or
Cook’s catheter; (x) membrane sweeping; (y) extra-amniotic PGE2; (z) sexual intercourse; (aa) acupuncture;
(ab) oral prostaglandins; and (ac) buccal/sublingual misoprostol. (continued )
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FIGURE 12 Rankograms for each of the 29 induction interventions for Apgar score < 7 at 5 minutes and NICU
admission. Ranking indicates the probability of being the best intervention, the second best, the third best, etc.
The x-axis shows the relative ranking and the y-axis the probability of each ranking. (a) No treatment; (b) placebo;
(c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel; (g) intracervical
PGE2; (h) vaginal pessary (normal release); (i) vaginal misoprostol (dose <50 µg); (j) vaginal misoprostol (dose ≥50 µg);
(k) oral misoprostol (dose <50 µg); (l) oral misoprostol (dose ≥50 µg); (m) titrated (low-dose) oral misoprostol solution;
(n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v. oxytocin plus amniotomy; (r) NO;
(s) mifepristone; (t) oestrogens; (u) Foley catheter; (v) laminaria including dilapan; (w) double balloon or
Cook’s catheter; (x) membrane sweeping; (y) extra-amniotic PGE2; (z) sexual intercourse; (aa) acupuncture;
(ab) oral prostaglandins; and (ac) buccal/sublingual misoprostol. (continued )
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FIGURE 12 Rankograms for each of the 29 induction interventions for Apgar score < 7 at 5 minutes and NICU
admission. Ranking indicates the probability of being the best intervention, the second best, the third best, etc.
The x-axis shows the relative ranking and the y-axis the probability of each ranking. (a) No treatment; (b) placebo;
(c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel; (g) intracervical
PGE2; (h) vaginal pessary (normal release); (i) vaginal misoprostol (dose <50 µg); (j) vaginal misoprostol (dose ≥50 µg);
(k) oral misoprostol (dose <50 µg); (l) oral misoprostol (dose ≥50 µg); (m) titrated (low-dose) oral misoprostol solution;
(n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v. oxytocin plus amniotomy; (r) NO;
(s) mifepristone; (t) oestrogens; (u) Foley catheter; (v) laminaria including dilapan; (w) double balloon or
Cook’s catheter; (x) membrane sweeping; (y) extra-amniotic PGE2; (z) sexual intercourse; (aa) acupuncture;
(ab) oral prostaglandins; and (ac) buccal/sublingual misoprostol. (continued )
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FIGURE 12 Rankograms for each of the 29 induction interventions for Apgar score < 7 at 5 minutes and NICU
admission. Ranking indicates the probability of being the best intervention, the second best, the third best, etc.
The x-axis shows the relative ranking and the y-axis the probability of each ranking. (a) No treatment; (b) placebo;
(c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel; (g) intracervical
PGE2; (h) vaginal pessary (normal release); (i) vaginal misoprostol (dose <50 µg); (j) vaginal misoprostol (dose ≥50 µg);
(k) oral misoprostol (dose <50 µg); (l) oral misoprostol (dose ≥50 µg); (m) titrated (low-dose) oral misoprostol solution;
(n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v. oxytocin plus amniotomy; (r) NO;
(s) mifepristone; (t) oestrogens; (u) Foley catheter; (v) laminaria including dilapan; (w) double balloon or
Cook’s catheter; (x) membrane sweeping; (y) extra-amniotic PGE2; (z) sexual intercourse; (aa) acupuncture;
(ab) oral prostaglandins; and (ac) buccal/sublingual misoprostol. (continued )
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FIGURE 12 Rankograms for each of the 29 induction interventions for Apgar score < 7 at 5 minutes and NICU
admission. Ranking indicates the probability of being the best intervention, the second best, the third best, etc.
The x-axis shows the relative ranking and the y-axis the probability of each ranking. (a) No treatment; (b) placebo;
(c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel; (g) intracervical
PGE2; (h) vaginal pessary (normal release); (i) vaginal misoprostol (dose <50 µg); (j) vaginal misoprostol (dose ≥50 µg);
(k) oral misoprostol (dose <50 µg); (l) oral misoprostol (dose ≥50 µg); (m) titrated (low-dose) oral misoprostol solution;
(n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v. oxytocin plus amniotomy; (r) NO;
(s) mifepristone; (t) oestrogens; (u) Foley catheter; (v) laminaria including dilapan; (w) double balloon or
Cook’s catheter; (x) membrane sweeping; (y) extra-amniotic PGE2; (z) sexual intercourse; (aa) acupuncture;
(ab) oral prostaglandins; and (ac) buccal/sublingual misoprostol. (continued )
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FIGURE 12 Rankograms for each of the 29 induction interventions for Apgar score < 7 at 5 minutes and NICU
admission. Ranking indicates the probability of being the best intervention, the second best, the third best, etc.
The x-axis shows the relative ranking and the y-axis the probability of each ranking. (a) No treatment; (b) placebo;
(c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel; (g) intracervical
PGE2; (h) vaginal pessary (normal release); (i) vaginal misoprostol (dose <50 µg); (j) vaginal misoprostol (dose ≥50 µg);
(k) oral misoprostol (dose <50 µg); (l) oral misoprostol (dose ≥50 µg); (m) titrated (low-dose) oral misoprostol solution;
(n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v. oxytocin plus amniotomy; (r) NO;
(s) mifepristone; (t) oestrogens; (u) Foley catheter; (v) laminaria including dilapan; (w) double balloon or
Cook’s catheter; (x) membrane sweeping; (y) extra-amniotic PGE2; (z) sexual intercourse; (aa) acupuncture;
(ab) oral prostaglandins; and (ac) buccal/sublingual misoprostol. (continued )
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Table 13 reports posterior mean ORs (95% CrI) for each intervention relative to placebo (full results are
reported in Appendix 12, Table 54). Relative to the size of the intervention effect estimates, moderate to
small between-trial heterogeneity was observed for this outcome [τ= 0.19 (95% CrI 0.01 to 0.46)].
Using placebo as the reference intervention, only two interventions resulted in significant reduction in
Apgar score < 7 at 5 minutes: NO and buccal/sublingual misoprostol.
Table 14 reports the absolute probabilities and posterior mean ranks for each intervention. The safest
intervention in terms of risk of Apgar score < 7 at 5 minutes was double-balloon or Cook’s catheter, with
a mean rank of ‘4’; however, the 95% CrI ranged from ‘1’ to ‘22’ out of 28 interventions, reflecting the
considerable uncertainty in this estimate. Double-balloon or Cook’s catheter also had the lowest absolute
probability of an event at 1.1% (CrI 0.02% to 6.5%). Buccal/sublingual misoprostol had a posterior
mean rank of ‘5’ (95% CrI 1 to 15) and an absolute probability of Apgar score < 7 at 5 minutes of 1.4%
(95% CrI 0.2% to 5%).
Table 14 also reports that three further interventions had a posterior mean rank of ‘7’: titrated (low-dose)
oral misoprostol solution, NO and oral prostaglandins. However, the uncertainty around these rankings is
considerable. Low ranking interventions include i.v. oxytocin with amniotomy, misoprostol vaginal pessary
(sustained release) and membrane sweeping. Note that the ORs relative to placebo did not achieve
statistical significance for any of these interventions (see Table 13).
Figure 12 reports the rankograms for Apgar score < 7 at 5 minutes. For all of the interventions the
rankograms are flat and indicative of considerable uncertainty around the probability that any intervention
is the ‘best’. Therefore, we did not include an assessment of probability for being the ‘best’ in our
summary for this outcome.
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FIGURE 12 Rankograms for each of the 29 induction interventions for Apgar score < 7 at 5 minutes and NICU
admission. Ranking indicates the probability of being the best intervention, the second best, the third best, etc.
The x-axis shows the relative ranking and the y-axis the probability of each ranking. (a) No treatment; (b) placebo;
(c) vaginal PGE2 (tablet); (d) vaginal PGE2 (gel); (e) vaginal PGE2 pessary (slow release); (f) PGF2 gel; (g) intracervical
PGE2; (h) vaginal pessary (normal release); (i) vaginal misoprostol (dose <50 µg); (j) vaginal misoprostol (dose ≥50 µg);
(k) oral misoprostol (dose <50 µg); (l) oral misoprostol (dose ≥50 µg); (m) titrated (low-dose) oral misoprostol solution;
(n) sustained-release misoprostol insert; (o) i.v. oxytocin; (p) amniotomy; (q) i.v. oxytocin plus amniotomy; (r) NO;
(s) mifepristone; (t) oestrogens; (u) Foley catheter; (v) laminaria including dilapan; (w) double balloon or
Cook’s catheter; (x) membrane sweeping; (y) extra-amniotic PGE2; (z) sexual intercourse; (aa) acupuncture;
(ab) oral prostaglandins; and (ac) buccal/sublingual misoprostol.
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TABLE 13 Odds ratios and 95% CrI for Apgar score < 7 at 5 minutes for every intervention compared with placebo
Active intervention vs. placebo
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI Trials
Extra-amniotic PGE2 Not estimable
a
– – 0
Double-balloon or Cook’s catheter 0.17 0.01 to 1.67 – – 0
Oral prostaglandins 0.35 0.06 to 1.68 – – 0
Buccal/sublingual misoprostol 0.41 0.15 to 0.99 – – 0
Titrated (low) oral misoprostol solution 0.46 0.19 to 1.09 – – 0
NO 0.49 0.20 to 0.95 0.94 0.39 to 1.88 5
Oral misoprostol tablet < 50 µg 0.53 0.13 to 2.08 – – 0
Acupuncture 0.54 0.14 to 1.87 0.82 0.15 to 2.49 3
Oral misoprostol tablet ≥ 50 µg 0.57 0.30 to 1.13 0.85 0.18 to 2.41 3
Intracervical PGE2 0.67 0.38 to 1.20 0.46 0.14 to 1.11 4
Vaginal PGE2 (tablet) 0.75 0.34 to 1.62 0.57 0.04 to 2.04 1
Mifepristone 0.77 0.23 to 3.37 0.78 0.16 to 2.59 2
Vaginal PGE2 pessary (normal release) 0.80 0.35 to 1.84 1.79 0.11 to 8.27 4
Foley catheter 0.82 0.41 to 1.65 – – 0
i.v. oxytocin 0.85 0.45 to 1.62 Not estimable
Vaginal misoprostol < 50 µg 0.92 0.49 to 1.69 0.04 0 to 0.32 1
Laminaria 0.92 0.25 to 3.41 – – 0
Sexual intercourse 0.97 0.02 to 37.3 – – 0
Vaginal misoprostol ≥ 50 µg 1.01 0.56 to 1.81 – – 0
Vaginal PGE2 (gel) 1.03 0.58 to 1.85 0.70 0.12 to 2.21 5
Vaginal PGE2 pessary (slow release) 1.06 0.43 to 2.60 – – 0
i.v. prostaglandin 1.12 0.29 to 4.25 – – 0
Amniotomy 1.30 0.37 to 4.61 – – 0
Membrane sweeping 1.85 0.63 to 5.40 – – 0
Sustained-release misoprostol vaginal pessary 1.91 0.57 to 6.35 – – 0
i.v. oxytocin with amniotomy 2.39 0.62 to 9.58 – – 0
a Not estimable because of comparison being based on a single trial with zero cells and connected to the network on
a spur.
Results from NMA and pairwise meta-analysis (when possible). An OR of > 1 favours placebo (i.e. fewer events occur on a
placebo than active intervention). An OR of < 1 favours the active intervention (i.e. fewer undesirable events occurred on
the active intervention). Empty cells indicate that direct evidence was not available for that comparison.
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TABLE 14 Absolute probability of Apgar score < 7 at 5 minutes across all 26 interventions and placebo/no
intervention included in the NMA
Intervention
Absolute probability of Apgar score < 7 at
5 minutes admission
Posterior mean
rank and 95% CrIPosterior mean 95% CrI
Double-balloon or Cook’s catheter 0.01 0.00 to 0.06 4 1 to 22
Oral prostaglandins 0.01 0.00 to 0.07 7 1 to 24
Buccal/sublingual misoprostol 0.01 0.00 to 0.05 5 1 to 15
Vaginal PGE2 (tablet) 0.02 0.00 to 0.07 12 3 to 23
Intracervical PGE2 0.02 0.00 to 0.07 10 5 to 16
Oral misoprostol tablet < 50 µg 0.02 0.00 to 0.08 9 1 to 24
Oral misoprostol tablet ≥ 50 µg 0.02 0.00 to 0.06 8 3 to 15
Titrated (low) oral misoprostol solution 0.02 0.00 to 0.06 7 2 to 17
NO 0.02 0.00 to 0.06 7 2 to 17
Acupuncture 0.02 0.00 to 0.09 9 1 to 25
Placebo 0.03 0.01 to 0.1 17 10 to 23
No intervention 0.03 0.00 to 0.11 17 7 to 25
Vaginal PGE2 (gel) 0.03 0.01 to 0.1 19 12 to 23
Vaginal PGE2 pessary (normal release) 0.03 0.00 to 0.10 13 4 to 24
Vaginal misoprostol < 50 µg 0.03 0.00 to 0.10 16 9 to 23
Vaginal misoprostol ≥ 50 µg 0.03 0.01 to 0.10 18 11 to 23
i.v. oxytocin 0.03 0.00 to 0.09 15 8 to 21
Mifepristone 0.03 0.00 to 0.13 14 2 to 27
Foley catheter 0.03 0.00 to 0.09 14 7 to 22
Laminaria 0.03 0.00 to 0.13 16 2 to 27
Vaginal PGE2 pessary (slow release) 0.04 0.01 to 0.12 18 7 to 25
i.v. prostaglandin 0.04 0.00 to 0.16 18 3 to 27
Amniotomy 0.05 0.00 to 0.18 20 4 to 27
Membrane sweeping 0.06 0.01 to 0.21 23 12 to 27
Sustained-release misoprostol
vaginal pessary
0.07 0.01 to 0.24 24 10 to 27
i.v. oxytocin with amniotomy 0.08 0.01 to 0.29 24 12 to 27
Sexual intercourse 0.08 0.00 to 0.59 15 1 to 27
Extra-amniotic PGE2
a Not estimable
a Single trial with zero events in one arm.
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Maternal satisfaction with care and induction of labour method
Less than 5% of the studies included in the review reported data relating to maternal satisfaction with the
induction process. In Table 15 we set out findings from these trials. We were unable to pool any results
from trials in either pairwise or NMA. The trials focused on a broad range of interventions (10/29 examined
oxytocin) and comparators. Furthermore, outcome definitions varied considerably. For mechanical methods,
the questions related to discomfort during the initial procedure (e.g. insertion of catheter or membrane
sweeping). For other methods there were more global assessments of the process. There were no
preferred methods and, in general, women were satisfied with (or at least accepted) the induction process.
Complementary methods
Unfortunately, it was not possible to assess the efficacy (VD within 24 hours) of trials of complementary
interventions or membrane sweeping. Relative to placebo, membrane sweeping performed marginally
better than acupuncture or sexual intercourse, with an OR of 0.74 (95% CrI 0.53 to 0.99) for CS and an
absolute probability of CS of 20% (95% CrI 3% to 54%) compared with 21% for both sexual intercourse
(95% CrI 3% to 58%) and acupuncture (95% CrI 3% to 57%). For instrumental delivery, membrane
sweeping was consistent, with both an increased and decreased odds of assisted birth, and was ranked
‘26’ (95% CrI 16 to 31) out of 32 interventions. For both ‘NICU admission’ and ‘Apgar score < 7 at
5 minutes’ outcomes, membrane sweeping was associated with a low absolute probability of either event.
Subgroup analyses
We planned to conduct subgroup analyses to explore the effect of different clinical subgroups on
effectiveness data. Here we present subgroup analyses for three outcomes: (1) failure to achieve VD within
24 hours of induction; (2) CS; and (3) Apgar score < 7 at 5 minutes. The prespecified confounders were
(1) women with intact or ruptured membranes; (2) different gestational ages; (3) women with or without a
previous CS; and (4) women with low (< 6) or higher (≥ 6) Bishop scores. Table 16 reports the breakdown
of trials for each of these possible subgroups.
Subgroup analysis for intact membranes compared with
ruptured membranes
When the analysis was limited to only those trials in which all women had intact membranes, 56 trials of
15 treatments formed a connected network for the outcome of no VD within 24 hours (see Appendix 15).
When restricted to those trials that included only women with ruptured membranes, a connected network
of 17 trials of 12 treatments was possible. Note that studies including women with both intact or ruptured
membranes, which did not report results for each subgroup separately, are not included here. Reported
results are based on the REs NMA model, assuming consistency (see Appendix 15). All active interventions
are compared with vaginal PGE2 gel, as placebo is no longer available in the restricted networks.
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Outcome: vaginal delivery not achieved within 24 hours
Results are reasonably robust across the analyses: Table 17 compares all treatments with vaginal PGE2 (gel)
for all studies and the two subgroups: (1) intact and (2) ruptured membranes. For the subgroup including
only women with intact membranes, i.v. oxytocin with amniotomy and vaginal misoprostol (≥ 50 µg) are
still ranked ‘best’ for achieving VD within 24 hours.
Amniotomy is clearly not a feasible option for women with ruptured membranes, and this is reflected in
the subgroup analysis for ruptured membranes, in which it does not feature in any of the trials. For this
subgroup the CrIs are extremely wide, reflecting extreme uncertainty in which treatment is best for women
with ruptured membranes.
Outcome: caesarean section
A total of 160 trials of 31 treatments were available for analysis when restricted to trials in which all
women had intact membranes. The subgroup for trials that included only women with ruptured
membranes formed a connected network of 47 trials of 17 treatments (see Appendix 15). As before,
studies reporting pooled data for women with both intact or ruptured membranes, or those who did not
report details for this characteristic, are not included here. Reported results are therefore based on the REs
NMA model, assuming consistency (see Appendix 15).
For the subgroup of women with intact membranes we note that the posterior mean rank for titrated
(low-dose) oral misoprostol solution has changed from ‘6’ to ‘14’, albeit with considerable uncertainty in
the relative ranking (95% CrI 3 to 28) (Table 18). Similarly, the mean rank for PGF2 gel has decreased from
11 to 21, with very wide CrIs (95% CrI 3 to 30), showing that there is considerable uncertainty in the
relative rankings. The mean rank for extra-amniotic PGE2 has improved from ‘22’ to ‘4’, although, again,
the CrIs indicate considerable uncertainty, which should be taken into consideration in any conclusions
(95% CrI 1 to 26).
TABLE 16 Subgroups by outcome
Trials included
VD not achieved CS Apgar
141 studies,
21 treatments
307 studies,
33 treatments
200 studies,
28 treatments
All women with a previous CS 0 studies Not connected 0 studies
No women with a previous CS 115 studies 215 studies 153 studies
All women with intact membranes 58 studies 161 studies 98 studies
19 treatments 29 treatments 28 treatments
All women with ruptured membranes 17 studies 49 studies 37 studies
12 treatments 17 treatments 18 treatments
All women with Bishop scores of ≥ 6 5 studies 13 studies 6 studies
5 treatments 8 treatments 7 treatments
All women with Bishop scores of < 6 106 studies 202 studies 128 studies
19 treatments 18 treatments 25 treatments
Apgar, Apgar score < 7 at 5 minutes.
Breakdown of number of trials and interventions included in each network, which are available to contribute to a
subgroup analyses.
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When limiting the network to trials that included only women with ruptured membranes, we observe that
vaginal misoprostol (both doses), intracervical PGE2, vaginal slow-release PGE2 pessary and titrated
low-dose oral misoprostol solution have the highest rankings, with 95% CrI including the best ranking.
As with other subgroup analyses the CrIs are very wide, making clinical interpretation quite difficult.
Outcome: Apgar score < 7 at 5 minutes
For the outcome of Apgar score < 7 at 5 minutes, the subgroup in which all women had intact
membranes was a connected network of 98 trials of 26 treatments. When the analysis was limited to only
those trials in which all women had ruptured membranes, 37 trials of 16 treatments assessed the outcome
of Apgar score < 7 at 5 minutes (see Appendix 15). However, we observed meaningful differences in the
posterior mean residual deviance, suggesting that there was evidence of unresolved inconsistency
(see Appendix 15). As such we do not report the findings for these subgroups.
Subgroup analysis for women with low Bishop score (< 6) or higher Bishop score (≥ 6)
Outcome: vaginal delivery not achieved within 24 hours
For the outcome of no VD within 24 hours when the analysis was limited to only those trials in which all
women had a Bishop score < 6, 106 trials of 17 treatments assessed the outcome of no VD within
24 hours. However, we observed meaningful differences in the posterior mean residual deviance, the DIC
values and the SDs, suggesting that there is evidence of inconsistency. Consequently, we do not report
results for this subgroup here. No meaningful analysis could be carried out on women with a Bishop score
≥ 6, as the network only included five studies comparing seven treatments and was not connected
(see Appendix 15).
Outcome: caesarean section
For the CS outcome, restricting to trials in which all women had a Bishop score < 6 allowed a connected
network of 203 trials comparing 28 treatments. When the analysis was limited to only those trials that
included women with a Bishop score ≥ 6, a connected network of 10 trials of 10 treatments assessed the
outcome of CS (see Appendix 15). Full results are shown in Table 19. Results are largely robust to the
analysis, only including studies with women with a Bishop score < 6. A posterior mean rank for extra-
amniotic PGE2 changed from ‘22’ to ‘4’ and this treatment became significantly better than placebo for
preventing a CS. Similarly, acupuncture changed from having a mean rank of ‘16’ to ‘3’ and became
significantly better than placebo.
Outcome: Apgar score < 7 at 5 minutes
For the outcome of Apgar score < 7 at 5 minutes, restricting the analysis to only those trials in which all
women had Bishop scores of < 6 produced a connected network of 128 trials comparing 24 treatments.
However, because of the number of zero events, the NMA model would not converge and therefore we
cannot report results. Similarly, we do not report results for women with a Bishop score ≥ 6 due to zero
events, as the network included only six studies and seven treatments.
Formal subgroup analysis either was not possible or did not show clear subgroup differences in terms of
cervical status. It is noteworthy that far fewer trials tested i.v. oxytocin with amniotomy in women with
unfavourable cervix than other interventions, such as PGE2, misoprostol and mechanical methods
(see Table 19). This is hardly surprising, given that amniotomy is very difficult or even impossible in women
with very unfavourable cervix. Overall, women with favourable cervix are more likely to achieve VD
within 24 hours, but this should not produce biased results in our NMA as this would apply to both the
experimental group (e.g. oxytocin with amniotomy) and the control group (e.g. any prostaglandin) as well
(i.e. the relative effect between two treatments is not affected). Nevertheless, as oxytocin with amniotomy
has been predominantly tested in women with favourable cervix, our recommendations relating to this
intervention are restricted to this subgroup.
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Gestational age and previous caesarean section subgroups
The reporting of gestational age by trial authors made it difficult to define mutually exclusive subgroups
and so we do not report analyses for this characteristic.
For women with a previous CS there were no trials remaining which would allow an analysis based on
failure to achieve VD within 24 hours, or Apgar score < 7 at 5 minutes (Table 20). There were only four
trials remaining for the outcome of CS; however, the network was not connected and so an analysis was
not possible.
Summary
We presented the impact of 31 interventions (excluding no treatment and placebo) on failure to achieve
VD within 24 hours, CS, instrumental delivery, uterine hyperstimulation, Apgar score < 7 at 5 minutes
and NICU admission. For a total of 17 methods (11 prostaglandins, two mechanical methods, oxytocin
with or without amniotomy, NO and mifepristone) we were able to produce rankings for all six outcomes
(Table 21). The data were incomplete for other methods and other key safety outcomes, namely neonatal
mortality/morbidity, maternal mortality/morbidity and maternal satisfaction, which we have described
narratively. Table 21 is intended to provide a broad summary of findings across outcomes; however, it
does not report CrIs. Therefore, it is important that this table is interpreted in the context of relevant tables
for each outcome, which set out the uncertainty around rankings.
TABLE 19 Trials recruiting women with unfavourable and favourable cervix for selected interventions
Interventions
Number of trials
reporting cervical status
Number of trials
recruiting women with
different cervical status
Percentage of trials
including only women
unfavourable cervix
Oxytocin with amniotomy 22 1 unfavourable
11 mixed
10 favourable
3 not reported
4.5
Vaginal and intracervical PGE2 284 233 unfavourable
43 mixed
8 favourable
11 not reported
82
Misoprostol 209 168 unfavourable
33 mixed
8 favourable
37 not reported
80
Mechanical methods 69 66 unfavourable
2 mixed
1 favourable
3 not reported
96
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TABLE 21 Summary of rankings (point estimates only)a
Induction method
Posterior mean rank
VD within 24 hours CS Ins del HS NICU
Apgar score < 7
at 5 minutes
Complete rankings
Prostaglandins
Titrated (low) oral misoprostol solution 5 6 19 10 11 7
Buccal/sublingual misoprostol 6 9 7 18 13 5
Vaginal misoprostol < 50 µg 6 9 11 14 14 16
Oral misoprostol tablet ≥ 50 µg 12 10 13 15 18 8
Oral misoprostol tablet < 50 µg 14 25 9 7 14 9
Vaginal PGE2 pessary (normal release) 4 17 23 8 18 13
Vaginal PGE2 pessary (slow release) 11 21 7 15 13 18
Vaginal PGE2 (tablet) 12 26 17 11 16 12
Vaginal misoprostol ≥ 50 µg 4 11 17 19 19 18
Sustained-release misoprostol pessary 5 22 16 18 8 24
Vaginal PGE2 (gel) 8 15 18 13 20 19
Other methods
Double-balloon or Cook’s catheter 10 27 9 2 9 4
Foley catheter 13 14 6 5 10 14
NO 15 17 17 3 17 7
i.v. oxytocin 14 23 24 12 15 15
i.v. oxytocin with amniotomy 2 20 17 16 27 24
Mifepristone 19 11 30 18 26 14
Incomplete rankings
Intracervical PGE2 14 18 15 9 – 10
Extra-amniotic PGE2 16 22 15 – 4 27
Laminaria – 15 12 3 23 16
Membrane sweeping – 12 26 – 16 23
Acupuncture – 16 13 – 14 9
Sexual intercourse – 17 25 – 6 15
Oral prostaglandins – 10 9 – 10 7
Amniotomy – 22 13 – 14 20
PGF2 gel – 11 14 – 8 –
Oestrogens – 27 8 – 14 –
i.v. prostaglandin – 33 30 – – 18
Relaxin – 16 25 – – –
Corticosteroids – 6 – – – –
Hyaluronidase – 7 – – – –
HS, hyperstimulation; Ins del, instrumental delivery.
Please see relevant tables for CrIs for rankings.
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We observed moderate heterogeneity across all of the analyses, with a considerable uncertainty in the
rankings of interventions across all outcomes.
Our analysis shows that i.v. oxytocin combined with amniotomy has the best chance of achieving VD
within 24 hours of induction, but this intervention is restricted to women with intact membranes.
Misoprostol (vaginal route, titrated oral solution, buccal/sublingual) and vaginal PGE2 normal-release
pessaries also performed well.
Compared with placebo, corticosteroids and titrated (low-dose) oral misoprostol achieved the lowest odds
of an eventual CS; however, there was considerable uncertainty in these findings.
For instrumental delivery, Foley catheter performed well taking into account the OR, posterior mean ranks
and absolute probabilities. However, we again note the uncertainty which surrounds these estimates and
the moderate degree of observed heterogeneity.
The safest intervention in terms of risk for uterine hyperstimulation was double-balloon or Cook’s catheter.
The intervention with the worst mean rank was vaginal misoprostol ≥ 50 µg, with a 9% absolute
probability of uterine hyperstimulation.
Neonatal intensive care unit admission and an Apgar score < 7 at 5 minutes were used as proxies
for neonatal safety outcomes in the absence of consistent definitions of neonatal mortality and
morbidity across the trials. The safest intervention in terms of risk of Apgar score < 7 at 5 minutes
was double-balloon or Cook’s catheter, with a mean rank of ‘4’; however, the 95% CrI ranged
from 1 to 22 out of 26 interventions, reflecting the considerable uncertainty in this estimate.
Unfortunately, it was not possible to assess the efficacy (VD within 24 hours) of trials of complementary
interventions or membrane sweeping. Relative to placebo, membrane sweeping performed marginally
better than acupuncture or sexual intercourse for CS. For both NICU admission and Apgar score < 7 at
5 minutes outcomes, membrane sweeping was associated with a low absolute probability of either event.
In broad terms, our subgroup analyses, when available, were consistent with overall results.
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Chapter 4 Assessment of cost-effectiveness
Introduction
In this chapter we compare the cost-effectiveness of different methods of induction of labour. We begin
by setting out our decision question. We then describe previous studies that have addressed this question;
however, we found that none of these provided a model that we could apply to compare the
cost-effectiveness of the different methods of induction identified in our review. We then describe our
de novo decision model, which we developed to answer our decision question, followed by a description
of the evidence sources that were used to provide inputs to the model effectiveness, treatment costs, other
resource-use (hospital) costs and utilities. We used the results of the NMA presented in Chapter 3 when
possible. Because modes of delivery are not independent (a woman must deliver one of three ways: CS,
VD within 24 hours or VD after 24 hours of induction), we need to estimate these outcomes jointly. In
order to include as many studies as possible in our analysis, we condition on CS. This means we use the
NMA for the CS outcome as presented in Chapter 3, but conduct a new NMA for the ‘failure to achieve
vaginal delivery within 24 hours’ outcome, conditional on not having had a CS, using the subset of studies
which reported both outcomes. We then present results and end with a discussion.
Decision question
Population
The population of interest was defined in accordance with the inclusion criteria for the systematic review
and NMA (i.e. pregnant women carrying a viable fetus and who are eligible for any method of third
trimester labour induction).
Interventions
We included all of the interventions that were identified in the systematic review (see Chapter 3) for which
we had sufficient information to evaluate the model. This meant that 19 interventions out of a total of 34
(Box 3) were included in the cost-effectiveness analysis, and the remaining 15 were excluded (PGF2α gel,
amniotomy, oestrogens, corticosteroids, relaxin, hyaluronidase, laminaria, membrane sweeping, i.v.
prostaglandin, sexual intercourse, acupuncture, breast stimulation, homeopathy, castor oil and oral
prostaglandins). Note that this does not mean that the excluded interventions were not cost-effective –
simply that we did not have enough information to assess their cost-effectiveness. The included
interventions were a variety of pharmacological and mechanical interventions. A further issue arose with
the vaginal PGE2 pessary (normal release) intervention which, as described in Chapter 3, was a
heterogeneous mix of interventions in which PGE2 was administered vaginally using a range of ‘pessaries’
(frequently produced in trial hospital pharmacies) that are either not readily reproducible or not currently
available to the NHS. It is important that this group is distinguished from PGE2 slow-release pessaries that
are used in current NHS practice. We included placebo in the results but interpret this as ‘no intervention’,
as it would be delivered on the NHS.
Outcomes
Obstetrics is different from most other medical specialties in that decision problems involve the health of
two patients (mother and child) and an intervention or treatment can affect the health of both. Often, an
intervention that is beneficial to the mother can carry a higher risk for the child and vice versa. The birth of
a child also has a major impact on the new mother, and the health of the child in the time immediately
following birth can have a significant impact on the mother’s own health. Our model includes both
maternal and neonatal outcomes, and we attempted to capture the costs and utilities of both mother and
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baby, giving equal weight to both individuals. We report expected total costs (treatment costs plus other
resource costs), expected utility (for mother and baby combined) and incremental cost-effectiveness ratios
(ICERs), which measure the additional expected cost per 1 unit of additional utility for one intervention
compared with another. We conducted a fully incremental analysis. We report a probabilistic sensitivity
analysis, which reflects uncertainty in model inputs. The probabilistic sensitivity analysis is summarised with
expected total costs, expected total benefits, ICER, an incremental cost-effectiveness plane and a cost-
effectiveness acceptability curve (CEAC), which plots the probability of each intervention being the most
cost-effective, based on expected net benefit for a given willingness-to-pay per unit increase in utility.
The National Institute for Health and Care Excellence (NICE) methods of technology appraisal guide954
suggests that the time horizon of the model applied should be long enough to capture all relevant costs
and benefit differences between the interventions. We acknowledge that there are some potential
long-term adverse events that are associated with the process of labour and that some outcomes, such as
CS and serious birth canal injuries, can have a life-long impact on health-related quality of life (e.g. urinary
incontinence) and costs. However, we assumed that most cost differences that are related to methods of
induction are likely to be realised during and immediately after the birth. The evidence sources that were
used to inform utilities did not explicitly state a time frame; however, they are unlikely to reflect many
consequences that occur post discharge. The time frame of the analysis was, therefore, taken to be from
induction to hospital discharge. We acknowledge that this is a limitation that ignores cost and utility
consequences in the longer term. Discounting was deemed unnecessary because of this short time frame.
We take a UK NHS perspective.
BOX 3 List of interventions included in base-case cost-effectiveness analysis
1. Vaginal PGE2 tablet.
2. Vaginal PGE2 gel.
3. Vaginal PGE2 pessary (slow release).
4. Intracervical PGE2.
5. Vaginal PGE2 pessary (normal release).
6. Vaginal misoprostol – dose < 50 µg.
7. Vaginal misoprostol – dose ≥ 50 µg.
8. Oral misoprostol – dose < 50 µg.
9. Oral misoprostol – dose ≥ 50 µg.
10. Titrated (low-dose) oral misoprostol solution.
11. Sustained-release misoprostol insert.
12. i.v. oxytocin.
13. i.v. oxytocin with amniotomy.
14. NO.
15. Mifepristone.
16. Mechanical methods – Foley catheter.
17. Mechanical methods – double-balloon or Cook’s catheter.
18. Extra-amniotic PGE2.
19. Buccal/sublingual misoprostol.
20. Placebo.
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Previous economic evaluations
We performed a review of the literature (details in Appendix 17) to identify previous studies that have
attempted to address our decision question. We identified two RCTs14,955 in which an economic evaluation
was also conducted. In both of these trials,14,955 only two methods of induction were compared using costs
and efficacy data that were collected alongside the trials; however, neither of them attempted to quantify
quality of life. Petrou et al.14 compared PGE2 gel to PGE2 tablets in a cost-effectiveness analysis with the
main outcome measure being incremental cost per hour prevented between induction and delivery.
Van Baaren et al.955 assessed the economic consequences of labour induction with Foley catheter
compared with PGE2 gel, in an economic evaluation conducted alongside the PROBAAT (prostaglandin or
balloon catheter for induction of labour at term) RCT. This study calculated the cost to prevent one CS, or
maternal/neonatal morbidity.
The latest clinical guideline on induction of labour produced by NICE in 2008 included a cost-effectiveness
analysis of the timing of the first offer of induction of labour.9 This analysis used a state-transition (Markov)
model to simulate the cost-effectiveness of the different timing strategies, with benefits measured in
quality-adjusted life-years (QALYs). The primary source of clinical data was the systematic review
undertaken as part of the guideline. The QALY estimation took into account only the health of the infant
and not the health of the mother, as no studies could be identified in the literature that estimated the
utility gain or loss to women as a result of induction. The assumption made was that a baby who survived
with a serious morbidity gained only 0.75 QALYs for each 1 QALY gained by a healthy baby.
Despite the large number of RCTs that were identified in our systematic review (see Chapter 3), there has
been no attempt to examine all induction methods together within an economic model. We have,
therefore, developed a de novo model (described below) to estimate the cost-effectiveness of various
methods for the induction of labour using the data obtained from the systematic review and NMA of
RCTs, along with hospital costs and utilities.
Health-economic model
A decision-analytic model956 was constructed to compare the costs and effects of the different methods of
induction of labour. Because we consider only short-term consequences, we chose to use a decision tree
to represent the costs and consequences of different methods of induction. A decision tree is a graphical
representation of different possible outcomes following a decision, in which probabilities are given to
different paths along the branches of the tree, and costs and utilities attached to each branch. This enables
us to compute probability-weighted costs and outcomes to arrive at an expected cost and utility value for
each alternative treatment option.
The outcomes included were rate of VD within 24 hours, CS rate and frequency of admission to the NICU,
as well as resource use and utilities. This structure was informed by the literature and expert opinion, and
was finalised through discussions with the steering group. An illustration of the model structure is provided
in Figure 13. Squares represent decision nodes for the method of delivery chosen, whereas circles
represent chance nodes at which different possible outcomes are assigned a probability, and triangles
represent outcomes.
The model starts by dividing the population into those who deliver vaginally within the first 24 hours;
have an emergency CS; and deliver vaginally after 24 hours.
Under each model of delivery, babies can either be born with no complications or be admitted to the NICU,
which, in the context of randomised trials, we assumed relates to intervention and/or mode of delivery
(CS or VD), but is less likely to relate to length of labour (i.e. whether a VD was within 24 hours of induction
or not). NICU admission is divided into transitional care for those babies who need some medical treatment
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but are well enough to be cared for at the mother’s bedside, high-dependency care for babies who are
recovering from critical illness and need a great deal of observation and support, and intensive care for
babies who have serious potential health problems and need constant care to be kept alive. Utility scores
and resource use were thought to vary depending on these levels of care.
Inputs to economic model
Effectiveness inputs
We required absolute probabilities for each of the paths in the branches of the tree shown in Figure 13,
for each intervention. The NMA presented in Chapter 3 provided information on relative effects on these
probabilities (in the form of ORs). In order to obtain absolute probabilities on all interventions we needed
to apply these relative effects to absolute probabilities on a reference intervention. The choice of reference
intervention is not important; however, it needs to be an intervention for which there is evidence available
on absolute probabilities for all paths in our decision tree, and that evidence is relevant to the decision
population under consideration. We chose vaginal PGE2 (tablet) as the reference intervention, as there
were several UK-based RCTs including this intervention for each of the probabilities that were required in
the model.
Induction of
labour
CS
VD24
Vaginal delivery
after 24 hours
NICU admission
NICU admission
NICU admission
No complications
No complications
No complications
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
Transitional care
Intensive care
High-dependency care
Transitional care
Intensive care
High-dependency care
Transitional care
Intensive care
High-dependency care
FIGURE 13 Decision tree for comparison of different methods of induction.
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The NMA presented in Chapter 3 analyses each of the outcomes independently. However, as can be seen
from Figure 13, these outcomes are not independent. For example, a failure to achieve a VD in 24 hours
includes both women who deliver by CS and those who deliver vaginally but not within 24 hours. A woman
has to deliver in one of three ways: a VD within 24 hours (VD24), a CS or a VD after 24 hours (VD> 24). We
therefore re-analysed the data, as described in Appendix 16, to estimate these three probabilities allowing
for the dependence in the data. We assumed that the relative effects for NICU admission are independent
of timing of delivery but dependent on mode of delivery. We also assumed that the probability of NICU
admission is 1.5 times higher for a CS delivery (according to data on 2837 inductions of labour for live births
in Liverpool Women’s NHS Foundation Trust in 2014). Under this assumption it can be verified that the
probability of NICU admission for VD, p(NICUvd), and the probability of NICU admission for CS, p(NICUcs),
can be obtained from the overall probability of NICU admission, p(NICU) using the following formulae:
p(NICUvd)= p(NICU) × 2/(2+ p(CS)) and p(NICUcs)= p(NICU) × 3/(2+ p(CS)).
The proportion of CS births, p(CS), is based on the NMA presented in Chapter 3 being applied to the
proportion estimated on the reference intervention, as described below and in Appendix 16. The relative
effects for NICU admission from the NMA in Chapter 3 are applied to the probability of NICU admission on
the reference intervention (Table 22) to obtain the absolute probability of NICU admission, p(NICU) for
each intervention. The formulae above are then used to obtain p(NICUvd) and p(NICUcs).
Note that all of these quantities are estimated using Bayesian Markov chain Monte Carlo (MCMC)
simulation, which samples directly from the joint posterior distribution. The decision tree is evaluated for
each of these simulated samples so that we have a simulation of utility and cost estimates for each
intervention. These simulations ensure that the uncertainty in the model inputs are fully reflected in the
estimation of costs and utilities.
There were five UK studies315,549,834,957 in our review that provided information on the probability of a CS on
the reference intervention. There was one UK study in our review that provided information on the
probability of VD within 24 hours, given no CS, on the reference intervention. There were two UK
studies834 providing information on the probability of NICU admission on the reference intervention. These
studies were chosen as they were the only UK-based studies that evaluated the reference treatment and
were therefore thought to be most representative of the target population. Where there was more than
one study, the reference intervention arms were pooled using single-arm meta-analysis (results shown in
Table 22). A REs model was used for both the probability of CS and the probability of NICU admission as a
result of the heterogeneity between the included studies. This is reflected in the wide CrIs for these
probabilities (see Table 22).
TABLE 22 Probabilities of events on reference treatment (PGE2 tablet)
Probability of Posterior mean estimate (%) 95% CrI
VD within 24 hours 46 30 to 69
VD after 24 hours 30 15 to 49
CS 24 8 to 36
NICU admission 14 0 to 71
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We applied the ORs from the NMAs (see Chapter 3 and Appendix 16) to the absolute probabilities for the
reference intervention (see Table 22), to obtain absolute probabilities for all interventions. Note that this
was done within the Bayesian MCMC simulation, which samples from the joint posterior distribution so
that all correlations and uncertainties are fully reflected in the estimates. The resulting estimates are given
in Tables 23–26. Note that these results differ from those presented in Chapter 3. First, we are using a
different reference intervention on which to apply relative effects. Second, because we are modelling the
mode of delivery jointly (so probabilities sum to 1), the number of studies from which the VD within
24 hours is estimated is reduced (as we require studies to report all delivery outcomes fully). One point to
note is that the estimate of the probability of a VD after 24 hours with i.v. oxytocin plus amniotomy is ‘0’,
based on a single small study (25 women in this arm) with no women delivering vaginally after 24 hours.
Cost inputs
The perspective adopted for the economic evaluation was that of the service provider (UK NHS). In
accordance with this perspective, the costs included in the economic analysis were the direct costs incurred
as a result of the interventions. These included the intervention costs, costs of method of delivery and
length of neonatal stay in level I, II or III units. The price year was 2012–13.
TABLE 23 Absolute probabilities of achieving VD within 24 hours
Treatment Probability of achieving VD within 24 hours 95% CrI
i.v. oxytocin with amniotomy 0.78 0.6 to 0.91
Buccal/sublingual misoprostol 0.64 0.43 to 0.81
Vaginal misoprostol: dose ≥ 50 µg 0.62 0.43 to 0.77
Titrated (low-dose) oral misoprostol solution 0.55 0.31 to 0.74
Vaginal misoprostol: dose < 50 µg 0.52 0.33 to 0.71
Vaginal PGE2 gel 0.51 0.3 to 0.69
Oral misoprostol tablet: dose ≥ 50 µg 0.48 0.28 to 0.66
i.v. oxytocin 0.47 0.24 to 0.69
Vaginal PGE2 tablet 0.46 0.3 to 0.69
Sustained-release misoprostol insert 0.44 0.14 to 0.74
Double-balloon or Cook’s catheter 0.42 0.2 to 0.65
Vaginal PGE2 pessary (normal release) 0.42 0.19 to 0.66
Vaginal PGE2 pessary (slow release) 0.41 0.21 to 0.62
Foley catheter 0.41 0.19 to 0.63
Intracervical PGE2 0.40 0.2 to 0.59
Extra-amniotic PGE2 0.36 0.09 to 0.7
Oral misoprostol tablet: dose < 50 µg 0.33 0.1 to 0.61
NO 0.27 0.06 to 0.57
Mifepristone 0.16 0.16 to 0.16
Placebo 0.14 0.03 to 0.32
Posterior mean and 95% CrI are reported.
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TABLE 24 Absolute probabilities of achieving VD after 24 hours
Treatment Probability of achieving VD after 24 hours 95% CrI
i.v. oxytocin with amniotomy 0 0 to 0
Buccal/sublingual misoprostol 0.19 0.06 to 0.39
Vaginal misoprostol: dose ≥ 50 µg 0.20 0.09 to 0.36
Titrated (low-dose) oral misoprostol solution 0.29 0.12 to 0.51
Vaginal PGE2 gel 0.30 0.15 to 0.49
Vaginal misoprostol: dose < 50 µg 0.30 0.14 to 0.49
Vaginal PGE2 tablet 0.30 0.15 to 0.49
i.v. oxytocin 0.31 0.12 to 0.54
Double-balloon or Cook’s catheter 0.33 0.13 to 0.56
Sustained-release misoprostol insert 0.33 0.07 to 0.65
Oral misoprostol tablet: dose ≥ 50 µg 0.34 0.16 to 0.53
Vaginal PGE2 pessary (slow release) 0.37 0.18 to 0.59
Vaginal PGE2 pessary (normal release) 0.38 0.15 to 0.63
Foley catheter 0.40 0.19 to 0.62
Intracervical PGE2 0.40 0.21 to 0.6
Extra-amniotic PGE2 0.41 0.1 to 0.73
Oral misoprostol tablet: dose < 50 µg 0.43 0.16 to 0.7
NO 0.53 0.21 to 0.77
Mifepristone 0.60 0.28 to 0.83
Placebo 0.63 0.41 to 0.8
Posterior mean and 95% CrI are reported.
DOI: 10.3310/hta20650 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 65
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Alfirevic et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
83
TABLE 25 Absolute probabilities of CS
Treatment Probability of CS 95% CrI
Titrated (low-dose) oral misoprostol solution 0.16 0.06 to 0.31
Buccal/sublingual misoprostol 0.17 0.07 to 0.33
Vaginal misoprostol: dose < 50 µg 0.18 0.07 to 0.34
Mifepristone 0.18 0.06 to 0.36
Oral misoprostol tablet: dose ≥ 50 µg 0.18 0.07 to 0.34
Vaginal misoprostol: dose ≥ 50 µg 0.18 0.07 to 0.35
Foley catheter 0.19 0.07 to 0.36
Vaginal PGE2 gel 0.19 0.08 to 0.36
NO 0.20 0.08 to 0.37
Vaginal PGE2 pessary (normal release) 0.20 0.08 to 0.38
Intracervical PGE2 0.20 0.08 to 0.38
Vaginal PGE2 pessary (slow release) 0.21 0.08 to 0.39
i.v. oxytocin with amniotomy 0.21 0.08 to 0.41
i.v. oxytocin 0.22 0.09 to 0.41
Extra-amniotic PGE2 0.23 0.08 to 0.44
Sustained-release misoprostol insert 0.23 0.09 to 0.43
Placebo 0.23 0.09 to 0.42
Vaginal PGE2 tablet 0.24 0.08 to 0.3
Oral misoprostol tablet: dose < 50 µg 0.25 0.09 to 0.46
Double-balloon or Cook’s catheter 0.25 0.1 to 0.46
Posterior mean and 95% CrI are reported.
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The costs of each method of delivery are given in Table 27, along with the minimum and maximum
estimates. These were taken from the NHS reference costs 2012/13,958 which are the average unit cost
to the NHS of providing secondary health care to NHS patients. These are calculated on a full absorption
basis to identify the full cost of delivering the service. It was assumed that a VD within 24 hours would
constitute a short stay under the costing code, whereas a VD after 24 hours would be coded as long stay
and therefore incur higher costs. The cost of a long-stay emergency CS was also used as most emergency
CSs result in a stay of > 24 hours. A uniform distribution for these costs was assumed in the model.
TABLE 26 Absolute probabilities of NICU admission
Treatment Probability of NICU admission 95% CrI
Extra-amniotic PGE2 0.09 0 to 0.57
Double-balloon or Cook’s catheter 0.11 0 to 0.66
Sustained-release misoprostol insert 0.11 0 to 0.66
Titrated (low-dose) oral misoprostol solution 0.12 0 to 0.69
Foley catheter 0.12 0 to 0.68
Vaginal PGE2 (tablet) 0.13 0 to 0.71
Vaginal PGE2 pessary (slow release) 0.13 0 to 0.7
Intracervical PGE2 0.13 0 to 0.71
Vaginal misoprostol: dose < 50 µg 0.13 0 to 0.7
Oral misoprostol tablet: dose < 50 µg 0.13 0 to 0.72
i.v. oxytocin 0.13 0 to 0.71
Buccal/sublingual misoprostol 0.13 0 to 0.7
Vaginal PGE2 (gel) 0.14 0 to 0.74
Vaginal PGE2 pessary (normal release) 0.14 0 to 0.74
Vaginal misoprostol: dose ≥ 50 µg 0.14 0 to 0.73
Oral misoprostol tablet: dose ≥ 50 µg 0.14 0 to 0.73
NO 0.14 0 to 0.73
i.v. oxytocin with amniotomy 0.19 0 to 0.84
Mifepristone 0.2 0 to 0.85
Placebo (no intervention) 0.16 0 to 0.77
Posterior mean and 95% CrI are reported.
TABLE 27 The NHS reference costs 2012–13958 for method of delivery and neonatal critical care admission
Outcome Cost (£) Lower (£) Upper (£) Currency code Distribution
VD within 24 hours 1110 815 1345 NZ30C NEI-S Uniform
VD after 24 hours 1919 1547 2344 NZ30C NEI-L Uniform
Emergency CS 3727 2926 4289 NEI-L Uniform
Neonatal critical care, transitional care (per day) 382 306 473 XA04Z Uniform
Neonatal critical care, intensive care (per day) 1118 819 1301 XA01Z Uniform
Neonatal critical care, high-dependency care
(per day)
791 685 902 XA02Z Uniform
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Supporting documents for the NHS Reference Costs958 indicate that all activity relating to healthy babies is
reported as part of the total costs of the maternity delivery episode, whereas babies who are unwell
generate their own admission record. All hospitalised infants incur per-patient/day costs. The unit cost for
an inpatient day is also given in Table 27.
Probability of admission to each level of neonatal care, and average length of stay in each level, was taken
from data on term admissions at Liverpool Women’s NHS Foundation Trust. The data from 100 at-term
NICU admissions between July and October 2014 showed that 19% of admissions were to intensive care,
7% were to high-dependency care and 74% were to transitional care. Median length of stay was 2 days
for intensive care, 1.5 days for high-dependency care and 2 days for transitional care.
The other costs included in the analysis were the costs that were associated with the different methods of
induction. These were taken from the British National Formulary (BNF)959 for the pharmacological
interventions and from the published literature or manufacturer costs for the mechanical interventions.
Vaginal PGE2 pessary (normal release) preparation varied considerably across trials and is not currently
available on the NHS (see Chapter 3). In order to include this method, we assumed that the cost is equal to
that for vaginal PGE2 tablet and gel. Given these uncertainties, we have presented results excluding this
intervention. The intervention costs are shown in Table 28.
TABLE 28 Costs of methods of induction
Induction method Cost (£) Source
NO 0.16 BNF959
Vaginal misoprostol: dose ≥ 50 µg 0.67 BNF959
Vaginal misoprostol: dose < 50 µg 1.02 BNF959
Oral misoprostol tablet: dose ≥ 50 µg 1.02 BNF959
i.v. oxytocin 1.71 BNF959
Oral misoprostol tablet: dose < 50 µg 2.04 BNF959
Titrated (low-dose) oral misoprostol solution 2.04 BNF959
Buccal sublingual misoprostol 2.04 BNF959
i.v. oxytocin with amniotomy 2.67 BNF959
Mechanical methods: Foley catheter 4.00 Van Baaren 2013955
Mifepristone 17.50 BNF959
Vaginal PGE2 (tablet) 26.56 BNF
959
Vaginal PGE2 (gel) 26.56 BNF
959
Intracervical PGE2 26.56 BNF
959
Vaginal PGE2 pessary (normal release) 26.56 Estimated
Vaginal PGE2 pessary (slow release) 30.00 BNF
959
Sustained-release misoprostol insert 30.00 BNF959
Mechanical methods: double-balloon or Cook’s catheter 47.90 Manufacturer cost
Extra-amniotic PGE2 47.90 BNF
959
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Utility inputs
Ideally, we would capture health-related outcomes using QALYs measured using the European Quality of
Life-5 Dimensions (EQ-5D™) instrument. However, our literature review did not identify any evidence on
the EQ-5D for the outcomes in our model. Furthermore, because of the short time-horizon of our model,
the EQ-5D is unlikely to be very sensitive to changes in outcomes in our model. Instead, we attributed a
utility score to each of the outcomes in our model, which represents the strength of preferences for a set
of health-related outcomes, where utility scores take values of between ‘0’ and ‘1’, with ‘1’ representing
perfect health.
It was necessary to identify the best available utility estimates for health states that were associated with
the consequences of induction of labour for use in the model. The health states used in the model
included emergency CS and VD for the mother, and transitional care, high-dependency care and intensive
care for the child.
A literature search was undertaken to identify evidence on these utility values within published literature.
A search was carried out in PubMed, The Cochrane Library [including Cochrane Database of Systematic
Reviews (CDSR), CENTRAL, Database of Abstracts of Reviews of Effects (DARE) and Economic Evaluations
Databases], NHS EED and the Health Technology Assessment (HTA) database. Details of the search
strategy are presented in Appendix 17. The number of studies retrieved in each search is shown in
Table 29.
Studies were also identified through searching specialist health economics resources, such as the Cost-
effectiveness Analysis Registry and reference list checking. After examining titles and abstracts to identify
those that were likely to be relevant, 12 studies were found and full papers were obtained. The full-text
papers were then screened by two reviewers (EK and NJW) to identify four relevant studies (Figure 14).
The list of excluded full articles and reasons for their exclusion can be found in Appendix 17.
Many of the studies that were deemed inappropriate to inform the model relied on the use of assumptions
or judgements obtained from expert panels to assign a utility value to the health states of emergency CS,
VD and NICU admission, rather than using empirical evidence. Three of the studies960–962 identified that
were deemed relevant elicited health-state valuations for these states using the standard gamble
technique, which is a recognised preference-based measures of health-related quality of life. The other
study963 elicited utilities using the prospective measure of preference method, which is a prospective
modification of the time trade-off method and standard gamble tools that have been previously described
and validated in other settings.964
TABLE 29 Number of studies retrieved in each search
Database Number retrieved
HTA database 199
NHS EED 2247
The Cochrane Library 8908
PubMed 30,029
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Table 30 lists the four studies,960–963 the utility values that the studies use and how they were derived.
Three of the studies used appropriate respondents (patients) of a sufficient sample size to give robust
estimates. The exception was the study by Plunkett and Grobman,962 which used a panel of five experts to
assign utilities.
None of the studies gives utility values for intensive, high dependency and transitional neonatal care, as
required in our model. Vandenbussche et al.960 gives utilities for ‘transient neurological symptoms’, and
Pham and Crowther961 give utilities for admission to ‘neonatal nursery’. It was not clear in either of these
studies if the utilities relate to the mother, baby, or both. In the absence of utilities specifically for the
health states in our model, we used the lower interval reported in these two studies (0.7 from Table 30) to
represent intensive care, the higher interval (0.99 from Table 30) to represent transitional care and the
midpoint (0.845) to represent high-dependency care. There is clearly a high degree of uncertainty in these
values, and so we conducted a sensitivity analysis as detailed in Table 31.
In sensitivity analyses 1 and 2 we vary the utility for high-dependency care to 0.7 (equal to intensive care),
and 0.7725 [midpoint between 0.7 and 0.845 (base case)]. In sensitivity analyses 3 and 4 we assume a
lower utility score for intensive care (0.57 based on our own small survey described below). In sensitivity
analysis 3 we use the midpoint between 0.57 and 0.99 (0.78) for high-dependency care, and in sensitivity
analysis 4 we use a quarter of the way between the 0.57 and 0.99 (0.675) for high-dependency care.
Both the Turner et al. study963 and the Plunkett and Grobman study962 provide estimates of utilities relating
to mode of delivery; however, we use only the values from Turner et al.,963 as it is based on 102 pregnant
women, rather than five experts. We therefore used the utility values of 0.92 and 0.59 for VD and
emergency CS, respectively, as reported in Turner et al.963 (see Table 30). However, no confidence intervals
are reported for these figures, so we cannot reflect the uncertainty in the estimates.
Potentially relevant articles identified from the
electronic search and screened for retrieval
(n = 41,383)
Total full papers screened
(n = 14)
Total papers included in the review
(n = 4)
Papers excluded from review
(N = 10)
•  Excluded as utilities not elicited from
    patients, n = 2
•  Excluded as no utilities measured, n = 6
•  Excluded owing to wrong patient
    population, n = 1
•  Excluded owing to lack of instrument to
    value health states, n = 1
Papers rejected at the title and
abstract stage
(n = 41,371)
FIGURE 14 Flow chart summarising the review process.
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TABLE 30 Included studies
Study
Utility value given for:
How derivedNICU VD Emergency CS
Turner et al.963
Vaginal delivery compared
with elective CS: the views
of pregnant women
and clinicians. BJOG
2008;115:1494–502
Pain during
labour: 0.92
0.59 Prospective Measure of
Preference method
Participant’s responses
indicating the maximum level
of risk (0–100%) that they
would accept before opting for
an elective CS were converted
into utility scores, which ranged
from 0 to 1 (n= 102 pregnant
women)
Vandenbussche et al.960
Differences in the valuation
of birth outcomes among
pregnant women, mothers,
and obstetricians. Birth
1999;26:178–83
Transient
neurological
symptoms:
median 0.99;
range 0.72–0.99
VAS and standard reference
gamble given to 12
obstetricians, 15 pregnant
women and 15 mothers
(Used utilities elicited
from mothers.)
Pham and Crowther961
Birth outcomes: utility
values that postnatal
women, midwives and
medical staff express.
BJOG 2003;110:121–7
Admission to
neonatal nursery:
median: 0.99,
range: 0.70–0.99
VAS and standard gamble
administered to 90 women in
postnatal ward: 59 midwives
and 31 medical staff
(Used utilities elicited from
postnatal women.)
Plunkett and Grobman962
Routine hepatitis C virus
screening in pregnancy: a
cost-effectiveness analysis.
Am J Obstet Gynecol
2005;192:1153–61
Disutility of
0.0027, range
0.0037–0.0017
Disutility of
0.0046, range
0.0056–0.0036
Panel of five experts assigned
utility values using time
trade-off technique
VAS, visual analogue scale.
TABLE 31 Sets of utility estimates varied in sensitivity analysis
Model run Intensive care High-dependency care Transitional care
Base case 0.7 0.845 0.99
Sensitivity analysis 1 0.7 0.7 0.99
Sensitivity analysis 2 0.7 0.7725 0.99
Sensitivity analysis 3 0.57 0.78 0.99
Sensitivity analysis 4 0.57 0.675 0.99
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Because of the limited evidence in the literature on utilities, we conducted our own small survey to help us
reflect uncertainty in the utilities and obtain limits for sensitivity analysis. We administered a questionnaire
asking respondents to rate different health states. The full questionnaire and results are given in Appendix 18.
An example question is given in Figure 15.
This type of rating scale is called a visual analogue scale (VAS) and is commonly used as a method of
measuring preferences for health outcomes.965
Ten respondents completed this questionnaire. This group included all members of the project steering
group including clinicians, health economists, systematic reviewers and a patient representative. The health
states evaluated were the health of the mother following normal VD and CS, and the health of the mother
and child following the child’s admission to the ICU, high dependency unit or transitional care unit. The
data were analysed using a model that accounted for the between-respondent variability in overall level of
the utility scores, and assumed common mean differences in utility scores for the different outcomes.
Details of the statistical model are given in Appendix 18.
The estimated scores from this questionnaire were 0.65 (CrI 0.51 to 0.79) for a VD and 0.42 (CrI 0.17 to
0.67) for CS. Interestingly, although the absolute values of the scores differ, the ratio of the utilities for VD
and CS taken from Turner et al.963 agrees almost exactly with those arising from our own questionnaire.
We therefore felt it appropriate to calibrate the scores from our questionnaire to those obtained in Turner
et al.963 to obtain uncertainty limits to put around the estimates from Turner et al.963 for use in the
economic model.
Our questionnaire obtained scores for intensive care, high-dependency care and transitional care from both
the mother’s and baby’s perspective. Summing these scores for mother and baby for transitional care gave
a value of ‘1’, very similar to the 0.99 obtained from the literature review. On this basis, summing the
values for mother and baby from our questionnaire for intensive care gives a value of 0.57, which we use
as a lower limit in our sensitivity analysis (detailed in Table 31).
The final utility values that went into the model are shown in Table 32.
The continuous scale below goes from the worst health state you can imagine to the best.
Please place a mark on the scale to indicate how you would rate your health if you had:
•   restricted mobility
•   pain requiring painkillers
•   a urinary catheter
•   inability to drive, carry heavy things
•   a wound that required cleaning and drying daily.
Worst
imaginable
health state
Best
imaginable
health state
FIGURE 15 Example question from questionnaire on different health states.
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Methods of economic evaluation
We present a probabilistic cost-effectiveness analysis, which reflects the joint uncertainties in model inputs.
This can be conceptualised as a hypothetical cohort of patients who vary in their probabilities, utilities and
costs, as described by our joint uncertainty in the parameter estimates, and who experience the
consequences of each induction strategy. Total utilities and costs are then averaged over this cohort to
obtain the expected total utility and expected total cost for each induction strategy. This allows the
assessment of multiple clinical outcomes as well as costs and cost-effectiveness and ensures that full joint
uncertainty and correlations between parameters are taken into account.
The cost-effectiveness model was evaluated using Microsoft Excel® version 2013 (Microsoft Corporation,
Redmond, WA, USA). The analysis requires simulated samples from the joint distributions of all model
inputs. For the cost parameters, Monte Carlo simulation was performed within Excel to obtain the
simulated samples. The absolute probabilities and utility inputs were estimated using Bayesian inference,
computed using MCMC simulation in OpenBUGS. A total of 60,000 MCMC samples from the posterior
distributions were taken from OpenBUGS and read into Excel, from which the simulated samples were
drawn for the model, taking care to preserve correlations from the MCMC.
For each intervention we present the expected total utility and expected total cost, averaged over the
simulation sample, together with 95% CrIs. We present an incremental analysis in which (1) interventions
are ordered by increasing expected cost; (2) interventions that are dominated (have a higher expected cost
and lower expected utility than another intervention) are identified; and (3) ICERs are computed for each
non-dominated intervention relative to the previous (lower expected cost) non-dominated intervention,
for which the ICER is:
ICER =
additional expected cost
additional expected utility
. (1)
The reported ICERs can be interpreted as the additional expected cost per additional unit gain in utility for
an intervention compared with the previous non-dominated intervention in the table.
We also report cost-efficiency frontiers, which plots expected cost against expected utility for each
intervention. The frontier line indicates the intervention with the lowest expected cost for a given expected
utility, so that interventions above the line are not cost-effective compared with interventions lower down
TABLE 32 Utility estimates used in model
Delivery mode: utility (95% CrI)
NICU admission (base-case
utility, see Table 27)
Delivery mode and NICU admission:
product of utilities (95% CrI)
VD 0.92 (0.72 to 1) None (1) 0.92 (0.72 to 1)
Transitional care (0.99) 0.91 (0.71 to 0.99)
High-dependency care (0.845) 0.78 (0.61 to 0.85)
Intensive care (0.7) 0.64 (0.50 to 0.7)
Emergency CS 0.59 (0.25 to 0.95) None (1) 0.59 (0.25 to 0.95)
Transitional care (0.99) 0.58 (0.25 to 0.94)
High-dependency care (0.845) 0.50 (0.21 to 0.80)
Intensive care (0.7) 0.41 (0.18 to 0.67)
The first column shows the utilities used for mode of delivery; the second column shows the utilities used for NICU
admission type of care; and the third column is the product of the first two columns, corresponding to branches of the
decision tree (see Figure 13).
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for a given expected utility. The choice between interventions on the frontier line will depend on
willingness-to-pay per additional unit of utility.
For each intervention we computed net benefit for given willingness-to-pay per additional unit of utility, λ,
(ceiling ratio) where net benefit is defined as:
Net benefit = utility*λ− cost. (2)
‘Net benefit’ converts utilities to a monetary scale, so that the costs and utilities can be compared directly.
Expected net benefit is the average net benefit over the simulation samples. For a given willingness-to-pay
threshold λ, the optimal intervention is that with the highest expected net benefit. We present expected
net benefit for λ= £20,000.
We present the uncertainty in the optimal intervention by plotting the probability that each intervention is
the most cost-effective (has highest net benefit) against willingness-to-pay per unit of utility (CEACs).
Probabilities that are close to 1 indicate that the optimal intervention is very certain, whereas probabilities
that are much lower indicate that there is uncertainty as to which intervention is best. Because CEACs
can be misleading when there are interventions with a very high degree of uncertainty,966 we exclude
interventions from the plot that have both a high probability of being most cost-effective and a high
probability of being least cost-effective.
We also present uncertainty using the incremental cost-effectiveness plane, which displays the incremental
cost of each treatment compared with vaginal PGE2 tablet from each simulated sample against the
incremental utility of each treatment compared with vaginal PGE2 tablet. Owing to the large numbers of
interventions being compared, and the high degree of overlap of some of these, we include only the top
three or four interventions (according to probability of being the most cost-effective) in the incremental
cost-effectiveness planes.
We use value of information methods967 to explore how sensitive the optimal intervention is to uncertainty
in the model inputs, and to guide research recommendations. If there was no uncertainty in the model
inputs then we would know the optimal intervention perfectly. The expected value of perfect information
(EVPI) measures the value (in terms of net benefit) resulting from elimination of uncertainty in all model
inputs. The expected value of partial perfect information (EVPPI) measures the value (in terms of net
benefit) from elimination of uncertainty in a some of the model inputs, and can be used to explore which
model inputs are the key drivers of decision uncertainty, and may be most beneficial for further research
efforts. We compute EVPI and EVPPI per person for a willingness-to-pay per unit of utility threshold of
£20,000. We also present population-level EVPI and EVPPI, given an annual incidence of labour inductions
in England and Wales of 150,000,2,3 and assuming a lifetime of the intervention of T= 1 year and 5 years,
respectively, discounted at 3.5%. The lifetime of the intervention represents the time until the intervention
becomes obsolete, for example by being superseded by a new intervention. EVPPI for subsets of
parameters were computed using a Gaussian process emulator968 using the Sheffield Accelerated Value of
Information web application.969
Results
Base-case results
Table 33 shows the expected total cost and expected total utility for each treatment, averaged over the
simulation sample along with their CrIs. Interventions are ordered by increasing expected total cost
(treatment costs plus resource costs), with buccal/sublingual misoprostol and i.v. oxytocin with amniotomy
having the lowest expected total cost, and placebo (no intervention) having the highest expected total
cost. Note that all methods of induction have lower expected total costs than placebo (no intervention)
because they reduce costly outcomes (VD in > 24 hours, CS and NICU admission). Titrated (low-dose) oral
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TABLE 33 Base case: expected total costs, expected total utilities, ICERs and expected net benefit at a £20,000
willingness-to-pay threshold
Treatment
Expected total cost,
£ (95% CI)
Expected total
utility (95% CI)
Expected net
benefit (£) ICER (£)
Buccal/sublingual misoprostol 1747.18
(1341.57 to 1472.34)
0.821 (0.68 to 0.95) 14,668.72
i.v. oxytocin with amniotomy 1747.80
(1275.41 to 2370.82)
0.82 (0.67 to 0.95) 14,652.13 Dominated
Vaginal misoprostol: dose ≥ 50 µg 1789.56
(1386.41 to 2270.74)
0.82 (0.68 to 0.95) 14,603.51 Dominated
Titrated (low-dose) oral misoprostol
solution
1799.55
(1403.44 to 2262.1)
0.823 (0.68 to 0.96) 14,658.28 21,190
Vaginal misoprostol: dose < 50 µg 1852.56
(1456.01 to 2325.54)
0.819 (0.68 to 0.95) 14,533.98 Dominated
Oral misoprostol tablet: dose ≥ 50 µg 1906.19
(1499.21 to 2384.89)
0.819 (0.68 to 0.95) 14,467.15 Dominated
Vaginal PGE2 gel 1935.79
(1517.97 to 2429.53)
0.817 (0.67 to 0.95) 14,402.37 Dominated
Foley catheter 1968.64
(1550.28 to 2463.38)
0.815 (0.67 to 0.95) 14,328.52 Dominated
i.v. oxytocin 1977.39
(1536.48 to 2518.6)
0.809 (0.66 to 0.95) 14,195.63 Dominated
Sustained-release misoprostol insert 1997.08
(1480.46 to 2597.86)
0.805 (0.65 to 0.95) 14,108.39 Dominated
Vaginal PGE2 pessary (normal release) 2015.76
(1569.43 to 2533.94)
0.811 (0.66 to 0.95) 14,210.27 Dominated
Intracervical PGE2 2033.03
(1614.6 to 2532.76)
0.633 (0.53 to 0.74) 10,617.17 Dominated
Vaginal PGE2 pessary (slow release) 2036.15
(1602.91 to 2551.89)
0.81 (0.66 to 0.95) 14,162.42 Dominated
Vaginal PGE2 tablet 2042.64
(1638.01 to 2565.19)
0.805 (0.65 to 0.95) 14,054.25 Dominated
Extra-amniotic PGE2 2093.96
(1567.05 to 2684.18)
0.804 (0.65 to 0.95) 13,982.18 Dominated
Double-balloon or Cook’s catheter 2097.74
(1618.43 to 2682.1)
0.8 (0.64 to 0.95) 13,906.29 Dominated
Oral misoprostol tablet: dose < 50 µg 2140.28
(1644.79 to 2738.28)
0.802 (0.64 to 0.94) 13,898.03 Dominated
NO 2141.74
(1662.1 to 2676.64)
0.816 (0.67 to 0.94) 14,179.69 Dominated
Mifepristone 2202.28
(1709.58 to 2742.8)
0.821 (0.69 to 0.95) 14,210.41 Dominated
Placebo (‘no intervention’) 2304.82
(1847.79 to 2822.48)
0.805 (0.65 to 0.94) 13,788.52 Dominated
CI, confidence interval.
Note
£21,190 is the additional expected cost per additional unit gain in utility required for titrated (low-dose) oral misoprostol
solution compared with buccal/sublingual misoprostol.
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misoprostol solution has the highest expected utility, very closely followed by buccal/sublingual
misoprostol, mifepristone, i.v. oxytocin with amniotomy and vaginal misoprostol (dose ≥ 50 µg).
Intracervical PGE2 has the lowest expected utility. As the majority of interventions (all except intracervical
PGE2) have no more than a 0.02 difference in expected utility between them, they could be assumed to be
clinically equivalent, so that a decision between them is effectively based on minimising total costs. Note
that the confidence intervals show that there is a high degree of uncertainty in these estimates.
Any intervention that has a higher expected cost and lower expected utility than another intervention is
said to be dominated by that intervention. As can be seen from Table 33, all treatments apart from titrated
low-dose oral misoprostol solution are dominated by buccal/sublingual misoprostol, which is more
effective, in terms of increased utility, and less expensive than the other interventions.
As titrated (low-dose) oral misoprostol solution is non-dominated relative to buccal/sublingual misoprostol,
an ICER is computed:
ICER =
additional expected cost
additional expected utility
=
£42.38
0.002
= £21,190. (3)
Therefore, £21,190 is the additional expected cost per additional unit gain in utility required for titrated
(low-dose) oral misoprostol solution compared with buccal/sublingual misoprostol.
The expected total costs and expected utilities are displayed graphically in a cost-efficiency frontier
(Figure 16). Any intervention above the line is not cost-effective compared with interventions lower down
for a given expected utility. The graph shows that all of the other interventions apart from buccal/
sublingual misoprostol and titrated (low-dose) oral misoprostol are above the line and are therefore
dominated, as they are more expensive and less effective. i.v. oxytocin lies very close to the line.
Intracervical PGE2 is removed from the graph for visualisation purposes, as it is considerably less effective
than the rest of the treatments and also relatively expensive, placing it far from the line. Placebo is the
treatment that has the highest expected total cost and is therefore far from the line.
The expected net benefit at a £20,000 willingness-to-pay threshold (see Table 33) is highest for buccal/
sublingual misoprostol (£14,669), closely followed by titrated (low-dose) oral misoprostol solution
(£14,658) and i.v. oxytocin with amniotomy (£14,652) and lowest for intracervical PGE2 (£10,617).
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FIGURE 16 Base case: cost-effectiveness efficiency frontier.
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
94
We present the uncertainty surrounding the cost-effectiveness of the various interventions, using a CEAC
(Figure 17) and the cost-effectiveness plane (Figure 18).
The CEACs (see Figure 17) plot the probability that each of the interventions is the most cost-effective by
computing the proportion of simulations for which that intervention had the highest net benefit for a
given willingness-to-pay per unit increase in utility. Out of the 19 interventions evaluated, only three had a
probability of > 10% of being cost-effective at any willingness-to-pay value: titrated (low-dose) oral
misoprostol solution, buccal/sublingual misoprostol and i.v. oxytocin with amniotomy. However, the results
for i.v. oxytocin with amniotomy were very uncertain, and i.v. oxytocin also had a high probability of being
the least cost-effective. To avoid misleading conclusions, we have removed i.v. oxytocin with amniotomy
from Figure 17, and, for clarity, give labels only for interventions for which it was clear that the probability
of being cost-effective is > 10%. Figure 17 shows that at any willingness-to-pay value up until around
£23,000, buccal/sublingual misoprostol has the highest probability of being cost-effective. Above this
threshold, titrated low-dose oral misoprostol solution has the highest probability of being cost-effective.
This probability is never > 35%, indicating a large degree of uncertainty in the optimal intervention.
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FIGURE 17 Base-case CEAC. Plotted against different willingness-to-pay per unit increase in utility (ceiling ratio).
Note the curves are unchanged for ceiling ratios of > £50,000. Note: The non-labelled interventions have not been
specified because of their close proximity to each other.
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The high degree of uncertainty between these interventions is seen clearly in the cost-effectiveness plane
(see Figure 18), which plots the simulated pairs of incremental utility and incremental cost values for each
intervention (compared with vaginal PGE2 tablet). As there are a large number of interventions to display,
and the majority of interventions were very similar in terms of costs and utilities, the plot is unreadable if
all interventions are included. For visual clarity, we plot only the interventions that were found to have had
a > 10% probability of being cost-effective of at any willingness-to-pay value, along with intracervical
PGE2, the intervention with the lowest average utility.
As can be seen from the graph, the majority of the points for buccal/sublingual misoprostol, titrated
(low-dose) oral misoprostol solution and i.v. oxytocin with amniotomy are plotted in the bottom right-hand
corner, indicating that these interventions are more effective and less expensive than vaginal PGE2 tablet.
However, the location of some of the points in the other quadrants indicates that this is not certain. All of
the points for intracervical PGE2, for example, are plotted in the top- and bottom-left quadrants, showing
that although there is uncertainty in the cost, intracervical PGE2 never has a utility score higher than
vaginal PGE2 tablet.
Sensitivity analysis to assumed utilities
Varying the utility estimates, as detailed in Table 31, had a very minor effect on the results. The
interventions were ranked from lowest to highest expected cost in the same order and the expected
utilities varied only on the second or third decimal point.
Subgroup analysis (i): women with intact membranes only
To examine the effect that membrane status had on the results, a scenario analysis was carried out
restricting to mothers with intact membranes only. When we included all interventions for which we had
sufficient information to evaluate the model, only 13 out of a total of 34 interventions (see Table 34 and
see Appendix 16) were included in analysis, and the remaining interventions were excluded. Note that
placebo (no intervention) was not included in this analysis, so comparisons with no intervention cannot
be made.
Table 34 shows the expected total utility and expected total cost for each treatment when the analysis is
limited to women with intact membranes. Interventions are again ordered in order of increasing expected
cost (treatment costs plus resource costs) with titrated (low-dose) oral misoprostol solution now having the
highest expected total cost and vaginal misoprostol (dose < 50 µg) and i.v. oxytocin with amniotomy
having the lowest expected cost. Titrated (low-dose) oral misoprostol solution still has the highest expected
utility, and intracervical PGE2 still has the lowest expected utility. The confidence intervals again show that
there is a high degree of uncertainty in these estimates.
As can be seen from Table 34, all interventions apart from titrated (low-dose) oral misoprostol solution and
i.v. oxytocin with amniotomy are dominated by vaginal misoprostol (dose < 50 µg), which is more effective
in terms of increased utility, and less expensive.
As i.v. oxytocin with amniotomy is non-dominated relative to vaginal misoprostol (dose < 50 µg), an ICER
is computed:
ICER =
additional expected cost
additional expected utility
=
£0.94
0.006
= £156.66. (4)
Therefore, £156.66 is the additional expected cost per additional unit gain in utility required for i.v.
oxytocin with amniotomy compared with vaginal misoprostol in women with intact membranes only.
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As titrated (low-dose) oral misoprostol solution is non-dominated relative to i.v. oxytocin with amniotomy,
an ICER is also computed:
ICER =
additional expected cost
additional expected utility
=
£474.02
0.012
= £39, 501.66. (5)
Therefore, £39,501.66 is the additional expected cost per additional unit gain in utility required for titrated
(low-dose) oral misoprostol solution compared with i.v. oxytocin with amniotomy in women with intact
membranes only.
The intervention with the highest expected net benefit at £20,000 threshold is i.v. oxytocin with
amniotomy (£14,586), followed by vaginal misoprostol (dose < 50 µg) (£14,464), and the intervention with
the lowest expected net benefit is intracervical PGE2 at £10,563.
TABLE 34 Subgroup analysis: women with intact membranes only, excluding vaginal PGE2 pessary (normal release)
a
Treatment
Expected total cost,
£ (95% CI)
Expected total
utility (95% CI)
Expected net
benefit (£) ICER (£)
Vaginal misoprostol: dose < 50 µg 1928.96
(1571.86 to 2338.89)
0.82 (0.69 to 0.94) 14,464.22
i.v. oxytocin with amniotomy 1929.9
(1487.64 to 2439.18)
0.826 (0.7 to 0.94) 14,586.48 156.66
Buccal/sublingual misoprostol 1936.01
(1516.6 to 1816.31)
0.817 (0.68 to 0.94) 14,400.68 Dominated
Vaginal misoprostol: dose ≥ 50 µg 2000.32
(1634.83 to 2416.3)
0.815 (0.69 to 0.94) 14,287.56 Dominated
Vaginal PGE2 pessary (normal release) 2018.92
(1612.79 to 2494.27)
0.814 (0.68 to 0.94) 14,252.13 Dominated
Oral misoprostol tablet: dose ≥ 50 µg 2028.67
(1662.47 to 2439.99)
0.82 (0.7 to 0.94) 14,362.26 Dominated
Foley catheter 2065.24
(1691.42 to 2497.22)
0.813 (0.68 to 0.94) 14,185.49 Dominated
Vaginal PGE2 gel 2165.47
(1777.15 to 2608.8)
0.813 (0.68 to 0.94) 14,096.27 Dominated
Vaginal PGE2 tablet 2193.74
(1809.57 to 2617.3)
0.803 (0.67 to 0.93) 13,861.77 Dominated
Intracervical PGE2 2195.47
(1809.48 to 2640.88)
0.638 (0.54 to 0.74) 10,563.31 Dominated
Vaginal PGE2 pessary (slow release) 2219.12
(1851.24 to 2668.99)
0.807 (0.68 to 0.93) 13,924.89 Dominated
Double-balloon or Cook’s catheter 2249.43
(1824.03 to 2759.69)
0.793 (0.65 to 0.93) 13,607.27 Dominated
Titrated (low-dose) oral misoprostol
solution
2403.92
(1841.58 to 3084.74)
0.832 (0.71 to 0.93) 14,224.30 39,501.66
CI, confidence interval.
a Expected total costs, expected total utilities, ICER and expected net benefit at a £20,000 willingness-to-pay value.
Note
£156.66 is the additional expected cost per additional unit gain in utility required for i.v. oxytocin with amniotomy
compared with vaginal misoprostol in women with intact membranes only.
£39,501 is the additional expected cost per additional unit gain in utility required for titrated (low-dose) oral misoprostol
solution compared with i.v. oxytocin with amniotomy in women with intact membranes only.
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The CEAC for women with intact membranes only is presented in Figure 19. i.v. oxytocin with amniotomy,
titrated (low-dose) oral misoprostol solution, buccal/sublingual misoprostol and vaginal misoprostol
(dose < 50 µg) were the only four treatments with a probability of being cost-effective of > 10% of any
willingness-to-pay value (ceiling ratio). i.v. oxytocin with amniotomy has the highest probability of being
cost-effective at any value of the ceiling ratio with a probability of around 45%.
The incremental cost-effectiveness plane for the four interventions with probability of being cost-effective
of > 10% is presented in Figure 20, showing the high degree of uncertainty in the costs and effects of
these interventions.
Subgroup analysis (ii): women with an unfavourable cervix only
To examine the effect that Bishop score had on the results, a scenario analysis was carried out restricting to
mothers with an unfavourable cervix (Bishop score < 6). When we included all of the interventions for which
we had sufficient information to evaluate the model, 19 interventions out of a total of 34 interventions (see
Table 35 and Appendix 16) were included in the analysis, and the remaining were excluded.
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FIGURE 20 Incremental cost-effectiveness plane for subgroup analysis (i): women with intact membranes only.
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FIGURE 19 Cost-effectiveness acceptability curve for subgroup analysis (i): women with intact membranes only.
Note: The non-labelled interventions have not been specified because of their close proximity to each other.
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Table 35 shows the expected total utility and expected total cost for each intervention when the analysis is
limited to women with an unfavourable cervix. Interventions are again ordered by increasing expected total
cost with buccal/sublingual misoprostol having the lowest expected total cost and placebo having the
highest expected total cost, as in the base case. Titrated (low-dose) oral misoprostol solution and buccal/
sublingual misoprostol have the highest expected utility, and intracervical PGE2 still has the lowest expected
utility. The confidence intervals again show that there is a high degree of uncertainty in these estimates.
TABLE 35 Subgroup analysis: women with an unfavourable cervix onlya
Treatment
Expected total cost,
£ (95% CI)
Expected total
utility (95% CI) ICER
Expected net
benefit (£)
Buccal/sublingual misoprostol 1803.03
(1209.38 to 2293.03)
0.805 (0.62 to 0.96) 14,296.29
Titrated (low-dose) oral misoprostol
solution
1833.93
(1228.19 to 2681.17)
0.805 (0.62 to 0.95) Dominated 14,268.94
Vaginal misoprostol: dose ≥ 50 µg 1860.48
(1237.3 to 2736.31)
0.799 (0.61 to 0.95) Dominated 14,125.24
Vaginal misoprostol: dose < 50 µg 1900.34
(1269.91 to 2767.69)
0.8 (0.61 to 0.95) Dominated 14,096.55
Oral misoprostol tablet: dose ≥ 50 µg 1922.13
(1281.71 to 2778.67)
0.8 (0.61 to 0.95) Dominated 14,083.50
Vaginal PGE2 gel 1966.08
(1316.53 to 2849.77)
0.796 (0.6 to 0.95) Dominated 13,958.18
Foley catheter 1984.89
(1332.08 to 2845.84)
0.796 (0.6 to 0.95) Dominated 13,937.91
Intracervical PGE2 2033.89
(1370.72 to 2917.34)
0.642 (0.5 to 0.8) Dominated 10,797.93
Vaginal PGE2 pessary (normal release) 2047.53
(1367.65 to 2942.25)
0.79 (0.58 to 0.95) Dominated 13,750.04
Sustained-release misoprostol insert 2082.66
(1352.56 to 3024.87)
0.784 (0.57 to 0.95) Dominated 13,594.43
Vaginal PGE2 pessary (slow release) 2102.42
(1412.2 to 2993.83)
0.788 (0.58 to 0.95) Dominated 13,666.30
Vaginal PGE2 tablet 2106.02
(1418.6 to 3012.11)
0.783 (0.57 to 0.94) Dominated 13,562.65
NO 2115.85
(1424.43 to 2958.84)
0.795 (0.59 to 0.94) Dominated 13,792.94
i.v. oxytocin 2137.78
(1433.27 to 3017.3)
0.787 (0.58 to 0.95) Dominated 13,604.63
Double-balloon or Cook’s catheter 2159.86
(1422.1 to 3114.44)
0.778 (0.55 to 0.94) Dominated 13,397.99
Oral misoprostol tablet: dose < 50 µg 2166.04
(1420.9 to 3096.83)
0.78 (0.56 to 0.95) Dominated 13,434.70
Mifepristone 2182.01
(1516.15 to 2987.41)
0.801 (0.61 to 0.95) Dominated 13,831.39
Placebo 2276.45
(1599 to 3112.04)
0.784 (0.57 to 0.94) Dominated 13,407.56
CI, confidence interval.
a Expected total costs, expected total utilities, and expected net benefit at a £20,000 willingness-to-pay value.
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As can be seen from Table 35, all other interventions are dominated by buccal/sublingual misoprostol,
which is more effective in terms of increased utility (or equivalent in the case of titrated (low-dose) oral
misoprostol) and less expensive than all other treatments. However, as in the other analyses, there is little
difference between the utility scores.
The intervention with the highest expected net benefit is buccal/sublingual misoprostol (£14,296) followed
by titrated (low-dose) oral misoprostol solution (£14,269) then vaginal misoprostol (dose ≥ 50 µg)
(£14,125), and the intervention with the lowest expected net benefit is intracervical PGE2 at £10,798.
The CEAC for women with an unfavourable cervix subgroup is presented in Figure 21. Buccal/sublingual
misoprostol has the highest probability of being most cost-effective, followed by titrated (low-dose) oral
misoprostol solution, but there is a high degree of uncertainty in these results, with the probability being
around 50%.
The incremental cost-effectiveness plane for the subgroup analysis (Figure 22) shows incremental costs
and utilities (compared with vaginal PGE2 tablet) for the two interventions that had a probability of being
cost-effective of > 10%. The majority of the points are located in the bottom right-hand quadrant,
indicating that they are likely to be less expensive and more effective than vaginal PGE2 tablet.
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FIGURE 21 Cost-effectiveness acceptability curve for subgroup analysis (ii): women with an unfavourable cervix
only. Note: The non-labelled interventions have not been specified because of their close proximity to each other.
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Value-of-information analysis
Table 36 shows the results of the value-of-information analyses for the base-case model at a willingness-
to-pay per unit utility threshold of £20,000. The per-woman EVPI is £187, which corresponds to a
population EVPI of £28M for all of the inductions in England and Wales over a 1-year time horizon,
increasing to £131M over a 5-year time horizon. This large value suggests that the decision is sensitive to
uncertainty in the model inputs, and so it is potentially of value to reduce this uncertainty through future
research studies. Comparing EVPPI for different subsets of model inputs indicates to which model inputs
the decision is most sensitive and where future research efforts may be best invested. EVPPI is higher for
cost parameters (£19) than for utility parameters (£0); however, EVPPI for both cost and utility parameters
together (£102) is higher than for cost parameters alone. This suggests that there is no value in reducing
uncertainty in either costs or utilities without also reducing uncertainty in the other. There is a high value in
reducing uncertainty in all of the transition parameters for mode of delivery (£114). We explored the
potential value of a new trial comparing the two interventions with the highest expected net benefit in the
base case [buccal/sublingual misoprostol vs. titrated (low-dose) oral misoprostol] providing information on
all transitions for those interventions, costs and utilities. This gives an EVPPI of £110, which corresponds to
a population EVPPI of £16.5M over a 1-year time horizon, increasing to £77M over a 5-year time horizon.
However, if costs and utilities are not collected then this value disappears (EVPPI of £2). This suggests that
a large well-conducted trial may be a worthwhile use of resources, but it is essential to collect information
on costs and utilities as well as transition probabilities for mode of delivery and NICU admission.
TABLE 36 Expected value of perfect information and EVPPI for various subsets of model parameters, at a £20,000
willingness-to-pay value per unit of utility
Model parameter subsets
EVPPI per woman
induced (£)
1-year population
EVPPI (£)
5-year population
EVPPI (£)
All (EVPI) 186.71 28,006,500 130,876,593
All costs 19.31 2,896,500 13,535,574
All utilities 0.09 13,500 63,087
All costs and utilities 101.71 15,256,500 71,294,833
All NICU transition probabilities 12.47 1,870,500 8,740,995
All mode of delivery transition probabilities 113.81 17,071,500 79,776,472
Buccal/sublingual misoprostol vs. titrated
(low-dose) oral misoprostol (transition
probabilities, costs, utilities)
110.08 16,512,000 77,161,884
Buccal/sublingual misoprostol vs. titrated
(low-dose) oral misoprostol (transition
probabilities only)
2.11 316,500 1,479,030
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Limitations
The model made a number of assumptions that need to be kept in mind when interpreting the results.
1. We were able to perform the analysis only for the interventions for which we had sufficient information
on all outcomes required in the model. This does not mean the excluded interventions are not
cost-effective, just that we have no evidence. Therefore, our conclusions on the cost-effectiveness of
the included interventions needs to be interpreted within the set of interventions that we were able to
include. However there were no interventions that were identified by the NMA as being effective that
were not included in the cost-effectiveness analysis. Furthermore, only a subset (86) of the studies
provided information on both VD within 24 hours and CS for the joint modelling required in the
economic model. Therefore, the economic evaluation is based on fewer studies than the NMA
presented in Chapter 3 for VD within 24 hours.
2. It is assumed that the proportion of babies who are admitted to NICU depends on mode of delivery
(CS or VD), but not on whether a VD was within 24 hours of induction or not. Of those admitted to
NICU, we assumed that the proportion of babies cared for in intensive (19%), high dependency (7%) or
transitional care (74%) would not vary depending on method (vaginal vs. CS) or timing of delivery
(< 24 hours; > 24 hours), or intervention.
3. It was also assumed that the length of stay in intensive, high dependency and transitional care was
fixed at 2, 1.5 and 2 days, respectively, based on the data from the Liverpool Women’s Hospital.
4. It was assumed that long-term costs and benefits would be equal across induction methods, and that
any variation would be captured in the time between induction and discharge.
5. The NMA gave estimates on the rate of instrumental delivery, Apgar score < 7 at 5 minutes and uterine
hyperstimulation, but these were assumed to be unnecessary in the model, as the differences in costs
and benefits would be captured in the other outcomes included.
6. Some important outcomes, such as post-partum haemorrhage, were not reported as an outcome in
trials and therefore could not be included in the economic model.
7. Although we would have liked to, we did not have enough evidence on parity to explore
cost-effectiveness in primiparous and multiparous women separately.
Conclusions
In summary, the base-case analysis found that all of the methods of induction were cost-saving compared
with no treatment. It is noteworthy that there is considerable uncertainty in our cost-effectiveness
estimates, with the majority of the interventions having very similar utility values, and mainly differing in
total costs.
With this caveat, buccal/sublingual misoprostol and titrated oral misoprostol were identified as being the
interventions with the highest expected net benefit and the highest probability of being cost-effective.
At any willingness-to-pay value of > £23,000 per unit increase in utility, titrated low-dose oral misoprostol
solution seems to be the intervention that is most likely to be the most cost-effective for use on the UK
NHS. Given that we were able to analyse only two subgroups (intact membranes and unfavourable cervix),
and the number of interventions compared – and studies included – were lower than in the base case, the
results of subgroup analyses should be interpreted cautiously (i.e. as hypothesis generating).
In the subgroup of women with intact membranes, and limiting to interventions feasible on the NHS,
i.v. oxytocin with amniotomy was identified as being the intervention with the highest expected net
benefit and the optimal intervention at any willingness-to-pay value. However, there was again a lot of
uncertainty in this estimate, with buccal/sublingual misoprostol and titrated (low-dose) oral misoprostol
also with a moderate probability of being most cost-effective.
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Buccal/sublingual misoprostol and titrated low-dose oral misoprostol solution were found to be the
interventions that were most likely to be cost-effective in women with an unfavourable cervix.
The majority of the interventions, with a few notable exceptions, such as intracervical PGE2, result in similar
expected utility and vary mainly in terms of cost. There is a considerable degree of uncertainty in these
estimates, demonstrated by the wide confidence intervals around the values.
There is a need to study further utilities on both mother and baby outcomes from both mother and baby
perspectives. This research should be conducted using preference-based measures on large samples and
with uncertainties fully reported. We would urge future trials in this area to present results according to
mutually exclusive clinically relevant subgroups (e.g. parity, membrane and cervical status, previous CS) to
allow more evidence to inform subgroup analyses. We would also urge trialists to report results in a format
that allows the construction of the number of vaginal deliveries within 24 hours, the number CSs and the
number of vaginal deliveries after 24 hours. It would also be useful to report the NICU admissions
according to mode of delivery. Haemorrhage and sepsis (antibiotic usage) are also important adverse
outcomes that have consequences for the economic evaluation but which are inconsistently reported. The
value-of-information analysis suggests that the decision is very sensitive to uncertainty in the model inputs,
and there is potential value in reducing this uncertainty through future research studies. Further large well-
conducted trials may be a worthwhile use of resources, but it is essential to collect information on costs
and utilities, as well as transition probabilities for mode of delivery and NICU admission.
DOI: 10.3310/hta20650 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 65
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Alfirevic et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
103

Chapter 5 Discussion
Statement of overall/principal findings
In this final chapter, we begin with a summary of the systematic review, NMA and the cost-effectiveness
analysis. We then set out the strengths and limitations of analyses before considering the clinical
implication of findings. Finally, we offer recommendations for future research.
Key findings of the systematic review and network meta-analysis
Thirty-four active treatment types/regimens were included in our review, including different dose regimes
and routes of administration. Overall, the search identified > 1000 studies and, after eligibility assessment
using our PICO (population, intervention and relevant comparators, outcomes) criteria, 611 trials were
included in the review. Together, these trials reported findings for > 100,000 women who were
randomised to different methods for third-trimester induction of labour.
The active interventions most likely to achieve VD within 24 hours were i.v. oxytocin with amniotomy,
misoprosotol (vaginal tablets – high and low dose; pessary – sustained release; low-dose oral solution; and
buccal/sublingual misoprotol) closely followed by vaginal administration of PGE2 (pessary – normal release).
It should be stressed that the rankings have wide CrIs for all of the above methods, indicating considerable
uncertainty. The rankings range from 1st to 6th and 1st to 9th for vaginal misoprostol (≥ 50 µg) and i.v.
oxytocin with amniotomy, respectively, to 1st to 13th for PGE2 pessary.
Compared with placebo, several treatments showed a statistically significant reduction in the odds of CS:
titrated low-dose misoprostol, vaginal misoprostol at both ≥ 50 µg and < 50 µg, vaginal PGE2 gel,
intracervical PGE2, oral misoprostol tablet (≥ 50 µg), Foley catheter, membrane sweeping and buccal/
sublingual misoprostol. In this group, titrated oral misoprostol achieved the lowest odds of an eventual CS
but there was still considerable uncertainty in this finding, as observed by the posterior mean rank of
6th (out of 33) and 95% CrI from 2nd to 13th (out of 33) for oral misoprostol solution. There was little to
distinguish between the other interventions with considerable uncertainty in treatment rankings. i.v.
prostaglandins performed worse than placebo and significantly increased the odds of CS. Other poorly
performing interventions included vaginal PGE2 tablet, oral misoprostol tablet < 50 µg, double-balloon
catheters and oestrogens.
Uterine hyperstimulation with FHR changes was one of the key safety outcomes. Here double-balloon
catheter, NO and laminaria had the highest probability of being among the best three treatments, whereas
i.v. oxytocin with amniotomy, slow-release misoprostol pessary and high-dose vaginal misoprostol tablets
(which was among the best treatments for efficacy) were most likely to increase the odds of excessive
uterine activity. For other safety outcomes there were insufficient data or too much uncertainty around
estimates to identify which treatments performed ‘best’.
Few studies collected information on women’s views. On the whole, women tended to have positive
views, or at least accepted the induction process, but there was insufficient information to determine
whether or not some methods were preferred over others.
Our findings also suggest that of the seemingly less ‘medicalised’ induction methods, there is little to
choose among them in terms of safety. Of interest is that none of the included studies examining these
methods (membrane sweeping, acupuncture and sexual intercourse) reported our effectiveness outcome –
failure to achieve VD within 24 hours – suggesting that when it comes to the urgency of delivery, the
expectations from these methods is very different.
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We planned to carry out subgroup analyses to check that our findings were robust in different groups of
women: women with intact amniotic membranes compared with ruptured amniotic membranes; women
with unfavourable Bishop scores compared with favourable Bishop scores; women who had had a previous
CS and women undergoing induction of labour at different gestational ages. Unfortunately, it was possible
to carry out only two of these analyses (membrane status and Bishop scores) owing to lack of data or
inconsistency in the results for other subgroups.
Our two subgroup analyses were restricted to only a fraction of 611 included trials and three outcomes
(VD within 24 hours, CS and low Apgar score). The results were broadly in agreement with overall results.
i.v. oxytocin with amniotomy and high-dose vaginal misoprostol tablets remained the most effective
interventions for achieving VD within 24 hours in women with intact membranes.
Key findings of the cost-effectiveness analysis
All methods of induction were cost-saving compared with no treatment, although there is considerable
uncertainty in our cost-effectiveness estimates. It is important to stress that the interventions have very
similar expected utility values, and differ mainly in expected total costs. Titrated (low-dose) oral misoprostol
and buccal/sublingual misoprostol had the highest probability of being the most cost-effective intervention
at any willingness-to-pay value. Given that we were able to analyse only two subgroups (intact membranes
and unfavourable cervix), and the number of interventions compared and studies included were lower than
in the base case, the results of subgroup analyses should be interpreted cautiously (i.e. as hypothesis
generating). In the subgroup of women with intact membranes, and limiting to interventions that were
feasible through the NHS, i.v. oxytocin with amniotomy was identified as the intervention that was most
likely to be most cost-effective. In the subgroup of women with an unfavourable cervix, buccal/sublingual
misoprostol and titrated low-dose oral misoprostol solution were found to be the interventions that were
most likely to be most cost-effective.
Strengths
In our systematic review we made considerable effort to include all RCTs with no language restrictions,
which led to the inclusion of > 600 trials, with data for > 100,000 women and babies. The NMA provided
an opportunity to examine the relative effectiveness of all treatments used for the induction of labour in a
coherent and methodologically robust way across important clinical outcomes. Although there are now
increasing numbers of NMAs reported in the literature, and some relate to competing treatments in
obstetrics,970 as far as we are aware this NMA includes more trials and participants than any other in this
topic area.
Network meta-analysis is only valid on the assumption that all of the treatments in the network would be
suitable for all included women. We were thorough in our evaluation of six important potential treatment
effect modifiers (previous CS, parity, membrane status, Bishop score, gestational age and single/multiple
pregnancy) and found no clinically important differences in the distribution of these potential effect
modifiers across the interventions. We also conducted informal and formal statistical checks of model fit
and inconsistency. When lack of fit and/or inconsistency between evidence sources was observed, it was
resolved by excluding studies that were assessed as being at high risk of bias.
To our knowledge this is the first attempt to simultaneously compare more than two treatments for the
induction of labour in a cost-effectiveness analysis. A study by Petrou et al.14 suggested that PGE2 gel was
more cost-effective than PGE2 tablets, and Van Baaren et al.’s study955 concluded that Foley catheter
induction was more cost-effective than PGE2 gel. These results are not directly comparable with the results
from this study, as they use different measures of benefit, but it is still worth mentioning that in our
cost-effectiveness analysis these interventions were found to be less effective and more expensive than
titrated (low-dose) oral misoprostol solution, vaginal PGE2 pessary (normal release) and vaginal misoprostol
(dose < 50 µg).
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Limitations
Systematic review and network meta-analysis
Broadly, the aim of induction of labour is to achieve early delivery of the baby with the minimum harm to
women and babies, and we selected outcomes to reflect these aims. However, not all of the included trials
provided data on all of our key outcomes. The number of women undergoing CS was generally well
reported. However, in view of high heterogeneity and apparent inconsistency it was necessary to restrict
our analysis to RCTs at low risk of bias for the allocation concealment domain.
The number of women who did not give birth vaginally within 24 hours (our main efficacy outcome) was
reported in less than one-quarter of trials.
Key safety outcomes were also reported relatively infrequently. Approximately one-third of trials were
included in the NMA for infant admission to NICU (205) and there was considerable heterogeneity
between trials (possibly as a result of inconsistent definitions of this outcome). Similarly, uterine
hyperstimulation and low infant Apgar score were reported in fewer than one-third of trials.
Overall, maternal mortality and severe morbidity and infant mortality event rates, when reported, were very
low. Unfortunately, these outcomes were too infrequently reported to make the pooled analysis possible.
We had also intended to report serious infant morbidity but this outcome was poorly reported and
inconsistently defined in trials. Consequently, we used admission to NICU as a proxy outcome for infant
morbidity. Neonatal mortality was reported in only 21.3% of these trials and the incidence was low at
0.3%. Of course, it should not be assumed that if infant mortality was not reported then it did not occur,
but it is probable that death rates were also low in those trials failing to report this important outcome.
Very few trials collected data and reported findings relating to women’s views about the induction process.
This was surprising, as some methods of induction are likely to be both painful and unpleasant. Again,
because of the dearth of data and inconsistency in the way outcomes were measured and reported across
trials, we were unable to include findings on maternal preferences and satisfaction in our formal
quantitative analysis. There was also insufficient information from trials evaluating alternative and
complementary methods to include them in the analysis of our main efficacy outcome. None of the trials
included for the analysis of number of women failing to deliver within 24 hours included an alternative
method of induction. For safety outcomes, alternative and complementary methods of induction did not
appear to be safer than pharmacological and mechanical methods.
The trials included in the review recruited women with varied clinical characteristics, and it is important to
bear this in mind when interpreting results. The indications for induction were not always reported and,
when they were, these varied across trials. Many trials excluded women with a history of CS or multiple
pregnancies. Predominantly, women recruited to trials were at > 37 weeks’ gestation, including post-term
pregnancies and term PROM. Most of the trials were carried out in hospital settings because most
methods of labour induction require constant attendance and monitoring by skilled clinical staff. However,
we did include 79 trials examining interventions that were carried out in outpatient, community or
home settings.
For all outcomes we observed moderate heterogeneity between study effects. This is not surprising, given
the clinical heterogeneity described above in settings and women who present for induction of labour.
Heterogeneity may also be attributable to the varied quality of included studies. Overall, approximately half
of the studies were assessed as being at high or unclear risk of bias. Consequently, we conducted REs
NMA for all outcomes to allow for this heterogeneity. We report the mean from the REs distribution of
study effects, although this assumes that our focus is on the effects observed in an ‘average study’,
whereas other summaries might be more appropriate, such as the shrunken estimate for the UK trials971 or
a prediction for a new study population.
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Although NMA offers the opportunity to rank treatments in terms of relative effects for each outcome, for
many results there was considerable uncertainty around effect estimates. Particularly for the analysis of safety
outcomes, the findings were not clear-cut (i.e. there were no clear ‘best’ or ‘worst’ treatments for most of
these outcomes). This uncertainty did not apply just to results for CS. This uncertainty is not necessarily
surprising, as a large number of interventions were examined in the network. Although some interventions
were examined in a large number of trials, data for other interventions were sparse, event rates for some
outcomes were very low, and some outcomes were also inconsistently defined (e.g. hyperstimulation
syndrome). This means that we were not able to use all of the available data in our analysis. In particular, the
low event rates for NICU admission meant that in some arms of trials no events were reported, which led to
problems in estimation of relative effects and also increased uncertainty in the economic analyses.
Heterogeneity in the analyses may also have been caused by the fact that trials were carried out over a
long time period during which induction and CS rates in particular have increased steadily. These temporal
changes could have contributed to heterogeneity and increased uncertainty of findings. More intensive
surveillance may also have led to apparent increases in some outcomes (e.g. hyperstimulation).
Cost-effectiveness analysis
Our cost-effectiveness analysis was confined to short-term outcomes up until discharge from hospital,
although we are aware that some outcomes may have a longer-term impact on women and their families,
and also on NHS resources. The analysis was complicated by the fact that outcomes related to both
women and their babies, and the two are interlinked. Women may be profoundly affected by any adverse
outcomes in their newborn and, conversely, the baby may be affected by adverse outcomes for the
mother. In our analysis the well-being of women and babies were combined in a single utility value for
each outcome. The evidence sources informing utilities for method of delivery were assumed to represent
the mothers’ well-being. However it was not clear whether the utilities for NICU admission and intensity of
care required represented utility for the mother, baby or both (and, if so, the relative weight given to
mother and baby: women (and even society) may value the health of the baby above their own).
We needed to distinguish those women who had a CS, those who had a VD within 24 hours, and those who
had a VD after 24 hours. We found that results from trials were not always reported in a way that allowed us
to estimate the outcomes together in this way. There was sufficient information to estimate effects for only
18 interventions and our conclusions on cost-effectiveness are therefore limited to this data subset.
The RCTs identified in the systematic review did not provide any evidence on the proportion of NICU
admissions following births by CSs, nor on the proportion of babies admitted to different intensities of
NICU care (intensive care, high-dependency care and transitional care). We have, therefore, used routinely
collected hospital activity data from Liverpool Women’s Hospital to inform these inputs to our model.
We identified only four studies960–963 reporting preference-based measures of utility relevant to the
outcomes in our model, none of which reported EQ-5D, our preferred measure. The health states did not
correspond directly with those in our model, and so assumptions were necessary. It was also not clear in
these studies960–963 whether or not the utility was for the mother, baby or both (and if so the relative
weight given to mother and baby). Furthermore, measures of uncertainty were not reported alongside the
utility estimates. In an attempt to address these limitations, we used our own small-scale survey to put
uncertainty limits on the literature-based utilities and to define sensitivity analyses. However, note that our
survey is severely limited due to being restricted to the project steering group and also limitations with the
VAS instrument that it used.972 Although the scores are bias prone and may not be comparable to utilities
elicited through other measures, the resulting ordinal preferences we obtained were found to have some
face validity (the patterns seen across respondents were broadly comparable and in line with intuition) and
can be considered as a first step towards defining utilities for mother/baby pairs. A large-scale study
measuring utilities (preferably using EQ-5D) on antenatal and postnatal women, reporting results (together
with uncertainty estimates) from both the mother and baby perspective, including time post discharge,
would be of great value in addressing the limitations described above.
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Discussion of the clinical implications of findings
Our NMA suggests that oxytocin with amniotomy and misoprostol are the most effective in achieving
vaginal births relatively quickly. Interestingly, there was little difference between different misoprostol
regimens, with the exception of oral tablets. Both high- and low-dose oral tablets, appear to be inferior to
low-dose oral solution, buccal/sublingual and all vaginal regimens. Vaginal PGE2 also performed well,
although our results favoured pessary (normal release) over methods currently available in the NHS (gel,
tablet and slow-release pessary). We have already mentioned that in our NMA the term ‘PGE2 pessary’
captures vaginal administration that could not be classified as tablets, gel or slow-release pessaries which
are currently commercially available. Consequently, this is a rather heterogeneous mix of study-specific
dinoprostone preparations, often produced by local pharmacies.
Intravenous oxytocin with amniotomy performed well, but this method was used only with intact membranes
and therefore can be recommended only in this subgroup. Furthermore, the majority of the trials evaluating
this method included women with more favourable cervix for whom delivery within 24 hours is more likely.
However, just because the absolute rate of VD in 24 hours is higher when the cervix is favourable does not
necessarily mean that the relative effects between tested interventions would differ. It is important to stress
again that oxytocin with amniotomy has been mainly tested, and has been shown to perform well, in women
with a favourable cervix, and the intervention is therefore recommended only for this group.
The safety profile of different methods was less clear. For example, misoprostol (low-dose vaginal tablets
and buccal/sublingual) was associated with relatively high hyperstimulation; however, this finding was not
borne out in increased rates of CS. One would expect that the two are related with persistent and clinically
important uterine hyperstimulation eventually resulting in CS.
The cost-effectiveness analysis suggested that titrated (low-dose) oral misoprostol solution had the highest
utility for mothers and babies, and buccal/sublingual misoprostol had the lowest cost to the NHS.
Notwithstanding the considerable uncertainty of cost-effectiveness results, it is still surprising that treatments
in common use in the NHS (e.g. PGE2 vaginal gel) did not appear to be the most effective, most cost-effective
or safest. Therefore, our findings may have important implications for clinical practice in the UK.
The current recommendation of the World Health Organization973 is for low-dose oral misoprostol tablets
rather than titrated oral solution and, therefore, not in line with the findings from this analysis.
Our main measure of efficacy was whether or not treatments resulted in VD within 24 hours. This
definition of efficacy may be controversial given that cervical ripening has often been regarded as a
distinctly different process from induction of labour. This view is reflected in the fact that changes in
Bishop scores were often the main measure of efficacy in many of the included randomised trials. We
argue that women and clinicians view cervical ripening and labour induction as part of the same seamless
process, with the main aim to achieve a safe vaginal birth of a healthy baby in the shortest time possible.
The outcomes we used in the cost-effectiveness analysis were VD within 24 hours, CS and NICU
admission; these outcomes were reported reasonably frequently and we thought that these outcomes
provided a reasonable balance of efficacy (benefit) and harm. At the same time, as we have seen from the
results of the NMA, there may be a trade-off in terms of harms and benefits of different treatments: those
agents that stimulate contractions and thereby achieve faster delivery may cause excessive uterine activity
that may lead to problems for women and babies.
We had expected that serious maternal and neonatal adverse events would be rare in the cohorts of
women recruited to RCTs of induction of labour. Nevertheless, it was disappointing how infrequently
mortality and serious morbidity were reported. Our assessment of safety was therefore limited to CS,
hyperstimulation with fetal heart changes, NICU admission and infant Apgar score, at best proxies for
serious adverse events.
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Observational data suggest that all prostaglandins (especially misoprostol) and oxytocin can cause uterine
rupture, with possible catastrophic consequences, particularly in women with previous CS. It was not
surprising to us that many trials included in the review excluded women with previous CS or uterine scar
for other reasons. The efficacy of induction agents that may cause excessive uterine activity must be seen
in this context.
We took the view that country of setting was not likely to be a critical treatment effect modifier, because
in all included RCTs intrapartum fetal monitoring and early access to CS were available to most women.
Even in those trials for which the induction agent was administered outside a hospital setting,
arrangements were in place for monitoring and emergency admission in case of complications. Given these
circumstances, the findings from our analysis are more likely to be applicable in high-resource settings,
such as the NHS.
Very few trials considered women’s views. Our own small-scale utility elicitation exercise showed that
respondents set great store by the health of babies and women may therefore would be likely to accept
induction if a clinician considered that this would potentially improve neonatal outcomes. At the same
time, given the similar utility values for a broad range of induction agents, there is surely scope for taking
women’s views into account. Women need to be informed of the advantages and drawbacks of different
methods of induction and to be aware that there is a choice of interventions available.
Recommendations for future research
The considerable uncertainty in our findings points the way for further research. In terms of populations,
it is striking how little randomised evidence relates to important subgroups, such as women with previous
CSs. Future studies should, at the very least, make available the results by subgroups when they
are included.
When induction of labour is clinically indicated, a placebo or no-intervention arm in a trial may not be
feasible or even ethical (our study shows that placebo is neither effective nor cost-effective). We suggest
that titrated oral misoprostol solution should be used as a comparator, particularly in the NHS setting, and
future RCTs should be powered to detect a method that is more cost-effective than misoprostol solution.
Clearly, the fact that this method is currently unlicensed with virtually no pharmacokinetic data poses a
considerable challenge.
We are conscious that, at present there are no internationally agreed core outcome sets for labour
induction studies. Until such time, we urge all triallists to report 11 outcomes included in this NMA in all
future RCTs:
l failure to achieve VD within 24 hours
l CS
l instrumental delivery
l uterine hyperstimulation resulting in FHR changes
l NICU admissions (by level of care and mode of delivery)
l Apgar score < 7 at 5 minutes
l neonatal deaths
l serious neonatal morbidity
l maternal deaths
l maternal serious morbidity
l maternal satisfaction.
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It is also important to report results separately for all clinically important subgroups (e.g. parity, membrane
and cervical status and previous CS) to allow individual patient data meta-analysis and network analysis.
There is also an urgent need to explore women’s views of the process as part of any future trial.
Finally, there is a need for well-conducted studies to measure utilities from the perspective of the mother
and baby, preferably using the EQ-5D instrument.
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Appendix 2 Search strategy: Cochrane Pregnancy
and Childbirth Group
Detailed search methods used to maintain and update the
Group’s database of trials
The Group’s information specialist:
l Runs a very broad generic preconception, pregnancy, childbirth and immediate postpartum/
breastfeeding search that aims to encompass our whole scope. See below for searches run and
strategies used.
l Screens the results, gets hard copies of all relevant papers.
l Assigns each paper reporting a RCT/clinical controlled trial (CCT) (by Cochrane definition) to a review
topic or topics, depending on the intervention, and adds it to the database with a topic classification
number to aid retrieval. The Group has a very detailed topic list.
For this project, all of the papers assigned to the ‘Induction of labour’ topic were identified using the broad
classification number for this topic.
Search strategies for the identification of studies
Electronic searches
MEDLINE
This current search strategy is run weekly via OVID MEDLINE and uses the Highly Sensitive Search Strategy
for identifying randomised trials in MEDLINE: sensitivity-maximising version (2008 revision) published in
chapter 6, section 6.4.11, of the Cochrane Handbook for Systematic Reviews of Interventions
(Version 5.0.2).
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp Pregnancy/
11. exp Pregnancy Complications/
12. exp Maternal Health Services/
13. exp Fetus/
14. exp Fetal Therapies/
15. exp Fetal Monitoring/
16. exp Prenatal Diagnosis/
17. Perinatal Care/
18. Labor pain/
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19. Analgesia, Obstetric/
20. exp Obstetric Surgical Procedures/
21. Infant, Newborn/
22. exp Postpartum Period/
23. Breastfeeding/
24. or/10-23
25. 9 and 24
26. exp animals/ not humans.sh.
27. 25 not 26
EMBASE
The following search strategy is run weekly via NHS Evidence: Health Information Resources.
1. CROSSOVER PROCEDURE/
2. allocat$.ti,ab
3. (cross ADJ over$).ti,ab
4. trial$.ti
5. placebo$.ti,ab
6. (doubl$ ADJ blind$).ti,ab
7. DOUBLE BLIND PROCEDURE/
8. crossover$.ti,ab
9. SINGLE BLIND PROCEDURE/
10. RANDOMIZED CONTROLLED TRIAL/
11. random$.ti,ab
12. 1 OR 3 OR 2 OR 6 OR 4 OR 5 OR 11 OR 7 OR 8 OR 9 OR 10
13. exp PREGNANCY/
14. exp PREGNANCY DISORDER/
15. exp OBSTETRIC PROCEDURE/
16. exp BREAST FEEDING/ OR exp BREAST FEEDING EDUCATION/
17. exp CHILDBIRTH/
18. CHILDBIRTH EDUCATION/
19. (antenatal* OR prenatal* OR puerper* OR postnatal* OR postpartum OR post ADJ partum OR post
ADJ natal* OR peripartum).ti,ab
20. (prepregnancy OR pre-pregnancy OR “pre pregnancy” OR preconception* OR “pre conception” OR
pre-conception* OR “pre conceptionally” OR periconceptional*).ti,ab
21. ((preterm OR premature) AND (labor OR labour)).ti,ab
22. (eclamp* OR preeclamp* OR pre-eclamp*).ti,ab
23. amniocentes*.ti,ab
24. (chorion* ADJ vill*).ti,ab
25. (breastfe* OR breast-fe* OR breast ADJ fe* OR lactation*).ti,ab
26. (cesarean OR caesarean OR cesarian OR caesarian OR cesarien OR caesarien).ti,ab
27. (newborn OR new ADJ born OR newborn).ti,ab
28. (pregnant OR pregnancy OR pregnancies).ti
29. (tocolysis OR tocolytic*).ti,ab
30. (fetal OR foetal OR fetus OR foetus).ti,ab
31. miscarriage*.ti,ab
32. LABOR PAIN/
33. OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR
28 OR 29 OR 30 OR 31 OR 32
34. 12 AND 33
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The Cochrane Library [includes Cochrane Database of Systematic Reviews
(CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), Database of
Abstracts of Reviews of Effects (DARE) and Economic Evaluations Databases]
This search is run monthly with each new issue of The Cochrane Library:
#1MeSH descriptor Pregnancy explode all trees
#2MeSH descriptor Pregnancy Complications explode all trees
#3MeSH descriptor Fetal Therapies explode all trees
#4MeSH descriptor Labor Pain explode all trees
#5MeSH descriptor Infant, Newborn explode all trees
#6MeSH descriptor Fetus explode all trees
#7MeSH descriptor Fetal Development explode all trees
#8MeSH descriptor Extraembryonic Membranes explode all trees
#9MeSH descriptor Heart Rate, Fetal explode all trees
#10MeSH descriptor Placenta explode all trees
#11MeSH descriptor Placental Function Tests explode all trees
#12MeSH descriptor Umbilical Cord explode all trees
#13MeSH descriptor Prenatal Diagnosis explode all trees
#14MeSH descriptor Uterine Monitoring explode all trees
#15MeSH descriptor Pelvimetry explode all trees
#16MeSH descriptor Fetal Monitoring explode all trees
#17MeSH descriptor Obstetrical Nursing explode all trees
#18MeSH descriptor Oxytocics explode all trees
#19MeSH descriptor Tocolytic Agents explode all trees
#20MeSH descriptor Tocolysis explode all trees
#21MeSH descriptor Anesthesia, Obstetrical explode all trees
#22MeSH descriptor Obstetric Surgical Procedures explode all trees
#23MeSH descriptor Maternal Health Services explode all trees
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#24MeSH descriptor Maternal-Child Nursing explode all trees
#25MeSH descriptor Analgesia, Obstetrical explode all trees
#26MeSH descriptor Midwifery explode all trees
#27MeSH descriptor Perinatal Care explode all trees
#28MeSH descriptor Parity explode all trees
#29MeSH descriptor Apgar Score explode all trees
#30MeSH descriptor Postpartum Period explode all trees
#31MeSH descriptor Breast Feeding explode all trees
#32MeSH descriptor Milk, Human explode all trees
#33 pregnan* in All Fields in all products
#34 fetus in All Fields in all products
#35 foetus in All Fields in all products
#36 fetal in All Fields in all products
#37 foetal in All Fields in all products
#38 newborn in All Fields in all products
#39 “new born”
#40 birth or childbirth in All Fields in all products
#41 labor or laboring in All Fields in all products
#42 labour* in All Fields in all products
#43 antepart* in All Fields in all products
#44 prenatal* in All Fields in all products
#45 antenatal* in All Fields in all products
#46 perinatal* in All Fields in all products
#47 postnatal* in All Fields in all products
#48 postpart* in All Fields in all products
#49 caesar* in All Fields in all products
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#50 cesar* in All Fields in all products
#51 obstetric* in All Fields in all products
#52 oxytoci* in All Fields in all products
#53 tocoly* in All Fields in all products
#54 placenta* in All Fields in all products
#55 prostaglandin in All Fields in all products
#56 parturi* in All Fields in all products
#57 preeclamp* in All Fields in all products
#58 pre next eclamp* in All Fields in all products
#59 eclamp* in All Fields in all products
#60 intrapart* in All Fields in all products
#61 puerper* in All Fields in all products
#62 episiotom* in All Fields in all products
#63 amnio* in All Fields in all products
#64matern* in All Fields in all products
#65 gestation* in All Fields in all products
#66 lactati* in All Fields in all products
#67 breastfe* in All Fields in all products
#68 breast next fe* in All Fields in all products
#69 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14
OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27
OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40
OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53
OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66
OR #67 OR #68)
DOI: 10.3310/hta20650 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 65
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Alfirevic et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
185
Cumulative Index to Nursing and Allied Health Literature
The following search strategy is run weekly via NHS Evidence: Health Information Resources.
1. exp CLINICAL TRIALS/
2. (clinic* ADJ trial*).ti,ab
3. (trebl* ADJ mask*).ti,ab
4. (tripl* ADJ blind*).ti,ab
5. (tripl* ADJ mask*).ti,ab
6. (doubl* ADJ blind*).ti,ab
7. (doubl* ADJ mask*).ti,ab
8. (singl* ADJ blind*).ti,ab
9. (singl* ADJ mask*).ti,ab
10. (randomi* ADJ control* ADJ trial*).ti,ab
11. RANDOM ASSIGNMENT/
12. (random* ADJ allocat*).ti,ab
13. placebo*.ti,ab
14. PLACEBOS/
15. QUANTITATIVE STUDIES/
16. (allocat* ADJ random*).ti,ab
17. breastfeeding.ti,ab
18. breastfed.ti,ab
19. exp BREAST FEEDING/
20. breast-fe*.ti,ab
21. exp PREGNANCY/
22. exp PREGNANCY COMPLICATIONS/
23. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16
24. (prenatal OR antenatal OR antepartum OR postpartum OR postnatal).ti,ab
25. (pregnant OR pregnancy).ti
26. ((preterm OR premature) AND (labor OR labour)).ti,ab
27. (midwife OR midwifery).ti,ab
28. CHILDBIRTH EDUCATION/
29. 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 24 OR 25 OR 26 OR 27 OR 28 123752.
30. 23 AND 29
ClinicalTrials.gov and World Health Organization International Clinical Trials
Registry Portal
preconception* or antenatal or prenatal or perinatal or puerperal or puerperium or postnatal or
postpartum or peripartum or post-natal or post-partum or ante-natal or ante-partum or obstetric*
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Journal and conference proceedings screening and trial identification
(hand-searching)
Journals
Acta Anaethesiologica Scandinavica (and supplements) 1950 and continuing
Acta Obstetricia et Gynecologica Scandinavica (and supplements) 1950 and continuing
Acta Paediatrica Scandinavica First issue to 1993
American Journal of Clinical Nutrition First issue and continuing
American Journal of Diseases of the Child 1950 to 1993
American Journal of Obstetrics and Gynecology 1950 and continuing
Anaesthesia and Intensive Care First issue and continuing
Anaesthesia 1950 and continuing
Anesthesia and Analgesia First issue and continuing
Anesthesiology 1950 and continuing
Archives of Diseases of the Child 1950–93
Australian and New Zealand Journal of Obstetrics and Gynaecology First issue and continuing
Birth First issue and continuing
British Medical Journal 1950–96
British Journal of Anaesthesia 1950 and continuing
British Journal of Obstetrics and Gynaecology First issue and continuing
Canadian Journal of Anaesthesia First issue and continuing
Canadian Medical Association Journal 1950–96
Clinical Pharmacology and Therapeutics First issue to 1998
Current Medical Research and Opinion First issue to 1993
Developmental Medicine and Child Neurology First issue to 1993
Early Human Development First issue to 1993
European Journal of Obstetrics & Gynaecology and Reproductive Biology First issue and continuing
Geburtshilfe und Frauenheilkunde 1950 and continuing
Gynecologic and Obstetric Investigation First issue to 1996, 2005 and continuing
Hypertension in Pregnancy 2006 and continuing
Indian Journal of Anaesthesia 2002 issue 3 to 2005 issue 5
Infectious Diseases in Obstetrics and Gynecology First issue and continuing
International Journal of Gynecology & Obstetrics First issue and continuing
International Journal of Obstetric Anaesthesia October 1994 to Oct 1995, January 2003
and continuing
Journal of the American Medical Association First issue to 1996
Journal of the American College of Surgeons 1950–03
Journal de Gynecologie, Obstetrique et Biologie de la Reproduction First issue to 1998
Journal of Human Lactation 2001 and continuing
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Journal of International Medical Research First issue to 1993
Journal of Midwifery and Women’s Health First issue and continuing
Journal of Obstetrics and Gynaecology First issue and continuing
Journal of Obstetrics and Gynaecology Research 2003 and continuing
Journal of Obstetric Gynecologic and Neonatal Nursing First issue to 1993, 2001–06
Journal of Pediatrics 1950–93
Journal of Pediatric Gastroenterology and Nutrition First issue to 1993
Journal of Perinatal Medicine First issue to 1998
Journal of Reproductive Medicine First issue to 2003
Lancet 1950–96
Medical Journal of Australia 1950–96
Midwifery First issue and continuing
New England Journal of Medicine 1950–96
Nurse Research First issue to 1993
New Zealand Medical Journal 1950–96
Obstetrics & Gynecology First issue and continuing
Pediatric Research First issue to 93
Pediatrics 1950–93
Practitioner 1950–96
Prostaglandins First issue to 1993
Regional Anesthesia and Pain Medicine First issue and continuing
Revista Brasileira de Anestesiologia 2003–06
Revista Brasileira de Ginecologia e Obstetricia 2001–05
South African Journal of Obstetrics and Gynaecology First issue to 1993
South African Medical Journal 1950–93
Surgery Gynecology and Obstetrics 1950–93
Ugeskrift for Laeger 1950–93
Ultrasound in Obstetrics and Gynecology 2002 and continuing
Zeitschrift fur Geburtshilfe und Perinatologie First issue to 1997
Zentrablatt fur Gynakologie First issue to 1997
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Conference proceedings
All India Congress of Obstetrics and Gynaecology 49th, 54th
American College of Obstetricians and Gynecologists’ Annual Meeting 36th, 37th, 39th, 40th, 41st,
55th, 58th
American Society of Anaesthesiologists Annual Meeting 2008, 2009
American Society of Regional Anesthesia and Pain Medicine Annual Spring Meeting 26th to 28th
American Society of Regional Anesthesia and Pain Medicine Annual Fall Meeting 2002, 2003, 2007
Argentinean Congress of Perinatology 3rd
Australian Perinatal Society 14th
Australian Society of Anaesthetists National Scientific Congress 58th, 61st
Birth Conference 1st to 9th
British Congress of Obstetrics and Gynaecology 23rd, 25th, 26th, 27th, 28th
British Maternal and Fetal Medicine Society 6th, 10th
British Paediatric Association Annual Meeting 14th, 15th, 27th, 60th, 61st,
62nd, 63rd, 65th
Congress of Nordic Federation of Societies of Obstetrics and Gynecology 34th
European Congress of Allied Specialists in Maternal and Neonatal Care 4th
European Congress of Obstetrical Anaesthesia and Analgesia 1st
European Congress of Obstetrics and Gynaecology 18th
European Congress of Perinatal Medicine 5th, 6th, 8th, 10th, 11th, 12th,
14th, 15th, 16th, 21st
European Congress on Prostaglandins in Reproduction 1st, 2nd
European Congress on Ultrasound in Medicine and Biology 6th
European Society of Regional Anesthesia and Pain Medicine 26th, 29th, 32nd
Federation of the Asia–Oceania Perinatal Societies’ Congress 6th, 9th
International Anesthesia Research Society Clinical and Scientific Congress 76th, 78th, 80th
International Confederation of Midwives Triennial Congress 24th
International Conference of Maternity Care Researchers 10th
International Congress on Psychosomatic Medicine in Obstetrics and Gynaecology 3rd, 5th
International Scientific Meeting of the Royal College of Obstetricians and Gynaecologists 4th
International Society for the Study of Hypertension in Pregnancy (ISSHP)
European Branch
1st
International Society for the Study of Hypertension in Pregnancy (ISSHP) World Branch 1st, 2nd, 4th to 16th, 18th
Japanese Society of Obstetrics and Gynecology 54th, 56th
Maternity Care Researchers International Conference 10th
Nordic Federation of Societies of Obstetrics and Gynecology Congress 34th, 35th, 38th
Obstetric Anaesthetists Association 2005, 2009
Pediatric Academic Society Annual Meeting 2004–13
Perinatal Society of Australia and New Zealand Annual Congress 4th, 7th
Priorities in Perinatal Care in South Africa 2nd, 4th, 7th, 9th, 10th, 11th,
12th, 14th, 15th, 16th, 17th
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Royal College of Obstetricians and Gynaecologists International Meeting 7th, 10th
Society of Obstetricians and Gynaecologists of Canada Annual Meeting 49th, 54th, 63rd
Society of Perinatal Obstetricians’ (USA) Annual Meeting 3rd, 6th to 10th, 14th,
17th, 18th
Society for Gynecologic Investigation (USA) Annual Program 31st, 34th, 37th, 39th, 40th
Society for Maternal–Fetal Medicine 19th to 22nd, 25th to 32nd,
33rd, 34th
Society for Obstetric Anesthesia and Perinatology Annual Meeting 30th, 31st, 33rd, 34th, 37th
Swiss Society of Gynecology and Obstetrics 19th to 22nd
World Congress of Perinatal Medicine 1st, 2nd, 5th, 10th, 11th
World Congress of Gynecology and Obstetrics 11th to 16th,19th, 20th
World Congress on Controversies in Obstetrics, Gynecology & Infertility 4th
World Congress on Twin Pregnancy 1st
World Congress on Ultrasound in Obstetrics and Gynecology 13th, 15th 16th, 17th, 18th,
19th, 20th, 21st
Other strategies
Current awareness
(a) ZETOC,The British Library’s Electronic Table of Contents service sends the contents tables, via e-mail, of
the journals listed below. The contents are reviewed by the Trials Search Co-ordinator. Hard copies of all
possible reports of RCTs/CCTs that are relevant to the scope of the group are obtained, reviewed and
added to the register by the Trials Search Co-ordinator if they meet the inclusion criteria.
l African Journal of Reproductive Health
l American Journal of Perinatology
l Archives of Disease in Childhood
l Archives of Disease in Childhood Fetal and Neonatal Edition
l Archives of Gynecology and Obstetrics
l Archives of Pediatrics and Adolescent Medicine
l British Journal of Midwifery
l Chinese Journal of Obstetrics and Gynecology
l Clinica e Investigacion en Ginecologia y Obstetricia
l Clinical and Experimental Obstetrics and Gynecology
l Clinical Obstetrics and Gynecology
l Current Obstetrics and Gynecology
l Current Opinion in Obstetrics and Gynaecology
l Fetal and Maternal Medicine Review
l Fetal Diagnosis and Therapy
l Ginecologia y Obstetricia de Mexico
l Giornale Italiano di Ostetricia e Ginecologia
l Gynakologisch Geburtshilfliche Rundschau
l Human Reproduction
l Hypertension in Pregnancy
l International Journal of Childbirth Education
l Italian Journal of Gynaecology and Obstetrics
l JOGC: Journal of Obstetrics and Gynecology Canada
l Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)
l Journal of Maternal Fetal and Neonatal Medicine
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l Journal of Paediatrics Obstetrics and Gynaecology
l Journal of Perinatology
l Journal of Prenatal and Perinatal Psychology and Health
l Journal of Psychosomatic Obstetrics and Gynaecology
l Journal of Reproductive Medicine
l Journal-New Zealand College of Midwives
l MCN, The American Journal of Maternal Child Nursing
l MIDIRS Midwifery Digest
l Obstetrical and Gynecological Survey
l Obstetrics, Gynaecology and Reproductive Medicine
l Prenatal Diagnosis
l Progresos de Obstetricia y Ginecologia
l Revista Chilena de Obstetricia y Ginecologia
l Taiwanese Journal of Obstetrics and Gynecology
l Tokogynecologica Praktica
l Women and Birth
l Zeitschrift fur Geburtshilfe und Neonatologie.
(b) BioMed Central (www.biomedcentral.com/home/) sends an e-mail alert every 30 days for anything new
published in the following:
l BMC: Pregnancy and Childbirth
l International Breastfeeding
l Anything related to the subject areas of pregnancy and childbirth, pediatrics or women’s health.
Specialised register inclusion criteria
Topic scope Controlled trials comparing alternative forms of care used either during pregnancy (but not to
terminate early pregnancy) or within 28 days of delivery.
Study design A controlled trial has been defined as a trial involving humans in which allocation to the
intervention has either been at random, or by some quasi-random method, such as by alternation, or on
the basis of the case record number or date of birth.
These criteria have been applied fairly liberally to avoid excluding potentially useful studies involving
concurrent comparisons of alternative policies. In other words, the register includes reports that, if
necessary, can subsequently be rejected as methodologically inadequate by a member of the Group
preparing a systematic review.
No language restrictions are applied.
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Appendix 3 Reference list for excluded studies
Abbassi RM, Sirichand P, Rizvi S. Safety and efficacy of oral versus vaginal misoprostol use for induction of
labour at term. J Coll Physicians Surg Pak 2008;18:625–9.
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Appendix 4 Characteristics of excluded studies
TABLE 37 Characteristics of excluded studies
Author Year Reason for exclusion
Abbassi RM 2008 Not a RCT
Abdellah MS 2011 Complex intervention
Abramovici D 1999 Methodological issues – not all women received intervention as protocol stated;
unclear. Women received catheter based on Bishop score
Abramovici D 1999 Complex intervention
Adewole IF 1993 No data
Afolabi BB 2005 Outcome data not usable
Aggarwal N 2006 Methodological inconsistencies
Aghamohammadi A 2011 Insufficient information for assessment
Akhtar A 2011 No details of doses or regimens
Akram H 2005 Not a RCT
Al-Assadi AF 2007 Not a relevant comparison
Amano K 1999 No relevant data; induction group received several methods not reported
separately
Method of randomisation unclear
Anderson G 1971 No relevant data. Results not reported by randomised group
Anderson GG 1972 Unclear if RCT
Andreasson B 1985 Not a relevant comparison. Intranasal oxytocin
Anonymous – Ferring
Pharmaceuticals
2010 Trial registration. No results reported
Arrieta OB 2000 Not a relevant comparison
Arsenijevic S 2012 Not clear for induction of labour
Arulkumaran S 1987 Not a relevant comparison. Regimen comparison
Arulkumaran S 1985 Not a relevant comparison. Regimen comparison
Ascher-Walsh C 2000 Dose comparison
Ashworth MF 1988 Not a relevant comparison. Pulsatile i.v. oxytocin vs. continuous oxytocin
Atad J 2000 Not a RCT
Atad J 1996 Methodological reasons. Crossover design
Atad J 1991 Complex intervention
Atkinson MW 2000 Dose comparison
Augensen K 1987 Not a relevant comparison
Augensen K 1986 Not a relevant comparison
Auner H 1993 Regimen comparison. Not a relevant comparison
Averill KA 1999 No relevant data
Azarkish F 2008 Insufficient information to assess
continued
DOI: 10.3310/hta20650 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 65
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Alfirevic et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
231
TABLE 37 Characteristics of excluded studies (continued )
Author Year Reason for exclusion
Azeem S 2006 Not a RCT
Azhari S 2006 No relevant outcome data
Babcock RJ 1959 No relevant data
Baev O 2011 No relevant data
Balintona J 2001 No outcome data
Bamford PN 1992 No outcome data
Barkai G 1997 Complex intervention
Barrilleaux PS 2002 Complex intervention
Bates CD 2003 No relevant outcome data
Baxi LV 1980 No data
Beard RJ 1975 Complex intervention
Beazley JM 1971 No data
Bebbington M 2003 Unclear definition of relevant outcomes. No usable data
Beigi A 2010 No data
Belfrage P 2000 Excluded for methodological reasons
Ben-Aroya Z 2001 Not a RCT
Bendvold E 1990 No relevant outcome data
Bergsjo P 1989 Complex intervention
Bergsjo P 1969 Not a relevant comparison. Intranasal oxytocin
Bernstein EP 1986 No relevant outcome data
Bex P 1990 No outcome data
Bi S 2000 Excluded for methodological reasons
Blackburn MG 1973 No relevant outcome data
Blakemore KJ 1990 Regimen comparison. Not a relevant comparison
Bloch B 1975 Not a RCT
Blumenthal PD 1990 Not a relevant comparison. Both interventions same code
Bo QX 2006 This study explored acupuncture for pain relief
Bolnick JM 2004 Complex intervention
Bonebrake R 2001 No data
Borisov I 1985 Insufficient information for assessment
Botero L 1998 Trial registration. No relevant outcome data
Bozhinova S 2007 Not a relevant comparison. Both arms high dose
Brandel E 1998 Excluded from 0317 – possibly allocation bias, primary outcome statistics not
adequately reported
Breart G 1991 Not clear that this trial is for induction. Not relevant intervention
Breart G 1982 Not clear that this trial is for induction. Not relevant intervention
Bredow V 1993 Not a RCT
Bredow V 1990 Not a RCT. Allocation by Bishop scores
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TABLE 37 Characteristics of excluded studies (continued )
Author Year Reason for exclusion
Bremme K 1987 Complex intervention
Bremme K 1984 Complex intervention
Bremme K 1980 Complex intervention
Browne MJ 1988 Insufficient information for assessment
Browne PC 2011 Trial registration. No data
Buccellato CA 2000 Complex intervention
Butler B 2004 Oral misoprostol review – no group denominators
Cabrol D 1990 Not a relevant participant group
Cai LL 2010 No relevant data
Calder AA 2008 Misoprostol group included both high- and low-dose regimens. Results were not
reported by dose
Calder AA 1975 Complex intervention
Calder AA 1974 No relevant data
Caliskan E 2005 No relevant data
Cameron A 1985 No usable outcome data. Denominators unclear
Cameron AD 1988 No data
Carbone JF 2013 Complex intervention
Carlan SJ 1997 Comparing tablet with gel
Carlan SJ 1995 Dose comparison, both high dose
Casey BM 1995 Complex intervention
Casey C 1993 Not a relevant comparison. Comparison group did not all receive the
same protocol
Castle B 1983 No outcome data, looking at absorption
Cecatti JG 2006 Both groups received 25 µg of vaginal misoprostol
Cetin A 1997 No outcome data
Chang YK 2003 Not a relevant comparison
Chen DC 2005 Exclude for methodological reasons
Chen DC 2004 Analysis not by randomisation group
Chestnut DH 1994 Not a relevant intervention
Chia YT 1993 Not a relevant comparison
Chipato T 1997 Not a relevant comparison
Chou MM 1991 No data
Christensen FC 2002 Complex intervention
Chua S 1991 Dose and regimen comparison. Not a relevant comparison
Cole RA 1975 Regiment comparison
Coleman FH 1997 Complex intervention
Collingham JP 2010 Complex intervention
Coltart TH 1974 Not a relevant comparison
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TABLE 37 Characteristics of excluded studies (continued )
Author Year Reason for exclusion
Craft I 1976 Not a RCT
Craft IL 1971 No relevant data
Crane J 1993 Regimen comparison. Not a relevant comparison
Critchley HOD 1994 Dose comparison
Cross WG 1978 Attrition
Culver J 2004 Complex intervention
Cummiskey KC 1990 Not a relevant comparison
D’Aniello G 2003 Not a RCT
D’Souza SW 1986 No relevant data
Damania KR 1988 Not a RCT
Danezis J 1962 Not a relevant comparison
Daniel-Spiegel E 2004 Regimen comparison
Danna P 1995 No outcome data
Dasgupta E 2012 Complex intervention
Davies NJ 1991 Regimen comparison
Day L 2009 No relevant data
De Laat WNGM 1991 No outcome data
De Leon-Casasola OA 1993 Not a relevant comparison
De Oliveira MGM 2003 No data
DebBarma AM 2013 Trial registration
Decker WH 1958 Not a RCT
Delaney S 2010 Not a relevant comparison
Delaney T 2001 Comparison of different dosing regimens
Delaney T 2001 Insufficient information
Deo S 2013 No data for primary outcomes
Di Lieto A 1989 No data
Dietl J 1987 Trial registration
Ding DC 2005 Not a RCT
Dionne MD 2011 Complex intervention
Dogra Y 2012 No data
Dommisse J 1981 No outcome data
Dorfman P 1987 Inadequate details of treatment/intervention
Dorr A 1990 Complex intervention
Du S 2000 Not a relevant comparison
Duhl A 1997 No data
Dundas KC 2000 Insufficient information
Dunn PA 1989 No relevant data
Dunston-Boone G 1991 Includes non-randomised participants
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TABLE 37 Characteristics of excluded studies (continued )
Author Year Reason for exclusion
Duru NK 1997 Not relevant participant group
Echeverria EL 1995 Not a RCT
Edelstein H 1964 Not a relevant comparison
Eftekhavi N 2002 Brief abstract, insufficient information
Ehrenberg-Buchner S 2013 No outcome data
Ekblad U 1994 Not a RCT
Ekerhovd E 2003 Not an induction of labour trial
Elliott CL 1998 No data
Elliott JP 1984 No data
Elliott JP 1983 No relevant data
El Sedeek MSh 2009 No relevant outcome data
El-Torkey M 1995 Not a relevant comparison
Emery S 1988 No relevant data
Engleman SR 1979 Not a RCT
Escalante G 1993 Results not reported by randomisation group
Evans MI 1983 Complex intervention
Ewert K 2006 Dose ranging study, same code
Fekih M 2009 Dose comparison study
Filho FAR 2007 Dose comparison: both low dose
Filshie GM 1992 Trial registration
Fitzpatrick CB 2012 Not a relevant comparison
Foong LC 2000 Not a relevant comparison
Freeman RK 1968 Not a relevant comparison
Friedman EA 1975 Dose comparison
Friedman EA 1975 Dose comparison
Friedman EA 1974 No relevant data
Fuchs AR 1984 Not a RCT
Fuchs K 2006 No outcome data
Fusi L 1989 No outcome data, no denominators
Garcia AA 1988 Not a RCT
Gauger LJ 1991 Data not in form we can use
Gemer O 2001 No data
Ghanaei MM 2013 No data
Ghanaei MM 2009 Complex intervention
Ghidini A 2001 Dose comparison: both high dose
Gibb DMF 1985 Dose comparison
Gibson KS 2013 Not a relevant comparison. Both code 24
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TABLE 37 Characteristics of excluded studies (continued )
Author Year Reason for exclusion
Gilad R 2012 No data
Gillot M 1974 Not a relevant comparison
Girija S 2006 Insufficient information
Glanville T 2002 No denominators and no relevant outcome data
Gloeb DJ 1989 No relevant outcome data
Goedken J 2000 No denominators
Goeree R 1995 Does not compare methods for the induction of labour
Gonen O 1997 Methodological issues. Women in the intervention group received multiple
interventions based on Bishop score, and data are not presented by this division
Goni S 1995 Dose comparison
Gonsoulin W 1989 No relevant outcome data
Gordon AJ 1977 No data
Gordon-Wright AP 1979 No outcome data
Gottschall D 1998 Dose comparison: both high dose
Gowenlock AH 1975 No relevant data
Granstrom L 1995 Both arms received the same intervention at different times
Green PS 1967 No data
Greenberg RA 2006 No data. Trial not complete
Greer IA 1988 No relevant data
Greer IA 1988 No outcome data
Griffin C 2003 > 20% attrition
Grudev D 1988 Not a relevant comparison
Grunstein S 1990 Dose comparison, both groups high dose
Guinn DA 2004 Complex intervention
Guinn DA 2000 Complex intervention
Güngördük K 2011 Complex intervention
Haddad N 1987 Trial registration
Haeri AD 1976 Not a RCT
Hage P 1993 No data
Hallak M 2008 Trial registration
Hannah ME 1992 Induction group received multiple methods; data reported represent
multiple methods
Harms K 2001 No relevant outcome data
Harrington K 2003 No data. Trial registration
Hassan AA 2005 Not a RCT
He HY 2000 Not a relevant comparison
Helal AMM 2004 Not a RCT
Hendricks CH 1964 Not a relevant comparison
Hennessey MH 1998 Not a relevant comparison
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TABLE 37 Characteristics of excluded studies (continued )
Author Year Reason for exclusion
Henry A 2013 Not a relevant comparison (inpatient vs. outpatient)
Henry A 2011 Complex intervention
Henry GR 1969 Intervention unclear
Henson BV 1987 No outcome data
Hernandez-Castro F 2008 Not clear that this is a trial. Insufficient information
Hibbard JU 1998 Complex intervention
Hill JB 2009 Complex intervention
Hill NCW 1991 Not induction of labour
Ho M 2010 Augmentation of labour
Hoesli I 2003 Insufficient information
Hoppe K 2014 Not a relevant comparison
Hourvitz A 1996 Dose comparison
Hu Y 2013 No data. Trial registration
Hughes L 2002 Complex intervention
Hunter G 1998 Mixed interventions, not possible to separate data
Hunter IWE 1984 Both arms received the same intervention, at different doses and times
Hunter IWE 1982 Both arms received the same intervention, at different doses and times
Hussein M 2012 No relevant data. Data not reported by randomisation group
Ifnan F 2006 Not a relevant comparison
Iftikhar M 1992 No outcome data reported
Imsuwan Y 1999 No relevant outcomes
Ingemarsson I 1991 No outcome data
Ismail AAA 1989 Not a RCT
Jackson NV 2000 Insufficient information
Jalilian N 2011 No relevant data – not reported by randomisation group
Jasper MP 2000 No relevant outcome data
Javaid MK 2008 Dose and frequency not stated. E-mail sent
Jazayeri A 2003 No group denominators
Jenssen H 1977 No usable outcome data
Jiang X 1997 Not a relevant comparison
Jigyasa S 2011 No denominators
Jindal P 2007 Complex intervention
Jonsson M 2011 Not a relevant comparison
Joo SH 2000 No outcome data or primary outcomes
Kadar N 1990 No relevant data
Kamat DS 2002 Not a RCT
Kanade T 2011 No group denominators
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TABLE 37 Characteristics of excluded studies (continued )
Author Year Reason for exclusion
Kanhai HHH 1989 Not a relevant participant group. This is a trial of induction for fetal death
Karjane NW 2006 Not a relevant comparison
Karpovich E 2006 No data. Trial registration
Kasdaglis T 2007 Complex intervention
Kashanian M 2009 Not a relevant comparison
Kashanian M 2008 Not a relevant comparison
Kashanian M 2008 Not a relevant comparison
Kehl S 2011 Complex intervention
Keirse MJNC 1983 No relevant outcome data
Keller JM 2010 No data. Trial registration
Khan ZA 2011 Not a RCT
Kjos SL 1993 Women had variety of induction methods
Klopper AI 1973 Not relevant intervention
Klopper AI 1969 Not a relevant comparison
Klopper AI 1962 No denominators
Knogler W 1988 No outcome data
Knox GE 1979 No outcome data
Krammer J 1995 No outcome data
Kubista E 1974 Not a RCT
Kupietz R 1994 Not a relevant comparison (comparing time of day PGE2 administered)
Ladfors L 1994 Dose comparison
Lamont RF 1991 No relevant data
Lange AP 1982 No relevant data
Lanka S 2012 No data. Trial registration
Larsen J 1983 Not a relevant comparison
Lass A 1994 No outcome data
Lazor LZ 1993 Dose comparison
Le Maire WJ 1972 No relevant data
Leiberman JR 1977 Not a RCT
Leijon I 1980 No relevant data
Leijon I 1979 No relevant data
Leszczynska-
Gorzelak B
2001 Dosage not clear
Leszczynska-
Gorzelak B
1999 Not a RCT
Leszczynska-
Gorzelak B
1993 No relevant data
Levy R 2004 Not a relevant comparison
Levy R 2000 Not a relevant comparison
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TABLE 37 Characteristics of excluded studies (continued )
Author Year Reason for exclusion
Li FM 2000 No group denominators, no outcome data
Li GQ 1996 No relevant data
Li WJ 1994 No relevant data
Lin A 1995 Complex intervention
Lin MG 2007 Not a relevant comparison
Lindblad A 1985 No outcome data
Lindholm P 1981 No relevant data
Lindmark G 1976 No relevant data
Lipshitz J 1984 Not a relevant comparison
Liu YL 2012 No relevant data reported
Lokugamage AU 2003 Both high dose
Long Z 1994 Not a relevant comparison
Lorentzen IP 2006 Trial not complete
Lorenz RP 1984 Not relevant participants, 25% < 20 weeks
Loria-Casanova ML 1989 Preterm labour only
Lorrain J 1982 Not a relevant comparison
Loto OM 2012 No outcome data or primary outcomes
Lotshaw RR 1994 Comparison of regimen. Both groups received intracervical PGE2
Lowensohn RI 1990 Regimen comparison
Lunkad A 2011 No denominators, no outcome data
Lutgendorf MA 2012 Not a relevant comparison
Luther ER 1983 Comparing synthetic and natural PGE2. Same dose
Lykkesfeldt G 1981 Not a relevant comparison
Lyndrup J 1992 This is a secondary analysis of Lyndrup 1991, Legarth 1988 and Legarth 1989.
No relevant outcome data
Lyons C 2001 No relevant data
Mackenzie I 2011 Trial for pain relief only
MacKenzie IZ 1997 Dose comparison
MacKenzie IZ 1988 Dose comparison
Mackenzie IZ 1988 No outcome data
MacKenzie IZ 1977 No outcome data
MacLennan AH 1988 No relevant outcome data
MacLennan AH 1981 Complex intervention
Macones GA 2012 Complex intervention
Macpherson M 1983 No relevant outcome data
Madhavi N 2011 No group denominators, no results
Mahendru R 2011 Interventions not clear
Mahomed K 1988 Complex intervention
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TABLE 37 Characteristics of excluded studies (continued )
Author Year Reason for exclusion
Majoko F 2002 Both high dose
Majoko F 2001 Comparison not relevant
Makarem MH 2013 Complex intervention
Makary NA 1990 Trial registration
Mamo J 1994 No relevant data
Manabe Y 1985 No relevant data
Mancuso S 1996 Not a RCT
Manidakis G 1999 No relevant data
Mansouri M 2003 Not a relevant comparison
Manyonda IT 2007 Trial registration
Marconi AM 2008 Control group included two different treatments
Martin DH 1978 > 20% excluded for labour outcomes; unbalanced treatment groups
Martin JN 1989 No relevant data
Martin RH 1955 Not only induction of labour
Martinez AC 2004 No relevant data
Marzouk AF 1975 Complex intervention
Mathews DD 1976 Not a relevant comparison
Mathie JG 1959 Not a relevant comparison
Mati JKG 1973 Not a relevant comparison
Mazhar SB 2003 Complex intervention
McColgin SW 1993 No relevant data
Megalo A 1999 No relevant outcomes
Megalo A 1998 No group denominators
Mercer B 1991 Dose comparison
Merrill DC 1999 Dose comparison
Milasinovic L 1997 Not a relevant comparison
Miller JF 1975 Complex intervention
Milliez JM 1993 Dose comparison study
Minaretzis D 1993 All women received intracervical PGE2
Mink D 1994 Not a RCT
Moghadam AD 2012 Not a relevant comparison
Moghadem DA 2013 Not a relevant comparison
Moghadem DA 2008 Insufficient information
Moise KJ 1991 No relevant outcome data
Mokgokong E 1976 Dose comparison
Mokgokong ET 1974 No relevant outcome data
Molina M 2000 Insufficient information
Mollo M 1991 No relevant outcome data
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TABLE 37 Characteristics of excluded studies (continued )
Author Year Reason for exclusion
Moran DJ 1994 Not a relevant comparison
Muhammad Ali A 2013 No group denominators
Mukhopadhyay M 2002 No data
Muller PR 1992 Not a relevant comparison. Regimen comparison
Muller T 2000 Very high sample attrition
Muller T 1995 Not a RCT
Mullin PM 2002 Complex intervention
Mundle WR 1996 Comparison not relevant
Murray CP 1975 No denominators
Nabors GC 1958 Complex intervention
Naismith WCMK 1972 Complex intervention
Nasir S 2012 Not a RCT
Nassief SA 1996 Not a relevant comparison
Neri I 2012 No group denominators
Nesbitt REL 1961 No relevant data
Neto CM 1988 No relevant outcome data
Nikolov A 2003 No outcome data
Nilsson B 1984 No relevant data
Niroomanesh S 2011 Insufficient information. No denominators
Noah ML 1985 Dose comparison
Norchi S 1993 No outcome data
Nunes FP 2006 Complex intervention
Nuthalapaty FS 2005 Not relevant participant group
Nuutila M 1997 No relevant outcomes reported
Obel EB 1975 Not a relevant comparison
Odem RR 1988 Not a relevant comparison. Regimen comparison
Odum CU 1993 Not relevant participant group
Ohel G 1996 High risk of bias
Omer H 1987 Not a RCT. A case–control study
Orhue A 1993 Regimen comparison
Orhue AAE 1994 Regimen comparison
Orhue AAE 1993 Dose comparison
Ozgur K 1997 Not a RCT
Ozsoy M 2004 Both high dose
Padayachi T 1988 For intrauterine death
Palermo MSF 1997 No relevant data
Parewijck W 1987 Insufficient information to assess
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TABLE 37 Characteristics of excluded studies (continued )
Author Year Reason for exclusion
Parker M 1990 No outcome data
Parpas G 1995 Not a relevant comparison. Regimen comparison
Patel A 2000 Augmentation not induction
Patnaik P 1995 Not a RCT
Patterson WM 1971 No relevant data
Paul R 1988 No relevant outcome data
Pavlou C 1978 Regimen comparison
Payne E 1993 Not randomised properly
Pearce DJ 1977 No relevant data
Pearson M 2002 No doses for miso stated
Pedersen S 1981 Complex intervention
Peedicayil A 1990 Not a relevant treatment
Peedicayil A 1989 Complex intervention
Penna LK 1991 Varying dosing regimens. Data not reported by dose
Pentecost AF 1973 Buccal oxytocin. Not a relevant comparison
Perales AJ 1994 No relevant outcome data
Perry KG 1998 Complex intervention
Pettker CM 2008 Complex intervention
Picasso DG 2012 Not a relevant comparison
Polvi HJ 1994 No relevant outcomes reported
Pongsatha S 2002 Dose comparison, same codes
Pongsatha S 2001 Dose comparison, same codes
Porat S 2006 No data
Porojanova V 2005 Not a RCT
Pranuthi R 2011 No relevant data
Rangarajan NS 1971 No data
Rasheed R 2007 Included non-randomised participants
Rath W 1985 Dose comparison
Raymond S 1989 Trial registration
Read MD 1974 Complex intervention
Rees AEJ 1992 No outcome data
Reichel R 1985 No relevant outcomes reported
Reid GJ 1995 Regimen comparison
Ridgway L 1991 Complex intervention
Rijnders MEB 2007 Control group received a range of induction methods
Roberts G 1970 Complex intervention
Robinson D 2011 Trial registration
Romer A 2000 No relevant outcome data
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TABLE 37 Characteristics of excluded studies (continued )
Author Year Reason for exclusion
Rosa P 1974 No relevant data
Ross EL 1998 Dose comparison
Rudra T 2012 No relevant data. Unclear
Rust O 2000 Not a relevant comparison
Rust OA 2001 Complex intervention
Saberi F 2008 No relevant data. Unclear
Sabir N 2007 No data
Sabra A 2000 Insufficient information
Sadaty A 1998 No outcome data
Sahin HG 2002 Methodological reasons. Women not in labour after 12 hours were excluded for
all outcomes, including 3/50 receiving misoprostol and 10/50 in the
oxytocin group
Saito K 1999 Not a relevant comparison
Salamalekis E 2000 Regimen comparison
Saldivar D 2001 No data
Salmanian R 2012 No relevant outcomes
Samal S 2000 Not a RCT
Sanchez-Ramos L 2002 Not a relevant comparison
Sanchez-Ramos L 1995 Both groups received PGE2
Sanchez-Ramos L 1993 Not a relevant comparison
Sasaki K 1982 Not a relevant comparison
Satin AJ 1994 Not a relevant comparison. Regimen comparison
Satin AJ 1991 Dose comparison
Scher J 1972 Observational study. Not a RCT
Schneider KTM 1994 Not a RCT
Schreyer P 1989 Incomplete reporting of data
Sciscione AC 2001 Not a relevant comparison – setting comparison
Seeras RC 1995 Dose comparison, both arms high dose
Seidl A 1976 No relevant data
Sellers S 1985 No outcome data
Shaala S 1989 Not a relevant intervention
Shanmugham D 2011 Not a RCT
Sharami SH 2010 No data
Sharami SH 2005 Complex intervention
Sharma C 2012 No data, not clear if completed
Sharma K 2014 Not a relevant comparison
Sheela SR 2006 Not a RCT
Shennan A 2006 Trial registration
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TABLE 37 Characteristics of excluded studies (continued )
Author Year Reason for exclusion
Shennan AH 1995 Not a relevant comparison
Shetty A 2002 Dose comparison
Shipman M 2000 Trial registration
Shravage J 2009 Complex intervention
Singh PM 1993 Not a relevant comparison. Dose comparison
Sivasuriya M 1978 > 20% excluded
Sjostedt S 1969 Intranasal oxytocin. Not a relevant comparison
Skajaa K 1991 Both groups received PGE2, same dose
Skupski D 2006 Complex intervention
Smith CV 1996 Dose comparison, both arms high dose
So LK 1979 No data
Solt I 2009 No denominators
Somell C 1987 Arms received different management protocols
Somell C 1983 One group primed and the other not; those failed at 8 hours excluded
Soni M 2000 Not a RCT
Sorensen MB 2008 No data
Sorensen S 1985 Not a relevant comparison
Sorokin Y 1992 No outcome data
Spellacy WN 1971 No relevant data
Spitzberg E 1991 No outcome data
Srisomboon J 1997 No code for intracervical misoprostol
Srividhya S 2001 Not a RCT
Steer PJ 1992 Trial registration
Steer PJ 1985 Regimen comparison
Steer PJ 1976 No relevant data
Stewart JD 1998 Complex intervention
Stewart P 1981 Not a relevant comparison
Stiver KH 1991 Dose comparison study
Suikkari AM 1983 Induction group received two different methods
Sullivan CA 1996 Complex intervention
Suri V 2000 No data
Swann RO 1958 No relevant data
Tadmor OP 1990 Not a relevant comparison
Tan ASA 1994 No outcome data
Tan LK 1999 Dose comparison, all high dose
Tan PC 2009 Complex intervention
Tan PC 2006 Complex intervention
Tan PC 2007 Complex intervention
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TABLE 37 Characteristics of excluded studies (continued )
Author Year Reason for exclusion
Tang L 1997 Dose comparison, all high dose
Tanir HM 2008 Complex intervention
Tedesco RP 2002 Both low dose
Thach TS 2000 Insufficient information
Thiery M 1981 Examining combination of methods
Thiery M 1979 Complex intervention. Control group received PGE2 plus oxytocin at the same time
Thiery M 1977 Not a relevant comparison. Regimen comparison
Thomas G 1974 Not a relevant comparison
Thompson JH 1987 Unclear group denominators
Thomsen AC 1987 Trial registration
Thornton S 1989 No relevant data
Tiwari N 2011 No data
Toplis PJ 1979 Insufficient information
Toppozada M 1992 No outcome data
Torres R 2001 Not a relevant comparison
Tsitsis V 2012 Not a RCT
Tsitsis V 2012 Not a RCT
Tuipae S 1999 No data. for primary outcomes
Turnquest MA 1997 Not a relevant comparison
Ulstein M 1979 Not a relevant comparison
Vaisanen-
Tommiska M
2008 No data
Van Dessel T 1991 Women were already in labour
Van Heerden J 1992 Data unclear
Varaklis K 1994 No outcome data
Varma R 1981 Not a RCT
Varma TR 1984 Not a RCT
Veligati P 1998 Insufficient information reported
Vengalil SR 1998 Not a relevant comparison
Vidanagamage RS 2011 No data
Vijitrawiwat A 2003 No data. for primary outcomes
Voss DH 1996 Dose comparison
Vroman S 1972 No relevant data
Walker E 1983 Dose comparison
Wang L 1997 Excluded for methodological reasons
Wang Z 1998 Not a relevant comparison
Ward SJ 1991 No relevant data
Webb GW 1997 No denominator data given
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TABLE 37 Characteristics of excluded studies (continued )
Author Year Reason for exclusion
Weeks AD 2013 No data. Trial registration
Wei ZT 2000 No relevant data
Weiss G 2009 No data
Weiss RR 1975 Dose comparison
Weissberg SM 1977 No relevant data
Welt SI 1987 Insufficient information reported to assess the trial
Westergaard JG 1983 Not a relevant comparison
Westergaard JG 1983 Not a relevant comparison
Wicker R 1995 Insufficient information
Wildemeersch DA 1976 No data
Wilk M 2001 Excluded for methodological reasons
Willcourt RJ 1994 Not a relevant comparison. Regimen comparison
Williams JK 1988 Not a relevant participant group. Induction for fetal death
Williams JK 1985 Dose comparison
Windrim R 1997 No clear comparison group (control group interventions differed)
Wing DA 2011 Sustained-release misoprostol – three doses
Wing DA 1998 No data. Trial stopped early
Wing DA 1996 Same dose each group
Witter FR 1989 Not a relevant comparison
Wolf SB 2005 Dose comparison
Wolfler MM 2006 Not a relevant comparison
Wyldes MP 1992 Trial never commenced
Yacoob T 1993 Not a relevant comparison
Yang Z 2000 Insufficient information in abstract
Yeung KK 1977 No usable outcome data
Young D 2001 Insufficient information, no group denominators, variable dose of
vaginal misoprostol
Zafarghandi A 2004 Not a relevant comparison
Zanini A 1991 Dose comparison, all high dose
Zhen-yun Y 1994 Not a relevant comparison
Zimmer EZ 1996 No relevant outcome data
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Appendix 5 Reference list for included studies
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Appendix 8 Example OpenBUGS code
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Appendix 9 Details of priors and
convergence checks
Prior distributions used in the network meta-analyses of
outcomes reported in the paper
No vaginal delivery within 24 hours
All prior distributions in the VD REs consistency model were vague.
Trial baseline parameter: mu∼dnorm(0, 0001)
Treatment effect parameter: d∼dnorm(0, 0001)
Heterogeneity parameter: sd∼dunif (0,5)
Caesarean section
All prior distributions in the CS REs consistency model were vague.
Trial baseline parameter: mu∼dnorm(0, 0001)
Treatment effect parameter: d∼dnorm(0, 0001)
Heterogeneity parameter: sd∼dunif (0,5)
Hyperstimulation
All prior distributions in the hyperstimulation REs consistency model were vague.
Trial baseline parameter: mu∼dnorm(0, 0001)
Treatment effect parameter: d∼dnorm(0, 0001)
Heterogeneity parameter: sd∼dunif (0,5)
Instrumental delivery
All prior distributions in the hyperstimulation REs consistency model were vague.
Trial baseline parameter: mu∼dnorm(0, 0001)
Treatment effect parameter: d∼dnorm(0, 0001)
Heterogeneity parameter: sd∼dunif (0,5)
Neonatal intensive care unit admission
All prior distributions in the hyperstimulation REs consistency model were vague.
Trial baseline parameter: mu∼dnorm(0, 0001)
Treatment effect parameter: d∼dnorm(0, 0001)
Heterogeneity parameter: sd∼dunif (0,5)
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Apgar score < 7 at 5 minutes
All prior distributions in the hyperstimulation REs consistency model were vague.
Trial baseline parameter: mu∼dnorm(0, 0001)
Treatment effect parameter: d∼dnorm(0, 0001)
Heterogeneity parameter: sd∼dunif (0, 2)
Details of convergence for all three outcomes reported in the
paper for random-effects consistency models
No vaginal delivery within 24 hours
Convergence was assessed using two chains using the Brooks–Gelman–Rubin tool in OpenBUGS, and
was achieved by 15,000 simulations for VD (REs consistency model). Estimates are based on a further
100,000 updates.
Caesarean section
Convergence was assessed using two chains using the Brooks–Gelman–Rubin tool in OpenBUGS, and was
achieved by 49,000 simulations for CS (REs consistency model – risk of bias – continuity corrected model).
Estimates are based on a further 150,000 updates.
Hyperstimulation
Convergence was assessed using two chains using the Brooks–Gelman–Rubin tool in OpenBUGS and was
achieved by 26,000 simulations (REs consistency – continuity corrected model). Estimates are based on a
further 75,000 updates.
Instrumental delivery
Convergence was assessed using two chains using the Brooks–Gelman–Rubin tool in OpenBUGS, and was
achieved by 58,000 simulations (REs consistency model). Estimates are based on a further 58,000 updates.
Neonatal intensive care unit admission
Convergence was assessed using two chains using the Brooks–Gelman–Rubin tool in OpenBUGS, and was
achieved by 36,000 simulations (REs consistency model – Rath 2007 removed). Estimates are based on a
further 100,000 updates.
Apgar score < 7 at 5 minutes
Convergence was assessed using two chains using the Brooks–Gelman–Rubin tool in OpenBUGS, and was
achieved by 68,000 simulations (REs consistency model). Estimates are based on a further 68,000 updates.
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Appendix 10 Total number of arms in trials
Treatment Number of arms
No treatment 108
Placebo 99
Vaginal PGE2 (tablet) 54
Vaginal PGE2 (gel) 103
Vaginal PGE2 pessary (slow release) 46
PGF2 gel 11
Intracervical PGE2 140
Vaginal PGE2 pessary (normal release) 37
Vaginal misoprostol (dose < 50 µg) 86
Vaginal misoprostol (dose ≥ 50 µg) 129
Oral misoprostol tablet (dose < 50 µg) 4
Oral misoprostol tablet (dose ≥ 50 µg) 67
Titrated (low-dose) oral misoprostol solution 12
Sustained-release misoprostol insert 2
i.v. oxytocin 135
Amniotomy 7
i.v. oxytocin plus amniotomy 25
NO 17
Mifepristone 9
Oestrogens 8
Corticosteroids 2
Relaxin 4
Hyaluronidase 2
Mechanical methods – Foley catheter 51
Mechanical methods – laminaria 16
Mechanical methods – double-balloon or Cook’s catheter 9
Membrane sweeping 30
Extra-amniotic PGE2 11
i.v. prostaglandin 7
Sexual intercourse 2
Acupuncture 11
Breast stimulation 4
Homeopathy 1
Castor oil 1
Oral prostaglandins 14
Buccal/sublingual misoprostol 19
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Appendix 11 Model fit and heterogeneity
Model fit and selection statistics by outcomes: fixed- and
random-effects models
For REs models we also compared the fit of consistency and inconsistency models.
TABLE 44 Vaginal delivery not achieved within 24 hours
Model
Number of
data points
Residual deviance
(posterior mean)
SD (posterior median)
and 95% CrI DIC
REs consistency 290 301.1 0.54 (0.44 to 0.65) 1854
REs inconsistency 290 293.2 0.48 (0.37 to 0.62) 1855
Convergence was assessed using two chains and was achieved by 15,000 simulations for VD (REs consistency model).
Estimates are based on a further 100,000 updates.
TABLE 45 Caesarean section
Model
Number of
data points
Residual deviance
(posterior mean)
SD (posterior median)
and 95% CrI DIC
REs consistency 1217 1275 0.25 (0.18 to 0.31) 6668
REs inconsistency 1217 1266 0.22 (0.15 to 0.3) 6729
REs consistency –
continuity corrected
1217 1248 0.2463 (0.1824 to 0.3075) 6678
REs inconsistency –
continuity corrected
1217 1242 0.2224 (0.1494 to 0.2927) 6741
FEs consistency – ROB 640 696.0 3607
REs consistency – ROB –
continuity corrected
640 650.6 0.1558 (0.02545 to 0.2502) 3600
REs inconsistency – ROB –
continuity corrected
640 647.7 0.1349 (0.014 to 0.243) 3658
FE, fixed effect; ROB, risk of bias.
Convergence was assessed using two chains and was achieved by 49,000 simulations for CS (REs consistency – ROB –
continuity corrected model). Estimates are based on a further 150,000 updates. ROB= assessment of model fit having
excluded studies at high risk of bias).
TABLE 46 Instrumental delivery
Model
Number of
data points
Residual deviance
(posterior mean)
SD (posterior median)
and 95% CrI DIC
REs consistency 616 622.8 0.1506 (0.028 to 0.269) 3198
REs inconsistency 616 617.4 0.1903 (0.047 to 0.325) 3266
Convergence was assessed using two chains and was achieved by 58,000 simulations for instrumental delivery (REs
consistency). Estimates are based on a further 58,000 updates.
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TABLE 48 Apgar score < 7 at 5 minutes
Model
Number of
data points
Residual deviance
(posterior mean)
SD (posterior mean)
and 95% CrI DIC
REs consistency 413 450 0.1867 (0.011 to 0.458) 1569
REs inconsistency 413 423.2 0.1617 (0.004 to 0.482) 1573
REs consistency –
continuity corrected
413 374.9 0.1323 (0.008 to 0.3486) 1626
REs consistency – zeros
in baseline removed
335 341.8 0.1547 (0.006 to 0.4242) 1337
REs consistency –
no zeros
250 213.5 0.1209 (0.005 to 0.3337) 1059
Convergence was assessed using two chains and was achieved by 68,000 simulations (REs consistency). Estimates are based
on a further 68,000 updates.
TABLE 47 Uterine hyperstimulation with FHR changes
Model
Number of
data points
Residual deviance
(posterior mean)
SD (posterior median)
and 95% CrI DIC
REs consistency 374 395.7 0.7008 (0.4895 to 0.9465) 1509
REs inconsistency 374 368.7 0.7053 (0.4656 to 0.9909) 1491
REs consistency – zeros
in baseline removed
284 283.3 0.5684 (0.3898 to 0.7779) 1226
REs consistency –
continuity corrected
374 349 0.54 (0.38 to 0.72) 1590
REs inconsistency –
continuity corrected
374 359.7 0.55 (0.36 to 0.77) 1630
Convergence was assessed using two chains and was achieved by 26,000 simulations (REs consistency – continuity
corrected). Estimates are based on a further 75,000 updates.
TABLE 49 Neonatal intensive care unit admission
Model
Number of
data points
Residual deviance
(posterior mean)
SD (posterior median)
and 95% CrI DIC
REs consistency 428 449.4 0.2843 (0.1801 to 0.3949) 2116
REs inconsistency 428 449.4 0.1983 (0.05142 to 0.3426) 2144
REs consistency – Rath
2007504 removed
426 454.4 0.1704 (0.044 to 0.293) 2091
REs inconsistency – Rath
2007504 removed
426 443.8 0.2021 (0.0397 to 0.3479) 2126
Convergence was assessed using two chains and was achieved by 21,000 simulations (REs consistency). Estimates are based
on a further 75,000 updates.
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Appendix 12 Results of active versus active
comparisons from network meta-analysis
Odds ratios and 95% CrIs for failure to achieve VD within 24 hours, CS, instrumental delivery, uterinehyperstimulation, NICU and Apgar score for every intervention compared with every other.
Results from NMA and pairwise meta-analysis (when possible). All are considered undesirable outcomes.
An OR of > 1 favours placebo (i.e. fewer events occur on a placebo than active treatment). An OR of
< 1 favours the active treatment (i.e. fewer undesirable events occurred on the active treatment). Empty
cells indicate that direct evidence was not available for that comparison.
TABLE 50 Vaginal delivery not achieved within 24 hours
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
No treatment Placebo 0.84 0.28 to 1.97
Vaginal PGE2 (tablet) 0.11 0.04 to 0.24
Vaginal PGE2 (gel) 0.09 0.04 to 0.18 0.38 0.08 to 1.14
Vaginal PGE2 pessary (slow release) 0.10 0.04 to 0.22
Intracervical PGE2 0.13 0.05 to 0.26
Vaginal PGE2 pessary (normal release) 0.06 0.02 to 0.15
Vaginal misoprostol (dose < 50 µg) 0.07 0.03 to 0.14
Vaginal misoprostol (dose ≥ 50 µg) 0.06 0.03 to 0.12 0.00 0 to 0
Oral misoprostol tablet (dose < 50 µg) 0.15 0.05 to 0.37
Oral misoprostol tablet (dose ≥ 50 µg) 0.11 0.05 to 0.22 0.13 0.04 to 0.32
Titrated (low-dose) oral misoprostol
solution
0.07 0.03 to 0.15
Sustained-release misoprostol vaginal
pessary
0.07 0.02 to 0.19
i.v. oxytocin 0.14 0.05 to 0.29
i.v. oxytocin plus amniotomy 0.04 0.01 to 0.11
NO 0.16 0.05 to 0.4
Mifepristone 0.58 0.12 to 1.77
Mechanical methods – Foley catheter 0.12 0.05 to 0.26
Mechanical methods – double-balloon or
Cook’s catheter
0.11 0.03 to 0.26
Extra-amniotic PGE2 0.28 0.05 to 0.94
Buccal/sublingual misoprostol 0.07 0.03 to 0.15
continued
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TABLE 50 Vaginal delivery not achieved within 24 hours (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Placebo Vaginal PGE2 (tablet) 0.15 0.06 to 0.29
Vaginal PGE2 (gel) 0.12 0.06 to 0.21
Vaginal PGE2 pessary (slow release) 0.14 0.06 to 0.26
Intracervical PGE2 0.17 0.08 to 0.29 0.09 0.03 to 0.19
Vaginal PGE2 pessary (normal release) 0.08 0.03 to 0.18
Vaginal misoprostol (dose < 50 µg) 0.09 0.05 to 0.17
Vaginal misoprostol (dose ≥ 50 µg) 0.08 0.04 to 0.14
Oral misoprostol tablet (dose > 50 µg) 0.20 0.07 to 0.45
Oral misoprostol tablet (dose ≥ 50 µg) 0.15 0.07 to 0.26 0.12 0.03 to 0.31
Titrated (low-dose) oral misoprostol
solution
0.09 0.04 to 0.18
Sustained-release misoprostol vaginal
pessary
0.09 0.03 to 0.23
i.v. oxytocin 0.18 0.08 to 0.34
i.v. oxytocin plus amniotomy 0.05 0.01 to 0.14
NO 0.21 0.08 to 0.42 1.07 0.3 to 2.78
Mifepristone 0.72 0.2 to 1.85 0.8148 0.16 to 2.52
Mechanical method – Foley catheter 0.16 0.07 to 0.31
Mechanical methods – double-balloon
or Cook’s catheter
0.14 0.05 to 0.32
Extra-amniotic PGE2 0.37 0.07 to 1.2
Buccal/sublingual misoprostol 0.10 0.04 to 0.18
Vaginal PGE2 (tablet) Vaginal PGE2 (gel) 0.83 0.51 to 1.27 0.9212 0.36 to 1.96
Vaginal PGE2 pessary (slow release) 0.97 0.57 to 1.55 1.384 0.39 to 3.58
Intracervical PGE2 1.19 0.74 to 1.82 1.512 0.42 to 3.93
Vaginal PGE2 pessary (normal release) 0.60 0.27 to 1.14
Vaginal misoprostol (dose < 50 µg) 0.67 0.41 to 1.03
Vaginal misoprostol (dose ≥ 50 µg) 0.57 0.37 to 0.85 0.495 0.27 to 0.84
Oral misoprostol tablet (dose < 50 µg) 1.41 0.57 to 2.92
Oral misoprostol tablet (dose ≥ 50 µg) 1.05 0.64 to 1.62 1.28 0.36 to 3.33
Titrated (low-dose) oral misoprostol
solution
0.65 0.35 to 1.1
Sustained-release misoprostol vaginal
pessary
0.67 0.24 to 1.49
i.v. oxytocin 1.28 0.71 to 2.13
i.v. oxytocin plus amniotomy 0.34 0.08 to 0.9 0.5467 0.09 to 1.77
NO 1.50 0.6 to 3.19
Mifepristone 5.39 1.36 to 14.92
Mechanical methods – Foley catheter 1.14 0.61 to 1.95
Mechanical methods – double-balloon or
Cook’s catheter
1.01 0.42 to 2.07
Extra-amniotic PGE2 2.62 0.53 to 8.07
Buccal/sublingual misoprostol 0.68 0.37 to 1.13
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TABLE 50 Vaginal delivery not achieved within 24 hours (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal PGE2 (gel) Vaginal PGE2 pessary (slow release) 1.19 0.78 to 1.73 1.415 0.34 to 3.97
Intracervical PGE2 1.45 1.05 to 1.96 1.455 0.85 to 2.33
Vaginal PGE2 pessary (normal release) 0.73 0.37 to 1.3
Vaginal misoprostol (dose < 50 µg) 0.82 0.59 to 1.1 1.346 0.6 to 2.63
Vaginal misoprostol (dose ≥ 50 µg) 0.70 0.51 to 0.93 0.6249 0.37 to 0.98
Oral misoprostol tablet (dose < 50 µg) 1.72 0.78 to 3.32 1.508 0.42 to 3.91
Oral misoprostol tablet (dose ≥ 50 µg) 1.28 0.9 to1.76 1.883 0.81 to 3.76
Titrated (low-dose) oral misoprostol
solution
0.79 0.5 to 1.19 1.15 0.61 to 1.99
Sustained-release misoprostol vaginal
pessary
0.81 0.31 to 1.75
i.v. oxytocin 1.56 1 to 2.32 3.315 1.04 to 8.21
i.v. oxytocin plus amniotomy 0.42 0.1 to 1.15
NO 1.83 0.81 to 3.62 0.5922 0.18 to 1.47
Mifepristone 6.57 1.78 to 17.45
Mechanical methods – Foley catheter 1.39 0.85 to 2.13 1.498 0.66 to 2.95
Mechanical methods – double-balloon or
Cook’s catheter
1.23 0.56 to 2.35 1.603 0.45 to 4.12
Extra-amniotic PGE2 3.20 0.67 to 9.66
Buccal/sublingual misoprostol 0.83 0.51 to 1.27
Vaginal PGE2 pessary
(slow release)
Intracervical PGE2 1.26 0.85 to 1.79 1.914 0.99 to 3.37
Vaginal PGE2 pessary (normal release) 0.63 0.31 to 1.15
Vaginal misoprostol (dose < 50 µg) 0.71 0.48 to 1.01 0.8789 0.34 to 1.86
Vaginal misoprostol (dose ≥ 50 µg) 0.60 0.41 to 0.85 0.5678 0.3 to 0.98
Oral misoprostol tablet (dose < 50 µg) 1.49 0.63 to 3.02
Oral misoprostol tablet (dose ≥ 50 µg) 1.10 0.72 to 1.63
Titrated (low-dose) oral misoprostol
solution
0.68 0.41 to 1.08 0.617 0.16 to 1.65
Sustained-release misoprostol vaginal
pessary
0.68 0.29 to 1.36 0.674 0.31 to 1.27
i.v. oxytocin 1.35 0.82 to 2.09 2.448 0.74 to 6.12
i.v. oxytocin plus amniotomy 0.36 0.09 to 1.01
NO 1.59 0.65 to 3.29
Mifepristone 5.68 1.49 to 15.4
Mechanical methods – Foley catheter 1.20 0.71 to 1.9 0.87 0.27 to 2.15
Mechanical methods – double-balloon or
Cook’s catheter
1.06 0.48 to 2.02 0.5246 0.15 to 1.37
Extra-amniotic PGE2 2.76 0.57 to 8.46
Buccal/sublingual misoprostol 0.71 0.42 to 1.15
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TABLE 50 Vaginal delivery not achieved within 24 hours (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Intracervical PGE2 Vaginal PGE2 pessary (normal release) 0.50 0.27 to 0.85 0.7594 0.39 to 1.34
Vaginal misoprostol (dose < 50 µg) 0.57 0.43 to 0.74 0.5204 0.34 to 0.75
Vaginal misoprostol (dose ≥ 50 µg) 0.49 0.36 to 0.64 0.4747 0.3 to 0.71
Oral misoprostol tablet (dose < 50 µg) 1.20 0.53 to 2.34
Oral misoprostol tablet (dose ≥ 50 µg) 0.89 0.64 to 1.2 0.955 0.49 to 1.68
Titrated (low-dose) oral misoprostol
solution
0.55 0.34 to 0.84
Sustained-release misoprostol vaginal
pessary
0.57 0.22 to 1.21
i.v. oxytocin 1.09 0.69 to 1.62
i.v. oxytocin plus amniotomy 0.29 0.07 to 0.8
NO 1.27 0.56 to 2.55
Mifepristone 4.57 1.25 to 12.05
Mechanical methods – Foley catheter 0.97 0.59 to 1.5
Mechanical methods – double-balloon or
Cook’s catheter
0.86 0.39 to 1.66
Extra-amniotic PGE2 2.23 0.47 to 6.71
Buccal/sublingual misoprostol 0.57 0.36 to 0.87
Vaginal PGE2 pessary
(normal release)
Vaginal misoprostol (dose < 50 µg) 1.23 0.63 to 2.17
Vaginal misoprostol (dose ≥ 50 µg) 1.05 0.54 to 1.86
Oral misoprostol tablet (dose < 50 µg) 2.60 0.93 to 5.85
Oral misoprostol tablet (dose ≥ 50 µg) 1.92 0.97 to 3.46
Titrated (low-dose) oral misoprostol
solution
1.19 0.55 to 2.27
Sustained-release misoprostol vaginal
pessary
1.22 0.39 to 2.96
i.v. oxytocin 2.34 1.13 to 4.35 37.7 2.63 to 187.2
i.v. oxytocin plus amniotomy 0.63 0.13 to 1.88
NO 2.76 0.96 to 6.37
Mifepristone 9.86 2.3 to 28.31
Mechanical methods – Foley
catheter
2.07 0.99 to 3.85 4.696 1.09 to 13.54
Mechanical methods – double-balloon or
Cook’s catheter
1.85 0.68 to 4.09
Extra-amniotic PGE2 4.81 0.89 to 15.63
Buccal/sublingual misoprostol 1.24 0.58 to 2.36
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TABLE 50 Vaginal delivery not achieved within 24 hours (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal misoprostol
(dose < 50 µg)
Vaginal misoprostol (dose ≥ 50 µg) 0.86 0.65 to 1.1 1.122 0.68 to 1.76
Oral misoprostol tablet (dose < 50 µg) 2.12 0.97 to 4.07 4.206 1.18 to 10.86
Oral misoprostol tablet (dose ≥ 50 µg) 1.57 1.17 to 2.08 1.347 0.84 to 2.07
Titrated (low-dose) oral misoprostol
solution
0.98 0.63 to 1.46 0.3878 0.15 to 0.8
Sustained-release misoprostol vaginal
pessary
1.00 0.39 to 2.15
i.v. oxytocin 1.92 1.27 to 2.8 1.843 0.75 to 3.83
i.v. oxytocin plus amniotomy 0.52 0.13 to 1.41
NO 2.26 0.98 to 4.56
Mifepristone 8.11 2.21 to 21.51
Mechanical methods – Foley catheter 1.71 1.07 to 2.61 2.508 1.17 to 4.81
Mechanical methods – double-balloon or
Cook’s catheter
1.52 0.69 to 2.93
Extra-amniotic PGE2 3.95 0.85 to 11.91
Buccal/sublingual misoprostol 1.01 0.67 to 1.47 1.045 0.61 to 1.68
Oral misoprostol tablet (dose < 50 µg) 2.49 1.12 to 4.84
Oral misoprostol tablet (dose ≥ 50 µg) 1.84 1.36 to 2.45 1.608 0.9 to 2.67
Titrated (low-dose) oral misoprostol
solution
1.15 0.72 to 1.74
Sustained-release misoprostol vaginal
pessary
1.17 0.46 to 2.5
i.v. oxytocin 2.25 1.47 to 3.32 2.558 0.78 to 6.32
i.v. oxytocin plus amniotomy 0.61 0.15 to 1.65
NO 2.64 1.17 to 5.24 2.17 0.52 to 6.15
Mifepristone 9.50 2.59 to 25.22
Mechanical methods – Foley catheter 2.01 1.24 to 3.08 1.646 0.43 to 4.45
Mechanical methods – double-balloon or
Cook’s catheter
1.78 0.81 to 3.43
Extra-amniotic PGE2 4.58 1.02 to 13.56 4.469 1.09 to 12.59
Buccal/sublingual misoprostol 1.19 0.78 to 1.74 1.01 0.49 to 1.84
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TABLE 50 Vaginal delivery not achieved within 24 hours (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Oral misoprostol tablet
(dose < 50 µg)
Oral misoprostol tablet (dose ≥ 50 µg) 0.84 0.38 to 1.62 1.395 0.37 to 3.72
Titrated (low-dose) oral misoprostol
solution
0.52 0.21 to 1.07
Sustained-release misoprostol vaginal
pessary
0.54 0.15 to 1.38
i.v. oxytocin 1.03 0.43 to 2.1
i.v. oxytocin plus amniotomy 0.28 0.05 to 0.85
NO 1.21 0.38 to 2.96
Mifepristone 4.35 0.93 to 13.12
Mechanical methods – Foley catheter 0.92 0.37 to 1.91
Mechanical methods – double-balloon or
Cook’s catheter
0.82 0.27 to 1.94
Extra-amniotic PGE2 2.11 0.36 to 7.05
Buccal/sublingual misoprostol 0.54 0.23 to 1.11
Oral misoprostol tablet
(dose ≥ 50 µg)
Titrated (low-dose) oral misoprostol
solution
0.63 0.39 to 0.96 3.052 0.57 to 9.83
Sustained-release misoprostol vaginal
pessary
0.65 0.25 to 1.4
i.v. oxytocin 1.24 0.8 to 1.82 0.8035 0.35 to 1.59
i.v. oxytocin plus amniotomy 0.33 0.08 to 0.91
NO 1.46 0.63 to 2.93
Mifepristone 5.21 1.42 to 13.82
Mechanical methods – Foley catheter 1.10 0.66 to 1.73
Mechanical methods – double-balloon or
Cook’s catheter
0.98 0.44 to 1.91
Extra-amniotic PGE2 2.54 0.54 to 7.7
Buccal/sublingual misoprostol 0.65 0.42 to 0.97 0.6002 0.24 to 1.25
Titrated (low-dose) oral
misoprostol solution
Sustained-release misoprostol vaginal
pessary
1.07 0.38 to 2.37
i.v. oxytocin 2.03 1.23 to 3.18 1.868 0.84 to 3.64
i.v. oxytocin plus amniotomy 0.55 0.13 to 1.56
NO 2.41 0.96 to 5.12
Mifepristone 8.61 2.23 to 23.54
Mechanical methods – Foley catheter 1.82 1.01 to 3.03
Mechanical methods – double-balloon or
Cook’s catheter
1.62 0.68 to 3.27
Extra-amniotic PGE2 4.21 0.85 to 13.02
Buccal/sublingual misoprostol 1.08 0.6 to 1.8
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TABLE 50 Vaginal delivery not achieved within 24 hours (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Sustained-release
misoprostol vaginal
pessary
i.v. oxytocin 2.29 0.84 to 5.1
i.v. oxytocin plus amniotomy 0.62 0.11 to 1.99
NO 2.70 0.76 to 7.03
Mifepristone 9.69 1.87 to 30.74
Mechanical methods – Foley catheter 2.04 0.73 to 4.57
Mechanical methods – double-balloon or
Cook’s catheter
1.80 0.55 to 4.46
Extra-amniotic PGE2 4.71 0.73 to 16.36
Buccal/sublingual misoprostol 1.22 0.43 to 2.74
i.v. oxytocin i.v. oxytocin plus amniotomy 0.28 0.06 to 0.78
NO 1.22 0.49 to 2.54
Mifepristone 4.29 1.19 to 11.25 4.687 0.83 to 15.59
Mechanical methods – Foley catheter 0.92 0.51 to 1.53
Mechanical methods – double-balloon or
Cook’s catheter
0.82 0.35 to 1.65
Extra-amniotic PGE2 2.12 0.43 to 6.54
Buccal/sublingual misoprostol 0.55 0.32 to 0.88 1.464 0.3 to 4.46
i.v. oxytocin
plus amniotomy
NO 6.34 1.23 to 20.21
Mifepristone 22.76 3.17 to 83.58
Mechanical methods – Foley catheter 4.80 1.12 to 14.05
Mechanical methods – double-balloon or
Cook’s catheter
4.27 0.85 to 13.41
Extra-amniotic PGE2 11.04 1.25 to 43.52
Buccal/sublingual misoprostol 2.80 0.71 to 7.82 5.601 0.73 to 21.59
NO Mifepristone 4.06 0.9 to 11.86
Mechanical methods – Foley catheter 0.87 0.34 to 1.84
Mechanical methods – double-balloon or
Cook’s catheter
0.77 0.25 to 1.86
Extra-amniotic PGE2 2.00 0.34 to 6.72
Buccal/sublingual misoprostol 0.52 0.2 to 1.08
Mifepristone Mechanical methods – Foley catheter 0.29 0.07 to 0.8
Mechanical methods – double-balloon or
Cook’s catheter
0.26 0.05 to 0.77
Extra-amniotic PGE2 0.68 0.08 to 2.56
Buccal/sublingual misoprostol 0.17 0.04 to 0.47
Mechanical methods –
Foley catheter
Mechanical methods – double-balloon or
Cook’s catheter
0.91 0.43 to 1.7 1.335 0.39 to 3.41
Extra-amniotic PGE2 2.41 0.48 to 7.48
Buccal/sublingual misoprostol 0.62 0.34 to 1.05
Mechanical methods –
double-balloon or
Cook’s catheter
Extra-amniotic PGE2 2.94 0.51 to 9.76
Buccal/sublingual misoprostol 0.76 0.31 to 1.55
Extra-amniotic PGE2 Buccal/sublingual misoprostol 0.40 0.08 to 1.22
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TABLE 51 Caesarean section
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
No treatment Placebo 1.2 0.91 to 1.44 0.53 0.05 to 1.91
Vaginal PGE2 (tablet) 1.2 0.9 to 1.57
Vaginal PGE2 (gel) 0.9 0.74 to 1.08 0.86 0.6 to 1.17
Vaginal PGE2 pessary (slow release) 1.0 0.8 to 1.28 16.68 0.43 to 105.7
PGF2 gel 0.8 0.44 to 1.35
Intracervical PGE2 0.9 0.78 to 1.14 0.92 0.65 to 1.27
Vaginal PGE2 pessary (normal release) 0.9 0.7 to 1.24 1.05 0.44 to 2.15
Vaginal misoprostol (dose < 50 µg) 0.8 0.65 to 0.97 0.55 0.25 to 1.04
Vaginal misoprostol (dose ≥ 50 µg) 0.8 0.68 to 1.01
Oral misoprostol tablet (dose < 50 µg) 1.3 0.73 to 2.08
Oral misoprostol tablet (dose ≥ 50 µg) 0.8 0.66 to 1.01 1.39 0.25 to 4.61
Titrated (low-dose) oral misoprostol
solution
0.7 0.53 to 0.92
Sustained-release misoprostol vaginal
pessary
1.1 0.68 to 1.77
i.v. oxytocin 1.1 0.89 to 1.27 1.16 0.93 to 1.44
Amniotomy 1.2 0.58 to 2.31
i.v. oxytocin plus amniotomy 1.0 0.66 to 1.53
NO 0.9 0.69 to 1.26 1.41 0.22 to 5.09
Mifepristone 0.8 0.48 to 1.29
Oestrogens 1.5 0.71 to 2.68
Corticosteroids 0.6 0.22 to 1.3 0.22 0 to 1.05
Relaxin 1.0 0.36 to 2.34
Hyaluronidase 0.7 0.38 to 1.17
Mechanical methods – Foley catheter 0.9 0.69 to 1.09
Mechanical methods – laminaria 0.9 0.51 to 1.51 0.92 0.51 to 1.49
Mechanical methods – double-balloon or
Cook’s catheter
1.3 0.84 to 1.87
Membrane sweeping 0.8 0.66 to 1.05 0.86 0.67 to 1.08
Extra-amniotic PGE2 1.1 0.65 to 1.82
i.v. prostaglandin 23.2 1.84 to 135.6
Sexual intercourse 1.0 0.65 to 1.39 0.95 0.66 to 1.36
Acupuncture 0.9 0.58 to 1.43 1.04 0.42 to 2.22
Oral prostaglandins 0.8 0.09 to 2.94
Buccal/sublingual misoprostol 0.8 0.58 to 1.02
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Placebo Vaginal PGE2 (tablet) 1.0 0.78 to 1.35 0.91 0 to 5.74
Vaginal PGE2 (gel) 0.8 0.65 to 0.94 0.95 0.63 to 1.37
Vaginal PGE2 pessary (slow release) 0.9 0.69 to 1.12 0.62 0.26 to 1.21
PGF2 gel 0.7 0.4 to 1.16 0.65 0.27 to 1.3
Intracervical PGE2 0.8 0.69 to 0.98 0.85 0.66 to 1.09
Vaginal PGE2 pessary (normal release) 0.8 0.62 to 1.09 0.76 0.41 to 1.29
Vaginal misoprostol (dose < 50 µg) 0.7 0.57 to 0.85 1.14 0.58 to 2.05
Vaginal misoprostol (dose ≥ 50 µg) 0.7 0.59 to 0.88 1.32 0.17 to 4.64
Oral misoprostol tablet (dose < 50 µg) 1.1 0.64 to 1.81
Oral misoprostol tablet (dose ≥ 50 µg) 0.7 0.58 to 0.88 0.60 0.35 to 0.96
Titrated (low-dose) oral misoprostol
solution
0.6 0.47 to 0.8
Sustained-release misoprostol vaginal
pessary
1.0 0.59 to 1.55
i.v. oxytocin 0.9 0.75 to 1.14 1.74 0.53 to 4.29
Amniotomy 1.1 0.51 to 2.02
i.v. oxytocin plus amniotomy 0.9 0.57 to 1.34
NO 0.8 0.62 to 1.06 1.05 0.7 to 1.49
Mifepristone 0.7 0.45 to 1.08 0.63 0.39 to 0.95
Oestrogens 1.3 0.62 to 2.32 1.97 0.66 to 4.49
Corticosteroids 0.5 0.2 to 1.12 0.72 0.25 to 1.65
Relaxin 0.9 0.33 to 1.98 0.90 0.32 to 2.03
Hyaluronidase 0.6 0.34 to 1 0.24 0.1 to 0.46
Mechanical methods – Foley catheter 0.8 0.61 to 0.95
Mechanical methods – laminaria 0.8 0.43 to 1.38
Mechanical methods – double-balloon or
Cook’s catheter
1.1 0.73 to 1.63
Membrane sweeping 0.7 0.53 to 0.99 1.78 0.22 to 6.41
Extra-amniotic PGE2 1.0 0.57 to 1.57 0.47 0.16 to 1.03
i.v. prostaglandin 19.9 1.61 to 120.5
Sexual intercourse 0.8 0.54 to 1.29
Acupuncture 0.8 0.52 to 1.2 0.76 0.46 to 1.16
Oral prostaglandins 0.7 0.08 to 2.59
Buccal/sublingual misoprostol 0.7 0.51 to 0.89
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal PGE2 (tablet) Vaginal PGE2 (gel) 0.77 0.6 to 0.96 0.84 0 to 0.83
Vaginal PGE2 pessary (slow release) 0.86 0.64 to 1.14
PGF2 gel 0.68 0.37 to 1.17
Intracervical PGE2 0.81 0.62 to 1.03 0.78 0 to 0.74
Vaginal PGE2 pessary (normal release) 0.80 0.57 to 1.11
Vaginal misoprostol (dose < 50 µg) 0.68 0.52 to 0.87
Vaginal misoprostol (dose ≥ 50 µg) 0.71 0.55 to 0.89 0.69 0 to 0.68
Oral misoprostol tablet (dose < 50 µg) 1.08 0.6 to 1.8
Oral misoprostol tablet (dose ≥ 50 µg) 0.70 0.53 to 0.9 0.95 0 to 0.89
Titrated (low-dose) oral misoprostol
solution
0.60 0.43 to 0.81
Sustained-release misoprostol vaginal
pessary
0.96 0.55 to 1.54
i.v. oxytocin 0.91 0.69 to 1.17 0.44 0 to 0.4
Amniotomy 1.03 0.48 to 1.98
i.v. oxytocin plus amniotomy 0.87 0.54 to 1.33
NO 0.80 0.57 to 1.09 0.88 0.01 to 0.81
Mifepristone 0.70 0.4 to 1.12
Oestrogens 1.24 0.58 to 2.32
Corticosteroids 0.52 0.19 to 1.14
Relaxin 0.86 0.3 to 1.98
Hyaluronidase 0.59 0.32 to 1.01
Mechanical methods – Foley catheter 0.74 0.56 to 0.96 0.99 0.01 to 0.88
Mechanical methods – laminaria 0.78 0.4 to 1.35
Mechanical methods – double-balloon or
Cook’s catheter
1.08 0.69 to 1.62
Membrane sweeping 0.72 0.49 to 1.01
Extra-amniotic PGE2 0.96 0.53 to 1.59
i.v. prostaglandin 19.56 1.54 to 118
Sexual intercourse 0.82 0.5 to 1.28
Acupuncture 0.79 0.47 to 1.25
Oral prostaglandins 0.70 0.08 to 2.55
Buccal/sublingual misoprostol 0.66 0.48 to 0.9
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal PGE2 (gel) Vaginal PGE2 pessary (slow release) 1.13 0.91 to 1.38 1.579 0.72 to 3.03
PGF2 gel 0.89 0.5 to 1.48 1.196 0.33 to 3.22
Intracervical PGE2 1.06 0.91 to 1.23 1.3 0.94 to 1.76
Vaginal PGE2 pessary (normal release) 1.05 0.8 to 1.35 1.753 0.59 to 4.1
Vaginal misoprostol (dose < 50 µg) 0.89 0.77 to 1.03 0.9487 0.73 to 1.2
Vaginal misoprostol (dose ≥ 50 µg) 0.93 0.8 to 1.06 0.8462 0.66 to 1.06
Oral misoprostol tablet (dose < 50 µg) 1.41 0.83 to 2.25 1.005 0.43 to 2.02
Oral misoprostol tablet (dose ≥ 50 µg) 0.91 0.77 to 1.07 1.107 0.77 to 1.55
Titrated (low-dose) oral misoprostol
solution
0.79 0.63 to 0.97 0.8214 0.61 to 1.08
Sustained-release misoprostol vaginal
pessary
1.25 0.76 to 1.95
i.v. oxytocin 1.19 1 to 1.4 1.156 0.47 to 2.4
Amniotomy 1.35 0.66 to 2.53 1.55 0.35 to 4.78
i.v. oxytocin plus amniotomy 1.14 0.76 to 1.66 0.7504 0.35 to 1.39
NO 1.05 0.79 to 1.35 0.9331 0.57 to 1.43
Mifepristone 0.91 0.55 to 1.41
Oestrogens 1.62 0.79 to 2.99
Corticosteroids 0.68 0.25 to 1.45
Relaxin 1.13 0.41 to 2.58
Hyaluronidase 0.78 0.44 to 1.29
Mechanical methods – Foley catheter 0.97 0.82 to 1.15 0.9701 0.76 to 1.22
Mechanical methods – laminaria 1.02 0.55 to 1.72
Mechanical methods – double-balloon or
Cook’s catheter
1.42 0.97 to 2.02 1.338 0.72 to 2.27
Membrane sweeping 0.94 0.69 to 1.25
Extra-amniotic PGE2 1.26 0.73 to 2
i.v. prostaglandin 25.56 2.05 to 155.1
Sexual intercourse 1.08 0.7 to 1.61
Acupuncture 1.04 0.65 to 1.59
Oral prostaglandins 0.92 0.1 to 3.29
Buccal/sublingual misoprostol 0.87 0.68 to 1.1
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal PGE2 pessary
(slow release)
PGF2 gel 0.80 0.44 to 1.35
Intracervical PGE2 0.94 0.76 to 1.17 0.9169 0.5 to 1.55
Vaginal PGE2 pessary (normal release) 0.94 0.68 to 1.26
Vaginal misoprostol (dose < 50 µg) 0.80 0.64 to 0.98 1.155 0.62 to 2
Vaginal misoprostol (dose ≥ 50 µg) 0.83 0.67 to 1.01 0.9019 0.61 to 1.26
Oral misoprostol tablet (dose < 50 µg) 1.26 0.72 to 2.06
Oral misoprostol tablet (dose ≥ 50 µg) 0.82 0.64 to 1.02
Titrated (low-dose) oral misoprostol
solution
0.70 0.53 to 0.91 0.4783 0.17 to 1.07
Sustained-release misoprostol vaginal
pessary
1.11 0.71 to 1.65 1.103 0.73 to 1.61
i.v. oxytocin 1.06 0.85 to 1.3 1.502 0.93 to 2.29
Amniotomy 1.21 0.58 to 2.3
i.v. oxytocin plus amniotomy 1.02 0.65 to 1.53
NO 0.93 0.67 to 1.26
Mifepristone 0.81 0.48 to 1.29
Oestrogens 1.44 0.69 to 2.69
Corticosteroids 0.61 0.22 to 1.3
Relaxin 1.01 0.36 to 2.33
Hyaluronidase 0.69 0.38 to 1.17
Mechanical methods – Foley catheter 0.87 0.69 to 1.08 0.7321 0.47 to 1.09
Mechanical methods – laminaria 0.91 0.48 to 1.57
Mechanical methods – double-balloon or
Cook’s catheter
1.26 0.85 to 1.83 0.9315 0.44 to 1.76
Membrane sweeping 0.84 0.6 to 1.13 0.6474 0.28 to 1.28
Extra-amniotic PGE2 1.12 0.63 to 1.82
i.v. prostaglandin 22.76 1.82 to 135.4
Sexual intercourse 0.96 0.6 to 1.47
Acupuncture 0.93 0.56 to 1.45
Oral prostaglandins 0.82 0.09 to 2.94
Buccal/sublingual misoprostol 0.78 0.58 to 1.02
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
PGF2 gel Intracervical PGE2 1.28 0.71 to 2.1
Vaginal PGE2 pessary (normal release) 1.27 0.67 to 2.18
Vaginal misoprostol (dose < 50 µg) 1.08 0.59 to 1.78
Vaginal misoprostol (dose ≥ 50 µg) 1.12 0.62 to 1.85
Oral misoprostol tablet (dose < 50 µg) 1.71 0.76 to 3.31
Oral misoprostol tablet (dose ≥ 50 µg) 1.10 0.6 to 1.83
Titrated (low-dose) oral misoprostol
solution
0.95 0.51 to 1.61
Sustained-release misoprostol vaginal
pessary
1.51 0.7 to 2.89
i.v. oxytocin 1.43 0.79 to 2.38 358,300 1.09 to 22,380
Amniotomy 1.63 0.63 to 3.56
i.v. oxytocin plus amniotomy 1.37 0.67 to 2.54
NO 1.26 0.67 to 2.16
Mifepristone 1.09 0.51 to 2.03
Oestrogens 1.95 0.76 to 4.11
Corticosteroids 0.82 0.25 to 1.96
Relaxin 1.36 0.42 to 3.47
Hyaluronidase 0.94 0.41 to 1.82
Mechanical methods – Foley catheter 1.17 0.65 to 1.94 0.7658 0.22 to 1.9
Mechanical methods – laminaria 1.23 0.52 to 2.47
Mechanical methods – double-balloon or
Cook’s catheter
1.71 0.85 to 3.09
Membrane sweeping 1.13 0.59 to 1.95
Extra-amniotic PGE2 1.51 0.68 to 2.91
i.v. prostaglandin 31.34 2.13 to 191
Sexual intercourse 1.30 0.63 to 2.41
Acupuncture 1.25 0.6 to 2.29
Oral prostaglandins 1.11 0.11 to 4.17
Buccal/sublingual misoprostol 1.05 0.55 to 1.79
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Intracervical PGE2 Vaginal PGE2 pessary (normal release) 1.00 0.76 to 1.3 1.12 0.57 to 2
Vaginal misoprostol (dose < 50 µg) 0.85 0.72 to 0.99 0.8757 0.61 to 1.23
Vaginal misoprostol (dose ≥ 50 µg) 0.88 0.75 to 1.03 1.035 0.74 to 1.4
Oral misoprostol tablet (dose < 50 µg) 1.34 0.78 to 2.17
Oral misoprostol tablet (dose ≥ 50 µg) 0.87 0.72 to 1.03 0.8622 0.54 to 1.3
Titrated (low-dose) oral misoprostol
solution
0.75 0.58 to 0.95
Sustained-release misoprostol vaginal
pessary
1.19 0.72 to 1.86
i.v. oxytocin 1.13 0.94 to 1.34 0.8863 0.46 to 1.56
Amniotomy 1.29 0.62 to 2.42
i.v. oxytocin plus amniotomy 1.08 0.7 to 1.6
NO 0.99 0.74 to 1.3
Mifepristone 0.86 0.52 to 1.34
Oestrogens 1.54 0.75 to 2.81 0.9795 0.33 to 2.32
Corticosteroids 0.65 0.24 to 1.38
Relaxin 1.07 0.39 to 2.46
Hyaluronidase 0.74 0.41 to 1.22
Mechanical methods – Foley catheter 0.92 0.76 to 1.12 1.085 0.59 to 1.83
Mechanical methods – laminaria 0.97 0.52 to 1.65
Mechanical methods – double-balloon or
Cook’s catheter
1.35 0.9 to 1.94 2.867 0.83 to 7.15
Membrane sweeping 0.89 0.66 to 1.18
Extra-amniotic PGE2 1.19 0.69 to 1.91 0.9298 0.01 to 4.69
i.v. prostaglandin 24.08 1.94 to 145.6
Sexual intercourse 1.02 0.66 to 1.54
Acupuncture 0.98 0.62 to 1.5
Oral prostaglandins 0.87 0.1 to 3.12
Buccal/sublingual misoprostol 0.82 0.64 to 1.06
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal PGE2 pessary
(normal release)
Vaginal misoprostol (dose < 50 µg) 0.86 0.65 to 1.12
Vaginal misoprostol (dose ≥ 50 µg) 0.90 0.68 to 1.16 0.6225 0.31 to 1.11
Oral misoprostol tablet (dose < 50 µg) 1.37 0.75 to 2.31
Oral misoprostol tablet (dose ≥ 50 µg) 0.88 0.66 to 1.16
Titrated (low-dose) oral misoprostol
solution
0.76 0.54 to 1.04 0.6755 0.26 to 1.42
Sustained-release misoprostol vaginal
pessary
1.21 0.7 to 1.97
i.v. oxytocin 1.15 0.87 to 1.49 0.8613 0.46 to 1.49
Amniotomy 1.31 0.61 to 2.51
i.v. oxytocin plus amniotomy 1.10 0.68 to 1.68 2.528 0.86 to 5.92
NO 1.01 0.7 to 1.42
Mifepristone 0.88 0.5 to 1.43
Oestrogens 1.56 0.73 to 2.96
Corticosteroids 0.66 0.24 to 1.43
Relaxin 1.09 0.38 to 2.55
Hyaluronidase 0.75 0.4 to 1.29
Mechanical methods – Foley catheter 0.94 0.7 to 1.25 2.107 0.86 to 4.39
Mechanical methods – laminaria 0.99 0.51 to 1.72
Mechanical methods – double-balloon or
Cook’s catheter
1.37 0.87 to 2.08
Membrane sweeping 0.91 0.62 to 1.28
Extra-amniotic PGE2 1.21 0.67 to 2.02 1.343 0.51 to 2.86
i.v. prostaglandin 24.70 1.95 to 147.7
Sexual intercourse 1.04 0.63 to 1.63
Acupuncture 1.00 0.59 to 1.6
Oral prostaglandins 0.89 0.1 to 3.19
Buccal/sublingual misoprostol 0.84 0.59 to 1.16
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal misoprostol
(dose < 50 µg)
Vaginal misoprostol (dose ≥ 50 µg) 1.04 0.9 to 1.21 1.22 0.86 to 1.69
Oral misoprostol tablet (dose < 50 µg) 1.59 0.94 to 2.52 2.442 1.11 to 4.72
Oral misoprostol tablet (dose ≥ 50 µg) 1.03 0.87 to 1.21 0.767 0.57 to 1.02
Titrated (low-dose) oral misoprostol
solution
0.89 0.7 to 1.11 0.7473 0.42 to 1.23
Sustained-release misoprostol vaginal
pessary
1.41 0.86 to 2.2
i.v. oxytocin 1.34 1.12 to 1.58 1.599 1.11 to 2.24
Amniotomy 1.52 0.74 to 2.87
i.v. oxytocin plus amniotomy 1.28 0.84 to 1.89
NO 1.18 0.88 to 1.54 0.6798 0.24 to 1.51
Mifepristone 1.02 0.62 to 1.6
Oestrogens 1.82 0.89 to 3.37
Corticosteroids 0.77 0.28 to 1.63
Relaxin 1.27 0.46 to 2.91
Hyaluronidase 0.87 0.49 to 1.45
Mechanical methods – Foley catheter 1.10 0.92 to 1.31 1.53 1.08 to 2.12
Mechanical methods – laminaria 1.15 0.62 to 1.95
Mechanical methods – double-balloon or
Cook’s catheter
1.60 1.08 to 2.3
Membrane sweeping 1.06 0.77 to 1.41
Extra-amniotic PGE2 1.41 0.81 to 2.26
i.v. prostaglandin 28.69 2.31 to 172.9
Sexual intercourse 1.21 0.78 to 1.82
Acupuncture 1.17 0.73 to 1.79
Oral prostaglandins 1.04 0.11 to 3.73
Buccal/sublingual misoprostol 0.98 0.78 to 1.21 1.09 0.81 to 1.45
Vaginal misoprostol
(dose ≥ 50 µg)
Oral misoprostol tablet (dose < 50 µg) 1.53 0.89 to 2.45
Oral misoprostol tablet (dose ≥ 50 µg) 0.99 0.84 to 1.15 1.092 0.83 to 1.39
Titrated (low-dose) oral misoprostol
solution
0.85 0.67 to 1.07 2.558 0.4 to 9.6
Sustained-release misoprostol vaginal
pessary
1.35 0.83 to 2.11
i.v. oxytocin 1.28 1.09 to 1.51 1.13 0.82 to 1.52
Amniotomy 1.46 0.71 to 2.75
i.v. oxytocin plus amniotomy 1.23 0.81 to 1.82
NO 1.13 0.85 to 1.47 1.055 0.49 to 1.96
APPENDIX 12
NIHR Journals Library www.journalslibrary.nihr.ac.uk
414
TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Mifepristone 0.98 0.59 to 1.53
Oestrogens 1.75 0.85 to 3.23
Corticosteroids 0.74 0.27 to 1.57
Relaxin 1.22 0.44 to 2.8
Hyaluronidase 0.84 0.47 to 1.39
Mechanical methods – Foley catheter 1.05 0.87 to 1.26 1.05 0.57 to 1.81
Mechanical methods – laminaria 1.11 0.59 to 1.87
Mechanical methods – double-balloon or
Cook’s catheter
1.53 1.03 to 2.21
Membrane sweeping 1.01 0.75 to 1.35
Extra-amniotic PGE2 1.36 0.79 to 2.14 3.248 0.95 to 8.74
i.v. prostaglandin 27.56 2.24 to 164.1
Sexual intercourse 1.17 0.75 to 1.75
Acupuncture 1.12 0.7 to 1.72
Oral prostaglandins 1.00 0.11 to 3.55
Buccal/sublingual misoprostol 0.94 0.74 to 1.17 0.8972 0.62 to 1.25
Oral misoprostol
tablet (dose < 50 µg)
Oral misoprostol tablet (dose ≥ 50 µg) 0.69 0.4 to 1.1 1.241 0.22 to 3.93
Titrated (low-dose) oral misoprostol
solution
0.59 0.34 to 0.97
Sustained-release misoprostol vaginal
pessary
0.94 0.45 to 1.75
i.v. oxytocin 0.90 0.51 to 1.44
Amniotomy 1.02 0.41 to 2.17
i.v. oxytocin plus amniotomy 0.86 0.43 to 1.55
NO 0.79 0.43 to 1.32
Mifepristone 0.69 0.32 to 1.28
Oestrogens 1.22 0.49 to 2.55
Corticosteroids 0.51 0.16 to 1.21
Relaxin 0.85 0.26 to 2.09
Hyaluronidase 0.59 0.26 to 1.13
Mechanical methods – Foley catheter 0.73 0.42 to 1.18
Mechanical methods – laminaria 0.77 0.34 to 1.51
Mechanical methods – double-balloon or
Cook’s catheter
1.07 0.55 to 1.88
Membrane sweeping 0.71 0.39 to 1.19
Extra-amniotic PGE2 0.95 0.44 to 1.77
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
i.v. prostaglandin 19.15 1.38 to 114
Sexual intercourse 0.81 0.41 to 1.47
Acupuncture 0.78 0.38 to 1.44
Oral prostaglandins 0.69 0.07 to 2.6
Buccal/sublingual
misoprostol
0.65 0.37 to 1.07
Oral misoprostol
tablet (dose ≥ 50 µg)
Titrated (low-dose) oral misoprostol
solution
0.87 0.66 to 1.11 1.942 0.6 to 4.84
Sustained-release misoprostol vaginal
pessary
1.38 0.83 to 2.17
i.v. oxytocin 1.31 1.07 to 1.58 1.05 0.54 to 1.83
Amniotomy 1.49 0.72 to 2.83
i.v. oxytocin plus amniotomy 1.25 0.81 to 1.88
NO 1.15 0.85 to 1.51
Mifepristone 1.00 0.59 to 1.57
Oestrogens 1.78 0.86 to 3.3
Corticosteroids 0.75 0.27 to 1.6
Relaxin 1.24 0.45 to 2.85
Hyaluronidase 0.86 0.47 to 1.42
Mechanical methods – Foley catheter 1.07 0.87 to 1.32
Mechanical methods – laminaria 1.13 0.6 to 1.92
Mechanical methods – double-balloon or
Cook’s catheter
1.56 1.04 to 2.28
Membrane sweeping 1.03 0.75 to 1.38
Extra-amniotic PGE2 1.38 0.79 to 2.22
i.v. prostaglandin 28.01 2.27 to 168.8
Sexual intercourse 1.19 0.76 to 1.8
Acupuncture 1.14 0.71 to 1.77
Oral prostaglandins 1.01 0.11 to 3.63
Buccal/sublingual misoprostol 0.95 0.74 to 1.21 0.7876 0.44 to 1.3
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Titrated (low-dose)
oral misoprostol
solution
Sustained-release misoprostol vaginal
pessary
1.61 0.94 to 2.58
i.v. oxytocin 1.53 1.18 to 1.94 1.57 0.76 to 2.93
Amniotomy 1.74 0.82 to 3.32
i.v. oxytocin plus amniotomy 1.46 0.92 to 2.23
NO 1.35 0.95 to 1.85
Mifepristone 1.17 0.68 to 1.88
Oestrogens 2.08 0.98 to 3.93
Corticosteroids 0.88 0.32 to 1.91
Relaxin 1.45 0.52 to 3.39
Hyaluronidase 1.00 0.54 to 1.7
Mechanical methods – Foley catheter 1.25 0.97 to 1.6
Mechanical methods – laminaria 1.31 0.69 to 2.28
Mechanical methods – double-balloon or
Cook’s catheter
1.82 1.18 to 2.71
Membrane sweeping 1.21 0.84 to 1.68
Extra-amniotic PGE2 1.61 0.91 to 2.62
i.v. prostaglandin 32.79 2.59 to 201
Sexual intercourse 1.39 0.85 to 2.15
Acupuncture 1.34 0.79 to 2.12
Oral prostaglandins 1.18 0.13 to 4.26
Buccal/sublingual misoprostol 1.12 0.81 to 1.5
Sustained-release
misoprostol vaginal
pessary
i.v. oxytocin 1.00 0.6 to 1.56
Amniotomy 1.14 0.47 to 2.39
i.v. oxytocin plus amniotomy 0.96 0.5 to 1.68
NO 0.88 0.5 to 1.43
Mifepristone 0.77 0.38 to 1.38
Oestrogens 1.37 0.57 to 2.78
Corticosteroids 0.57 0.19 to 1.33
Relaxin 0.95 0.3 to 2.32
Hyaluronidase 0.66 0.31 to 1.24
Mechanical methods – Foley catheter 0.82 0.5 to 1.28
Mechanical methods – laminaria 0.86 0.39 to 1.65
Mechanical methods – double-balloon or
Cook’s catheter
1.19 0.65 to 2.04
Membrane sweeping 0.79 0.45 to 1.28
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Extra-amniotic PGE2 1.06 0.51 to 1.96
i.v. prostaglandin 21.53 1.59 to 126.3
Sexual intercourse 0.91 0.47 to 1.6
Acupuncture 0.88 0.44 to 1.58
Oral prostaglandins 0.77 0.08 to 2.85
Buccal/sublingual
misoprostol
0.73 0.42 to 1.18
i.v. oxytocin Amniotomy 1.14 0.56 to 2.15
i.v. oxytocin plus amniotomy 0.96 0.63 to 1.41 1.115 0.58 to 1.95
NO 0.89 0.65 to 1.17
Mifepristone 0.77 0.46 to 1.2 3.904 0.58 to 14.91
Oestrogens 1.37 0.67 to 2.5
Corticosteroids 0.58 0.21 to 1.22
Relaxin 0.95 0.34 to 2.19
Hyaluronidase 0.66 0.36 to 1.1
Mechanical methods – Foley catheter 0.82 0.67 to 1.01
Mechanical methods – laminaria 0.86 0.47 to 1.45
Mechanical methods – double-balloon or
Cook’s catheter
1.20 0.8 to 1.74
Membrane sweeping 0.79 0.59 to 1.04
Extra-amniotic PGE2 1.06 0.61 to 1.71
i.v. prostaglandin 21.48 1.76 to 127.4 19.76 1.7 to 87.58
Sexual intercourse 0.91 0.59 to 1.36
Acupuncture 0.88 0.55 to 1.35
Oral prostaglandins 0.77 0.09 to 2.74 0.7501 0.07 to 2.74
Buccal/sublingual misoprostol 0.74 0.56 to 0.95
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Amniotomy i.v. oxytocin plus amniotomy 0.92 0.48 to 1.59 0.3188 0.45 to 1.67
NO 0.87 0.39 to 1.64
Mifepristone 0.75 0.3 to 1.53
Oestrogens 1.34 0.47 to 3.05
Corticosteroids 0.56 0.16 to 1.41
Relaxin 0.94 0.25 to 2.46
Hyaluronidase 0.65 0.25 to 1.38
Mechanical methods – Foley catheter 0.81 0.38 to 1.48
Mechanical methods – laminaria 0.85 0.31 to 1.82
Mechanical methods – double-balloon or
Cook’s catheter
1.18 0.51 to 2.29
Membrane sweeping 0.78 0.35 to 1.48
Extra-amniotic PGE2 1.04 0.41 to 2.18
i.v. prostaglandin 20.98 1.35 to 123.2
Sexual intercourse 0.89 0.37 to 1.8
Acupuncture 0.86 0.35 to 1.75
Oral prostaglandins 0.76 0.07 to 2.87
Buccal/sublingual misoprostol 0.72 0.33 to 1.36
i.v. oxytocin
plus amniotomy
NO 0.96 0.58 to 1.48
Mifepristone 0.83 0.43 to 1.44
Oestrogens 1.48 0.64 to 2.95
Corticosteroids 0.62 0.21 to 1.39
Relaxin 1.03 0.34 to 2.46
Hyaluronidase 0.71 0.35 to 1.3
Mechanical methods – Foley catheter 0.89 0.57 to 1.31
Mechanical methods – laminaria 0.93 0.44 to 1.74
Mechanical methods – double-balloon or
Cook’s catheter
1.30 0.74 to 2.11
Membrane sweeping 0.86 0.52 to 1.33
Extra-amniotic PGE2 1.15 0.57 to 2.05
i.v. prostaglandin 23.58 1.74 to 143
Sexual intercourse 0.98 0.54 to 1.66
Acupuncture 0.95 0.51 to 1.63
Oral prostaglandins 0.84 0.09 to 3.09
Buccal/sublingual misoprostol 0.79 0.49 to 1.21 1.191 0.11 to 4.07
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
NO Mifepristone 0.88 0.51 to 1.43
Oestrogens 1.57 0.74 to 2.99
Corticosteroids 0.66 0.24 to 1.43
Relaxin 1.09 0.39 to 2.56
Hyaluronidase 0.75 0.4 to 1.3
Mechanical methods – Foley catheter 0.95 0.7 to 1.27
Mechanical methods – laminaria 0.99 0.5 to 1.75
Mechanical methods – double-balloon or
Cook’s catheter
1.38 0.86 to 2.11
Membrane sweeping 0.91 0.62 to 1.3
Extra-amniotic PGE2 1.22 0.67 to 2.04
i.v. prostaglandin 24.59 1.96 to 148.3
Sexual intercourse 1.05 0.63 to 1.66
Acupuncture 1.01 0.6 to 1.6
Oral prostaglandins 0.89 0.1 to 3.22
Buccal/sublingual misoprostol 0.84 0.59 to 1.17
Mifepristone Oestrogens 1.87 0.8 to 3.77
Corticosteroids 0.79 0.26 to 1.8
Relaxin 1.31 0.41 to 3.21
Hyaluronidase 0.90 0.43 to 1.67
Mechanical methods – Foley catheter 1.13 0.68 to 1.79
Mechanical methods – laminaria 1.19 0.54 to 2.33
Mechanical methods – double-balloon or
Cook’s catheter
1.65 0.88 to 2.86
Membrane sweeping 1.09 0.61 to 1.79
Extra-amniotic PGE2 1.46 0.7 to 2.66
i.v. prostaglandin 29.53 2.14 to 184.7
Sexual intercourse 1.25 0.65 to 2.22
Acupuncture 1.20 0.63 to 2.09
Oral prostaglandins 1.07 0.11 to 3.96
Buccal/sublingual misoprostol 1.01 0.58 to 1.64
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Oestrogens Corticosteroids 0.47 0.14 to 1.19
Relaxin 0.78 0.22 to 2.03
Hyaluronidase 0.54 0.21 to 1.13
Mechanical methods – Foley catheter 0.67 0.32 to 1.25
Mechanical methods – laminaria 0.71 0.27 to 1.5
Mechanical methods – double-balloon or
Cook’s catheter
0.98 0.43 to 1.92
Membrane sweeping 0.65 0.3 to 1.22
Extra-amniotic PGE2 0.87 0.35 to 1.8
i.v. prostaglandin 17.12 1.16 to 103.7
Sexual intercourse 0.74 0.32 to 1.47
Acupuncture 0.71 0.3 to 1.42
Oral prostaglandins 0.64 0.06 to 2.46
Buccal/sublingual misoprostol 0.60 0.28 to 1.12
Corticosteroids Relaxin 2.01 0.48 to 5.89
Hyaluronidase 1.39 0.45 to 3.38
Mechanical methods – Foley catheter 1.74 0.66 to 3.89
Mechanical methods – laminaria 1.83 0.57 to 4.58
Mechanical methods – double-balloon or
Cook’s catheter
2.54 0.89 to 5.91
Membrane sweeping 1.67 0.62 to 3.79
Extra-amniotic PGE2 2.24 0.74 to 5.43
i.v. prostaglandin 44.81 2.65 to 274.6
Sexual intercourse 1.92 0.67 to 4.5
Acupuncture 1.85 0.64 to 4.31
Oral prostaglandins 1.66 0.14 to 6.9
Buccal/sublingual misoprostol 1.55 0.58 to 3.5
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Relaxin Hyaluronidase 0.85 0.26 to 2.1
Mechanical methods – Foley catheter 1.07 0.37 to 2.38
Mechanical methods – laminaria 1.13 0.33 to 2.79
Mechanical methods – double-balloon or
Cook’s catheter
1.56 0.51 to 3.66
Membrane sweeping 1.03 0.34 to 2.36
Extra-amniotic PGE2 1.38 0.42 to 3.36
i.v. prostaglandin 28.53 1.53 to 182.5
Sexual intercourse 1.19 0.38 to 2.81
Acupuncture 1.14 0.37 to 2.66
Oral prostaglandins 1.00 0.08 to 4.01
Buccal/sublingual misoprostol 0.95 0.33 to 2.13
Hyaluronidase Mechanical methods – Foley catheter 1.35 0.76 to 2.21 0.5359 0.24 to 1.04
Mechanical methods – laminaria 1.42 0.6 to 2.85
Mechanical methods – double-balloon or
Cook’s catheter
1.96 0.98 to 3.52
Membrane sweeping 1.30 0.68 to 2.28
Extra-amniotic PGE2 1.74 0.78 to 3.36
i.v. prostaglandin 35.16 2.49 to 212.7
Sexual intercourse 1.49 0.72 to 2.77
Acupuncture 1.43 0.7 to 2.63
Oral prostaglandins 1.27 0.13 to 4.74
Buccal/sublingual misoprostol 1.20 0.65 to 2.05
Mechanical methods –
Foley catheter
Mechanical methods – laminaria 1.06 0.56 to 1.81
Mechanical methods – double-balloon or
Cook’s catheter
1.46 1 to 2.08
Membrane sweeping 0.97 0.7 to 1.31
Extra-amniotic PGE2 1.30 0.74 to 2.09
i.v. prostaglandin 26.39 2.11 to 158.7
Sexual intercourse 1.11 0.7 to 1.69
Acupuncture 1.07 0.66 to 1.66
Oral prostaglandins 0.95 0.11 to 3.4
Buccal/sublingual misoprostol 0.90 0.68 to 1.16
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TABLE 51 Caesarean section (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Mechanical methods –
laminaria
Mechanical methods – double-balloon or
Cook’s catheter
1.51 0.73 to 2.8
Membrane sweeping 0.99 0.53 to 1.71
Extra-amniotic PGE2 1.33 0.58 to 2.59
i.v. prostaglandin 27.45 1.9 to 158.3
Sexual intercourse 1.14 0.56 to 2.09
Acupuncture 1.10 0.51 to 2.08
Oral prostaglandins 0.97 0.1 to 3.64
Buccal/sublingual misoprostol 0.92 0.48 to 1.63
Mechanical methods –
double-balloon or
Cook’s catheter
Membrane sweeping 0.68 0.42 to 1.06
Extra-amniotic PGE2 0.92 0.46 to 1.61
i.v. prostaglandin 18.82 1.39 to 113.3
Sexual intercourse 0.79 0.44 to 1.3
Acupuncture 0.76 0.41 to 1.28
Oral prostaglandins 0.67 0.07 to 2.46
Buccal/sublingual misoprostol 0.63 0.4 to 0.94
Membrane sweeping Extra-amniotic PGE2 1.36 0.74 to 2.29
i.v. prostaglandin 27.89 2.19 to 163.7
Sexual intercourse 1.17 0.74 to 1.79
Acupuncture 1.13 0.67 to 1.81
Oral prostaglandins 1.00 0.11 to 3.6
Buccal/sublingual misoprostol 0.94 0.65 to 1.33
Extra-amniotic PGE2 i.v. prostaglandin 21.62 1.56 to 125.8
Sexual intercourse 0.92 0.46 to 1.66
Acupuncture 0.88 0.43 to 1.61
Oral prostaglandins 0.78 0.08 to 2.87
Buccal/sublingual misoprostol 0.74 0.42 to 1.23
i.v. prostaglandin Sexual intercourse 0.15 0.01 to 0.54
Acupuncture 0.14 0.01 to 0.52
Oral prostaglandins 0.12 0 to 0.61
Buccal/sublingual misoprostol 0.12 0.01 to 0.42
Sexual intercourse Acupuncture 1.00 0.53 to 1.73
Oral prostaglandins 0.89 0.09 to 3.25
Buccal/sublingual misoprostol 0.84 0.51 to 1.3
Acupuncture Oral prostaglandins 0.93 0.1 to 3.47
Buccal/sublingual misoprostol 0.88 0.52 to 1.4
Oral prostaglandins Buccal/sublingual misoprostol 2.04 0.26 to 8.56
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TABLE 52 Instrumental delivery
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
No treatment Placebo 0.9 0.71 to 1.21
Vaginal PGE2 (tablet) 0.8 0.66 to 1.08 0.96 0.46 to 1.77
Vaginal PGE2 (gel) 0.9 0.7 to 1.04 0.99 0.61 to 1.49
Vaginal PGE2 pessary (slow release) 0.7 0.48 to 0.9
PGF2 gel 0.8 0.52 to 1.19
Intracervical PGE2 0.8 0.66 to 1.02 1.05 0.56 to 1.77
Vaginal PGE2 pessary (normal release) 1.0 0.76 to 1.29 0.74 0.37 to 1.32
Vaginal misoprostol (dose < 50 µg) 0.7 0.57 to 0.94 1.37 0.41 to 3.43
Vaginal misoprostol (dose ≥ 50 µg) 0.9 0.68 to 1.05
Oral misoprostol tablet (dose < 50 µg) 0.7 0.32 to 1.28
Oral misoprostol tablet (dose ≥ 50 µg) 0.8 0.61 to 0.97 1.73 0.46 to 4.66
Titrated (low-dose) oral misoprostol
solution
0.9 0.59 to 1.36
Sustained-release misoprostol vaginal
pessary
0.9 0.43 to 1.56
i.v. oxytocin 1.0 0.84 to 1.19 1.09 0.86 to 1.4
Amniotomy 0.8 0.47 to 1.24
i.v. oxytocin plus amniotomy 0.9 0.63 to 1.16 0.20 0.05 to 0.52
NO 0.9 0.6 to 1.21 2.03 0.27 to 7.93
Mifepristone 1.6 0.92 to 2.56 1.06 0.12 to 3.85
Oestrogens 0.6 0.3 to 1.19
Relaxin 1.4 0.58 to 2.73
Mechanical methods – Foley catheter 0.6 0.48 to 0.82
Mechanical methods – laminaria 0.8 0.44 to 1.24
Mechanical methods – double-balloon or
Cook’s catheter
0.7 0.45 to 1.03
Membrane sweeping 1.1 0.87 to 1.38 1.07 0.82 to 1.37
Extra-amniotic PGE2 0.9 0.45 to 1.44
i.v. prostaglandin 1.9 0.81 to 3.8
Sexual intercourse 1.2 0.68 to 1.95 1.20 0.64 to 2.06
Acupuncture 0.8 0.46 to 1.19 0.49 0.2 to 0.98
Homeopathy 2.0 0.1 to 9.79
Oral prostaglandins 0.7 0.44 to 1.04 1.28 0.34 to 3.48
Buccal/sublingual misoprostol 0.6 0.42 to 0.92
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TABLE 52 Instrumental delivery (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Placebo Vaginal PGE2 (tablet) 0.9 0.67 to 1.22
Vaginal PGE2 (gel) 0.9 0.72 to 1.18 1.18 0.38 to 2.85
Vaginal PGE2 pessary (slow release) 0.7 0.5 to 0.99 1.05 0.4 to 2.26
PGF2 gel 0.9 0.58 to 1.25 0.74 0.43 to 1.2
Intracervical PGE2 0.9 0.68 to 1.14 1.09 0.61 to 1.79
Vaginal PGE2 pessary (normal release) 1.1 0.79 to 1.45 0.98 0.5 to 1.75
Vaginal misoprostol (dose < 50 µg) 0.8 0.59 to 1.05 0.64 0.09 to 2.23
Vaginal misoprostol (dose ≥ 50 µg) 0.9 0.7 to 1.18 1.21 0.35 to 3.12
Oral misoprostol tablet (dose < 50 µg) 0.7 0.34 to 1.38
Oral misoprostol tablet (dose ≥ 50 µg) 0.8 0.63 to 1.09 0.54 0.25 to 1
Titrated (low-dose) oral misoprostol
solution
1.0 0.62 to 1.52
Sustained-release misoprostol vaginal
pessary
0.9 0.46 to 1.71
i.v. oxytocin 1.1 0.83 to 1.39
Amniotomy 0.9 0.5 to 1.38
i.v. oxytocin plus amniotomy 0.9 0.64 to 1.31
NO 0.9 0.69 to 1.21 0.91 0.61 to 1.28
Mifepristone 1.7 1.05 to 2.59 1.84 1.08 to 2.98
Oestrogens 0.7 0.32 to 1.28 0.75 0.25 to 1.71
Relaxin 1.4 0.66 to 2.78 1.45 0.65 to 2.87
Mechanical methods – Foley catheter 0.7 0.5 to 0.91
Mechanical methods – laminaria 0.8 0.47 to 1.38
Mechanical methods – double-balloon or
Cook’s catheter
0.8 0.47 to 1.14
Membrane sweeping 1.2 0.84 to 1.66 15.45 1.56 to 71.26
Extra-amniotic PGE2 0.9 0.49 to 1.52 0.88 0.32 to 1.91
i.v. prostaglandin 2.0 0.85 to 4.12
Sexual intercourse 1.3 0.68 to 2.24
Acupuncture 0.8 0.51 to 1.26 1.08 0.57 to 1.85
Homeopathy 2.1 0.11 to 10.24 2.18 0.09 to 11.64
Oral prostaglandins 0.7 0.45 to 1.16
Buccal/sublingual misoprostol 0.7 0.44 to 1.03
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TABLE 52 Instrumental delivery (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal PGE2 (tablet) Vaginal PGE2 (gel) 1.0 0.8 to 1.28 0.74 0.41 to 1.23
Vaginal PGE2 pessary (slow release) 0.8 0.56 to 1.08 0.61 0.21 to 1.38
PGF2 gel 1.0 0.61 to 1.45
Intracervical PGE2 1.0 0.76 to 1.26
Vaginal PGE2 pessary (normal release) 1.2 0.87 to 1.59 1.02 0.31 to 2.56
Vaginal misoprostol (dose < 50 µg) 0.9 0.66 to 1.15
Vaginal misoprostol (dose ≥ 50 µg) 1.0 0.81 to 1.26 1.13 0.76 to 1.61
Oral misoprostol tablet (dose < 50 µg) 0.8 0.38 to 1.55
Oral misoprostol tablet (dose ≥ 50 µg) 0.9 0.71 to 1.19 1.25 0.55 to 2.44
Titrated (low-dose) oral misoprostol
solution
1.1 0.7 to 1.67
Sustained-release misoprostol vaginal
pessary
1.0 0.51 to 1.88
i.v. oxytocin 1.2 0.94 to 1.51 1.77 0.92 to 3.12
Amniotomy 0.9 0.56 to 1.51
i.v. oxytocin plus amniotomy 1.0 0.74 to 1.4 0.91 0.46 to 1.6
NO 1.0 0.7 to 1.48
Mifepristone 1.9 1.05 to 3.11
Oestrogens 0.8 0.35 to 1.44
Relaxin 1.6 0.69 to 3.25
Mechanical methods – Foley catheter 0.8 0.56 to 0.99 1.03 0.32 to 2.5
Mechanical methods – laminaria 0.9 0.53 to 1.49 1.58 0.24 to 5.53
Mechanical methods – double-balloon or
Cook’s catheter
0.8 0.52 to 1.25
Membrane sweeping 1.3 0.93 to 1.82
Extra-amniotic PGE2 1.0 0.55 to 1.7 1.21 0.52 to 2.41
i.v. prostaglandin 2.3 0.95 to 4.58
Sexual intercourse 1.4 0.76 to 2.45
Acupuncture 0.9 0.54 to 1.47
Homeopathy 2.4 0.11 to 11.74
Oral prostaglandins 0.8 0.5 to 1.26 1.61 0.21 to 5.53
Buccal/sublingual misoprostol 0.8 0.5 to 1.12
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TABLE 52 Instrumental delivery (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal PGE2 (gel) Vaginal PGE2 pessary (slow release) 0.8 0.57 to 1.03 0.55 0.28 to 0.97
PGF2 gel 0.9 0.61 to 1.39
Intracervical PGE2 1.0 0.79 to 1.16 0.91 0.56 to 1.4
Vaginal PGE2 pessary (normal release) 1.2 0.89 to 1.51
Vaginal misoprostol (dose < 50 µg) 0.9 0.69 to 1.06 1.35 0.87 to 2.05
Vaginal misoprostol (dose ≥ 50 µg) 1.0 0.83 to 1.19 0.94 0.63 to 1.33
Oral misoprostol tablet (dose < 50 µg) 0.8 0.39 to 1.46 0.72 0.31 to 1.46
Oral misoprostol tablet (dose ≥ 50 µg) 0.9 0.73 to 1.12 0.99 0.43 to 1.95
Titrated (low-dose) oral misoprostol
solution
1.1 0.73 to 1.53 1.07 0.67 to 1.61
Sustained-release misoprostol vaginal
pessary
1.0 0.51 to 1.82
i.v. oxytocin 1.2 0.97 to 1.42 0.85 0.45 to 1.47
Amniotomy 0.9 0.56 to 1.43 0.96 0.39 to 1.99
i.v. oxytocin plus amniotomy 1.0 0.75 to 1.34 1.27 0.68 to 2.12
NO 1.0 0.72 to 1.38 1.08 0.57 to 1.86
Mifepristone 1.8 1.07 to 2.99
Oestrogens 0.7 0.35 to 1.38
Relaxin 1.6 0.69 to 3.17
Mechanical methods – Foley catheter 0.7 0.59 to 0.92 0.74 0.51 to 1.03
Mechanical methods – laminaria 0.9 0.53 to 1.42 0.73 0.32 to 1.41
Mechanical methods – double-balloon or
Cook’s catheter
0.8 0.54 to 1.18 0.82 0.38 to 1.56
Membrane sweeping 1.3 0.95 to 1.72
Extra-amniotic PGE2 1.0 0.53 to 1.68
i.v. prostaglandin 2.2 0.94 to 4.43
Sexual intercourse 1.4 0.77 to 2.37
Acupuncture 0.9 0.54 to 1.41
Homeopathy 2.3 0.11 to 11.5
Oral prostaglandins 0.8 0.51 to 1.21 2.18 0.1 to 10.86
Buccal/sublingual misoprostol 0.7 0.5 to 1.07 0.00 0 to 0
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TABLE 52 Instrumental delivery (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal PGE2 pessary
(slow release)
PGF2 gel 1.2 0.75 to 1.93 0.00 0 to 0
Intracervical PGE2 1.3 0.92 to 1.7 1.45 0.57 to 3.08
Vaginal PGE2 pessary (normal release) 1.5 1.06 to 2.17
Vaginal misoprostol (dose < 50 µg) 1.1 0.8 to 1.56
Vaginal misoprostol (dose ≥ 50 µg) 1.3 0.96 to 1.74 1.41 0.58 to 2.91
Oral misoprostol tablet (dose < 50 µg) 1.1 0.48 to 2.01
Oral misoprostol tablet (dose ≥ 50 µg) 1.2 0.86 to 1.62
Titrated (low-dose) oral misoprostol
solution
1.4 0.87 to 2.19
Sustained-release misoprostol vaginal
pessary
1.3 0.71 to 2.21 1.31 0.68 to 2.3
i.v. oxytocin 1.5 1.12 to 2.07 1.18 0.4 to 2.75
Amniotomy 1.2 0.69 to 2.02
i.v. oxytocin plus amniotomy 1.3 0.88 to 1.92
NO 1.3 0.86 to 1.96
Mifepristone 2.4 1.3 to 4.12
Oestrogens 1.0 0.44 to 1.88
Relaxin 2.1 0.86 to 4.27
Mechanical methods – Foley catheter 1.0 0.7 to 1.32 0.71 0.34 to 1.31
Mechanical methods – laminaria 1.2 0.65 to 1.97
Mechanical methods – double-balloon or
Cook’s catheter
1.1 0.66 to 1.62 7.10 0.87 to 30.16
Membrane sweeping 1.7 1.16 to 2.44 1.20 0.3 to 3.24
Extra-amniotic PGE2 1.3 0.67 to 2.3
i.v. prostaglandin 2.9 1.19 to 6.07
Sexual intercourse 1.8 0.95 to 3.24
Acupuncture 1.2 0.67 to 1.94
Homeopathy 3.1 0.15 to 15.33
Oral prostaglandins 1.1 0.62 to 1.67
Buccal/sublingual misoprostol 1.0 0.61 to 1.49
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TABLE 52 Instrumental delivery (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
PGF2 gel Intracervical PGE2 1.1 0.69 to 1.57
Vaginal PGE2 pessary (normal release) 1.3 0.81 to 1.95
Vaginal misoprostol (dose < 50 µg) 1.0 0.6 to 1.44
Vaginal misoprostol (dose ≥ 50 µg) 1.1 0.72 to 1.62
Oral misoprostol tablet (dose < 50 µg) 0.9 0.37 to 1.78
Oral misoprostol tablet (dose ≥ 50 µg) 1.0 0.65 to 1.49
Titrated (low-dose) oral misoprostol
solution
1.2 0.66 to 1.99
Sustained-release misoprostol vaginal
pessary
1.1 0.49 to 2.17
i.v. oxytocin 1.3 0.86 to 1.88 1.01 0.52 to 1.78
Amniotomy 1.0 0.54 to 1.77
i.v. oxytocin plus amniotomy 1.1 0.68 to 1.74
NO 1.1 0.68 to 1.71
Mifepristone 2.0 1.06 to 3.51
Oestrogens 0.8 0.35 to 1.64
Relaxin 1.7 0.7 to 3.63
Mechanical methods – Foley catheter 0.8 0.52 to 1.23 1.41 0.25 to 4.6
Mechanical methods – laminaria 1.0 0.51 to 1.76
Mechanical methods – double-balloon or
Cook’s catheter
0.9 0.5 to 1.49
Membrane sweeping 1.4 0.87 to 2.23
Extra-amniotic PGE2 1.1 0.53 to 1.97
i.v. prostaglandin 2.4 0.94 to 5.19
Sexual intercourse 1.5 0.75 to 2.88
Acupuncture 1.0 0.54 to 1.68
Homeopathy 2.5 0.13 to 12.5
Oral prostaglandins 0.9 0.49 to 1.5
Buccal/sublingual misoprostol 0.8 0.47 to 1.34
Intracervical PGE2 Vaginal PGE2 pessary (normal release) 1.2 0.93 to 1.58 1.39 0.69 to 2.53
Vaginal misoprostol (dose < 50 µg) 0.9 0.71 to 1.13 0.67 0.41 to 1.05
Vaginal misoprostol (dose ≥ 50 µg) 1.0 0.86 to 1.26 1.09 0.74 to 1.55
Oral misoprostol tablet (dose < 50 µg) 0.8 0.4 to 1.57
Oral misoprostol tablet (dose ≥ 50 µg) 1.0 0.76 to 1.18 0.98 0.51 to 1.72
Titrated (low-dose) oral misoprostol
solution
1.1 0.73 to 1.67
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TABLE 52 Instrumental delivery (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Sustained-release misoprostol vaginal
pessary
1.1 0.53 to 1.9
i.v. oxytocin 1.2 1 to 1.5 1.60 0.94 to 2.59
Amniotomy 1.0 0.58 to 1.54
i.v. oxytocin plus amniotomy 1.1 0.76 to 1.43 2.60 0.6 to 7.76
NO 1.1 0.74 to 1.47 2.27 0.03 to 13.17
Mifepristone 1.9 1.11 to 3.14
Oestrogens 0.8 0.37 to 1.43 1.09 0.29 to 2.78
Relaxin 1.7 0.71 to 3.35
Mechanical methods – Foley catheter 0.8 0.6 to 0.99 0.90 0.45 to 1.62
Mechanical methods – laminaria 0.9 0.56 to 1.5 1.23 0.53 to 2.42
Mechanical methods – double-balloon or
Cook’s catheter
0.9 0.56 to 1.25 0.51 0.08 to 1.58
Membrane sweeping 1.4 0.98 to 1.82
Extra-amniotic PGE2 1.0 0.56 to 1.77
i.v. prostaglandin 2.3 0.97 to 4.64
Sexual intercourse 1.5 0.79 to 2.49
Acupuncture 0.9 0.56 to 1.49
Homeopathy 2.4 0.12 to 11.99
Oral prostaglandins 0.8 0.53 to 1.28 1.95 0.29 to 7.01
Buccal/sublingual misoprostol 0.8 0.52 to 1.13
Vaginal PGE2 pessary
(normal release)
Vaginal misoprostol (dose < 50 µg) 0.7 0.55 to 1
Vaginal misoprostol (dose ≥ 50 µg) 0.9 0.66 to 1.12 0.84 0.33 to 1.79
Oral misoprostol tablet (dose < 50 µg) 0.7 0.32 to 1.32
Oral misoprostol tablet (dose ≥ 50 µg) 0.8 0.58 to 1.04
Titrated (low-dose) oral misoprostol
solution
0.9 0.58 to 1.43
Sustained-release misoprostol vaginal
pessary
0.9 0.42 to 1.61
i.v. oxytocin 1.0 0.79 to 1.29 0.78 0.51 to 1.14
Amniotomy 0.8 0.47 to 1.29
i.v. oxytocin plus amniotomy 0.9 0.61 to 1.22 1.41 0.55 to 3.04
NO 0.9 0.59 to 1.26
Mifepristone 1.6 0.91 to 2.65
Oestrogens 0.6 0.3 to 1.23
Relaxin 1.4 0.58 to 2.8
Mechanical methods – Foley catheter 0.6 0.47 to 0.85 0.84 0.34 to 1.7
Mechanical methods – laminaria 0.8 0.44 to 1.31
Mechanical methods – double-balloon or
Cook’s catheter
0.7 0.45 to 1.07
Membrane sweeping 1.1 0.78 to 1.55
Extra-amniotic PGE2 0.9 0.45 to 1.49
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TABLE 52 Instrumental delivery (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
i.v. prostaglandin 1.9 0.8 to 3.96
Sexual intercourse 1.2 0.64 to 2.09
Acupuncture 0.8 0.45 to 1.26
Homeopathy 2.0 0.1 to 9.89
Oral prostaglandins 0.7 0.42 to 1.09
Buccal/sublingual
misoprostol
0.6 0.41 to 0.97
Vaginal misoprostol
(dose < 50 µg)
Vaginal misoprostol (dose ≥ 50 µg) 1.2 0.94 to 1.43 1.07 0.71 to 1.54
Oral misoprostol tablet (dose < 50 µg) 0.9 0.44 to 1.78
Oral misoprostol tablet (dose ≥ 50 µg) 1.1 0.83 to 1.34 1.61 0.92 to 2.66
Titrated (low-dose) oral misoprostol
solution
1.3 0.81 to 1.88 2.32 0.09 to 11.01
Sustained-release misoprostol vaginal
pessary
1.2 0.58 to 2.17
i.v. oxytocin 1.4 1.07 to 1.74 2.61 0.44 to 9
Amniotomy 1.1 0.64 to 1.73
i.v. oxytocin plus amniotomy 1.2 0.83 to 1.64
NO 1.2 0.81 to 1.68
Mifepristone 2.2 1.21 to 3.56
Oestrogens 0.9 0.4 to 1.64
Relaxin 1.8 0.79 to 3.74
Mechanical methods – Foley catheter 0.9 0.66 to 1.11 1.03 0.56 to 1.74
Mechanical methods – laminaria 1.1 0.6 to 1.71
Mechanical methods – double-balloon or
Cook’s catheter
1.0 0.62 to 1.41
Membrane sweeping 1.5 1.07 to 2.09
Extra-amniotic PGE2 1.2 0.61 to 2.02
i.v. prostaglandin 2.6 1.08 to 5.27
Sexual intercourse 1.6 0.88 to 2.83
Acupuncture 1.1 0.62 to 1.69 9.47 0.15 to 63.5
Homeopathy 2.7 0.13 to 13.49
Oral prostaglandins 0.9 0.58 to 1.46
Buccal/sublingual misoprostol 0.9 0.58 to 1.24 0.89 0.4 to 1.73
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TABLE 52 Instrumental delivery (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal misoprostol
(dose ≥ 50 µg)
Oral misoprostol tablet (dose < 50 µg) 0.8 0.38 to 1.51
Oral misoprostol tablet (dose ≥ 50 µg) 0.9 0.76 to 1.1 0.86 0.65 to 1.11
Titrated (low-dose) oral misoprostol
solution
1.1 0.71 to 1.6 1.49 0.14 to 5.9
Sustained-release misoprostol vaginal
pessary
1.0 0.51 to 1.84
i.v. oxytocin 1.2 0.97 to 1.43 1.68 1.1 to 2.51
Amniotomy 0.9 0.56 to 1.47
i.v. oxytocin plus amniotomy 1.0 0.74 to 1.37
NO 1.0 0.72 to 1.42
Mifepristone 1.9 1.07 to 3.04
Oestrogens 0.8 0.35 to 1.4
Relaxin 1.6 0.69 to 3.2
Mechanical methods – Foley catheter 0.7 0.58 to 0.94 1.02 0.22 to 2.96
Mechanical methods – laminaria 0.9 0.53 to 1.46
Mechanical methods – double-balloon or
Cook’s catheter
0.8 0.54 to 1.21
Membrane sweeping 1.3 0.95 to 1.76
Extra-amniotic PGE2 1.0 0.54 to 1.69
i.v. prostaglandin 2.2 0.95 to 4.48
Sexual intercourse 1.4 0.77 to 2.41
Acupuncture 0.9 0.54 to 1.42
Homeopathy 2.4 0.12 to 11.54
Oral prostaglandins 0.8 0.51 to 1.23
Buccal/sublingual misoprostol 0.8 0.51 to 1.06 0.37 0.18 to 0.65
Oral misoprostol
tablet (dose < 50 µg)
Oral misoprostol tablet (dose ≥ 50 µg) 1.3 0.6 to 2.39 1.01 0.12 to 3.64
Titrated (low-dose) oral misoprostol
solution
1.5 0.66 to 3.02
Sustained-release misoprostol vaginal
pessary
1.4 0.51 to 3.23
i.v. oxytocin 1.6 0.78 to 3.11
Amniotomy 1.3 0.54 to 2.67
i.v. oxytocin plus amniotomy 1.4 0.65 to 2.75
NO 1.4 0.64 to 2.77
Mifepristone 2.6 1.04 to 5.43
Oestrogens 1.0 0.36 to 2.39
Relaxin 2.2 0.71 to 5.28
Mechanical methods – Foley catheter 1.0 0.48 to 1.97
Mechanical methods – laminaria 1.3 0.52 to 2.67
Mechanical methods – double-balloon or
Cook’s catheter
1.1 0.49 to 2.3
Membrane sweeping 1.8 0.82 to 3.53
Extra-amniotic PGE2 1.4 0.54 to 3.06
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TABLE 52 Instrumental delivery (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
i.v. prostaglandin 3.1 0.99 to 7.47
Sexual intercourse 2.0 0.75 to 4.28
Acupuncture 1.3 0.51 to 2.61
Homeopathy 3.3 0.14 to 16.77
Oral prostaglandins 1.1 0.47 to 2.3
Buccal/sublingual misoprostol 1.0 0.46 to 2.08
Oral misoprostol
tablet (dose ≥ 50 µg)
Titrated (low-dose) oral
misoprostol solution
1.2 0.76 to 1.79
Sustained-release misoprostol
vaginal pessary
1.1 0.55 to 2.04
i.v. oxytocin 1.3 1.05 to 1.61 1.06 0.65 to 1.63
Amniotomy 1.0 0.6 to 1.64
i.v. oxytocin plus amniotomy 1.1 0.8 to 1.52
NO 1.1 0.77 to 1.58
Mifepristone 2.0 1.16 to 3.36
Oestrogens 0.8 0.39 to 1.54
Relaxin 1.8 0.75 to 3.54
Mechanical methods – Foley catheter 0.8 0.62 to 1.06
Mechanical methods – laminaria 1.0 0.57 to 1.63
Mechanical methods – double-balloon or
Cook’s catheter
0.9 0.58 to 1.35
Membrane sweeping 1.4 1.03 to 1.96
Extra-amniotic PGE2 1.1 0.58 to 1.9
i.v. prostaglandin 2.5 1.04 to 4.95
Sexual intercourse 1.6 0.83 to 2.66
Acupuncture 1.0 0.59 to 1.58
Homeopathy 2.6 0.13 to 12.62
Oral prostaglandins 0.9 0.55 to 1.37
Buccal/sublingual misoprostol 0.8 0.57 to 1.15 1.38 0.74 to 2.34
continued
DOI: 10.3310/hta20650 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 65
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Alfirevic et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
433
TABLE 52 Instrumental delivery (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Titrated (low-dose)
oral misoprostol
solution
Sustained-release misoprostol vaginal
pessary
1.0 0.44 to 1.91
i.v. oxytocin 1.1 0.74 to 1.69
Amniotomy 0.9 0.47 to 1.55
i.v. oxytocin plus amniotomy 1.0 0.59 to 1.51
NO 1.0 0.58 to 1.55
Mifepristone 1.8 0.9 to 3.17
Oestrogens 0.7 0.3 to 1.44
Relaxin 1.5 0.59 to 3.25
Mechanical methods – Foley catheter 0.7 0.46 to 1.06
Mechanical methods – laminaria 0.9 0.45 to 1.52
Mechanical methods – double-balloon or
Cook’s catheter
0.8 0.45 to 1.29
Membrane sweeping 1.3 0.76 to 1.95
Extra-amniotic PGE2 1.0 0.46 to 1.77
i.v. prostaglandin 2.1 0.82 to 4.56
Sexual intercourse 1.4 0.65 to 2.51
Acupuncture 0.9 0.45 to 1.51
Homeopathy 2.3 0.1 to 11.24
Oral prostaglandins 0.8 0.42 to 1.31
Buccal/sublingual misoprostol 0.7 0.41 to 1.17
Sustained-release
misoprostol
vaginal pessary
i.v. oxytocin 1.3 0.64 to 2.32
Amniotomy 1.0 0.43 to 2.05
i.v. oxytocin plus amniotomy 1.1 0.52 to 2.06
NO 1.1 0.52 to 2.09
Mifepristone 2.0 0.83 to 4.14
Oestrogens 0.8 0.29 to 1.83
Relaxin 1.7 0.58 to 4.12
Mechanical methods – Foley catheter 0.8 0.4 to 1.47
Mechanical methods – laminaria 1.0 0.41 to 2
Mechanical methods – double-balloon or
Cook’s catheter
0.9 0.41 to 1.7
Membrane sweeping 1.4 0.68 to 2.63
Extra-amniotic PGE2 1.1 0.43 to 2.33
i.v. prostaglandin 2.4 0.8 to 5.81
Sexual intercourse 1.5 0.61 to 3.25
Acupuncture 1.0 0.42 to 1.97
Homeopathy 2.6 0.11 to 13.06
Oral prostaglandins 0.9 0.38 to 1.74
Buccal/sublingual misoprostol 0.8 0.37 to 1.56
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TABLE 52 Instrumental delivery (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
i.v. oxytocin Amniotomy 0.8 0.48 to 1.24 0.91 0.24 to 2.37
i.v. oxytocin plus amniotomy 0.9 0.63 to 1.15 1.19 0.34 to 3.08
NO 0.9 0.61 to 1.2
Mifepristone 1.6 0.91 to 2.56
Oestrogens 0.6 0.3 to 1.19
Relaxin 1.4 0.59 to 2.71
Mechanical methods – Foley catheter 0.6 0.49 to 0.81
Mechanical methods – laminaria 0.8 0.45 to 1.24
Mechanical methods – double-balloon or
Cook’s catheter
0.7 0.45 to 1.02
Membrane sweeping 1.1 0.82 to 1.45
Extra-amniotic PGE2 0.9 0.46 to 1.43
i.v. prostaglandin 1.9 0.82 to 3.72 1.86 0.73 to 3.95
Sexual intercourse 1.2 0.66 to 2.01
Acupuncture 0.8 0.46 to 1.2
Homeopathy 2.0 0.1 to 9.73
Oral prostaglandins 0.7 0.45 to 1.01 0.64 0.33 to 1.13
Buccal/sublingual misoprostol 0.6 0.42 to 0.93
Amniotomy i.v. oxytocin plus amniotomy 1.1 0.7 to 1.75
NO 1.2 0.64 to 1.93
Mifepristone 2.1 1.01 to 3.86
Oestrogens 0.8 0.34 to 1.76
Relaxin 1.8 0.67 to 3.94
Mechanical methods – Foley catheter 0.8 0.49 to 1.35
Mechanical methods – laminaria 1.0 0.49 to 1.92
Mechanical methods – double-balloon or
Cook’s catheter
0.9 0.49 to 1.61
Membrane sweeping 1.5 0.84 to 2.42
Extra-amniotic PGE2 1.1 0.51 to 2.13
i.v. prostaglandin 2.5 0.94 to 5.49
Sexual intercourse 1.6 0.73 to 3.06
Acupuncture 1.0 0.5 to 1.84
Homeopathy 2.7 0.12 to 13.54
Oral prostaglandins 0.9 0.48 to 1.59
Buccal/sublingual misoprostol 0.9 0.45 to 1.44
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TABLE 52 Instrumental delivery (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
i.v. oxytocin
plus amniotomy
NO 1.0 0.66 to 1.52
Mifepristone 1.9 1 to 3.15
Oestrogens 0.8 0.34 to 1.45
Relaxin 1.6 0.66 to 3.28
Mechanical methods – Foley catheter 0.7 0.52 to 1.04
Mechanical methods – laminaria 0.9 0.5 to 1.51
Mechanical methods – double-balloon or
Cook’s catheter
0.8 0.5 to 1.28
Membrane sweeping 1.3 0.88 to 1.88
Extra-amniotic PGE2 1.0 0.51 to 1.75
i.v. prostaglandin 2.2 0.92 to 4.65
Sexual intercourse 1.4 0.73 to 2.48
Acupuncture 0.9 0.51 to 1.5
Homeopathy 2.4 0.11 to 11.72
Oral prostaglandins 0.8 0.5 to 1.25 0.62 0.22 to 1.37
Buccal/sublingual misoprostol 0.8 0.47 to 1.15 1.87 0.29 to 6.64
NO Mifepristone 1.9 1.05 to 3.06
Oestrogens 0.8 0.34 to 1.45
Relaxin 1.6 0.68 to 3.2
Mechanical methods – Foley catheter 0.8 0.51 to 1.07
Mechanical methods – laminaria 0.9 0.49 to 1.57
Mechanical methods – double-balloon or
Cook’s catheter
0.8 0.49 to 1.3
Membrane sweeping 1.3 0.85 to 1.93
Extra-amniotic PGE2 1.0 0.51 to 1.76
i.v. prostaglandin 2.2 0.9 to 4.63
Sexual intercourse 1.4 0.72 to 2.55
Acupuncture 0.9 0.52 to 1.46
Homeopathy 2.3 0.12 to 11.58
Oral prostaglandins 0.8 0.47 to 1.32
Buccal/sublingual misoprostol 0.8 0.45 to 1.2
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TABLE 52 Instrumental delivery (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Mifepristone Oestrogens 0.4 0.17 to 0.89
Relaxin 0.9 0.35 to 1.95
Mechanical methods – Foley catheter 0.4 0.24 to 0.71
Mechanical methods – laminaria 0.5 0.24 to 0.99
Mechanical methods – double-balloon or
Cook’s catheter
0.5 0.24 to 0.83
Membrane sweeping 0.8 0.41 to 1.27
Extra-amniotic PGE2 0.6 0.26 to 1.09
i.v. prostaglandin 1.3 0.46 to 2.8
Sexual intercourse 0.8 0.36 to 1.57
Acupuncture 0.5 0.26 to 0.93
Homeopathy 1.3 0.06 to 6.52
Oral prostaglandins 0.5 0.23 to 0.84
Buccal/sublingual misoprostol 0.4 0.22 to 0.77
Oestrogens Relaxin 2.4 0.77 to 5.89
Mechanical methods – Foley catheter 1.1 0.52 to 2.16
Mechanical methods – laminaria 1.3 0.57 to 2.74
Mechanical methods – double-balloon or
Cook’s catheter
1.2 0.53 to 2.48
Membrane sweeping 2.0 0.89 to 3.81
Extra-amniotic PGE2 1.5 0.57 to 3.2
i.v. prostaglandin 3.3 1.05 to 8.1
Sexual intercourse 2.1 0.81 to 4.64
Acupuncture 1.4 0.56 to 2.81
Homeopathy 3.6 0.15 to 18.23
Oral prostaglandins 1.2 0.51 to 2.51
Buccal/sublingual misoprostol 1.1 0.49 to 2.22
Relaxin Mechanical methods – Foley catheter 0.5 0.23 to 1.09
Mechanical methods – laminaria 0.7 0.24 to 1.44
Mechanical methods – double-balloon or
Cook’s catheter
0.6 0.23 to 1.27
Membrane sweeping 1.0 0.39 to 1.94
Extra-amniotic PGE2 0.7 0.26 to 1.6
i.v. prostaglandin 1.6 0.48 to 4.03
Sexual intercourse 1.0 0.36 to 2.34
Acupuncture 0.7 0.26 to 1.42
Homeopathy 1.7 0.07 to 8.78
Oral prostaglandins 0.6 0.22 to 1.27
Buccal/sublingual misoprostol 0.6 0.22 to 1.15
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TABLE 52 Instrumental delivery (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Mechanical methods –
Foley catheter
Mechanical methods – laminaria 1.2 0.7 to 2.02
Mechanical methods – double-balloon or
Cook’s catheter
1.1 0.75 to 1.56 1.14 0.66 to 1.85
Membrane sweeping 1.8 1.24 to 2.46
Extra-amniotic PGE2 1.4 0.72 to 2.33
i.v. prostaglandin 3.0 1.26 to 6.11
Sexual intercourse 1.9 1.01 to 3.31
Acupuncture 1.2 0.72 to 1.98
Homeopathy 3.2 0.15 to 15.55
Oral prostaglandins 1.1 0.67 to 1.71
Buccal/sublingual misoprostol 1.0 0.66 to 1.49
Mechanical methods –
laminaria
Mechanical methods – double-balloon or
Cook’s catheter
1.0 0.49 to 1.71
Membrane sweeping 1.5 0.84 to 2.58
Extra-amniotic PGE2 1.2 0.52 to 2.29
i.v. prostaglandin 2.6 0.93 to 5.84
Sexual intercourse 1.7 0.73 to 3.24
Acupuncture 1.1 0.51 to 1.95
Homeopathy 2.8 0.12 to 13.79
Oral prostaglandins 0.9 0.47 to 1.72
Buccal/sublingual misoprostol 0.9 0.45 to 1.61
Mechanical methods –
double-balloon or
Cook’s catheter
Membrane sweeping 1.7 1.01 to 2.57
Extra-amniotic PGE2 1.3 0.61 to 2.35
i.v. prostaglandin 2.8 1.1 to 6.01
Sexual intercourse 1.8 0.86 to 3.3
Acupuncture 1.2 0.6 to 2
Homeopathy 3.0 0.14 to 14.77
Oral prostaglandins 1.0 0.56 to 1.73
Buccal/sublingual misoprostol 1.0 0.54 to 1.55
Membrane sweeping Extra-amniotic PGE2 0.8 0.4 to 1.39
i.v. prostaglandin 1.7 0.72 to 3.59
Sexual intercourse 1.1 0.59 to 1.88
Acupuncture 0.7 0.4 to 1.15
Homeopathy 1.8 0.09 to 9.03
Oral prostaglandins 0.6 0.38 to 0.99
Buccal/sublingual misoprostol 0.6 0.36 to 0.89
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TABLE 52 Instrumental delivery (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Extra-amniotic PGE2 i.v. prostaglandin 2.4 0.87 to 5.32 17.37 0.18 to 73.85
Sexual intercourse 1.5 0.65 to 3.1
Acupuncture 1.0 0.46 to 1.89
Homeopathy 2.6 0.12 to 13.14
Oral prostaglandins 0.9 0.42 to 1.64
Buccal/sublingual misoprostol 0.8 0.4 to 1.53
i.v. prostaglandin Sexual intercourse 0.7 0.26 to 1.67
Acupuncture 0.5 0.17 to 1.04
Homeopathy 1.2 0.05 to 5.98
Oral prostaglandins 0.4 0.16 to 0.91
Buccal/sublingual misoprostol 0.4 0.15 to 0.82
Sexual intercourse Acupuncture 0.7 0.32 to 1.32
Homeopathy 1.8 0.08 to 9.06
Oral prostaglandins 0.6 0.3 to 1.16
Buccal/sublingual misoprostol 0.6 0.28 to 1.05
Acupuncture Homeopathy 2.7 0.13 to 13.58
Oral prostaglandins 0.9 0.48 to 1.68
Buccal/sublingual misoprostol 0.9 0.47 to 1.49
Homeopathy Oral prostaglandins 1.4 0.07 to 7.09
Buccal/sublingual misoprostol 1.3 0.06 to 6.64
Oral prostaglandins Buccal/sublingual misoprostol 1.0 0.53 to 1.64
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TABLE 53 Hyperstimulation with fetal heart changes
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
No treatment Placebo 0.88 0.26 to 2.19
Vaginal PGE2 (tablet) 1.60 0.46 to 4.13
Vaginal PGE2 (gel) 1.86 0.64 to 4.34 28,310.00 0.42 to 3659
Vaginal PGE2 pessary (slow release) 2.40 0.76 to 5.92
Intracervical PGE2 1.35 0.5 to 3.01 1.64 0.38 to 4.68
Vaginal PGE2 pessary (normal release) 1.12 0.23 to 3.35
Vaginal misoprostol (dose < 50 µg) 2.21 0.77 to 5.06
Vaginal misoprostol (dose ≥ 50 µg) 3.52 1.26 to 8 2.79 0.28 to 11.03
Oral misoprostol tablet (dose < 50 µg) 0.90 0.18 to 2.82
Oral misoprostol tablet (dose ≥ 50 µg) 2.29 0.78 to 5.37
Titrated (low-dose) oral misoprostol
solution
1.55 0.43 to 3.99
Sustained-release misoprostol vaginal
pessary
4.51 0.96 to 13.54
i.v. oxytocin 1.70 0.56 to 4.06 1.95 0.15 to 8.08
i.v. oxytocin plus amniotomy 5.98 0.18 to 33.89
NO 0.31 0.01 to 1.34
Mifepristone 315.50 0.69 to 309.5
Mechanical methods – Foley catheter 0.73 0.22 to 1.84 0.38 0 to 2.36
Mechanical methods – laminaria 0.41 0 to 2.13
Mechanical methods – double-balloon
or Cook’s catheter
0.21 0 to 1.02
Buccal/sublingual misoprostol 3.41 1.01 to 8.65
Placebo Vaginal PGE2 (tablet) 1.99 0.78 to 4.25 0.78 0 to 5.12
Vaginal PGE2 (gel) 2.33 1.1 to 4.4 5.81 0.32 to 29.93
Vaginal PGE2 pessary (slow release) 2.97 1.36 to 5.73 27.00 2.01 to 131.2
Intracervical PGE2 1.70 0.87 to 3.05 1.65 0.57 to 3.88
Vaginal PGE2 pessary (normal release) 1.40 0.37 to 3.68 0.46 0 to 3
Vaginal misoprostol (dose < 50 µg) 2.75 1.36 to 5.04 2.46 0.25 to 10.23
Vaginal misoprostol (dose ≥ 50 µg) 4.40 2.22 to 7.94 28.54 0.53 to 159.4
Oral misoprostol tablet (dose < 50 µg) 1.13 0.28 to 3.15
Oral misoprostol tablet (dose ≥ 50 µg) 2.85 1.41 to 5.2 7.75 1.22 to 30.55
Titrated (low-dose) oral misoprostol
solution
1.93 0.73 to 4.19
Sustained-release misoprostol vaginal
pessary
5.58 1.58 to 14.57
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TABLE 53 Hyperstimulation with fetal heart changes (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
i.v. oxytocin 2.12 0.97 to 4.1 0.34 0 to 2.19
i.v. oxytocin plus amniotomy 7.44 0.27 to 40.66
NO 0.38 0.02 to 1.54
Mifepristone 329.20 1.12 to 357.1 144,400.00 0.84 to 9849
Mechanical methods – Foley catheter 0.92 0.37 to 1.93
Mechanical methods – laminaria 0.52 0.01 to 2.62
Mechanical methods – double-balloon
or Cook’s catheter
0.26 0 to 1.18
Buccal/sublingual misoprostol 4.25 1.71 to 9.02
Vaginal PGE2
(tablet)
Vaginal PGE2 (gel) 1.28 0.61 to 2.41 1.99 0.4 to 6.21
Vaginal PGE2 pessary (slow release) 1.65 0.73 to 3.24 2.37 0.2 to 10.35
Intracervical PGE2 0.95 0.44 to 1.79
Vaginal PGE2 pessary (normal release) 0.78 0.2 to 2.08
Vaginal misoprostol (dose < 50 µg) 1.53 0.72 to 2.89
Vaginal misoprostol (dose ≥ 50 µg) 2.41 1.25 to 4.29 1.84 0.78 to 3.73
Oral misoprostol tablet (dose < 50 µg) 0.62 0.15 to 1.75
Oral misoprostol tablet (dose ≥ 50 µg) 1.58 0.74 to 2.99 10,220.00 0.39 to 3491
Titrated (low-dose) oral misoprostol
solution
1.07 0.39 to 2.33
Sustained-release misoprostol vaginal
pessary
3.09 0.85 to 8.13
i.v. oxytocin 1.18 0.52 to 2.33
i.v. oxytocin plus amniotomy 4.14 0.15 to 22.8
NO 0.21 0.01 to 0.8 0.39 0 to 2.49
Mifepristone 194.30 0.55 to 208.3
Mechanical methods – Foley catheter 0.51 0.2 to 1.08
Mechanical methods – laminaria 0.28 0 to 1.44
Mechanical methods – double-balloon
or Cook’s catheter
0.14 0 to 0.65
Buccal/sublingual misoprostol 2.34 0.93 to 4.98
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TABLE 53 Hyperstimulation with fetal heart changes (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal PGE2 (gel) Vaginal PGE2 pessary (slow release) 1.33 0.7 to 2.32
Intracervical PGE2 0.76 0.45 to 1.2 0.87 0.16 to 2.67
Vaginal PGE2 pessary (normal release) 0.62 0.19 to 1.51 17,770.00 0.4 to 6593
Vaginal misoprostol (dose < 50 µg) 1.22 0.76 to 1.85 1.38 0.54 to 2.86
Vaginal misoprostol (dose ≥ 50 µg) 1.95 1.25 to 2.92 1.18 0.55 to 2.26
Oral misoprostol tablet (dose < 50 µg) 0.49 0.15 to 1.22 0.77 0.14 to 2.47
Oral misoprostol tablet (dose ≥ 50 µg) 1.27 0.74 to 2.02 2.13 0.24 to 8.62
Titrated (low-dose) oral misoprostol
solution
0.85 0.41 to 1.52 1.28 0.5 to 2.68
Sustained-release misoprostol vaginal
pessary
2.50 0.77 to 6.12
Intravenous oxytocin 0.95 0.51 to 1.62
Intravenous oxytocin plus amniotomy 3.29 0.13 to 17.77
NO 0.17 0.01 to 0.66
Mifepristone 140.90 0.48 to 168.7
Mechanical methods – Foley catheter 0.41 0.2 to 0.71 0.64 0.21 to 1.43
Mechanical methods – double-balloon
or Cook’s catheter
0.23 0 to 1.1 1.31 0 to 6.91
Extra-amniotic PGE2 0.11 0 to 0.5 0.14 0 to 0.84
Buccal/sublingual misoprostol 1.89 0.9 to 3.52 2189.00 0.4 to 4820
Vaginal PGE2
pessary
(slow release)
Intracervical PGE2 0.60 0.33 to 1.01 0.99 0.26 to 2.57
Vaginal PGE2 pessary (normal release) 0.50 0.14 to 1.26
Vaginal misoprostol (dose < 50 µg) 0.98 0.54 to 1.64 0.33 0.02 to 1.4
Vaginal misoprostol (dose ≥ 50 µg) 1.55 0.9 to 2.51 2.71 1.11 to 5.69
Oral misoprostol tablet (dose < 50 µg) 0.40 0.1 to 1.07
Oral misoprostol tablet (dose ≥ 50 µg) 1.01 0.54 to 1.73
Titrated (low-dose) oral misoprostol
solution
0.68 0.29 to 1.34 2.12 0.28 to 7.9
Sustained-release misoprostol vaginal
pessary
1.88 0.73 to 4 1.89 0.72 to 4.09
Intravenous oxytocin 0.75 0.39 to 1.31 0.87 0.21 to 2.37
Intravenous oxytocin plus amniotomy 2.63 0.1 to 14.43
NO 0.14 0.01 to 0.53
Mifepristone 106.00 0.38 to 136.4
Mechanical methods – Foley catheter 0.32 0.14 to 0.62 0.04 0 to 0.21
Mechanical methods – laminaria 0.18 0 to 0.91
Mechanical methods – double-balloon
or Cook’s catheter
0.09 0 to 0.39 0.10 0 to 0.62
Buccal/sublingual misoprostol 1.50 0.67 to 2.97
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TABLE 53 Hyperstimulation with fetal heart changes (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Intracervical PGE2 Vaginal PGE2 pessary (normal release) 0.85 0.25 to 2.07
Vaginal misoprostol (dose < 50 µg) 1.65 1.06 to 2.47 1.47 0.7 to 2.78
Vaginal misoprostol (dose ≥ 50 µg) 2.64 1.76 to 3.83 3.04 1.53 to 5.53
Oral misoprostol tablet (dose < 50 µg) 0.68 0.19 to 1.75
Oral misoprostol tablet (dose ≥ 50 µg) 1.71 1.07 to 2.61 2.12 0.75 to 4.91
Titrated (low-dose) oral misoprostol
solution
1.16 0.52 to 2.23
Sustained-release misoprostol vaginal
pessary
3.37 1.07 to 8.18
i.v. oxytocin 1.28 0.72 to 2.1 3.33 0.52 to 11.85
i.v. oxytocin plus amniotomy 4.50 0.18 to 24.61
NO 0.23 0.01 to 0.88 0.79 0 to 5.18
Mifepristone 200.70 0.67 to 223.4
Mechanical methods – Foley catheter 0.55 0.27 to 1.01 1.17 0 to 7.37
Mechanical methods – laminaria 0.31 0 to 1.48 0.24 0 to 1.53
Mechanical methods – double-balloon
or Cook’s catheter
0.15 0 to 0.69
Buccal/sublingual misoprostol 2.55 1.24 to 4.73
Vaginal PGE2
pessary
(normal release)
Vaginal misoprostol (dose < 50 µg) 2.53 0.79 to 6.34 0.59 0.01 to 3.34
Vaginal misoprostol (dose ≥ 50 µg) 4.05 1.31 to 10.04 22,750.00 3.18 to 28,850
Oral misoprostol tablet (dose < 50 µg) 1.04 0.19 to 3.38
Oral misoprostol tablet (dose ≥ 50 µg) 2.64 0.81 to 6.76
Titrated (low-dose) oral misoprostol
solution
1.77 0.46 to 4.85
Sustained-release misoprostol vaginal
pessary
5.17 1 to 16.23
i.v. oxytocin 1.95 0.59 to 4.98 18.29 0.22 to 103.5
i.v. oxytocin plus amniotomy 5.90 0.26 to 31.66 12.32 0.28 to 71.07
NO 0.35 0.01 to 1.57
Mifepristone 271.00 0.74 to 350.2
Mechanical methods – Foley catheter 0.83 0.24 to 2.14 2.26 0.09 to 11.72
Mechanical methods – laminaria 0.47 0.01 to 2.53
Mechanical methods – double-balloon
or Cook’s catheter
0.24 0 to 1.18
Buccal/sublingual misoprostol 3.92 1.06 to 10.62
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TABLE 53 Hyperstimulation with fetal heart changes (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal misoprostol
(dose < 50 µg)
Vaginal misoprostol (dose ≥ 50 µg) 1.63 1.1 to 2.35 1.95 0.78 to 4.19
Oral misoprostol tablet (dose < 50 µg) 0.41 0.13 to 1.02 0.33 0.05 to 1.1
Oral misoprostol tablet (dose ≥ 50 µg) 1.06 0.68 to 1.59 0.61 0.25 to 1.23
Titrated (low-dose) oral misoprostol
solution
0.71 0.34 to 1.29 0.22 0.02 to 0.77
Sustained-release misoprostol vaginal
pessary
2.09 0.66 to 5.05
i.v. oxytocin 0.79 0.45 to 1.29 2.27 0.42 to 7.45
i.v. oxytocin plus amniotomy 2.77 0.11 to 15.05
NO 0.14 0.01 to 0.55
Mifepristone 121.10 0.41 to 139.8
Mechanical methods – Foley catheter 0.34 0.17 to 0.59 0.37 0.1 to 0.91
Mechanical methods – laminaria 0.19 0 to 0.94
Mechanical methods – double-balloon
or Cook’s catheter
0.10 0 to 0.43
Buccal/sublingual misoprostol 1.57 0.82 to 2.76 1.47 0.5 to 3.42
Vaginal misoprostol
(dose ≥ 50 µg)
Oral misoprostol tablet (dose < 50 µg) 0.26 0.08 to 0.66
Oral misoprostol tablet (dose ≥ 50 µg) 0.66 0.44 to 0.93 0.77 0.43 to 1.25
Titrated (low-dose) oral misoprostol
solution
0.45 0.21 to 0.83
Sustained-release misoprostol vaginal
pessary
1.29 0.42 to 3.06
i.v. oxytocin 0.49 0.3 to 0.76 0.29 0.1 to 0.65
i.v. oxytocin plus amniotomy 1.72 0.07 to 9.37
NO 0.09 0 to 0.33 0.06 0 to 0.39
Mifepristone 77.21 0.26 to 86.53
Mechanical methods – Foley catheter 0.21 0.11 to 0.37 0.43 0.04 to 1.58
Mechanical methods – double-balloon
or Cook’s catheter
0.12 0 to 0.58
Extra-amniotic PGE2 0.06 0 to 0.26
Buccal/sublingual misoprostol 0.97 0.52 to 1.68 1.02 0.42 to 2.09
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TABLE 53 Hyperstimulation with fetal heart changes (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Oral misoprostol
tablet
(dose < 50 µg)
Oral misoprostol tablet (dose ≥ 50 µg) 3.39 0.95 to 8.72
Titrated (low-dose) oral
misoprostol solution
2.26 0.56 to 6.25
Sustained-release misoprostol
vaginal pessary
6.66 1.21 to 21.51
i.v. oxytocin 2.52 0.68 to 6.71
i.v. oxytocin plus amniotomy 8.79 0.25 to 49.68
NO 0.46 0.02 to 2.04
Mifepristone 349.30 0.9 to 442.9
Mechanical methods – Foley catheter 1.08 0.28 to 2.95
Mechanical methods – laminaria 0.61 0.01 to 3.26
Mechanical methods – double-balloon
or Cook’s catheter
0.30 0 to 1.54
Buccal/sublingual misoprostol 5.01 1.27 to 13.91
Oral misoprostol
tablet
(dose ≥ 50 µg)
Titrated (low-dose) oral
misoprostol solution
0.70 0.31 to 1.34
Sustained-release misoprostol
vaginal pessary
2.02 0.63 to 4.95
i.v. oxytocin 0.76 0.45 to 1.2 0.85 0.37 to 1.68
i.v. oxytocin plus amniotomy 2.70 0.1 to 14.79
NO 0.14 0.01 to 0.53
Mifepristone 118.70 0.4 to 135.8
Mechanical methods – Foley catheter 0.33 0.16 to 0.61
Mechanical methods – double-balloon
or Cook’s catheter
0.19 0 to 0.91
Extra-amniotic PGE2 0.09 0 to 0.42
Buccal/sublingual misoprostol 1.52 0.76 to 2.77 2.76 0.23 to 12.25
Titrated (low-dose)
oral misoprostol
solution
Sustained-release misoprostol
vaginal pessary
3.22 0.87 to 8.6
i.v. oxytocin 1.23 0.52 to 2.48
i.v. oxytocin plus amniotomy 4.26 0.15 to 23.41
NO 0.22 0.01 to 0.9
Mifepristone 191.90 0.56 to 221.2
Mechanical methods – Foley catheter 0.52 0.22 to 1.07
Mechanical methods – laminaria 0.30 0 to 1.52
Mechanical methods – double-balloon
or Cook’s catheter
0.15 0 to 0.67
Buccal/sublingual misoprostol 2.45 0.95 to 5.28
continued
DOI: 10.3310/hta20650 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 65
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Alfirevic et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
445
TABLE 53 Hyperstimulation with fetal heart changes (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Sustained-release
misoprostol
vaginal pessary
i.v. oxytocin 0.48 0.15 to 1.18
i.v. oxytocin plus amniotomy 1.70 0.05 to 9.65
NO 0.09 0 to 0.38
Mifepristone 70.70 0.19 to 87.16
Mechanical methods – Foley catheter 0.21 0.06 to 0.54
Mechanical methods – laminaria 0.12 0 to 0.62
Mechanical methods – double-balloon
or Cook’s catheter
0.06 0 to 0.27
Buccal/sublingual misoprostol 0.97 0.27 to 2.54
i.v. oxytocin i.v. oxytocin plus amniotomy 3.68 0.14 to 20.13
NO 0.19 0.01 to 0.75
Mifepristone 152.30 0.55 to 182.9
Mechanical methods – Foley catheter 0.45 0.2 to 0.87
Mechanical methods – laminaria 152.30 0.55 to 182.9 87,840.00 0.13 to 1813
Mechanical methods – double-balloon
or Cook’s catheter
0.25 0 to 1.27
Buccal/sublingual misoprostol 2.10 0.96 to 4.05
i.v. oxytocin plus
amniotomy
NO 0.25 0 to 1.56
Mifepristone 155.00 0.11 to 229.8
Mechanical methods – Foley catheter 0.57 0.02 to 2.85
Mechanical methods – double-balloon
or Cook’s catheter
0.33 0 to 2.15
Extra-amniotic PGE2 0.16 0 to 1.05
Buccal/sublingual misoprostol 2.74 0.09 to 14.33
NO Mifepristone 2238.00 2.26 to 2959
Mechanical methods – Foley catheter 8.59 0.54 to 46.06
Mechanical methods – laminaria 5.14 0.02 to 29.25
Mechanical methods – double-balloon
or Cook’s catheter
2.50 0.01 to 14.17
Buccal/sublingual misoprostol 39.35 2.53 to 210.4
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TABLE 53 Hyperstimulation with fetal heart changes (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Mifepristone Mechanical methods – Foley catheter 0.16 0 to 0.83
Mechanical methods – laminaria 0.09 0 to 0.63
Mechanical methods – double-balloon
or Cook’s catheter
0.05 0 to 0.29
Buccal/sublingual misoprostol 0.76 0.01 to 3.86
Mechanical
methods – Foley
catheter
Mechanical methods – double-balloon
or Cook’s catheter
0.61 0.01 to 3.06
Mechanical methods – laminaria 0.30 0 to 1.38
Buccal/sublingual misoprostol 5.04 2.05 to 10.57
Mechanical
methods –
laminaria
Mechanical methods – double-balloon
or Cook’s catheter
5.50 0.01 to 31.59
Buccal/sublingual misoprostol 107.70 1.51 to 539.2
Mechanical
methods –
double-balloon or
Cook’s catheter
Buccal/sublingual misoprostol 629.00 3.28 to 947.3
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TABLE 55 Neonatal intensive care unit admission
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
No treatment Placebo 1.07 0.7 to 1.56 0.7355 0 to 0.77
Vaginal PGE2 (tablet) 0.85 0.48 to 1.41 0.5082 0.08 to 1.63
Vaginal PGE2 (gel) 0.91 0.7 to 1.15 0.899 0.56 to 1.36
Vaginal PGE2 pessary (slow release) 0.75 0.52 to 1.05
PGF2 gel 0.58 0.19 to 1.34
Intracervical PGE2 0.78 0.56 to 1.05 0.8517 0.16 to 2.54
Vaginal PGE2 pessary (normal release) 0.91 0.57 to 1.36 1.535 0.71 to 2.91
Vaginal misoprostol (dose < 50 µg) 0.76 0.58 to 0.97 12.27 0.03 to 42.75
Vaginal misoprostol (dose ≥ 50 µg) 0.88 0.67 to 1.13 1.238 0.46 to 2.64
Oral misoprostol tablet (dose < 50 µg) 0.81 0.35 to 1.61
Oral misoprostol tablet (dose ≥ 50 µg) 0.85 0.64 to 1.12 1.335E+28 0.52 to 9.656E+21
Titrated (low-dose) oral misoprostol
solution
0.69 0.45 to 1.01
Sustained-release misoprostol vaginal
pessary
0.61 0.35 to 0.99
i.v. oxytocin 0.79 0.63 to 0.97 0.7211 0.54 to 0.93
Amniotomy 0.86 0.24 to 2.19
i.v. oxytocin plus amniotomy 1.64 0.82 to 2.96 2.001 0.61 to 4.99
NO 0.87 0.5 to 1.37 1.247 0.13 to 5.08
Mifepristone 1.80 0.73 to 3.83
Oestrogens 1.50 0.01 to 8.27
Mechanical methods – Foley catheter 0.68 0.48 to 0.94 0.6182 0.11 to 1.75
Mechanical methods – laminaria 1.59 0.43 to 4.34
Mechanical methods – double-balloon or
Cook’s catheter
0.62 0.3 to 1.13
Membrane sweeping 0.85 0.52 to 1.33 0.9813 0.57 to 1.57
Extra-amniotic PGE2 0.41 0.17 to 0.81
Sexual intercourse 0.49 0.16 to 1.12 0.4972 0.16 to 1.16
Acupuncture 1.00 0.11 to 3.69 0.09124 0 to 0.17
Oral prostaglandins 0.70 0.1 to 2.4
Buccal/sublingual misoprostol 0.75 0.47 to 1.15
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TABLE 55 Neonatal intensive care unit admission (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Placebo Vaginal PGE2 (tablet) 0.83 0.42 to 1.44
Vaginal PGE2 (gel) 0.88 0.59 to 1.26 0.7141 0.26 to 1.58
Vaginal PGE2 pessary (slow release) 0.73 0.44 to 1.11 29.03 0.45 to 156.3
PGF2 gel 0.56 0.18 to 1.36
Intracervical PGE2 0.76 0.48 to 1.12 1.059 0.08 to 4.41
Vaginal PGE2 pessary (normal release) 0.88 0.51 to 1.4 0.8597 0.3 to 1.94
Vaginal misoprostol (dose < 50 µg) 0.74 0.49 to 1.06 0.9459 0.38 to 1.94
Vaginal misoprostol (dose ≥ 50 µg) 0.85 0.57 to 1.23
Oral misoprostol tablet (dose < 50 µg) 0.79 0.31 to 1.63
Oral misoprostol tablet (dose ≥ 50 µg) 0.83 0.55 to 1.2 0.7459 0.28 to 1.61
Titrated (low-dose) oral misoprostol
solution
0.67 0.39 to 1.07
Sustained-release misoprostol vaginal
pessary
0.59 0.31 to 1.03
i.v. oxytocin 0.76 0.5 to 1.12 0.7765 0.06 to 3.02
Amniotomy 0.84 0.22 to 2.26
i.v. oxytocin plus amniotomy 1.60 0.71 to 3.06
NO 0.82 0.54 to 1.2 0.9191 0.56 to 1.43
Mifepristone 1.71 0.73 to 3.55 1.149 0.38 to 2.75
Oestrogens 1.43 0.01 to 7.8 2.287 0.02 to 12.21
Mechanical methods – Foley catheter 0.66 0.41 to 1
Mechanical methods – laminaria 1.54 0.4 to 4.31
Mechanical methods – double-balloon or
Cook’s catheter
0.60 0.26 to 1.15
Membrane sweeping 0.83 0.43 to 1.46 1.141 0.01 to 6.19
Extra-amniotic PGE2 0.40 0.16 to 0.82
Sexual intercourse 0.48 0.14 to 1.17
Acupuncture 0.94 0.11 to 3.36 1.429 0.13 to 5.95
Oral prostaglandins 0.68 0.09 to 2.4
Buccal/sublingual misoprostol 0.73 0.42 to 1.19
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TABLE 55 Neonatal intensive care unit admission (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal PGE2
(tablet)
Vaginal PGE2 (gel) 1.14 0.65 to 1.88 0.9833 0.01 to 5.19
Vaginal PGE2 pessary (slow release) 0.94 0.5 to 1.6
PGF2 gel 0.72 0.22 to 1.82
Intracervical PGE2 0.98 0.55 to 1.64
Vaginal PGE2 pessary (normal release) 1.14 0.56 to 2.09
Vaginal misoprostol (dose < 50 µg) 0.95 0.54 to 1.56
Vaginal misoprostol (dose ≥ 50 µg) 1.10 0.64 to 1.77 0.8967 0.33 to 1.93
Oral misoprostol tablet (dose < 50 µg) 1.02 0.37 to 2.21
Oral misoprostol tablet (dose ≥ 50 µg) 1.07 0.62 to 1.74 1.136 0.38 to 2.65
Titrated (low-dose) oral misoprostol
solution
0.86 0.44 to 1.52
Sustained-release misoprostol vaginal
pessary
0.76 0.36 to 1.44
i.v. oxytocin 0.99 0.56 to 1.64
Amniotomy 1.09 0.27 to 3.01
i.v. oxytocin plus amniotomy 2.06 0.85 to 4.28
NO 1.08 0.52 to 2.03 0.09229 0 to 0.47
Mifepristone 2.26 0.78 to 5.32
Oestrogens 1.88 0.02 to 10.41
Mechanical methods – Foley catheter 0.85 0.47 to 1.43 1.641 0.33 to 5.09
Mechanical methods – laminaria 1.99 0.48 to 5.81
Mechanical methods – double-balloon or
Cook’s catheter
0.77 0.31 to 1.59
Membrane sweeping 1.08 0.51 to 2.08
Extra-amniotic PGE2 0.51 0.19 to 1.11
Sexual intercourse 0.62 0.17 to 1.57
Acupuncture 1.26 0.12 to 4.97
Oral prostaglandins 0.88 0.11 to 3.2
Buccal/sublingual misoprostol 0.94 0.48 to 1.69
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TABLE 55 Neonatal intensive care unit admission (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal PGE2 (gel) Vaginal PGE2 pessary (slow release) 0.83 0.58 to 1.14
PGF2 gel 0.64 0.22 to 1.48
Intracervical PGE2 0.86 0.65 to 1.13 0.8812 0.43 to 1.61
Vaginal PGE2 pessary (normal release) 1.01 0.62 to 1.53
Vaginal misoprostol (dose < 50 µg) 0.84 0.67 to 1.04 0.9043 0.62 to 1.3
Vaginal misoprostol (dose ≥ 50 µg) 0.97 0.77 to 1.21 1.194 0.76 to 1.8
Oral misoprostol tablet (dose < 50 µg) 0.89 0.4 to 1.74 0.7755 0.21 to 1.99
Oral misoprostol tablet (dose ≥ 50 µg) 0.95 0.73 to 1.2 0.5218 0.23 to 1
Titrated (low-dose) oral misoprostol
solution
0.76 0.51 to 1.09 0.835 0.45 to 1.42
Sustained-release misoprostol vaginal
pessary
0.68 0.39 to 1.09
i.v. oxytocin 0.87 0.67 to 1.12
Amniotomy 0.95 0.27 to 2.4 1.437 0.35 to 4.07
i.v. oxytocin plus amniotomy 1.81 0.92 to 3.23 1.459 0.57 to 3.01
NO 0.96 0.57 to 1.49 1.03 0.37 to 2.29
Mifepristone 1.99 0.81 to 4.26
Oestrogens 1.66 0.02 to 9.07
Mechanical methods – Foley catheter 0.75 0.56 to 1.01 0.7575 0.43 to 1.21
Mechanical methods – laminaria 1.75 0.49 to 4.72 1.061 0.07 to 4.61
Mechanical methods – double-balloon or
Cook’s catheter
0.68 0.34 to 1.22 0.5625 0.22 to 1.18
Membrane sweeping 0.95 0.54 to 1.56
Extra-amniotic PGE2 0.46 0.19 to 0.89
Sexual intercourse 0.55 0.17 to 1.29
Acupuncture 1.11 0.12 to 4.03
Oral prostaglandins 0.78 0.11 to 2.67
Buccal/sublingual misoprostol 0.83 0.53 to 1.24
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TABLE 55 Neonatal intensive care unit admission (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal PGE2
pessary
(slow release)
PGF2 gel 0.78 0.26 to 1.83
Intracervical PGE2 1.07 0.72 to 1.51 7.959 0.51 to 41.36
Vaginal PGE2 pessary (normal release) 1.24 0.72 to 1.99
Vaginal misoprostol (dose < 50 µg) 1.04 0.74 to 1.41 1.177 0.52 to 2.28
Vaginal misoprostol (dose ≥ 50 µg) 1.20 0.86 to 1.63 1.089 0.57 to 1.92
Oral misoprostol tablet (dose < 50 µg) 1.11 0.46 to 2.24
Oral misoprostol tablet (dose ≥ 50 µg) 1.17 0.81 to 1.63
Titrated (low-dose) oral misoprostol
solution
0.94 0.58 to 1.42 5.206E+12 8.7 to
553,300,000,000
Sustained-release misoprostol vaginal
pessary
0.82 0.55 to 1.18 0.8202 0.53 to 1.22
i.v. oxytocin 1.08 0.76 to 1.48 1.217 0.62 to 2.13
Amniotomy 1.18 0.32 to 3.06
i.v. oxytocin plus amniotomy 2.25 1.03 to 4.25
NO 1.18 0.65 to 1.97
Mifepristone 2.45 0.96 to 5.35
Oestrogens 2.03 0.02 to 11.13
Mechanical methods – Foley catheter 0.93 0.65 to 1.27 0.7907 0.45 to 1.28
Mechanical methods – laminaria 2.17 0.57 to 5.94
Mechanical methods – double-balloon or
Cook’s catheter
0.84 0.41 to 1.52 2.092 0.49 to 6.2
Membrane sweeping 1.18 0.64 to 2.01 0.2399 0 to 1.11
Extra-amniotic PGE2 0.56 0.23 to 1.13
Sexual intercourse 0.67 0.2 to 1.62
Acupuncture 1.37 0.15 to 5.05
Oral prostaglandins 0.96 0.13 to 3.29
Buccal/sublingual misoprostol 1.03 0.62 to 1.62
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TABLE 55 Neonatal intensive care unit admission (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
PGF2 gel Intracervical PGE2 1.71 0.57 to 3.98
Vaginal PGE2 pessary (normal release) 2.00 0.61 to 4.91
Vaginal misoprostol (dose < 50 µg) 1.66 0.57 to 3.86
Vaginal misoprostol (dose ≥ 50 µg) 1.93 0.65 to 4.49
Oral misoprostol tablet (dose < 50 µg) 1.78 0.44 to 4.91
Oral misoprostol tablet (dose ≥ 50 µg) 1.87 0.63 to 4.36
Titrated (low-dose) oral misoprostol
solution
1.52 0.49 to 3.65
Sustained-release misoprostol vaginal
pessary
1.33 0.41 to 3.31
i.v. oxytocin 1.73 0.58 to 4.05
Amniotomy 1.90 0.34 to 6.14
i.v. oxytocin plus amniotomy 3.60 0.97 to 9.39
NO 1.90 0.57 to 4.67
Mifepristone 3.96 0.93 to 11.34
Oestrogens 3.26 0.02 to 18.77
Mechanical methods – Foley catheter 1.47 0.53 to 3.3 1.479 0.52 to 3.4
Mechanical methods – laminaria 3.48 0.61 to 11.7
Mechanical methods – double-balloon or
Cook’s catheter
1.35 0.37 to 3.5
Membrane sweeping 1.89 0.55 to 4.73
Extra-amniotic PGE2 0.91 0.22 to 2.49
Sexual intercourse 1.09 0.21 to 3.35
Acupuncture 2.18 0.18 to 9.13
Oral prostaglandins 1.55 0.16 to 6.24
Buccal/sublingual misoprostol 1.65 0.51 to 4.01
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TABLE 55 Neonatal intensive care unit admission (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Intracervical PGE2 Vaginal PGE2 pessary (normal release) 1.18 0.7 to 1.88
Vaginal misoprostol (dose < 50 µg) 0.98 0.76 to 1.26 0.9989 0.66 to 1.47
Vaginal misoprostol (dose ≥ 50 µg) 1.14 0.87 to 1.47 1.187 0.73 to 1.83
Oral misoprostol tablet (dose < 50 µg) 1.05 0.45 to 2.07
Oral misoprostol tablet (dose ≥ 50 µg) 1.11 0.82 to 1.46 1.15 0.39 to 2.71
Titrated (low-dose) oral misoprostol
solution
0.90 0.57 to 1.33
Sustained-release misoprostol vaginal
pessary
0.79 0.45 to 1.3
i.v. oxytocin 1.03 0.75 to 1.38
Amniotomy 1.13 0.31 to 2.91
i.v. oxytocin plus amniotomy 2.14 1.01 to 4
NO 1.13 0.65 to 1.82
Mifepristone 2.34 0.94 to 5.1
Oestrogens 1.94 0.02 to 10.61
Mechanical methods – Foley catheter 0.88 0.63 to 1.2 0.9001 0.44 to 1.64
Mechanical methods – laminaria 2.05 0.57 to 5.51 4.442 0.68 to 17.69
Mechanical methods – double-balloon or
Cook’s catheter
0.80 0.38 to 1.47
Membrane sweeping 1.12 0.62 to 1.89
Extra-amniotic PGE2 0.54 0.22 to 1.06
Sexual intercourse 0.64 0.19 to 1.54
Acupuncture 1.30 0.14 to 4.82
Oral prostaglandins 0.91 0.13 to 3.17
Buccal/sublingual misoprostol 0.98 0.61 to 1.49
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TABLE 55 Neonatal intensive care unit admission (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal PGE2
pessary
(normal release)
Vaginal misoprostol (dose < 50 µg) 0.87 0.54 to 1.34 4.653 0.01 to 21.17
Vaginal misoprostol (dose ≥ 50 µg) 1.01 0.64 to 1.54 1.879 0.76 to 4.08
Oral misoprostol tablet (dose < 50 µg) 0.93 0.36 to 1.98
Oral misoprostol tablet (dose ≥ 50 µg) 0.98 0.61 to 1.51
Titrated (low-dose) oral misoprostol
solution
0.79 0.45 to 1.31 1.523 0.51 to 3.63
Sustained-release misoprostol vaginal
pessary
0.70 0.35 to 1.26
i.v. oxytocin 0.91 0.57 to 1.38 1.478 0.15 to 5.7
Amniotomy 1.00 0.26 to 2.7
i.v. oxytocin plus amniotomy 1.89 0.81 to 3.7
NO 0.99 0.52 to 1.72
Mifepristone 2.06 0.78 to 4.64
Oestrogens 1.73 0.02 to 9.35
Mechanical methods – Foley catheter 0.79 0.46 to 1.26
Mechanical methods – laminaria 1.83 0.46 to 5.18
Mechanical methods – double-balloon or
Cook’s catheter
0.71 0.31 to 1.41
Membrane sweeping 0.99 0.5 to 1.77
Extra-amniotic PGE2 0.47 0.18 to 0.97 0.9191 0.23 to 2.48
Sexual intercourse 0.57 0.16 to 1.41
Acupuncture 1.14 0.12 to 4.29
Oral prostaglandins 0.81 0.11 to 2.9
Buccal/sublingual misoprostol 0.87 0.47 to 1.49
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TABLE 55 Neonatal intensive care unit admission (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Vaginal misoprostol
(dose < 50 µg)
Vaginal misoprostol (dose ≥ 50 µg) 1.16 0.94 to 1.42 1.441 0.85 to 2.31
Oral misoprostol tablet (dose < 50 µg) 1.07 0.47 to 2.08 1.825 0.42 to 5.4
Oral misoprostol tablet (dose ≥ 50 µg) 1.13 0.9 to 1.4 0.9496 0.64 to 1.35
Titrated (low-dose) oral misoprostol
solution
0.91 0.61 to 1.31 0.5433 0.13 to 1.43
Sustained-release misoprostol vaginal
pessary
0.81 0.48 to 1.29
i.v. oxytocin 1.05 0.82 to 1.33 1.681 0.96 to 2.72
Amniotomy 1.15 0.32 to 2.93
i.v. oxytocin plus amniotomy 2.18 1.07 to 3.97
NO 1.15 0.68 to 1.8
Mifepristone 2.39 0.98 to 5.13
Oestrogens 1.99 0.02 to 10.82
Mechanical methods – Foley catheter 0.90 0.67 to 1.19 0.9504 0.5 to 1.66
Mechanical methods – laminaria 2.10 0.58 to 5.67
Mechanical methods – double-balloon or
Cook’s catheter
0.82 0.4 to 1.48
Membrane sweeping 1.14 0.65 to 1.88
Extra-amniotic PGE2 0.55 0.23 to 1.06
Sexual intercourse 0.66 0.2 to 1.54
Acupuncture 1.33 0.15 to 4.81
Oral prostaglandins 0.93 0.13 to 3.18
Buccal/sublingual misoprostol 0.99 0.66 to 1.45 1.043 0.53 to 1.83
Vaginal misoprostol
(dose ≥ 50 µg)
Oral misoprostol tablet (dose < 50 µg) 0.93 0.4 to 1.82
Oral misoprostol tablet (dose ≥ 50 µg) 0.98 0.79 to 1.2 1.234 0.87 to 1.7
Titrated (low-dose) oral misoprostol
solution
0.79 0.53 to 1.12 0.7044 0.23 to 1.65
Sustained-release misoprostol vaginal
pessary
0.70 0.41 to 1.11
i.v. oxytocin 0.90 0.71 to 1.14 0.9313 0.55 to 1.48
Amniotomy 0.99 0.28 to 2.54
i.v. oxytocin plus amniotomy 1.89 0.92 to 3.46
NO 0.99 0.59 to 1.56 0.01104 0 to 0.1
Mifepristone 2.07 0.84 to 4.41
Oestrogens 1.72 0.02 to 9.36
Mechanical methods – Foley catheter 0.78 0.57 to 1.04 1.725 0.42 to 4.97
Mechanical methods – laminaria 1.82 0.5 to 4.9
Mechanical methods – double-balloon or
Cook’s catheter
0.71 0.34 to 1.28
Membrane sweeping 0.99 0.56 to 1.63
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TABLE 55 Neonatal intensive care unit admission (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Extra-amniotic PGE2 0.47 0.2 to 0.89 0.4223 0.11 to 1.07
Sexual intercourse 0.57 0.17 to 1.33
Acupuncture 1.15 0.13 to 4.26
Oral prostaglandins 0.81 0.11 to 2.77
Buccal/sublingual misoprostol 0.86 0.57 to 1.25 1.078 0.47 to 2.11
Oral misoprostol
tablet
(dose < 50 µg)
Oral misoprostol tablet (dose ≥ 50 µg) 1.21 0.54 to 2.4 2.856 0.18 to 12.83
Titrated (low-dose) oral
misoprostol solution
0.98 0.4 to 2.02
Sustained-release misoprostol
vaginal pessary
0.87 0.33 to 1.91
i.v. oxytocin 1.12 0.49 to 2.25
Amniotomy 1.23 0.26 to 3.68
i.v. oxytocin plus amniotomy 2.33 0.78 to 5.43
NO 1.23 0.47 to 2.67
Mifepristone 2.56 0.73 to 6.67
Oestrogens 2.14 0.02 to 12.26
Mechanical methods – Foley catheter 0.97 0.41 to 1.97
Mechanical methods – laminaria 2.25 0.48 to 6.95
Mechanical methods – double-balloon or
Cook’s catheter
0.88 0.29 to 2.06
Membrane sweeping 1.22 0.45 to 2.68
Extra-amniotic PGE2 0.58 0.18 to 1.43
Sexual intercourse 0.70 0.17 to 1.94
Acupuncture 1.42 0.13 to 5.56
Oral prostaglandins 1.00 0.11 to 3.76
Buccal/sublingual misoprostol 1.07 0.43 to 2.25
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TABLE 55 Neonatal intensive care unit admission (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Oral misoprostol
tablet
(dose ≥ 50 µg)
Titrated (low-dose) oral misoprostol
solution
0.81 0.54 to 1.19
Sustained-release misoprostol vaginal
pessary
0.72 0.42 to 1.17
i.v. oxytocin 0.93 0.72 to 1.19 0.8406 0.5 to 1.33
Amniotomy 1.03 0.28 to 2.63
i.v. oxytocin plus amniotomy 1.94 0.94 to 3.57
NO 1.02 0.6 to 1.61
Mifepristone 2.13 0.86 to 4.58
Oestrogens 1.77 0.02 to 9.78
Mechanical methods – Foley catheter 0.81 0.57 to 1.1
Mechanical methods – laminaria 1.88 0.51 to 5.07
Mechanical methods – double-balloon or
Cook’s catheter
0.73 0.35 to 1.34
Membrane sweeping 1.02 0.57 to 1.68
Extra-amniotic PGE2 0.49 0.21 to 0.95
Sexual intercourse 0.58 0.18 to 1.37
Acupuncture 1.18 0.13 to 4.3
Oral prostaglandins 0.83 0.12 to 2.84
Buccal/sublingual misoprostol 0.89 0.58 to 1.3 0.7847 0.38 to 1.43
Titrated (low-dose)
oral misoprostol
solution
Sustained-release misoprostol vaginal
pessary
0.91 0.49 to 1.58
i.v. oxytocin 1.18 0.78 to 1.73 31.66 0.89 to 177.1
Amniotomy 1.30 0.34 to 3.4
i.v. oxytocin plus amniotomy 2.46 1.11 to 4.75
NO 1.30 0.69 to 2.21
Mifepristone 2.70 1.02 to 6.11
Oestrogens 2.25 0.02 to 12.26
Mechanical methods – Foley catheter 1.02 0.65 to 1.54
Mechanical methods – laminaria 2.38 0.61 to 6.66
Mechanical methods – double-balloon or
Cook’s catheter
0.92 0.42 to 1.79
Membrane sweeping 1.29 0.66 to 2.28
Extra-amniotic PGE2 0.61 0.25 to 1.23
Sexual intercourse 0.74 0.22 to 1.82
Acupuncture 1.50 0.16 to 5.6
Oral prostaglandins 1.06 0.14 to 3.72
Buccal/sublingual misoprostol 1.13 0.64 to 1.83
continued
DOI: 10.3310/hta20650 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 65
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Alfirevic et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
479
TABLE 55 Neonatal intensive care unit admission (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Sustained-release
misoprostol
vaginal pessary
i.v. oxytocin 1.37 0.8 to 2.2
Amniotomy 1.51 0.37 to 4.05
i.v. oxytocin plus amniotomy 2.86 1.17 to 5.83
NO 1.51 0.72 to 2.76
Mifepristone 3.13 1.1 to 7.26
Oestrogens 2.59 0.02 to 14.3
Mechanical methods – Foley catheter 1.18 0.69 to 1.9
Mechanical methods – laminaria 2.76 0.68 to 7.86
Mechanical methods – double-balloon or
Cook’s catheter
1.07 0.46 to 2.1
Membrane sweeping 1.50 0.71 to 2.8
Extra-amniotic PGE2 0.72 0.26 to 1.56
Sexual intercourse 0.86 0.24 to 2.17
Acupuncture 1.75 0.18 to 6.59
Oral prostaglandins 1.22 0.16 to 4.34
Buccal/sublingual misoprostol 1.31 0.68 to 2.3
i.v. oxytocin Amniotomy 1.11 0.31 to 2.82
i.v. oxytocin plus amniotomy 2.10 1.03 to 3.85
NO 1.11 0.65 to 1.76
Mifepristone 2.29 0.94 to 4.83 7.815 1.31 to 28.37
Oestrogens 1.91 0.02 to 10.47
Mechanical methods – Foley catheter 0.87 0.62 to 1.19
Mechanical methods – laminaria 2.03 0.55 to 5.49
Mechanical methods – double-balloon or
Cook’s catheter
0.79 0.38 to 1.44
Membrane sweeping 1.10 0.63 to 1.77
Extra-amniotic PGE2 0.53 0.22 to 1.03
Sexual intercourse 0.63 0.2 to 1.46
Acupuncture 1.28 0.14 to 4.67
Oral prostaglandins 0.89 0.13 to 3.01
Buccal/sublingual misoprostol 0.96 0.61 to 1.45
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TABLE 55 Neonatal intensive care unit admission (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Amniotomy i.v. oxytocin plus amniotomy 2.56 0.64 to 7.17 2.553E+23 21.92 to 1.433E+22
NO 1.37 0.34 to 3.81
Mifepristone 2.86 0.57 to 9.12
Oestrogens 2.36 0.02 to 14.08
Mechanical methods – Foley catheter 1.08 0.3 to 2.87
Mechanical methods – laminaria 2.51 0.39 to 8.88
Mechanical methods – double-balloon or
Cook’s catheter
0.97 0.23 to 2.83
Membrane sweeping 1.36 0.34 to 3.74
Extra-amniotic PGE2 0.65 0.14 to 1.99
Sexual intercourse 0.79 0.13 to 2.65
Acupuncture 1.61 0.1 to 7.07
Oral prostaglandins 1.11 0.1 to 4.65
Buccal/sublingual misoprostol 1.19 0.32 to 3.22
i.v. oxytocin plus
amniotomy
NO 0.58 0.25 to 1.18
Mifepristone 1.22 0.38 to 3.03
Oestrogens 1.03 0.01 to 5.84
Mechanical methods – Foley catheter 0.46 0.22 to 0.86
Mechanical methods – laminaria 1.07 0.24 to 3.24
Mechanical methods – double-balloon or
Cook’s catheter
0.42 0.15 to 0.92
Membrane sweeping 0.58 0.24 to 1.18
Extra-amniotic PGE2 0.28 0.09 to 0.66
Sexual intercourse 0.33 0.08 to 0.88
Acupuncture 0.68 0.06 to 2.62
Oral prostaglandins 0.48 0.06 to 1.77
Buccal/sublingual misoprostol 0.51 0.22 to 1.01
NO Mifepristone 2.16 0.83 to 4.75
Oestrogens 1.81 0.02 to 9.98
Mechanical methods – Foley catheter 0.83 0.47 to 1.38
Mechanical methods – laminaria 1.94 0.49 to 5.52
Mechanical methods – double-balloon or
Cook’s catheter
0.75 0.32 to 1.51
Membrane sweeping 1.05 0.5 to 1.94
Extra-amniotic PGE2 0.50 0.19 to 1.07
Sexual intercourse 0.60 0.17 to 1.52
Acupuncture 1.20 0.13 to 4.31
Oral prostaglandins 0.86 0.11 to 3.09
Buccal/sublingual misoprostol 0.92 0.49 to 1.6
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TABLE 55 Neonatal intensive care unit admission (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Mifepristone Oestrogens 0.97 0.01 to 5.52
Mechanical methods – Foley catheter 0.45 0.17 to 0.94
Mechanical methods – laminaria 1.04 0.21 to 3.26
Mechanical methods – double-balloon or
Cook’s catheter
0.41 0.12 to 0.98
Membrane sweeping 0.57 0.19 to 1.26
Extra-amniotic PGE2 0.27 0.07 to 0.69
Sexual intercourse 0.33 0.07 to 0.93
Acupuncture 0.65 0.06 to 2.58
Oral prostaglandins 0.47 0.05 to 1.8
Buccal/sublingual misoprostol 0.50 0.18 to 1.08
Oestrogens Mechanical methods – Foley catheter 9.68 0.08 to 49.08
Mechanical methods – laminaria 20.18 0.12 to 102.9
Mechanical methods – double-balloon or
Cook’s catheter
8.64 0.07 to 43.03
Membrane sweeping 12.43 0.09 to 62.02
Extra-amniotic PGE2 5.32 0.04 to 28.61
Sexual intercourse 6.83 0.04 to 33.44
Acupuncture 10.98 0.05 to 64.12
Oral prostaglandins 9.58 0.04 to 50.55
Buccal/sublingual misoprostol 10.48 0.09 to 52.25
Mechanical
methods –
Foley catheter
Mechanical methods – laminaria 2.37 0.64 to 6.44
Mechanical methods – double-balloon or
Cook’s catheter
0.91 0.45 to 1.64
Membrane sweeping 1.29 0.71 to 2.19
Extra-amniotic PGE2 0.62 0.25 to 1.23
Sexual intercourse 0.74 0.22 to 1.79
Acupuncture 1.50 0.16 to 5.53
Oral prostaglandins 1.05 0.14 to 3.65
Buccal/sublingual misoprostol 1.12 0.69 to 1.75
Mechanical
methods –
laminaria
Mechanical methods – double-balloon or
Cook’s catheter
0.54 0.12 to 1.56
Membrane sweeping 0.76 0.18 to 2.12
Extra-amniotic PGE2 0.36 0.07 to 1.11
Sexual intercourse 0.43 0.07 to 1.42
Acupuncture 0.89 0.06 to 3.85
Oral prostaglandins 0.62 0.05 to 2.58
Buccal/sublingual misoprostol 0.66 0.16 to 1.81
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TABLE 55 Neonatal intensive care unit admission (continued )
Control treatment Active treatment
NMA Pairwise meta-analysis
OR 95% CrI OR 95% CrI
Mechanical
methods – double-
balloon or
Cook’s catheter
Membrane sweeping 1.55 0.64 to 3.23
Extra-amniotic PGE2 0.74 0.24 to 1.72
Sexual intercourse 0.89 0.22 to 2.39
Acupuncture 1.80 0.17 to 7.02
Oral prostaglandins 1.27 0.15 to 4.7
Buccal/sublingual misoprostol 1.36 0.6 to 2.7
Membrane
sweeping
Extra-amniotic PGE2 0.51 0.18 to 1.11
Sexual intercourse 0.61 0.17 to 1.54
Acupuncture 1.24 0.13 to 4.69
Oral prostaglandins 0.87 0.11 to 3.13
Buccal/sublingual misoprostol 0.93 0.46 to 1.68
Extra-amniotic PGE2 Sexual intercourse 1.38 0.33 to 3.8
Acupuncture 2.79 0.25 to 11.14
Oral prostaglandins 1.98 0.22 to 7.6
Buccal/sublingual misoprostol 2.11 0.85 to 4.5
Sexual intercourse Acupuncture 2.59 0.2 to 11.03
Oral prostaglandins 1.83 0.19 to 7.23
Buccal/sublingual misoprostol 1.98 0.59 to 5.17
Acupuncture Oral prostaglandins 1.59 0.07 to 8.28
Buccal/sublingual misoprostol 1.70 0.19 to 7.02
Oral prostaglandins Buccal/sublingual misoprostol 2.06 0.3 to 7.72
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Appendix 13 Sensitivity analysis excluding trials
at high risk of bias
Comparison of mean ranks (95% CrI) from complete analysis and ranks, having removed studies at highrisk of bias on the allocation concealment domain.
TABLE 56 Vaginal delivery not achieved within 24 hours
Intervention
All studies (141 trials)
Only studies at low ROB
(97 trials)
Mean rank 95% CrI Mean rank 95% CrI
No treatment 21 19 to 21 19 14 to 21
Placebo 20 19 to 21 21 19 to 21
Vaginal PGE2 (tablet) 12 6 to 17 9 3 to 16
Vaginal PGE2 (gel) 8 5 to 12 7 3 to 11
Vaginal PGE2 pessary (slow release) 11 6 to 16 12 7 to 16
Intracervical PGE2 14 10 to 17 12 8 to 16
Vaginal PGE2 pessary (normal release) 4 1 to 11 10 2 to 17
Vaginal misoprostol (dose < 50 µg) 6 3 to 9 6 3 to 9
Vaginal misoprostol (dose ≥ 50 µg) 4 2 to 7 3 1 to 6
Oral misoprostol tablet (dose < 50 µg) 14 5 to 18 15 6 to 19
Oral misoprostol tablet (dose ≥ 50 µg) 12 8 to 16 9 5 to 14
Titrated (low-dose) oral misoprostol solution 5 2 to 10 4 2 to 9
Sustained-release misoprostol insert 5 1 to 16 10 2 to 18
i.v. oxytocin 14 9 to 18 11 5 to 16
i.v. oxytocin plus amniotomy 2 1 to 10 1 1 to 8
NO 15 6 to 18 18 13 to 20
Mifepristone 19 17 to 21 19 15 to 21
Mechanical methods – Foley catheter 13 7 to 17 12 6 to 17
Mechanical methods – double-balloon or Cook’s catheter 10 2 to 18 12 4 to 17
Extra-amniotic PGE2 16 4 to 20 16 4 to 21
Buccal/sublingual misoprostol 6 2 to 11 4 2 to 9
ROB, risk of bias.
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TABLE 57 Uterine hyperstimulation
Intervention
All studies (180 trials)
Only studies at low ROB
(127 trials)
Mean rank 95% CrI Mean rank 95% CrI
No treatment 8 3 to 17 8 3 to 17
Placebo 6 3 to 10 4 3 to 7
Vaginal PGE2 (tablet) 11 6 to 17 9 4 to 16
Vaginal PGE2 (gel) 13 9 to 17 13 9 to 17
Vaginal PGE2 pessary (slow release) 15 10 to 19 13 8 to 18
Intracervical PGE2 10 6 to 13 9 5 to 14
Vaginal PGE2 pessary (normal release) 8 3 to 16 5 3 to 14
Vaginal misoprostol (dose < 50 µg) 15 11 to 18 15 11 to 18
Vaginal misoprostol (dose ≥ 50 µg) 19 17 to 21 17 15 to 19
Oral misoprostol tablet (dose < 50 µg) 6 2 to 15 7 3 to 16
Oral misoprostol tablet (dose ≥ 50 µg) 15 11 to 18 14 10 to 18
Titrated (low-dose) oral misoprostol solution 11 5 to 17 11 5 to 17
Sustained-release misoprostol insert 18 11 to 21 11 3 to 19
i.v. oxytocin 12 7 to 17 12 6 to 17
i.v. oxytocin plus amniotomy 14 3 to 21 15 3 to 19
NO 3 1 to 8 2 1 to 2
Mifepristone 19 7 to 21 20 20 to 20
Mechanical methods – Foley catheter 5 3 to 9 6 3 to 11
Mechanical methods – laminaria 3 1 to 13 Not in network
Mechanical methods – double-balloon or Cook’s catheter 2 1 to 6 1 1 to 2
Buccal/sublingual misoprostol 18 13 to 21 17 11 to 19
ROB, risk of bias.
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TABLE 58 Neonatal intensive care unit admission (excluding trials at high risk of bias)
Intervention
All studies (204 trials)
Only studies at low ROB
(145 trials)
Mean rank 95% CrI Mean rank 95% CrI
No treatment 23 16 to 27 19 10 to 25
Placebo 23 13 to 28 19 8 to 25
Vaginal PGE2 (tablet) 16 4 to 27 20 5 to 27
Vaginal PGE2 (gel) 20 13 to 25 18 11 to 24
Vaginal PGE2 pessary (slow release) 13 6 to 23 14 6 to 24
PGF2 gel 8 1 to 26 8 1 to 25
Intracervical PGE2 14 7 to 23 13 5 to 24
Vaginal PGE2 pessary (normal release) 18 6 to 27 15 4 to 25
Vaginal misoprostol (dose < 50 µg) 13 7 to 20 12 6 to 19
Vaginal misoprostol (dose ≥ 50 µg) 19 12 to 25 19 12 to 24
Oral misoprostol tablet (dose < 50 µg) 14 2 to 28 13 2 to 26
Oral misoprostol tablet (dose ≥ 50 µg) 18 10 to 24 16 8 to 23
Titrated (low-dose) oral misoprostol solution 11 4 to 22 12 4 to 23
Sustained-release misoprostol insert 8 2 to 22 9 1 to 24
i.v. oxytocin 15 8 to 22 15 7 to 23
Amniotomy 14 1 to 29 13 1 to 27
i.v. oxytocin plus amniotomy 27 17 to 29 24 7 to 27
NO 17 5 to 26 17 5 to 26
Mifepristone 26 13 to 29 24 11 to 27
Oestrogens 14 1 to 29 13 1 to 27
Mechanical methods – Foley catheter 10 5 to 19 10 4 to 20
Mechanical methods – laminaria 23 4 to 29 Not in network
Mechanical methods – double-balloon or Cook’s catheter 9 2 to 25 9 2 to 24
Membrane sweeping 16 5 to 27 12 3 to 25
Extra-amniotic PGE2 4 1 to 15 4 1 to 16
Sexual intercourse 6 1 to 25 5 1 to 23
Acupuncture 14 1 to 29 12 1 to 27
Oral prostaglandins 10 1 to 29 Not in network
Buccal/sublingual misoprostol 13 4 to 25 13 4 to 24
ROB, risk of bias.
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TABLE 59 Instrumental delivery (excluding trials at high risk of bias)
Intervention
All studies (299 trials)
Only studies at low
ROB (163)
Mean rank 95% CrI Mean rank 95% CrI
No treatment 24 17 to 29 17 9 to 23
Placebo 21 12 to 28 18 8 to 24
Vaginal PGE2 (tablet) 17 8 to 26 12 3 to 23
Vaginal PGE2 (gel) 18 11 to 24 12 7 to 19
Vaginal PGE2 pessary (slow release) 7 2 to 17 7 1 to 17
PGF2 gel 14 2 to 28 8 1 to 22
Intracervical PGE2 15 8 to 23 19 11 to 25
Vaginal PGE2 pessary (normal release) 23 13 to 30 24 18 to 27
Vaginal misoprostol (dose < 50 µg) 11 4 to 20 12 5 to 21
Vaginal misoprostol (dose ≥ 50 µg) 17 10 to 24 16 8 to 23
Oral misoprostol tablet (dose < 50 µg) 9 1 to 29 6 1 to 23
Oral misoprostol tablet (dose ≥ 50 µg) 13 6 to 21 14 7 to 22
Titrated (low-dose) oral misoprostol solution 19 5 to 30 15 4 to 25
Sustained-release misoprostol insert 16 1 to 31
Intravenous oxytocin 24 18 to 29 19 11 to 24
Amniotomy 13 2 to 29 10 1 to 25
Intravenous oxytocin plus amniotomy 17 6 to 28 13 2 to 25
NO 17 5 to 28 13 3 to 24
Mifepristone 30 22 to 32 26 21 to 27
Oestrogens 8 1 to 28 9 1 to 25
Relaxin 25 4 to 32 22 4 to 27
Mechanical methods – Foley catheter 6 2 to 12 4 1 to 9
Mechanical methods – laminaria 12 1 to 29
Mechanical methods – double-balloon or Cook’s catheter 9 1 to 24 11 2 to 24
Membrane sweeping 26 16 to 31 21 9 to 26
Extra-amniotic PGE2 15 1 to 30 8 1 to 26
Intravenous prostaglandin 30 15 to 32
Sexual intercourse 25 7 to 32 19 4 to 27
Acupuncture 13 1 to 28 12 2 to 25
Homeopathy 18 1 to 32
Oral prostaglandins 9 1 to 25
Buccal/sublingual misoprostol 7 1 to 20 11 2 to 23
ROB, risk of bias.
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Appendix 14 Data files for all outcomes
considered in network meta-analysis
Data file for OpenBUGS analysis of failure to achieve vaginal
delivery within 24 hours
Treatments included in analysis:
1. no treatment
2. placebo
3. vaginal PGE2 (tablet)
4. vaginal PGE2 (gel)
5. vaginal PGE2 pessary (slow release)
6. intracervical PGE2
7. vaginal PGE2 pessary (normal release)
8. vaginal misoprostol (dose < 50 µg)
9. vaginal misoprostol (dose ≥ 50 µg)
10. oral misoprostol tablet (dose < 50 µg)
11. oral misoprostol tablet (dose ≥ 50 µg)
12. titrated (low-dose) oral misoprostol solution
13. sustained-release misoprostol insert
14. i.v. oxytocin
15. i.v. oxytocin plus amniotomy
16. NO
17. mifepristone
18. mechanical methods – Foley catheter
19. mechanical methods – double-balloon or Cook’s catheter
20. extra-amniotic PGE2
21. buccal/sublingual misoprostol.
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Data file for OpenBUGS analysis of caesarean section
Treatments included in analysis:
1. no treatment
2. placebo
3. vaginal PGE2 (tablet)
4. vaginal PGE2 (gel)
5. vaginal PGE2 pessary (slow release)
6. PGF2 gel
7. intracervical PGE2
8. vaginal PGE2 pessary (normal release)
9. vaginal misoprostol (dose < 50 µg)
10. vaginal misoprostol (dose ≥ 50 µg)
11. oral misoprostol tablet (dose < 50 µg)
12. oral misoprostol tablet (dose ≥ 50 µg)
13. titrated (low-dose) oral misoprostol solution
14. sustained-release misoprostol insert
15. i.v. oxytocin
16. amniotomy
17. i.v. oxytocin plus amniotomy
18. NO
19. mifepristone
20. oestrogens
21. corticosteroids
22. relaxin
23. hyaluronidase
24. mechanical methods – Foley catheter
25. mechanical methods – laminaria
26. mechanical methods – double-balloon or Cook’s catheter
27. membrane sweeping
28. extra-amniotic PGE2
29. i.v. prostaglandin
30. sexual intercourse
31. acupuncture
32. oral prostaglandins
33. buccal/sublingual misoprostol.
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Data file for OpenBUGS analysis of instrumental delivery
Treatments included in analysis:
1. no treatment
2. placebo
3. vaginal PGE2 (tablet)
4. vaginal PGE2 (gel)
5. vaginal PGE2 pessary (slow release)
6. PGF2 gel
7. intracervical PGE2
8. vaginal PGE2 pessary (normal release)
9. vaginal misoprostol (dose < 50 µg)
10. vaginal misoprostol (dose ≥ 50 µg)
11. oral misoprostol tablet (dose < 50 µg)
12. oral misoprostol tablet (dose ≥ 50 µg)
13. titrated (low-dose) oral misoprostol solution
14. sustained-release misoprostol insert
15. i.v. oxytocin
16. amniotomy
17. i.v. oxytocin plus amniotomy
18. NO
19. mifepristone
20. oestrogens
21. relaxin
22. mechanical methods – Foley catheter
23. mechanical methods – laminaria
24. mechanical methods – double-balloon or cook’s catheter
25. membrane sweeping
26. extra-amniotic PGE2
27. i.v. prostaglandin
28. sexual intercourse
29. acupuncture
30. homeopathy
31. oral prostaglandins
32. buccal/sublingual misoprostol.
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Data file for OpenBUGS analysis of hyperstimulation with fetal
heart rate changes
Treatments included in analysis:
1. no treatment
2. placebo
3. vaginal PGE2 (tablet)
4. vaginal PGE2 (gel)
5. vaginal PGE2 pessary (slow release)
6. intracervical PGE2
7. vaginal PGE2 pessary (normal release)
8. vaginal misoprostol (dose < 50 µg)
9. vaginal misoprostol (dose ≥ 50 µg)
10. oral misoprostol tablet (dose < 50 µg)
11. oral misoprostol tablet (dose ≥ 50 µg)
12. titrated (low-dose) oral misoprostol solution
13. sustained-release misoprostol insert
14. i.v. oxytocin
15. i.v. oxytocin plus amniotomy
16. NO
17. mifepristone
18. mechanical methods – Foley catheter
19. mechanical methods – laminaria
20. mechanical methods – double-balloon or Cook’s catheter
21. buccal/sublingual misoprostol.
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Data file for OpenBUGS analysis of Neonatal mortality and
serious morbidity
Treatments included in analysis:
1. no treatment
2. placebo
3. vaginal PGE2 (tablet)
4. vaginal PGE2 (gel)
5. vaginal PGE2 pessary (slow release)
6. PGF2 gel
7. intracervical PGE2
8. vaginal PGE2 pessary (normal release)
9. vaginal misoprostol (dose < 50 µg)
10. vaginal misoprostol (dose ≥ 50 µg)
11. oral misoprostol tablet (dose ≥ 50 µg)
12. titrated (low-dose) oral misoprostol solution
13. i.v. oxytocin
14. i.v. oxytocin plus amniotomy
15. NO
16. mechanical methods – Foley catheter
17. mechanical methods – laminaria
18. membrane sweeping
19. extra-amniotic PGE2
20. i.v. prostaglandin
21. sexual intercourse
22. breast stimulation
23. oral prostaglandins
24. buccal/sublingual misoprostol.
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Data file for OpenBUGS analysis of maternal mortality and
serious morbidity
Treatments included in analysis:
1. no treatment
2. placebo
3. vaginal PGE2 (tablet)
4. vaginal PGE2 (gel)
5. vaginal PGE2 pessary (slow release) Intracervical PGE2
6. intracervical PGE2
7. vaginal misoprostol (dose < 50 µg)
8. vaginal misoprostol (dose ≥ 50 µg)
9. oral misoprostol tablet (dose ≥ 50 µg)
10. i.v. oxytocin
11. i.v. oxytocin plus amniotomy
12. mifepristone
13. mechanical methods – Foley catheter
14. mechanical methods – laminaria
15. buccal/sublingual misoprostol.
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Data file for OpenBUGS analysis of NICU admission
Treatments included in analysis:
1. no treatment
2. placebo
3. vaginal PGE2 (tablet)
4. vaginal PGE2 (gel)
5. vaginal PGE2 pessary (slow release)
6. PGF2 gel
7. intracervical PGE2
8. vaginal PGE2 pessary (normal release)
9. vaginal misoprostol (dose < 50 µg)
10. vaginal misoprostol (dose ≥ 50 µg)
11. oral misoprostol tablet (dose < 50 µg)
12. oral misoprostol tablet (dose ≥ 50 µg)
13. titrated (low-dose) oral misoprostol solution
14. sustained-release misoprostol insert
15. i.v. oxytocin
16. amniotomy
17. i.v. oxytocin plus amniotomy
18. NO
19. mifepristone
20. oestrogens
21. mechanical methods – Foley catheter
22. mechanical methods – laminaria
23. mechanical methods – double-balloon or Cook’s catheter
24. membrane sweeping
25. extra-amniotic PGE2
26. sexual intercourse
27. acupuncture
28. oral prostaglandins
29. buccal/sublingual misoprostol.
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Data file for OpenBUGS analysis of Apgar score < 7 at 5 minutes
Treatments included in analysis:
1. no treatment
2. placebo
3. vaginal PGE2 (tablet)
4. vaginal PGE2 (gel)
5. vaginal PGE2 pessary (slow release)
6. PGF2 gel
7. intracervical PGE2
8. vaginal PGE2 pessary (normal release)
9. vaginal misoprostol (dose < 50 µg)
10. vaginal misoprostol (dose ≥ 50 µg)
11. oral misoprostol tablet (dose < 50 µg)
12. oral misoprostol tablet (dose ≥ 50 µg)
13. titrated (low-dose) oral misoprostol solution
14. sustained-release misoprostol insert
15. i.v. oxytocin
16. amniotomy
17. i.v. oxytocin plus amniotomy
18. NO
19. mifepristone
20. mechanical methods – Foley catheter
21. mechanical methods – laminaria
22. mechanical methods – double-balloon or Cook’s catheter
23. membrane sweeping
24. extra-amniotic PGE2
25. i.v. prostaglandin
26. sexual intercourse
27. acupuncture
28. oral prostaglandins
29. buccal/sublingual misoprostol.
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Appendix 15 Subgroup analysis for intact
membranes compared with ruptured membranes
Outcome: vaginal delivery not achieved within 24 hours
1
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5
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7
89
10
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FIGURE 23 Network for intact membranes only. Treatments are numbered as follows: 1, no treatment; 2, vaginal
PGE2 (tablet); 3, vaginal PGE2 (gel); 4, vaginal PGE2 pessary (slow release); 5, intracervical PGE2; 6, vaginal PGE2
pessary (normal release); 7, vaginal misoprostol (dose < 50µg); 8, vaginal misoprostol (dose ≥ 50 µg); 9, oral
misoprostol tablet (dose ≥ 50µg); 10, titrated (low-dose) oral misoprostol solution; 11, i.v. oxytocin; 12, i.v. oxytocin
plus amniotomy; 13, mechanical methods – Foley catheter; 14, mechanical methods – double-balloon or Cook’s
catheter; 15, buccal/sublingual misoprostol.
TABLE 68 Model fit and heterogeneity for intact membranes: VD 24 hours
Number of data points totresdeva Between-study SD: posterior mean (95% Crl) DIC
REs consistency: 118 119.9 0.42 (0.27 to 0.60) 750
REs inconsistency: 118 119.1 0.43 (0.24 to 0.66) 756.6
a Residual deviance.
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Outcome: vaginal delivery not achieved in 24 hours
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FIGURE 24 Network for ruptured membranes only. Treatments are numbered as follows: 1, no treatment; 2,
placebo; 3, vaginal PGE2 (gel); 4, vaginal PGE2 pessary (slow release); 5, intracervical PGE2; 6, vaginal misoprostol
(dose < 50 µg); 7, vaginal misoprostol (dose ≥ 50 µg); 8, oral misoprostol tablet (dose < 50 µg); 9, oral misoprostol
tablet (dose ≥ 50 µg); 10, titrated (low-dose) oral misoprostol solution; 11, i.v. oxytocin; 12, mifepristone.
TABLE 69 Model fit and heterogeneity for ruptured membranes: VD 24 hours
Number of data points totresdeva Between-study SD: posterior mean (95% Crl) DIC
REs consistency: 34 35.42 0.90 (0.08 to 2.38) 199.8
a Residual deviance.
Note: The REs inconsistency model would not compile.
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Outcome: caesarean section
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FIGURE 25 Network for intact membranes only. Treatments are numbered as follows: 1, no treatment; 2, placebo;
3, vaginal PGE2 (tablet); 4, vaginal PGE2 (gel); 5, vaginal PGE2 pessary (slow release); 6, PGF2 gel; 7, intracervical
PGE2; 8, vaginal PGE2 pessary (normal release); 9, vaginal misoprostol (dose < 50µg); 10, vaginal misoprostol (dose
≥ 50µg); 11, oral misoprostol tablet (dose < 50µg); 12, oral misoprostol tablet (dose ≥ 50 µg); 13, titrated (low-dose)
oral misoprostol solution; 14, i.v. oxytocin; 15, amniotomy; 16, i.v. oxytocin plus amniotomy; 17, NO; 18,
mifepristone; 19, oestrogens; 20, corticosteroids; 21, relaxin; 22, hyaluronidase; 23, mechanical methods – Foley
catheter; 24, mechanical methods – laminaria; 25, mechanical methods – double-balloon or Cook’s catheter;
26, membrane sweeping; 27, extra-amniotic PGE2; 28, i.v. prostaglandin; 29, sexual intercourse; 30, acupuncture;
31, buccal/sublingual misoprostol.
TABLE 70 Model fit and heterogeneity for intact membranes: CS
Number of data points totresdeva Between-study SD: posterior mean (95% Crl) DIC
REs consistency: 335 346.2 0.1823 (0.008 to 0.32) 1890
REs inconsistency: 335 340.1 0.2 (0.04 to 0.36) 1928
a Residual deviance.
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FIGURE 26 Network for ruptured membranes only. Treatments are numbered as follows: 1, no treatment;
2, placebo; 3, vaginal PGE2 tablet; 4, vaginal PGE2 (gel); 5, vaginal PGE2 pessary (slow release); 6, PGF2 gel;
7, intracervical PGE2; 8, vaginal PGE2 pessary (normal release); 9, vaginal misoprostol (dose < 50 µg); 10, vaginal
misoprostol (dose ≥ 50 µg); 11, oral misoprostol tablet (dose < 50 µg); 12, oral misoprostol tablet (dose ≥ 50µg);
13, titrated (low-dose) oral misoprostol solution; 14, i.v. oxytocin; 15, mifepristone; 16, mechanical methods – Foley
catheter; 17, acupuncture.
TABLE 71 Model fit and heterogeneity for ruptured membranes: CS
Number of data points totresdeva Between-study SD: posterior mean (95% Crl) DIC
REs consistency: 98 87.02 0.11 (0.004 to 0.297) 520.4
REs inconsistency: 98 87.19 0.11 (0.007 to 0.324) 529.9
a Residual deviance.
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Outcome: Apgar score < 7 at 5 minutes
Subgroup analysis for women with low Bishop score (< 6) or higher Bishop score ( ≥ 6)
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FIGURE 27 Network for intact membranes only. Treatments are numbered as follows: 1, no treatment; 2, placebo;
3, vaginal PGE2 (tablet); 4, vaginal PGE2 (gel); 5, vaginal PGE2 pessary (slow release); 6, intracervical PGE2;
7, vaginal PGE2 pessary (normal release); 8, vaginal misoprostol (dose < 50 µg); 9, vaginal misoprostol (dose ≥ 50µg);
10, oral misoprostol tablet (dose < 50 µg); 11, oral misoprostol tablet (dose ≥ 50µg); 12, titrated (low-dose) oral
misoprostol solution; 13, i.v. oxytocin; 14, amniotomy; 15, i.v. oxytocin plus amniotomy; 16, NO; 17, mifepristone;
18, mechanical methods – Foley catheter; 19, mechanical methods – laminaria; 20, mechanical methods – double-
balloon or Cook’s catheter; 21, membrane sweeping; 22, i.v. prostaglandin; 23, sexual intercourse; 24, acupuncture;
25, oral prostaglandins; 26, buccal/sublingual misoprostol.
TABLE 72 Model fit and heterogeneity for intact membranes: Apgar score < 7 at 5 minutes
Number of data points totresdeva Between-study SD: posterior mean (95% Crl) DIC
REs consistency: 205 230.8 0.36 (0.01 to 0.898) 762
REs inconsistency: 205 209.9 0.47 (0.03 to 1.34) 760
a Residual deviance.
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Subgroup analysis for women with low Bishop score (< 6) or higher Bishop
score (≥ 6)
Outcome: vaginal delivery not achieved within 24 hours
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FIGURE 28 Network for unfavourable cervix only. Treatments are numbered as follows: 1, no treatment;
2, placebo; 3, vaginal PGE2 (tablet); 4, vaginal PGE2 (gel); 5, vaginal PGE2 pessary (slow release); 6, intracervical PGE2;
7, vaginal PGE2 pessary (normal release); 8, vaginal misoprostol (dose < 50µg); 9, vaginal misoprostol (dose ≥ 50µg);
10, oral misoprostol tablet (dose < 50µg); 11, oral misoprostol tablet (dose ≥ 50µg); 12, titrated (low-dose) oral
misoprostol solution; 13, sustained-release misoprostol insert; 14, i.v. oxytocin; 15, NO; 16, mifepristone;
17, mechanical methods – Foley catheter; 18, mechanical methods – double-balloon or Cook’s catheter;
19, buccal/sublingual misoprostol.
TABLE 73 Model fit and heterogeneity for unfavourable cervix: VD not achieved in 24 hours
Number of data points totresdeva Between-study SD: posterior mean (95% Crl) DIC
REs consistency: 221 233.5 0.59 (0.47 to 0.73) 1429
REs inconsistency: 221 225.8 0.53 (0.38 to 0.70) 1429
a Residual deviance.
APPENDIX 15
NIHR Journals Library www.journalslibrary.nihr.ac.uk
564
12
3
4
5
6
7
FIGURE 29 Network for favourable cervix only. Treatments are numbered as follows: 1, vaginal PGE2 (tablet);
2, vaginal PGE2 (gel); 3, oral misoprostol tablet (dose ≥ 50µg); 4, titrated (low-dose) oral misoprostol solution;
5, i.v. oxytocin; 6, i.v. oxytocin plus amniotomy; 7, buccal/sublingual misoprostol.
Outcome: caesarean section
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FIGURE 30 Network for unfavourable cervix only. Treatments are numbered as follows: 1, no treatment;
2, placebo; 3, vaginal PGE2 (tablet); 4, vaginal PGE2 (gel); 5, vaginal PGE2 pessary (slow release); 6, PGF2 gel;
7, intracervical PGE2; 8, vaginal PGE2 pessary (normal release); 9, vaginal misoprostol (dose < 50 µg); 10, vaginal
misoprostol (dose ≥ 50 µg); 11, oral misoprostol tablet (dose < 50 µg); 12, oral misoprostol tablet (dose ≥ 50 µg);
13, titrated (low-dose) oral misoprostol solution; 14, sustained-release misoprostol insert; 15, i.v. oxytocin; 16, i.v.
oxytocin plus amniotomy; 17, NO; 18, mifepristone; 19, oestrogens; 20, relaxin; 21, hyaluronidase; 22, mechanical
methods – Foley catheter; 23, mechanical methods – laminaria; 24, mechanical methods – double-balloon or Cook’s
catheter; 25, membrane sweeping; 26, extra-amniotic PGE2; 27, acupuncture; 28, i.v. prostaglandin.
TABLE 74 Model fit and heterogeneity for unfavourable cervix: CS
Number of data points totresdeva Between-study SD: posterior mean (95% Crl) DIC
REs consistency: 429 440 0.2 (0.09 to 0.3) 2461
REs inconsistency: 429 440.7 0.19 (0.05 to 0.32) 2505
a Residual deviance.
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FIGURE 31 Network for favourable cervix only. Treatments are numbered as follows: 1, no treatment; 2, placebo;
3, vaginal PGE2 (tablet); 4, vaginal PGE2 (gel); 5, vaginal PGE2 pessary (normal release); 6, oral misoprostol tablet
(dose ≥ 50 µg); 7, titrated (low-dose) oral misoprostol solution; 8, i.v. oxytocin; 9, amniotomy; 10, i.v. oxytocin plus
amniotomy; 11, corticosteroids; 12, relaxin, 13; buccal/sublingual misoprostol.
TABLE 75 Favourable cervix only
Number of data points totresdeva Between-study SD: posterior mean (95% Crl) DIC
REs consistency: 20 19.8 1.17 (0.04 to 4.23) 110.4
REs inconsistency: 20 19.77 1.05 (0.03 to 3.49) 110.4
a Residual deviance.
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Outcome: Apgar score < 7 at 5 minutes
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FIGURE 32 Network for unfavourable cervix only. Treatments are numbered as follows: 1, no treatment;
2, placebo; 3, vaginal PGE2 (tablet); 4, vaginal PGE2 (gel); 5, vaginal PGE2 pessary (slow release); 6, intracervical PGE2;
7, vaginal PGE2 pessary (normal release); 8, vaginal misoprostol (dose < 50 µg); 9, vaginal misoprostol (dose ≥ 50µg);
10, oral misoprostol tablet (dose < 50 µg); 11, oral misoprostol tablet (dose ≥ 50µg); 12, titrated (low-dose) oral
misoprostol solution; 13, sustained-release misoprostol insert; 14, i.v. oxytocin; 15, NO; 16, mifepristone;
17, mechanical methods – Foley catheter; 18, mechanical methods – laminaria; 19, mechanical methods –
double-balloon or Cook’s catheter; 20, membrane sweeping; 21, extra-amniotic PGE2; 22, acupuncture;
23, oral prostaglandins; 24, buccal/sublingual misoprostol.
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FIGURE 33 Network for favourable cervix only. Treatments are numbered as follows: 1, no treatment; 2, vaginal
PGE2 (tablet); 3, vaginal PGE2 (gel); 4, vaginal PGE2 pessary (normal release); 5, oral misoprostol tablet (dose
≥ 50µg); 6, amniotomy; 7, i.v. oxytocin plus amniotomy; 8, corticosteroids; 9, buccal/sublingual misoprostol.
Model would not converge because of sparse network and small number of events on some arms.
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Appendix 16 Joint estimation of intervention
efficacy for use in economic model
A fter induction of labour there are three mutually exclusive outcomes that can occur: VD within24 hours (VD24), VD after 24 hours (VD> 24) and CS. If a study reports all outcomes then we can
jointly estimate the probability of each of these outcomes using a multinomial likelihood, which ensures
that the three outcome probabilities sum to 1. However, not all of our included studies report all of these
outcomes. Restricting to only studies that report all three outcomes substantially reduces the number of
studies that are included to 86. In order to include as many studies as possible, we note that the
multinomial likelihood with three outcomes can be written as two conditionally independent binomial
likelihoods. We therefore first estimate the relative effects (ORs) for CS using the NMA presented in
Chapter 3 (including 307 studies). Then, conditional on not having a CS, we estimate the relative effects
(ORs) for a VD within 24 hours compared with after 24 hours, in an additional NMA performed specifically
for the economic model (including 86 studies – see below). Care is required to ensure that the correct
denominator (number of women who did not have a CS) is used in this analysis.
Given estimates of the probability of (1) a VD within 24 hours and (2) CS conditional on failure to achieve
a VD in 24 hours, for the reference treatment, ref, we can apply the ORs estimated in the NMA to obtain
probabilities for these outcomes for any intervention k using the relationship: log–odds (probability
(k))= log–odds (probability(ref)) + log–odds ratio.
We can then find the overall p(VD24)= (1 – p(CS)) x p(VD24 given no CS). The probability of a VD in
> 24 hours, p(VD> 24), can be computed as p(VD> 24)= 1 – p(VD24) – p(CS).
For the additional NMA for a VD within 24 hours given no CS, after excluding trials with zero events in all
arms and those that did not report both CS and failure to deliver vaginally within 24 hours, 86 trials of
21 interventions were incorporated, including placebo and no intervention comparisons. The network plot
is shown in Figure 34.
For the additional NMA for a VD within 24 hours given no CS, in the subgroup of women with intact
membranes only, 33 trials of 13 interventions were included. The network plot is shown in Figure 35.
For the additional NMA for a VD within 24 hours given no CS in the subgroup of women with an
unfavourable cervix only, 63 trials of 19 interventions were incorporated, including placebo and no
intervention. The network plot is shown in Figure 36.
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FIGURE 34 Vaginal delivery within 24 hours, given no CS. Network diagram of all of the studies included in
analysis. The width of the lines is proportional to the number of trials comparing directly each pair of
interventions. The size of each node is proportional to the number of randomised participants (sample size).
Interventions are numbered as follows: 1, no intervention; 2, placebo; 3, vaginal PGE2 (tablet); 4, vaginal PGE2 (gel);
5, vaginal PGE2 pessary (slow release); 6, intracervical PGE2; 7, vaginal PGE2 pessary (normal release); 8, vaginal
misoprostol (dose < 50 µg); 9, vaginal misoprostol (dose ≥ 50µg); 10, oral misoprostol tablet (dose < 50µg); 11, oral
misoprostol tablet (dose ≥ 50µg); 12, titrated (low-dose) oral misoprostol solution; 13, sustained-release
misoprostol insert; 14, i.v. oxytocin; 15, i.v. oxytocin plus amniotomy; 16, NO; 17, mifepristone; 18, mechanical
methods – Foley catheter; 19, mechanical methods – double-balloon or Cook’s catheter; 20, extra-amniotic PGE2;
21, buccal/sublingual misoprostol.
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FIGURE 35 Subgroup analysis (i): women with intact membranes only. VD within 24 hours, given no CS. Network
diagram of all of the studies included in analysis. The width of the lines is proportional to the number of trials
comparing directly each pair of interventions. The size of each node is proportional to the number of randomised
participants (sample size). Interventions are numbered as follows: 1, vaginal PGE2 (tablet); 2, vaginal PGE2 (gel);
3, vaginal PGE2 pessary (slow release); 4, intracervical PGE2; 5, vaginal PGE2 pessary (normal release); 6, vaginal
misoprostol (dose < 50 µg); 7, vaginal misoprostol (dose ≥ 50µg); 8, oral misoprostol tablet (dose ≥ 50 µg);
9, titrated (low-dose) oral misoprostol solution; 10, i.v. oxytocin plus amniotomy; 11, mechanical methods – Foley
catheter; 12, mechanical methods – double-balloon or Cook’s catheter; 13, buccal/sublingual misoprostol.
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FIGURE 36 Subgroup analysis (ii): women with an unfavourable cervix only. VD within 24 hours given no CS.
Network diagram of all of the studies included in analysis. Interventions are numbered as follows: 1, no
intervention; 2, placebo; 3, vaginal PGE2 (tablet); 4, vaginal PGE2 (gel); 5, vaginal PGE2 pessary (slow release);
6, intracervical PGE2; 7, vaginal PGE2 pessary (normal release); 8, vaginal misoprostol (dose < 50 µg); 9, vaginal
misoprostol (dose ≥ 50 µg); 10, oral misoprostol tablet (dose < 50 µg); 11, oral misoprostol tablet (dose ≥ 50 µg);
12, titrated (low-dose) oral misoprostol solution; 13, sustained-release misoprostol insert; 14, i.v. oxytocin; 15, NO;
16, mifepristone; 17, mechanical methods – Foley catheter; 18, mechanical methods – double-balloon or Cook’s
catheter; 19, buccal/sublingual misoprostol.
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Appendix 17 Review of economic evidence
The economic search strategy is shown below for The Cochrane Library. The same strategy wastranslated for the other databases searched. Table 76 gives a list of excluded studies for model inputs
for utilities, with reasons.
ID Search Hits
#1 MeSH descriptor: [Pregnancy] explode all trees 5896
#2 MeSH descriptor: [Pregnancy Complications] explode all trees 8008
#3 MeSH descriptor: [Infant, Newborn] explode all trees 13,392
#4 MeSH descriptor: [Maternal Health Services] explode all trees 1652
#5 MeSH descriptor: [Maternal-Child Nursing] explode all trees 194
#6 MeSH descriptor: [Perinatal Care] explode all trees 436
#7 pregnan* (Word variations have been searched) 31,254
#8 birth or childbirth 16,329
#9 labour or laboring 4572
#10 labour* 4470
#11 caesar* 3126
#12 cesar* 6306
#13 obstetric* 26,797
#14 matern* 12,662
#15 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14) 64,641
#16 Economics 23,886
#17 (exp "Costs and Cost Analysis") 15
#18 exp Models, Economic 662
#19 Decision Trees 2207
#20 econom$ 12
#21 cba 404
#22 cea 861
#23 cua 70
#24 (monteadjcarlo) 30
#25 (decision adj3 (tree$ or analys$)) 90
#26 (cost or costs or costing$ or costly or costed) 60,137
#27 #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 63,745
#28 "Quality of Life" 43,721
#29 quality of life 50,815
#30 “Value of Life” 168
#31 Quality-Adjusted Life Years 6281
#32 quality adjusted life 10,178
#33 (qaly$ or qald$ or qale$ or qtime$) 3670
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ID Search Hits
#34 Health Status Indicators 2532
#35 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortformthirtysix or
shortform thirty six or short form thirtysix or short form thirty six)
9841
#36 sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six 11718
#37 sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short
form twelve
9713
#38 sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or
short form sixteen
6468
#39 sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or
short form twenty
7651
#40 euroqol or euro qol or eq5d or eq 5d 2773
#41 qol or hql or hqol or hrqol 7840
#42 hye or hyes 53
#43 health$ year$ equivalent$ 2861
#44 utilit* 11,896
#45 hui or hui1 or hui2 or hui3 1263
#46 disutili* 205
#47 quality of well-being 996
#48 quality of well-being 3585
#49 qwb 68
#50 willingness-to-pay 1337
#51 standard gamble$ 528
#52 time trade-off 66
#53 time trade-off 939
#54 tto 95
#55 #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or
#41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53
or #54
67,456
#56 #27 or #55 109,206
#57 #15 and #27 8908
#58 #56 and #57 8908
ID, search line number identifier; MeSH, medical subject heading.
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Appendix 18 Elicitation of utilities
Visual analogue scale
The VAS consists of a single line with anchors representing best possible health and death (or some
alternative). Respondents are asked to place each health state on the line, such that the intervals between
the placements reflect their perceived differences between the health states. Our VAS depicted a 10-point
horizontal line ranging from ‘worst imaginable health state’ (lower anchor) to ‘best imaginable health
state’ (upper anchor). Each respondent was asked to draw a horizontal line on the VAS to indicate where
they thought the described maternal and neonatal health states should be positioned, taking the top and
bottom anchors into consideration.
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Utility elicitation questionnaire
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Statistical analysis
The responses for each of the 10 respondents are plotted in Figure 37. Overall utility scores are very
variable across respondents, but similar patterns are seen between health states. We fitted a normal
distribution to the utility scores for the first state (VD from the mother’s perspective), giving an estimated
mean score 0.65, across respondents, and estimated between respondent SD of 2.05. Then for each of
the other health states we estimate the mean difference in score relative to state 1 (VD from the mother’s
perspective) and between-respondent SD in these differences. Modelling differences in this way accounts
for the variability between respondents and allows for correlations between scores from the same
respondent. Adding the estimated mean difference to the mean score for health state 1 gives an absolute
score for each health state, and dividing by 10 gives a value on the interval 0–1. The OpenBUGS code is
given below.
Table 77 shows how the utility scores from the questions in the VAS questionnaire are combined to obtain
the utility scores for the health states required in our model. Note that to obtain the utility scores for the
mother’s perspective only the first term is used for each state, whereas for the utilities from the baby’s
perspective only the second term is used for each state.
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FIGURE 37 Utility scores from the VAS questionnaire. Each line represents a different respondent. The health
states valued are given on the x-axis, where CS= caesarean section, IC= intensive care, HD=high dependency,
TC= transitional care. ‘Mother’ indicates the perspective of the mother, and ‘Baby’ indicates the perspective of the
baby. If not specified then score represents the perspective of the mother.
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TABLE 77 Derivation of the utilities for each health state as functions of the estimated utility from the VAS
questionnaire (numbered 1–9 as indicated in Figure 37). Each state is a sum of the utility from the mother’s
perspective and the utility from the baby’s perspective
Health state Derivation
VD with no neonatal complications utility1+ 1
Emergency CS with no neonatal complications utility3+ 1
VD with transitional care utility1*utility8+ utility9
VD with intensive care utility1*utility6+ utility7
VD with high-dependency care utility1*utility4+ utility5
Emergency CS with transitional care utility3*utility8+ utility9
Emergency CS with intensive care utility3*utility6+ utility7
Emergency CS with high-dependency care utility3*utility4+ utility5
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OpenBUGS Code for analysis of utility scores from visual
analogue scale questionnaire
model{ 
 
for (i in 1:10){ 
 x[1,i]~dnorm(theta[1],prec[1]) #Vaginal Delivery outcome 
likelihood 
 for (j in 2:9){ 
  x[j,i]~dnorm(mu[i,j],prec[j]) #Other outcomes likelihood 
  mu[i,j]<-x[1,i] + d[j]     # d[j] = mean difference 
for outcome j compared to outcome 1, allowing for individual correlations 
 } 
} 
 
theta[1]~dnorm(0,.001) 
for (j in 2:9){ 
 theta[j]<-theta[1]+d[j]  #Estimated mean utility for outcome j 
 d[j]~dnorm(0,.001)    #prior for d's 
} 
 
for (j in 1:9){ 
 prec[j]<-pow(sd[j],-2) 
 sd[j]~dunif(0,5)    #prior for sd's 
 
 utility[j]<-theta[j]/10   #utilities for each outcome 
} 
 
#Derive utility scores for health states in model (Table B.1) 
VD<-utility[1]+1 
VD.TC<-(utility[1]*utility[8]) + utility[9] 
VD.HD<-(utility[1]*utility[6]) + utility[7] 
VD.IC<-(utility[1]*utility[4]) + utility[5] 
 
CS<-utility[3] + 1 
CS.TC<-(utility[3]*utility[8]) + utility[9] 
CS.HD<-(utility[3]*utility[6]) + utility[7] 
CS.IC<-(utility[3]*utility[4]) + utility[5] 
 
 
} 
 
#DATA 
#Note column=respondent i, row=health outcome, j as defined in Fig. B.1 
x[,1] x[,2] x[,3] x[,4] x[,5] x[,7] x[,8] x[,9] x[,10] 
8 7.5 5.5 4.5 4.1 9.5 6.1 6.5 7 7.6 
5.5 5.5 3.7 3.5 3.1 9.1 4.1 3.85 6 6.5 
3.8 3.5 2.5 2.8 2.1 8.6 2.1 2.5 6 5.2 
4.8 2.5 0.5 0.5 0.1 4 5.1 5.25 3 8.2 
1.2 1.5 0.5 0.5 0.1 2 1.1 2.8 3 1.3 
5.2 3.5 2.1 0.5 0.1 6 6.1 5.25 4 8.3 
1 1.5 2.1 0.5 1.1 4 2.1 4.8 4 2.4 
6.6 7.5 7.5 3.5 2.1 8 7.1 6.8 8 9.6 
4.1 5.5 7.6 3.5 2.1 7.5 5.1 5.5 8 6.7 
END 
 
#INITIAL VALUES 
list(theta=c(5,NA,NA,NA,NA, NA,NA,NA,NA), sd=c(1,1,1,1,1, 1,1,1,1), 
d=c(NA, 2, 2, 2, 2,  2,2,2,2)) 
 
list(theta=c(8,NA,NA,NA,NA, NA,NA,NA,NA), sd=c(2,3,1,0.5,1.5,
 2,1.5,2,3), d=c(NA, 5, 4, 2, 3,  1,3,4,5))
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